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1.1 The nicotinic acetylcholine receptors  
The nicotinic acetylcholine receptors (nAChRs) are transmembrane excitatory 
receptors physiologically activated by the neurotransmitter acetylcholine (ACh). [1, 2] They 
are widely distributed in the central and the peripheral nervous system, [2] in the immune 
system and in several peripheral tissues, where they play critical roles [3] in the 
maintenance of cognitive, autonomic and immune homeostasis. [4] Neuronal nAChRs 
present on the postsynaptic neuronal terminals or acting as presynaptic receptors indirectly 
modulate the release of a variety of key neurotransmitters including serotonin, dopamine, 
-aminobutyric acid (GABA), glutamate, histamine, and norepinephrine. [5] Thus, nAChRs 
represent a class of validated therapeutic targets for a variety of pathologies and disorders, 
including Alzheimer's and Parkinson's diseases, addiction disorders, schizophrenia, pain 
management and inflammation-mediated processes, in which significant unmet medical 
needs still remain. [6] Moreover, nicotinic receptors are involved in the modulation of 
nociceptive neurotransmission, thus representing a promising target for non-opioid 
analgesics. [4]  
The nAChRs are members of the large superfamily of pentameric transmembrane 
ligand-gated ion channels, [7] and are formed by combinations of five subunits, 
symmetrically arranged around a central aqueous pore that is permeable to cations. The 
high degree of complexity is conferred by 16 different alpha (alpha1-alpha10) and non-
alpha (beta1-beta4, gamma, delta and epsilon) subunits which may assemble to form 
homomeric or heteromeric receptors (Figure 1). The former consist of only one type of 
subunit, i.e. alpha7 nAChRs, while the latter are formed by a combinations of various alpha 
and beta subunits. [8] Depending on the different association of the subunits, the resulting 
nAChR possesses distinct structural and functional properties, including different agonist 
affinity and different kinetics of activation, closure, desensitization, resensitization and 
internalization. [9] Structurally, each subunit of the pentameric neuronal nAChR is 
composed of a number of distinct functional domains (Figure 1): [10] an extended N-
terminal extracellular domain, which represents the binding domain for endogenous 
neurotransmitter (ACh) or exogenous ligands, a transmembrane domain, constituted by 
four highly hydrophobic α-helices (M1 - M4), a long cytoplasmic loop between the M3 and 
M4 domains and a short extracellular C-terminal region. 
Each subunit is encoded by a single gene, thus generating a cluster of 16 different 
genes widely distributed in the 23 human chromosomes. [11, 12] These encoding genes 
have progressively diverged from a common ancestor by mechanisms of gene duplications 
and mutations, leading to the gene structures currently present in humans. [13] In this 
respect, the ionotropic channels present in bacteria are characterized by a high degree of 
structural homology with the human nAChRs and therefore are useful prototypes in the 
elucidation of the tridimensional structure of the nAChRs. [14, 15] 
The orthosteric binding sites of the receptor are situated at the alpha/beta or 
alpha/alpha subunits interface respectively in the heteromeric or homopentameric 
subtypes. The homopentameric subtypes can host and bind up to five different molecules 
of ACh, while in the heteromeric receptors, the ratio of alpha and beta subunits determines 
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the number of ligands that can be bound. Consequently the binding of the endogenous 
neurotransmitter ACh or exogenous orthosteric ligands, the nAChR undergoes a 
conformational change in its structure, resulting in rapid channel opening and a net influx 
of cations (usually Na+, Ca2+ and K+) through the membrane. The cation influx causes 
channel depolarization of the cell membrane and increase of neuronal excitability, thereby 
an excitatory postsynaptic potential is generated.  
 
 
 
Figure 1. Structure of the nicotinic acetylcholine receptors. a. A schematic representation of 
the quaternary structure of the receptor, showing the arrangement of the subunits in the muscle-type 
receptor, the location of the two acetylcholine (ACh)-binding sites the axial cation-conducting 
channel. b. The threading pattern of receptor subunits through the membrane. c. Structures of 
heteropentameric and homopentameric nAChRs. ACh binding sites are depicted as red triangles. 
(adapted from Nature Reviews Neuroscience 2010, 11, 389-401 and Frontiers in Phychiatry 2013, 4, 
1-16 ). 
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1.2 The alpha7 nAChR subtype 
The alpha7 receptor is one of the two most abundant nAChR subtype in the central 
nervous system (CNS), where is mainly localized in the cortex, hippocampus and auditory 
cortex regions. Because of its wide distribution, the alpha7 subtype is involved in a broad 
range of central disorders, i.e. Alzheimer’s and Parkinson’s diseases, attention deficit 
hyperactivity disorder (ADHD), schizophrenia, anxiety and depression, which can be 
addressed by alpha7 subtype-selective ligands. [5, 12, 16, 17, 18, 19] Besides its 
neuroprotective potential, the alpha7 nAChR displays sensory gating and regulation of 
inflammatory properties, thus representing a promising pharmacological target for the 
treatment of chronic pain and inflammatory diseases.  
The alpha7 nAChR is characterized by a number of unique physiological and 
pharmacological properties. [20] By virtue of its unique high permeability to calcium, [21] 
besides electrical signaling, alpha7 receptors may play a role also in direct activation of 
calcium-dependent processes, such as interneuron excitability, release of excitatory and 
inhibitory neurotransmitters and neuroprotection. As previously introduced, in this 
pentameric receptor structure five potential ligand-binding domains (LBDs) are hosted and 
located at the interface between two alpha subunits (Figure 1). [20] In addition to these 
orthosteric binding sites, the alpha7 nAChR subtype hosts multiple allosteric sites, [21] 
structurally distinct from the orthosteric one and bound by the allosteric modulators. 
Compounds like these are usually not able to evoke channel opening by their own, but they 
influence the ability of orthosteric ligands to effect channel gating, by increasing (positive 
allosteric modulator, PAMs) or decreasing (negative allosteric modulators, NAMs) the 
response evoked.  
The alpha7 subtype is characterized by a lower affinity for ACh compared to other 
nicotinic subtypes and a very low probability of channel opening during agonist evoked 
currents, [22] which creates a peculiar challenge for its pharmacological characterization. In 
respect of its unique kinetic properties, [20] this subtype shows a unique form of 
concentration-dependent rapid reversible desensitization, [23] by which application of an 
agonist in concentrations sufficiently high to produce saturation of the binding sites induces 
the maximal synchronous transient activation when only a fraction of the agonist binding 
site are occupied. [24] The observed phenomenon relies on two main effects: non-
conducting conformations of the receptor promoted by application of high agonist 
concentration [20] and receptor responses faster than solution exchange kinetics. [23] 
Alpha7 maximal channel activation induced by ACh occurs at a concentration of 300 M. 
Application of greater concentrations produce larger peak currents, but not larger response 
as a result of progressive increment in synchronization of channel activation. For alpha7 
receptor, peak currents take place at relatively low agonist concentration, resulting in 
extremely sharp macroscopic responses with minimal area and in an over estimation of the 
agonist concentrations responsible for maximum channel opening. [25] Conversely, net 
charges better estimate the agonist concentration-response relationship for the alpha7 
receptor, since they are not affected by the amount of synchronization of channel opening 
induced by rapid change in agonist concentration. 
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1.2.1 Different conformational states of the alpha7 nAChR 
subtype 
The nAChRs are protein dynamic structures which can exists in multiple discrete 
functional conformations or states (Figure 2). [26] The equilibria and the rate of transition 
between two conformational states are determined by the differences in the free energy 
values of the different states and by the chemical nature and the amount of ligand bound 
to the receptor. [20] Ligand binding at the LBD influences the equilibria by reversibly and 
differentially stabilizing the receptor conformation to which the ligand has the greatest 
affinity. [26] 
 
 
Figure 2. Representation of the different conformational states of the nAChRs (adapted from 
Biochemical pharmacology 2014). [20] 
 
The alpha7 nAChR can be present in at least four interconvertible and functionally distinct 
states (Figure 3): [27] 
 a resting closed state (C), populated in absence of agonists, in which no ion influx 
through the channel can be detected; 
 an active open state (O*), transiently stabilized by the presence of agonists; it is a very 
short-lasting cation-permeable open state characterized by detectable ion fluxes 
through the receptor channel; 
 desensitized closed states (D), stabilized by the sustained presence of the agonist but 
with no ion fluxes detected. 
Upon complete washout and depending on the nature of the agonist, the nAChR can 
rapidly recover from the desensitization, thus converting again to a close resting state, or 
show a residual inhibition or desensitization. [28] 
In Figure 3, the models depicted in the first panel represent the energy situation 
and state transitions for the alpha7 depending on various levels of agonist occupancy. 
Under all conditions, this receptor has a very low open probability and very brief open 
times, which are usually less than 100 s, thus reflecting in a really steep energy barrier to 
enter the open state. [26] Under resting conditions, in absence of a ligand, the resting 
closed state (C) is the most stable receptor conformation, with some equilibration between 
the closed and the desensitized (D) states, and negligible probability of channel opening. 
[20, 26] Specific hydrophobic residues (leucine and valine) form a gate in the central 
portion of the receptor, acting as a block for ions permeation through the channel. Upon 
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interaction between a ligand and the receptor LDB, there is an increased probability for the 
receptor to enter the active open state (O*), undergoing conformational changes that lead 
channel opening and the subsequent permeation of ions through it. In particular, the O* 
state is a short-lived open-state characteristic of the alpha7 receptor subtype: [24] 
transition from the closed to the open state is a rapid and transient process, in a range of 
micro- to milli-seconds, and occurs before saturation of the agonist binding sites. In the 
heteromeric nAChRs, channel opening is induced by a single agonist binding site occupied 
and further agonist bindings exert a cooperative effect, promoting the stability of a long-
lived open state. [26] Conversely, in homomeric alpha7 nAChRs, this positive cooperativity 
does not occur, since high agonist concentrations promote a rapid desensitization of the 
receptor. For the alpha7 nAChRs, the energy difference between the desensitized and the 
resting states are very small. Binding of an agonist to the nAChR orthosteric sites stabilizes 
the active open state of the channel, whereas a competitive antagonist promotes the 
resting closed state. Allosteric modulators can affect the transition rates between different 
conformational states as well, by interfering in the resting-open equilibria or in the 
desensitization kinetics.  
 
 
Figure 3. Proposed models for the activation, desensitization, and modulation of alpha7 
nAChR. Qualitative representations of minimal models for 7 nAChR conformational states, their 
relative energy levels, and transition rates are represented (adapted from Molecular Pharmacology 
2011). [24] 
 
Similarly to other nAChRs, protracted agonist stimulation of the alpha7 subtype 
induces receptor desensitization, thus promoting a specific receptor conformation in which, 
even though the agonist is bound, the receptor is a closed state and no activation can 
CHAPTER I - Introduction 
 
 
10 
occur. [28] Two distinct forms of alpha7 desensitization, namely Ds and Di, have been 
identified and distinguished for being sensitive or insensitive to be converted to open states 
by a type II PAM of the alpha7 receptor, such as the PNU-120596 (Figure 3, second and 
third rows). The Ds state represents a rapid form of desensitization unique to the alpha7 
receptor, similar to the long-lived open state observed for the heteromeric nAChRs and 
occurs as a long burst or as groups of openings separated by very short closures. [26] 
Sensitive to and destabilized by the presence of the PAM PNU-120596, the Ds state has a 
greater stability compared to the closed O* state and it is preferentially entered in 
presence of high levels of agonist occupancy. The second desensitized conformational state 
of the alpha7 nAChR is called Di, because it is insensitive to the PAM PNU-120596. The Di 
state is promoted by high levels of agonist or PAM PNU-120596 occupancy [24] and 
represents the true intrinsic desensitized state of the alpha7 receptor. [26] Compared to 
the heteromeric desensitized states, the alpha7 Di has a lower stability that results in a 
lower free energy difference between the Di and the close state in presence of high agonist 
occupancy. Because of the different effects induced in combination with type II PAM, Ds 
and Di might involve different intracellular signaling pathways. [28] Although lacking of 
ability to conduct net ion-currents through the receptor, alpha7 desensitized states are 
functionally relevant and a signal transduction pathway mediated by the alpha7 receptor 
independent from ion channel activation, and rather more similar to a metabotropic 
transmission, has been hypothesized. [29, 30] Therefore, identification of compounds able 
to preferentially stabilize the desensitized states, and in particular the Ds state, may 
represent an innovative approach to investigate phenomena modulated by the alpha7 
receptor and to develop novel therapeutics.  
 
1.2.2 The human alpha7 nAChR genes CHRNA7 and CHRFAM7A 
Phylogenetically, the alpha7 gene represents the closest form to the ancestor 
nAChR, a protein evolved millions of years ago in organism not relying on fast chemical 
neurotransmission. [20] The human gene encoding for the alpha7 subunit is the CHRNA7 
gene and is located on the human chromosome 15, locus q13,14 (Figure 4). [31, 32] The 
CHRNA7 gene possesses 10 exons localized to highly conserved splice-junction positions. 
[32] The alpha7 receptor locus is unusually large compared to other species and this 
evidence led to the discovery of duplicated alpha7 nAChR sequence (Figure 4). Six 
duplicated exons (5-10) of the human alpha7 nAChR gene were identified to be located 
more than 1.6 Mb 5’ upstream from the original alpha7 nAChR gene and, in addition, four 
completely novel exons have been identified, which create a new open reading frame 
(ORF). This ORF and the duplicated 5-10 exons form a new human alpha7 nAChR gene 
called CHRFAM7A or dupalpha7nAChR. [33] The CHRFAM7A is structurally related to the 
classical alpha7 receptor and retains a significant portion of the original LBD, so that it can 
successfully take part to the pentameric arrangement. [33] It is able to change cell 
responsiveness to the classical alpha7 nAChR or CHRN7A. It is a human specific and 
evolutionarily new gene and therefore, not investigable in animal models.  
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The CHRFAM7A is low expressed in human brain, but is overexpressed in human 
leukocytes. The vagus nerve regulates systemic and local anti-inflammatory responses 
through the alpha7 receptor on leukocytes activated by the ACh and the identification of 
unique human alpha7-like gene CHRFAM7A and its preferential expression in peripheral 
tissues suggests the possibility of specific mechanisms in anti-inflammatory responses 
regulated by the alpha7 receptor, thus affecting the therapeutic development of new drugs 
targeting this receptor subtype for injury, infection and inflammation. [33] The impact of 
dupalpha7 gene expression in peripheral tissues in human inflammatory responses needs 
to be further investigated.  
 
 
 
 Figure 4. The human genes encoding for the alpha7 nAChRs. The human CHRNA7 gene (top 
row) and the partial duplication process (from top to bottom) of CHRNA7 that leads to the human-
specific duplicated CHRFAM7A gene (adapted from Journal of Leukocyte Biology 2015). [33] 
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1.3 Involvement of the alpha7 nAChR in the cholinergic anti-
inflammatory pathway 
Recent evidences report the involvement of alpha7 receptors in modulation of 
cellular functions beyond the synaptic transmission. [21]  Despite the great abundancy in 
the CNS, the alpha7 subtype is expressed in non-neuronal tissues, like microglia and B-cells, 
monocytes, dendritic cells, lymphocytes, macrophages, intestinal/lung endothelial and 
epithelial cells. [34, 35]  In these cells the alpha7 receptor is an essential regulator of pro-
inflammatory responses mediated by the cholinergic anti-inflammatory pathway, a 
signaling transduction pathway that involves both the nervous and immune systems. 
Consequently, [36] this receptor represents a potential therapeutic target for various 
inflammatory-related diseases and conditions in which systemic inflammation is strongly 
present, like asthma, sepsis, osteoarthritis, obesity, type 2 diabetes and chronic pain, via 
pro-inflammatory cytokines modulation. Although a well-controlled inflammation 
constitutes the physiological responses to noxious stimuli and helps restoring homeostatic 
conditions, excessive inflammation may induce serious health problems, including tissue 
injury, organ dysfunction and death, and is one of the principal causes of human morbidity 
and mortality. [35]  
Acetylcholine was proven to inhibit the release of pro-inflammatory cytokines, such 
as TNF-, through a post-transcriptional mechanism dependent on the alpha7 nAChR 
subtype. [37] To assess the critical role of the alpha7 receptor in the cholinergic inhibition 
of TNF release, antisense oligonucleotides specific for this subunit were synthesized. 
Macrophages exposed to these antisense oligonucleotides showed a lower sensitivity 
towards inhibition of TNF release after nicotine administration. [37] Moreover, alpha7 
knockout mice showed higher serum levels of TNF-, IL-1 and IL-6 after administration of 
bacterial endotoxin compared to wild-type animals, confirming the role of the alpha7 
subunit in the cholinergic anti-inflammatory pathway (Figure 5) [33, 38] 
The afferent vagus nerve terminals are activated by an inflammatory stimulus and 
act by means of spleen-dependent or spleen-independent mechanisms. [33, 38, 39] In both 
cases, the inhibition of inflammation occurs via release of the major vagal neurotransmitter 
ACh in organs of the reticuloendothelial system, including lungs, spleen, liver, kidneys, and 
the gastrointestinal tract. [40, 41] Upon release, ACh interacts with the alpha7 nAChRs 
expressed on cells of both innate and adaptive immunity, including macrophages 
neutrophils, monocytes, B cells and T cells, and other cytokine-producing cells, thus 
suppressing the release of TNF-α, down-regulating pro-inflammatory cytokines synthesis 
and preventing tissue damage. The proposed mechanisms involve NF-κB (nuclear factor 
kappa) and JAK2-STAT3 (janus kinase–signal transducers and activator of transcription) 
signaling pathways, which may converge to suppress inflammatory responses. More recent 
insights suggest the involvement in this modulation of other signaling cascades, such as 
PI3K (phosphatidylinositol 3-kinase). [39] Upon pro-inflammatory stimulation, alpha7 
receptors in macrophages inhibit nuclear translocation of NF-κB which regulates the 
expression of pro-inflammatory cytokines (Figure 5). [39, 40] In the cellular cytoplasm, NF-
κB is present as latent and inactive complex bound to I-κB. Inflammatory injury induces 
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phosphorylation and degradation of I-κB and therefore release and translocation of NF-κB 
subunits to the cell nucleus where transcription of pro-inflammatory cytokines is evoked. 
Activation of the alpha7 receptor prevents NF-κB nuclear translocation in macrophages and 
contrasts inflammation. To date, the exact mechanism by which activation of alpha7 in 
macrophages causes the blockade of NF-κB nuclear translocation is still unclear. [42]  
 
 
Figure 5. The cholinergic anti-inflammatory pathway mediated by the alpha7 nAChR. 
Activation of the vagus nerve leads to ACh release and binding to alpha7 receptors on cytokine 
producing cells, affecting different intracellular signaling pathways involved in the anti-inflammatory 
responses (adapted from The Journal of Experimental Medicine 2005, 202(8), 1017-1021). 
 
The JAK2–STAT3 signaling cascade mediated by the alpha7 in macrophages 
regulates cytokine responses (Figure 5) [39, 43] by phosphorylating transcription factors 
and activating other kinases. These mechanisms influence the transcription of several genes 
involved in immunity, inflammation, and controlled cell death. Alpha7 activation 
determines JAK2 recruitment and auto-phosphorylation, followed by recruitment and 
phosphorylation of STAT3 by JAK2. The phosphorylated STAT3 dimerize and translocate to 
the nucleus where they negatively regulate production and release of pro-inflammatory 
cytokines. Alternatively, unphosphorylated STAT3 may form a complex with the NF-κB and 
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prevent NF-κB activation. Mice lacking the STAT3 showed reduced anti-inflammatory 
response to vagus nerve stimulation, thus confirming the role for STAT3 in the cholinergic 
anti-inflammatory pathway. [40] Alpha7 agonist administration prevents STAT3 
phosphorylation and inhibits TNF-α release in wild-type but not in alpha7 knockout mice, 
and these effects are inhibited by alpha7 selective antagonists and by selective inhibitors of 
JAK2 phosphorylation. [44, 45]  
Although traditionally considered as a ligand-gated ion channel, very recently 
alpha7 receptor presence in non-neuronal tissues and in particular in not excitable cells of 
the immune system raised the hypothesis of an alternative ion-independent and 
metabotropic-like mechanism of signal transduction mediated by this subtype. [33] This 
metabotropic mechanism is associated with non-conducting states of the receptor and is 
involved in the modulation of the cholinergic anti-inflammatory pathway. [25, 46, 39] The 
absence of alpha7 macroscopic currents in the immune cells may be due to the abundant 
expression of the duplicated alpha7 nAChR gene CHRFAM7A in non-neuronal tissues.  
 
 
 
1.4 Alpha7 nAChR Positive Allosteric Modulators (PAMs) 
Allosteric modulators are ligands able to bind nAChRs in sites topographically 
distinct from the orthosteric binding sites of acetylcholine, including sites located in the 
transmembrane region of the receptor [2] and represent an alternative strategy to 
investigate the activation of the alpha 7 nAChR. They usually lack intrinsic activity and 
enhance receptor function through endogenous cholinergic neurotransmission, thus 
potentiating the binding and/or signaling of an orthosteric ligand. [47]  
According to the current classification, two different generations of alpha7 PAMs can be 
identified. The first generation includes calcium ions, which were the very first alpha7 PAMs 
described, the anthelminthic agent ivermectin, genistein and 5-hydroxyindole and lacks of 
potency, selectivity and efficacy. [26] On the other hand, in the second generation two 
different profiles for allosteric modulation, type I and type II (Figure 6), are included and 
they differ in the ability to impact the equilibrium between active and desensitized state of 
the alpha7 receptor. According to the energy landscapes depicted in Figure 7, PAMs 
influence the conformational states equilibria in two distinct ways. The first model matches 
both type I and type II PAMs mode of action and claims for a decrease in the energy barrier 
between the close and the long-lived open state, together with an increase in the energetic 
difference between the open and the desensitized state. Therefore, the probability of 
channel openings overcomes the desensitization and increases immediately after agonist 
application. In this case, the absolute energy differences between the states are not 
influenced. [24] Alternatively, the increase of open probability induced by PAMs may be 
due to destabilization of the desensitized state, altering the equilibrium between the active 
and the desensitized states of the alpha7 receptor, providing prolonged activations of 
previously desensitized receptors and exerting large effects under equilibrium conditions. 
The second model illustrated is possessed only by type II PAM.  
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Figure 6. Structure of known type I and type II positive allosteric modulators (PAMs) of the 
alpha7 nAChR (adapted from Biochemical Pharmacology 2011). [26] 
 
 
 
 
Figure 7. Mechanisms of PAMs influence in the equilibria between different conformational 
states of the alpha7 nAChR subtype (adapted from Biochemical Pharmacology 2011). [26] 
 
In details, type II PAMs revert the Ds state into a conductive long-lived open state in 
a manner dependent on both agonist and modulator concentrations. At fixed PAM amount, 
increasing agonist concentration generate responses characterized by a greatest peak at 
intermediate and lower at higher agonist concentrations, so that the efficacy does not 
reach a true plateau. A similar effect is observed when modulator concentrations are 
increased in presence of fixed agonist concentration. Relatively low occupancy of agonist 
and PAM binding sites results in an equilibrium between the different open, Ds and Di states 
and in large prolonged steady-state currents, while at high occupancy the Di state is 
preferentially induced, possibly to protect the cell from toxicity. [26] 
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Positive allosteric modulators offer a wide range of advantages compared to 
conventional agonists and represent a relevant alternative to the development of receptor 
agonists, limited in therapeutic benefits by the low probability of channel opening and the 
rapid desensitization of the alpha7 receptor: [26]  
 PAMs act synergizing and enhancing the responses evoked by endogenous ligands, thus 
preserving a more physiological spatial and temporal selectivity [26] and restricting the 
drug effects to regions where ACh was is being released; [21, 26, 48]  
 the magnitude of alpha7 potentiation induced by PAMs depends on agonist 
concentration, enhancing lower agonist concentration with minimal effects on higher 
concentrations; [2]  
 the “ceiling effect”: allosteric modulation is a saturable process and after occupancy of 
the allosteric binding sites no additional effects are observed, resulting in reduced 
toxicity compared to agonists. [2, 47] The sustained activation and desensitization of 
the nAChR occurring with subtype selective agonists chronic treatment are not 
observed with PAMs; 
 subtype selectivity may be easily achieving with allosteric ligands because their binding 
sites are distinct from the well-conserved orthosteric binding domains.  
On the contrary, PAMs presents also some limitations as therapeutic approach to target the 
alpha7 receptor. These limitations are linked to the need of the endogenous agonist in 
sufficient concentrations to evoke potentiated responses. [26, 21] Therefore, pathological 
conditions affecting the ACh concentrations may influence potentiation induced by PAMs. 
Indeed, lacking of intrinsic receptor activation, PAMs may exert a reduced effect in patients 
with decreased levels of endogenous agonist, i.e. advanced stages of neurodegeneration. 
Conversely, under trauma, ACh concentrations may become unregulated, resulting in an 
over-stimulation in presence of PAMs. Other pathological events are associated with 
undesired alpha7 activation (cell proliferation, angiogenesis and inhibition of apoptosis in 
some cancers) and in these cases PAM potentiation would exacerbate them. [26] A further 
limitation to PAM stimulation is due to the Di state of the alpha7 receptor, which is known 
to be insensitive to conversion to an open state by PAMs. At the same time, however, the 
Di state represents a safety mechanism to avoid dramatic potentiation induced by PAMs.  
Interestingly, a competition between type I and type II PAMs has been observed 
and co-application of 5-HI (type I) with PNU-120596 (type II) caused a significant reduction 
in the potentiation compared with the effects of PNU-120596 alone. The present 
competition may be ascribed to a common binding site of the receptor or to mechanistic 
interference at sites required for the effects of the compounds. [24] Competitive binding 
assays between a different type I PAM (NS1738) and PNU-120596 on mutated alpha7 
nAChR confirmed the hypothesis of a similar site of interaction for them, since co-
application of NS1738 with PNU-120596 resulted in a dose-dependent inhibition of 
recovery from desensitization. The common binding site for allosteric modulators has been 
identified and located between the four transmembrane helices of a single alpha7 subunit. 
[2] Both type I and type II PAMs showed therapeutic efficacy in in vivo studies, for example 
in reverting learning impairment induced by scopolamine [27] or improving short-term 
recognition memory and sensory gating deficits induced by amphetamine in rat models.  
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1.4.1 Alpha7 PAMs in inflammatory processes 
Several experimental evidences, performed in in vitro and in vivo models with type I 
and type II PAMs, support the therapeutic potential of alpha7 allosteric modulation in the 
treatment of inflammation and chronic pain. [49] For instance, in literature is reported that 
the type I PAM genistein inhibits I-kB phosphorylation and significantly reduces 
translocation of NF-kB to the nucleus, [50] thus preventing binding of NF-kB to its target 
DNA and blocking transcription of NF-kB downstream genes. Additionally, in inflammation 
models induced by LPS stimulation, in vitro administration of genistein attenuates pro-
inflammatory cytokines overproduction in macrophages resulting in decrease of both TNF-
 and IL-6 levels (Figure 8). [51]  
 
 
 
Figure 8. Inhibitory effect of genistein on TNF- and IL-6 mRNA levels in LPS-treated 
macrophages. Cells were pretreated with genistein (0.1-10 M) for 1h and then incubated with LPS (1 
mg/mL) for 24h, IL-6 and TNF- mRNA levels were quantified (adapted from PLOS ONE 2012). [51] 
 
Furthermore, the alpha7 nAChR is involved in the chronic low grade inflammation 
associated with obesity and modulates inflammatory gene expression in human adipocytes. 
Compared to normal weight subjects, obese patients showed appreciably decreased 
expression of the alpha7 nAChR levels. [52] Stimulation of differentiated primary human 
adipocytes with 10 M of genistein induced relevant up-regulation of alpha7 receptor 
expression, together with significant modulation of pro-inflammatory genes (TNF- and IL-
6) (Figure 9).  Two different types of PAMs, NS-1738 and PNU-120596, were investigated in 
neuropathic pain models represented by carrageenan-induced inflammatory pain and 
chronic constriction injury (CCI) (Figure 10). [49] Both of them significantly reduced thermal 
hyperalgesia at doses of 10 and 30 mg/kg and PNU-120596 significantly attenuated the paw 
edema after carrageenan infusion. These effects were observed only in pain conditions, 
since in sham-operated mice did not occurred and the involvement of the alpha7 receptor 
was proved by systemic pre-treatment with mecamylamine (MLA), a selective alpha7 
antagonist, which completely reverted the observed anti-inflammatory effects.  
 
 
 
CHAPTER I - Introduction 
 
 
18 
 
 
 
Figure 9. Effects of genistein stimulation in in vitro differentiated human adipocytes.  
Expression levels of alpha7 nAChR were increased in percentage after 3h stimulation with 5, 10 and 
25 M genistein (left panel). 10 M genistein stimulation of in in vitro differentiated human 
adipocytes reduced the expression levels of inflammatory genes (IL6 and MCP-1) compared to the 
control (CTR) (right panel) (adapted from International Journal of Obesity 2012). [52] 
 
 
 
 
 
Figure 10. Effects of alpha7 PAMs NS-1738 and PNU-120596 on carrageenan-induced 
hyperalgesia and edema in mice. NS1738 (30mg/kg) or PNU-120596 (4mg/kg) were administrated 15 
min before carrageenan intraplantar injection and hyperalgesia and paw edema were assessed 6h 
later (adapted from Neuropharmacology 2013). [49] 
 
In particular, PNU-120596 showed long-lasting and dose-dependent anti-
hyperalgesic and anti-allodynic effects in the chronic constriction injury (CCI) neuropathic 
pain model. [49, 53, 54] The differences in the observed anti-inflammatory effects of the 
two PAMs may be ascribable to their distinct mechanism of alpha7 modulation. To explain 
the antinociceptive effects of PNU-120596 different mechanisms have been hypothesized, 
including potentiation of ACh effects in counteracting inflammation, modulation of 
inhibitory neurotransmitter and stimulation of spinal alpha7 receptor. The last mechanism, 
however, is unlikely since several reports suggested that central alpha7 receptor are not 
involved in thermal and mechanical nociceptive hypersensitivity in mice.  
Interestingly, in situations poorly responsive to nonsteroidal anti-inflammatory 
drugs (NSAID), or when such agents are contra-indicated, PAMs can be successfully 
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exploited in the treatment of inflammatory pain conditions. [55] The effects of the NSAID 
diclofenac and PNU-120596 on pro-inflammatory cytokine levels induced by carrageenan 
administration were evaluated (Figure 11). Both agents attenuated paw swelling and 
reduced levels of the pro-inflammatory cytokine IL-6 within the hind paw edema, but only 
PNU-120596 significantly decreased the carrageenan-induced increase in levels of TNF-. 
The antagonization of these inflammatory effects induced by MLA proved alpha7 
mediation.  
 
 
Figure 11. Anti-hyperalgesic actions of PAM PNU-120596 mediated by activation of alpha7 
nAChR. The rats were injected with either CFA (left panel) or carrageenan (right panel) into the 
plantar surface of the hind paw. They were then administered either drug or vehicle and the effects of 
PNU-120596 and vehicle on mechanical hyperalgesia were evaluated (left panel). The anti-
hyperalgesic actions of PNU-120596 are mediated via activation of alpha7 nAChRs (right panel): MLA 
reverted the PNU-120596 effects. Diclofenac was included as a positive control and data expressed as 
a percentage of diclofenac mediated anti-hyperalgesia. [55] 
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1.5 Alpha7 nAChR Silent agonists 
The profile of an alpha7 silent agonist is revealed by electrophysiological 
experiments performed in presence of the compound of interest, the control acetylcholine 
and a type II PAM. The representative traces of the alpha7 receptor responses evoked by 
applications of a silent agonist, collected on human alpha7 nAChRs expressed in Xenopus 
leavis oocytes, are depicted in Figure 12. [30, 56] A compound acting as a silent ligand is 
characterized by lack of agonist activity (Figure 12, panel A):  its application to the alpha7 
receptor subtype results in no or very weak activation and channel opening, so that no ion 
channel fluxes are measured, proving that a silent agonist does not act like a conventional 
alpha7 agonist. Co-application of a silent agonist with the agonist ACh causes inhibition of 
the alpha7 receptor responsivity to acetylcholine and therefore diminished ion currents 
evoked by the agonist (Figure 12, panel B). This inhibition proves that the silent agonist 
binds the alpha7 receptor at the acetylcholine orthosteric binding site.  
 
 
 
Figure 12. Representative traces of the alpha7 nAChR response to applications of a silent 
agonist. Blue bars represent duration of ACh applications, green bars the silent agonist application, 
and the red bar represents PNU-120596 application (adapted from Bioorganic & Medicinal Chemistry 
Letters 2013). [30] 
 
A silent compound preferentially induces non-conducting alpha7 receptor states (Ds or Di), 
thus appearing as an agonist when co-applied with a type II PAM, namely PNU-120596. 
Evoking a very large channel response in co-application with PNU-120596 (Figure 12, panel 
C), the silent agonist reveals to selectively promote the desensitized state Ds of the 
receptor. By definition, the type II PAM does not possess alpha7 detectable activity by its 
own, but it is able to destabilize a form of desensitization unique to this receptor subtype, 
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thereby promoting protracted bursts of channel opening. [56]  In the light of the described 
electrophysiological profile, a silent agonist is a ligand that binds to the orthosteric binding 
site of the receptor, acts as a desensitizer when applied alone, inducing conformational 
changes converting the alpha7 nAChR subtype from a resting state selectively into a 
desensitized state that can be probed by type II PAM (PNU-120596) and behaves as a 
channel activator in the presence of type II PAM. Alpha7 silent agonists. The binding of a 
silent agonist to the alpha7 receptor subtype does not promote the typical nAChRs 
ionotropic activation and the corresponding pharmacological profile associated is 
independent from ion channel currents, but rather more similar to a metabotropic signal 
transduction mechanism. Therefore, silent agonists represent molecular tools of great 
interest to study functions of the alpha7 nAChR that do not involve ion conducting states, 
and may constitute a new potential alternative for the development of alpha7 nAChR 
therapeutics. Despite being electrophysiologically revealed by co-application with a type II 
PAM, silent agonists do not require this co-application in order to exert their 
pharmacological activities in in vitro and in vivo tests. [56] 
 
1.5.1 Pharmacophore model for alpha7 Silent agonism 
Because of the intriguing profile displayed by silent agonists, a preliminar 
pharmacophore model for alpha7 silent agonism has been hypothesized and defined 
starting from the chemical structures of the known alpha7 silent agonists KC-1 and NS-6740 
(Figure 13).  
 
 
 
Figure 13. Structures of two alpha7 silent agonists and the putative pharmacophore model 
for alpha7 silent agonism (adapted from adapted from Bioorganic & Medicinal Chemistry Letters 
2013). [30] 
Despite quite different molecular skeletons, some relevant structural features are 
commonly present in compounds KC-1 and NS-6740: 
 a positively charged centre;  
 a heterocyclic ring with hydrogen bonding capability; 
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 an aryl group, potentially suitable for a wide range of structural modifications.  
All the elements of the pharmacophore model are in specific angular relationships between 
each other. The positively charge centre of the illustrated pharmacophore can be 
represented by either a permanently positively charged ion, i.e. a quaternary ammonium 
head, or by a protonable nitrogen. Therefore, tertiary amines, protonable at physiological 
pH, constitute a good alternative to permanently charged quaternary ammonium salts. 
According to more recent evidences, the minimal pharmacophore for the alpha7 
silent agonism corresponds to the tetraethylammonium (TEA) group, which selectively 
induces the Ds state of the receptor. [57] This finding originates from the minimum 
requirements for selective agonist activation of the human alpha7 nAChR subtype, i.e. 
diethyldimethylammonium (diEdiMA). Starting from it, progressive replacement of methyl 
groups with ethyl groups led first to triethylmethylammonium (triEMA), a partial agonist of 
the alpha7 receptor, and then to TEA, an alpha7 silent agonist (Figure 14).  
 
 
 
Figure 14. Structures and relative electrophysiological profiles of diEdiMA, triEMA and TEA. 
Concentration-response studies reported the orthosteric (drug applied alone) and allosterically 
potentiated (drug co-applied with 10 M PNU-120596) activation of alpha7 nAChR (adapted from 
The Journal of Pharmacology and Experimental Therapeutics 2014). [57] 
 
The observed pharmacological profiles suggest that additional ethyl group makes the 
positively charged nitrogen atom of the compound bulkier, more shielded and less effective 
for forming the cation-π bond interaction responsible for receptor activation. An optimal 
Connolly solvent-excluded volume for alpha7 silent agonism has been hypothesized as well 
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and, according to electrostatic effects, in order to possess the desired silent profile, the 
core pharmacophore elements should possess an estimated solvent-excluded volume 
between 130 and 180 Å3. 
 
1.5.2 Alpha7 Silent agonists in inflammatory processes 
Recent evidences highlighted alpha7 signal transductions not dependent from ion 
channel activation and the linkage between this alpha7 metabotropic-like transmission and 
inflammation. Indeed, silent agonists by triggering metabotropic ways proved to be useful 
pharmacological tools in the treatment of inflammatory conditions. [29, 56]  
The alpha7 silent agonist NS-6740 (Figure 13) preferentially induces non-conducting 
desensitized conformational states of the receptor and data collected on this compound 
revealed its therapeutic potential in treating chronic pain and inflammation diseases. 
NS-6740, with an agonist activity less than 2% compared to ACh, was first characterized as a 
very weak agonist [29] and subsequently revealed to be a silent agonist when co-applied 
with the PAM PNU-120596, promoting the conformational changes associated with 
desensitization rather than activation. [56] In preliminary in vitro studies, [29] NS-6740 
appeared to be more efficacious than classical alpha7 agonists in modulating the 
inflammatory function of microglia and suppressing LPS-stimulated secretion of TNF- in 
rat cultured cells, with some effects at 25 M and complete inhibition at 50 and 100 M 
(Figure 15). 
 
 
 
Figure 15. Effects of the alpha7 agonist choline, PAM PNU-120596 and silent agonist NS-
6740 on LPS-induced TNF- release in rat microglia enriched cultures. Rat microglia enriched cultures 
were exposed to 0.3–10 M choline, 0.01–100 μM PNU-120596 or 0.01–100 μM NS6740 for 30 min 
before adding 10 ng/ml LPS for another 4h after which the culture media were collected and 
submitted to an ELISA for TNF-α (adapted from Journal of Neuroimmunology 2012). [29] 
 
Since the same effects were not observed with alpha7 agonists (i.e. choline) or alpha7 
PAMs (i.e. PNU-120596), the hypothesis of receptor non-conducting states involved in 
modulation of inflammation was further suggested. Although nicotine is effective in 
reducing pro-inflammatory cytokines release after LPS stimulation in cultured rodent 
microglia by alpha7 receptor mediation, these anti-inflammatory effects occur at high 
nicotine concentrations, known to promote desensitization of the alpha7 receptor and, 
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therefore, the neuroprotective and anti-inflammatory effects of nicotine are hypothesized 
to depend on this conformational state 
In in vivo mouse models of chronic pain, including peripheral neuropathy, NS-6740 recently 
showed significant dose- and time-dependent antinoceptive activity in several pain models. 
[56] In the formalin test, NS-6740 reduced inflammation both in the early and the late 
phases (Figure 16) and pretreatment with MLA totally blocked the observed anti-
nociceptive effects, thus proving the alpha7 mediation. In addition, NS-6740 decreased the 
edema associated with inflammation in the formalin test, as measured by the difference in 
the ipsilateral paw diameter before and after injection of the compound (Figure 18). 
 
 
 
Figure 16. The anti-nociceptive effects of NS-6740 in in vivo mouse models of chronic pain. 
The anti-nociceptive effects of NS-6740 after administration of various doses (0.1, 1, 3, and 9 mg/kg, 
i.p.) on formalin-induced pain behavior in the mouse. The cumulative pain response of time of licking 
was measured during the period of 0-5 min (first phase) and 20-40 min (second phase) (upper left 
panel). Blockage of NS-6740 antinociceptive effects in the formalin test by the alpha7 antagonist 
MLA (10 mg/kg, s.c.) given 15 min before an active dose of 3 mg/kg of NS6740 or vehicle. Fifteen min 
later, mice were injected with formalin and then observed for pain behaviors (upper right panel). 
Anti-edema effect of NS-6740 (9 mg/kg) in the formalin test as measured by the difference in the 
ipsilateral paw diameter before and after injection (PD) (lower panel) (adapted from 
Neuropharmacology 2015). [56] 
 
Furthermore, NS-6740 significantly attenuated the chronic pain associated with chronic 
constrictive injury (CCI) and showed anti-allodynic effects in a dose- and time-dependent 
way (Figure 17). The anti-allodynic effects of NS-6740 were mediated by the alpha7 
receptor since they were totally blocked by pretreatment with MLA (Figure 19). 
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Figure 17. The antiallodynic effects of NS-6740 in chronic constrictive injury (CCI) 
neuropathic model are dose-dependent (left panel) and mediated by the alpha7 nAChR, since blocked 
by mecamylamine (MLA) (right panel). NS-6740 (1, 3, and 9 mg/kg, i.p.) significantly attenuated CCI-
induced mechanical allodynia in a dose-related manner (left panel). Blockade of the antiallodynic 
effect of NS-6740 in the CCI test by MLA (10 mg/kg, s.c.) given 15 min before an active dose of 9 
mg/kg of NS-6740 or vehicle proved alpha7 mediation (adapted from Neuropharmacology 2015). 
[56] 
 
According to time and concentration dependence, the observed effects were consistent 
with an alpha7 desensitized state induced by NS-6740, supporting the thesis that analgesia 
can be achieve through non conducting state of alpha7 nAChR signal transduction.  
All these evidences underlined the therapeutic potential of alpha7 selective silent agonists 
in mouse models of tonic and chronic pain and in the treatment of diseases characterized 
by strong inflammatory components. While alpha7 agonists better treat cognitive diseases, 
silent agonists show greater activity on pain and inflammation inhibition, suggesting that 
therapeutic agents like NS-6740 or other silent agonists favor peripheral pain and 
inflammatory disorders treatment over cognitive diseases. A possible explanation consists 
in the peculiar alpha7 receptors expressed by immune cells, which are not conductive in 
response to ACh and therefore may modulate unique intracellular signaling pathways. 
 
. 
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The current PhD research project aimed at investigating the role of the alpha7 
nAChRs in the cholinergic inflammatory cascade to elucidate the mechanistic complexity 
surrounding this research area through the design, synthesis and pharmacological 
evaluation of novel heterocyclic ligands targeting and selectively activating this subtype.  
With the purpose of deepening the inflammatory processes mediated by the alpha7 
nicotinic cholinergic pathway, this research focused on the allosteric modulation, less 
explored with respect to the orthosteric activation, and on the new emerging silent 
agonism mode of stimulating the alpha7 receptor. [26, 30] As reported in the introduction, 
both these alpha7 activators are involved in the modulation of inflammatory signals.   
 
 
2.1 Alpha7 PAM derivatives 
The first part of the present research project aimed at identifying and 
characterizing novel alpha7 PAMs. To this purpose, it was exploited the molecular 
hybridization approach which is an emerging structural modification tool to design new 
molecules with improved bioactivity when compared to the parent compounds. This 
strategy was applied to the alpha7 type I PAMs, 5-hydroxyindole (5-HI) and genistein, 
(Figure 18). 5-HI shows a quite low alpha7 PAM activity (EC50 1.6 mM [26]) but it’s 
characterized by a simple and flexible structure prone to molecular functionalization. On 
the other hand, the alpha7 PAM activity of genistein is fairly greater (EC50 40 M [26]). Both 
these two PAMs are characterized by biological activities other than the alpha7 allosteric 
modulation. 5-HI possesses potentiating effect on 5-HT3 serotonin receptors, due to its 
structural similarity to serotonin, [58, 59, 60] whereas genistein is endowed with tyrosine 
kinases inhibitory effect and estrogen-like properties. [61, 62] Therefore, the hybridization 
approach aimed at both enhancing the 5-HI PAM activity by means of genistein elements 
introduction and reducing the unwanted side biological properties of the parent 
compounds to achieve a more selective biological profile.  
 
 
Figure 18. Hybridization approach to novel PAM derivatives. 
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By comparing the structures of the two model compounds, similarities between the 
molecular scaffolds were highlighted:  
 the hetero aromatic nucleus: 3-phenyl-4H-chromen-4-one and indole moiety 
 a hydroxyl group in position 7 and in position 5 of genistein and 5-HI, respectively 
 a hydrogen bonding acceptor group: ketone carbonyl fuction and nitrogen atom. 
Conversely, the most prominent difference is represented by the presence of a phenyl ring 
in position 3 of genistein which is not detected in 5-HI. According to these observations, 
two first sets of derivatives, 1a-g and 2a-g, (Figure 19) were planned to overcome the 
underlined disparity. Indeed, the heteroaromatic nucleus of 5-hydroxyindole was 
connected to a variable substituted phenyl ring by exploring two different positions of 
linking, the nitrogen or the adjacent carbon atom in position 2, thus obtaining the two 
parallel series of target compounds 1a-g and 2a-g,respectively.  
 
 
Figure 19. Structures of target compounds related to 5-HI as novel potential alpha7 PAMs. 
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In both series of the new derivatives, hydrophilic substituents were inserted in para 
position of the phenyl ring to evaluate potential polar interaction within the binding pocket 
of the receptor. Besides, the relevance of coplanarity between the heteroaromatic nucleus 
and the phenyl ring in the ligand-receptor interaction was assessed by introduction of a 
methyl group or a chloro atom in ortho position.  
Data collected on preliminary electrophysiological experiments performed on these 
derivatives (1a-g and 2a-g) evidenced the promising enhancement in PAM activity of 
compounds 2b, 2f and 2g. Considering their structural features, new modifications were 
planned to further investigate the C-aryl substitution of 5-HI and novel derivatives 2h-m 
(Figure 19) were synthetized. Derivative 2h combines the ortho-methyl group of derivative 
2b and the para-methylamino group of derivative 2g. In compounds 2i and 2j the chloro 
atom of 2f and 2g was shifted from ortho to meta position, while conserving the para 
substituent, in order to study the correlation between position and substituent nature on 
allosteric activity. To further explore para-polar substitutions and in analogy to the type II 
PAM TQS (Figure 6), sulfonamide and methylsulfonamide groups were introduced (2k-m). 
The 5-HI nucleus was then linked to 4-pyrrole in derivative 3 (Figure 19) to investigate the 
effect of heteroaromatic substitution, while preserving hydrogen bond and polar 
interaction capability. Finally, taking into account the type II PAM PNU-120596 (Figure 6), 
derivatives 4a-b (Figure 19) were designed by introducing a 1,2-isoxazole ring on 5-HI, with 
the aim of studying also the effect of an enhanced hindrance on PAM profile. 
To evaluate the alpha7 PAM activity with respect to a further structural similarity 
between the new 5-HI derivatives and genistein, a small set of compounds 5a-c (Figure 20) 
were parallelly prepared by introducing a few exploited substituents on the phenyl ring of 
genistein. Compounds 5a and 5c were already known for their estrogenic activity. [63] 
 
 
Figure 20. Structures of target compounds related to genistein as novel potential alpha7 PAMs 
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2.2 Alpha7 Silent agonist derivatives 
In addition to positive allosteric modulators, the current research project was 
focused on the investigation of alpha7 nAChR signal transduction mediated by compounds 
characterized by the silent agonism profile. As previously mentioned, silent agonists 
represent an emerging mode of activation of the alpha7 receptor not involving ion-channel 
transduction and a preliminary pharmacophore model for alpha7 silent agonism has been 
recently defined (Figure 13). [30, 57] To further shed light on the pharmacophore 
characteristics and on the peculiar pharmacological profile of silent agonists in the 
modulation of inflammatory conditions, three different series of new potential silent 
derivatives were designed and synthesized.  
 
2.2.1 diEPP derivatives 
The compound N,N-diethyl-N'-phenylpiperazinium (diEPP) (Figure 21) was recently 
reported to present the alpha7 silent agonism profile [57] and it was therefore selected to 
be the model compound for the first series of new derivatives. The structure of diEPP well 
lends the compound to functionalization and thus investigation of potential further 
enhancement of the silent agonist activity.  
 
 
Figure 21. Structures of the alpha7 silent agonist diEPP and the alpha7 agonist diMPP. 
 
The model compound diEPP arose from an initial comparison between the minimal 
pharmacophore for selective activation of the alpha7 receptor subtype, i.e. the 
diethyldimethylammonium (diEdiMA) cation, and the one for alpha7 silent agonism, i.e. the 
tetraethylammonium (TEA) cation. [57] The ganglionic agonist diMPP (N,N-dimethyl-N'-
phenylpiperazinium) (Figure 21), resembles the diEdiMA cation accountable for selective 
alpha7 activation, but also proved to be a full agonist of this subtype. According to the TEA 
minimal pharmacophore for silent agonism, substitution of both the methyl groups of 
diMPP with ethyl groups was hypothesized to turn diMPP into an alpha7 silent agonist. The 
current hypothesis was confirmed by diEPP, the diethyleted equivalent of diMPP. 
Replacement of methyl groups with ethyl ones led to loss of the alpha3beta4 efficacy 
component present in the parent compound diMPP. 
Detailed investigation of the diEPP profile showed that the compound was unable to evoke 
an agonist response after application at 30 M (Figure 22, green dots), but co-application 
of diEPP with the PAM PNU-120596 led to an activation of the alpha7 receptor (Figure 22, 
pink dots), thus revealing the alpha7 silent agonism profile.  
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Figure 22. diEPP electrophysiological data on human alpha7 nAChRs expressed in Xenopus 
oocytes. Normalized response refers to receptor response to application of test compound at the 
concentration specified. Normalized potentiated response refers to receptor response of co-
application of test compound at the concentration specified and 10 M PNU-120596. Data are 
reported as net charge mean ± SEM (standard error of mean) and relative to the control ACh. 
 
In order to investigate the ability of the phenyl ring of diEPP to establish additional 
interaction within the alpha7 binding pocket, the structure of the diEPP backbone was 
varied addressing different parts of the parent compound moiety (Figure 23). The first set 
of derivatives 6a-u aimed at investigating the effects of different substituents on the phenyl 
ring of diEPP on the electrophysiological behaviour, with the goal to obtain compounds 
with an improved IC50. In the second set of derivatives (7 and 8) the nature of the linkage 
between the two rings was modified to test the role of the N-aryl linkage for the silent 
agonist activity. Functionalization of the phenyl ring led to diEPP derivatives 6a-u (Figure 
23), characterized by variations in both functional groups identity and position to study 
their influences on the silent profile. Several different groups were introduced in the ortho, 
meta and para positions of the aromatic ring, aiming at extended structure-activity 
relationships between nature and/or positon of the substituent and the alpha7 silent 
agonism profile. The different substituents were selected focusing on their capability of 
establishing different electrostatic, bonding and spatial interactions within the binding 
pocket, potentially affecting the alpha7 silent agonism profile. Electron donor and electron 
acceptor, H-bond donor and acceptor, polar and non-polar, halogens and different bulky 
groups were inserted on the aromatic part of the parent compound diEPP. Methyl and 
methoxide groups were the first introduced, then the trifluoromethyl group, bioisoster of 
the methyl one, was investigated, followed by the halogen atoms. The choice of the 
trifluoromethyl group was guided by the known silent agonist NS-6740, which presents a 
CF3 group on the meta position of the phenyl ring. Subsequently, cyano and the 
corresponding amide groups were taken into account. Finally, hydroxyl and naphthalene 
groups were introduced to investigate the influence of a more polar and a more bulky 
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group respectively. The ortho substitution was considered aiming at investigating the 
impact of the aromatic ring orientation in the space on the corresponding activity. 
 
 
Figure 23. Structures of target compounds related to diEPP as novel potential alpha7 silent agonists.  
 
The second set of diEPP analogues (Figure 23) arose from the idea of testing different 
spatial orientation of the molecule and the variations addressed the nature of the linkage 
between the aliphatic and the aromatic rings. The piperazines ring of the parent compound 
was replaced by the corresponding piperidine one and two different linkages between the 
aromatic portion and the piperidine moiety were investigated for testing the importance of 
the N-aryl linkage in the reference compound . The two rings were indeed connected 
through an amino (7) or a methylene (8) bridge, which, conferring a different grade of 
flexibility and interaction capability to the molecule, might affect the interactions within the 
binding pocket.  
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2.2.2 Quinuclidine derivatives 
Two series of compounds characterized by a quinuclidine spirocyclic-2-isoxazoline 
nucleus (9a-h and 10a-h) and a 3-substituted-5-(quinuclidin-3-ylmethyl)-1,2,4-oxadiazole 
(11a-m and 12a-m) were designed and synthesized. These derivatives were planned 
according to the structural and electrostatic features described in the preliminar 
pharmacophore model of a typical alpha7 silent agonist. [30] These characteristics make 
the silent agonism prone to well bear a wide range of structural modifications. The 
positively charged centre, in particular, may be represented by both a permanent positively 
charged ion, i.e. a quaternary ammonium cation, or by a protonatable nitrogen. Therefore, 
tertiary amines, which can be protonated at physiological pH, may be a suitable alternative 
to permanently charged quaternary ammonium salts. 
 
2.2.2.1 Spirocyclic quinuclidinyl-Δ2-isoxazoline derivatives 
In the recent past years the research group in which I developed the current PhD 
project has extensively studied the nicotinic cholinergic transmission through the design 
and synthesis of numerous ligands interacting with different nACh receptor subtypes. [64, 
65] Within this research line, a library of quaternary ammonium compounds previously 
synthesized as alpha7 subtype-selective nicotinic ligands, but endowed with a high alpha7 
binding affinity (Ki > 3 μM), has been selected to be analyzed as potential silent agonists. 
From the screening four compounds ICH-12, SG-3, SG-6 and MR-6 (Figure 24) revealed to 
possess the alpha7 silent agonism profile of interest.  
 
 
 
Figure 24. Structures and corresponding electrophysiological data of ICH-12, SG-3, SG-6 and 
MR-6 collected on human alpha7 nAChRs expressed in Xenopus oocytes. Normalized response refers 
to receptor response to 30 M application of test compound. Normalized potentiated response to 
receptor response with 30 M test compound and 10 M PNU-120596 co-application. Data are 
reported as net charge mean ± SEM (standard error of mean) and relative to the control ACh. 
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Therefore, among them has been chosen the model compound for developing the new 
series of quinuclidine spirocyclic-2-isoxazoline derivatives. In particular, the emerged 
compounds ICH-12, SG-3, SG-6, MR-6 appeared to have structural characteristics conform 
to the general pharmacophoric requirements described for the silent agonism and resulted 
to have a good silent profile:  
 they all lack of agonist activity: the agonist evoked response, normalized for the 
acetylcholine response, is less than 10% (green bars); 
 co-application of the compound with the type II PAM PNU-120596 evoked great 
responses of the alpha7 receptor, thus revealing their ability to selectively induce a 
desensitized PNU-sensitive state of the alpha7 receptor, typical characteristic of silent 
agonism (pink bars). 
Despite the highlighted common features, the four compounds differ in the ratio of silent 
agonist (pink bars) versus agonist activity (green bars). In particular, SG-6, showed the 
greatest sensibility to PNU-120596 co-application, but it also had the highest agonist 
activity. Conversely, ICH-12 possessed a good silent agonism, with a potentiated response 
6-fold greater than the acetylcholine control and a non-detectable agonism. Consequently, 
because of the optimum ratio of silent agonist over agonist activity, ICH-12 resulted to be 
the best candidate to be further manipulated and it was selected as model compound for 
designing the new silent derivatives. To identify the best portion of the molecule to which 
address the modifications, the structure of ICH-12 was divided into three major fragments: 
the quinuclidine ring, the Δ2-isoxazoline nucleus and the benzyl moiety. The quinuclidine 
ring, common to two out of four tested compounds, was hypothesized to be relevant for 
silent agonism and it was therefore preserved in the new designed derivatives. Similarly, 
the heterocyclic isoxazoline ring was maintained since prevalently present in the emerged 
compounds. The benzyl moiety of ICH-12 represents the most variable portion within the 
analysed set of compounds and therefore, the planned modifications were addressed to 
this fragment. In particular, preserving the spiro quinuclidinyl-Δ2-isoxazoline core as key 
element, novel derivatives 9a-h and 10a-h (Figure 25) arose by introduction of different 
suitable substituents in the meta position of the phenyl ring analogously to the silent 
compound NS6740. The substituent groups introduced were selected according to their 
different nature and represent a reasonable set of diversification in terms of electrostatic 
properties, bonding interactions and bulky features, thus potentially able of establishing 
putative additional interaction within the alpha7 binding pocket. The new derivatives were 
designed either as protonatable tertiary amines or permanently charged quaternary methyl 
ammonium salts. The trifluoromethyl group is present in the structure of the known alpha7 
silent agonists NS-6740 and it was therefore the first substituent introduced on the benzyl 
ring (9a and 10a). To investigate the potential influence of halogen bond interactions over 
the silent agonist activity of the parent compound, derivatives 9b-e and 10b-e were 
designed by inserting the different halogen atoms in the meta position of the aromatic 
moiety. Furthermore, a methyl group (9f and 10f) as bioisosteric replacement of the 
trifluoromethyl group and a methoxide group (9g and 10g) as fragment able of accepting 
hydrogen-bond interactions were introduced. Finally, the naphthalene (9h and 10h) moiety 
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was picked to evaluate whether the binding pocket of the receptor would bear a greater 
steric hindrance and still preserve the silent agonist activity.  
 
 
 
Figure 25. Structures of target compounds related to ICH-12 as novel potential alpha7 silent agonists.  
 
   
2.2.2.2 Quinuclidine-1,2,4-oxadiazole derivatives 
To further explore the pharmacophore requirements for alpha7 silent agonism, a 
second series of quinuclidine-related compounds (11a-m and 12a-m, Figure 26) was 
designed. In comparison with the previous series, the new derivatives differs in the nature 
of the central portion of the scaffold, bearing a 1,2,4-oxadiazole ring instead of an 
isoxazoline one. Noteworthy, the 1,2,4-oxadiazole ring was chosen according to the 
structural and spatial determinants of the known silent agonist NS-6740. The distances 
between the basic core and the atom with hydrogen bond properties of NS-6740 are 
maintained in the new derivatives. With respect to the 2-isoxazoline system, the additional 
nitrogen atom of the 1,2,4-oxadiazole nucleus should contribute to investigate the 
relevance of hydrogen bonding in the receptor interaction of this pharmacophoric region. 
The quinuclidine basic core was preserved as positively charged centre and was linked 
through a methylene bridge to the position 5 of the oxadiazole which is connected in 
position 3 to an aliphatic/aromatic substituent. In particular, suitably substituted phenyl 
rings and heteroaromatic cores (i.e. pyridine, furan and thiophene) were linked to the 1,2,4-
oxadiazole nucleus. The phenyl ring linked to the oxadiazole moiety was substituted with 
trifluoromethyl, fluoro, chloro, bromine and iodine groups, respectively 11a-e and 12a-e, in 
comparison with the previous set of compounds. The corresponding oxadiazoles derivatives 
of ICH-12 was designed as well, therefore unsubstituted phenyl compounds (11f and 12f) 
were planned and synthesized, and besides the methyl and methoxide derivatives (11g-h 
and 12g-h) were introduced. To evaluate the influence of a different side aromatic centre, 
analogues containing heteroaromatic rings, like pyridine, furan and thiophene were 
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selected and introduced in position 3 of the oxadiazoles ring (11j-m and 12j-m). The target 
compounds wer designed either as protonatable tertiary amines or quaternary methyl 
ammonium salts. 
 
 
Figure 26. Structures of target compounds containing the 1,2,4-oxadiazole nucleus as novel potential 
alpha7 silent agonists.  
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3.1 Synthetic approaches to the PAM derivatives  
3.1.1 5-Hydroxyindole derivatives 
3.1.1.1 Synthesis of compounds 1a-g 
The novel N-aryl 5-hydroxyindole-related derivatives 1a-g were achieved through 
the two steps general synthetic approach depicted in Schemes 1, following known 
literature procedures that have been optimized depending on the aryl group introduced. 
The key step for the synthesis was represented by a copper-catalyzed Ullmann-type aryl 
amination between commercially available 5-methoxyindole (13) and the appropriate aryl 
halide, a reaction largely exploited to obtain N-arylindoles, promoted and accelerated by 
the alpha-amino acid. [66, 67, 68, 69]  Among the different amino acids, proline was the 
best choice because of its low reactivity toward coupling with aryl halides. [67] Therefore, 
the key reaction step to derivatives 1a-g was performed by treating 13 with the 
conveniently substituted aryl halides in presence of the catalytic complex formed by copper 
iodide and D-proline. The reaction proceeded smoothly and afforded the desired coupled 
intermediates 20-22 and 24 in quite good yields (29-74%).  
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Alternatively, amine derivatives 23 and 25 were prepared by reacting 5-methoxyindole (13) 
and the appropriate aryl halides in presence of N,N’-dimethylethylenediamine, a ligand 
evenly able to promote the nitrogen-carbon bond formation as well as the alpha-amino 
acids. [70] Attempts to obtain intermediate 26, applying both the synthetic routes 
illustrated, failed, also when protection of the hydroxyl group was introduced. Therefore, 
compound 1g was not achieved. Cleavage of the methoxide protecting group in strong 
acidic conditions afforded the desired final compounds 1a-f. [71] Compound 1f quickly 
degraded to a violet oil even under argon atmosphere at -20°C and, consequently, it was 
not submitted to pharmacological assays. 
When the coupling reaction involved a methylated aniline, the aryl halide of interest was 
obtained from the corresponding aromatic amine through a reductive amination in 
presence of formaldehyde and sodium borohydride (Scheme 2). [72] This protocol allowed 
to selectively achieve mono-methylation of the aniline to give 14-17. Methyl anilines 14 and 
15 were reacted with 13 to obtain derivatives 23 and 25, whereas 16 and 17, here 
described, were reacted with only N-Boc-5-methoxy-2-indolylboronic acid (27) to obtain 
derivatives 35 and 36 of the next series of 5-hydroxyindole derivatives 2a-m. 
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3.1.1.2 Synthesis of compounds 2a-m and 3 
As shown in Scheme 3, to obtain compounds 2a-m, the synthetic key step is 
represented by a Suzuki cross-coupling reaction between the commercially available N-Boc-
5-methoxy-2-indolylboronic acid (27) and the appropriate aryl halides, by using the 
palladium catalyst tetrakis(triphenylphosphine)palladium(0) in basic medium. [73]  
 
 
 
The reaction conditions illustrated allowed achieving the coupling intermediates 28-40 in 
good to excellent yields (39-100%). The methyl anilines 14-17 to obtain derivatives 31, 33, 
35 and 36 were synthesized as previously mentioned (Scheme 2). [72] Conversely, for 
intermediates 38 and 39, the benzenesulfonamides 18 and 19 were synthesized in 
quantitative yields starting from the corresponding sulfonyl chloride and the appropriate 
amine, according to the procedure reported in Scheme 4. [74]  
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Methoxide and Boc groups were simultaneously removed by treatment of 
intermediates 28-40 with a solution of boron tribromide to provide the target compounds 
2a–m.  
Finally, compound 3 was synthesized applying the Suzuki coupling to the Boc intermediate 
41, quantitately prepared from 4-bromopyrazole according to a common literature 
procedure, [75] followed by the usual deprotection (Scheme 5). 
 
 
 
3.1.1.3 Synthesis of compounds 4a-b 
The synthetic route to indole derivatives 4a and 4b is illustrated in Scheme 6. 
Despite the several procedures reported in literature, [76, 77] direct iodination of the 
carbon 2 of 5-methoxyindole was not successful. Therefore, the iodide intermediate 43 was 
obtained by treatment of the boronic acid 27 with N-iodosuccinimide (NIS) in acetonitrile. 
[78, 79]  Subsequent Sonogashira coupling between 43 and trimethylsilylacetylene in 
presence of bis(triphenylphosphine)palladium(II) dichloride, copper iodide and 
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trimethylamine afforded the protected alkyne derivate 44 quantitatively. In order to obtain 
the free alkyne key intermediate 45, the silyl protecting group of 44 was removed in strong 
acidic condition by treatment with tetrabutylammonium fluoride.  
 
 
 
The 1,3-dipolar cycloaddition between the dienophile alkyne 45 and the 
appropriate nitrile oxides, in situ by dehydrochlorination of the corresponding hydroximoyl 
chlorides, [80] led to the formation of the corresponding 3,5-disubstituted-1,2-isoxazole 47 
and 48. Hydroximoyl chlorides are the stable precursor of the 1,3-dipole nitrile oxide and 
are readily prepared by treating the corresponding aldehyde oxime with 
benzyl(trimethyl)ammonium tetrachloroiodate (BTMA ICl4). [65] Finally, the methoxide and 
Boc groups, were cleaved by reacting intermediates 47 and 48 with boron tribromide, 
affording the desired compounds 4a and 4b. 
 
 
 
CHAPTER III – Chemistry 
 
 
43 
3.1.2 Genistein derivatives 5a-c 
The synthetic approaches to the novel genistein-related derivatives 5a-c, adapted 
from known literature procedures, are depicted in Schemes 7 and 8. Attempts to obtain an 
enamino ketone by reacting N,N-dimethylformamide dimethyl acetal directly with 49 were 
not successful, presumably because dimethylformamide dimethyl acetal is capable of 
reacting with phenols. [81, 82] Therefore, protection of two hydroxyl substituents in the 
triol moiety was considered to be crucial. Scheme 7 illustrates the general optimized 
synthetic approach applied to achieve the desired key intermediate 3-iodochromone 52 
through a three steps synthetic procedure. Commercially available trihydroxyacetophenone 
49 was first protected by treatment with 2-methoxyethoxymethyl chloride (MEMCl) and 
N,N-diisopropylethylamine (DIPEA) to give the desired protected intermediate 50, which 
was subsequently and quantitatively converted into the corresponding enamino ketone 51 
by reaction with dimethylformamide dimethyl acetal (DMF/DMA). The reaction was 
explored heating either with the support of the microwaves or in routine conditions (oil 
bath), and no significant differences were observed. In presence of iodine, 51 underwent 
tandem cyclization and iodination to provide 52. [81]  
 
 
 
In addition to the desired product, the reaction with iodine caused the formation of 
a phenyl ring iodinated by-product. The amount of by-product was limited, even if not 
completely avoided, by reducing the amount of iodine added from an equimolar to 0.9:1 
ratio with intermediate 51 and its portionwise addition to the reaction mixture. The 3-
iodochromone 52 is a key intermediate in the synthesis of the isoflavones because of the 
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excellent electrophilic properties of iodine and its strategic position next to the double 
bond, which favor palladium catalyzed Suzuki reaction to insert the final ring of the 
isoflavones (Scheme 8). [83] Compound 52 was reacted with the appropriate phenyl 
boronic acid in basic medium using palladium on charcoal as catalyst to give the 
corresponding protected intermediates 53-55. If not commercially available, boronic acid 
intermediates were obtained reacting the corresponding aryl halides with triisopropyl 
borate. [84] 
 
 
 
Cleavage of the ether MEM protecting groups of intermediates 53-55 to afford the target 
compounds 5a-c was performed in strong acidic conditions, in presence of hydrochloric acid 
or boron tribromide. Refluxing 53 with concentrate hydrochloric acid provided the model 
compound genistein which was synthesized to obtain comparable pharmacological data. 
Depending on the different reaction conditions, deprotection of the intermediate 54 
afforded derivatives 5a or 5b: treatment with boron tribromide led to cleavage of both the 
MEM and the methoxide groups thus affording 5a, while, by reaction with concentrate 
hydrochloric acid, cleavage of only MEM groups was achieved leading to 5b. Finally, the 
aminoalchol 5c, together with salification of the aniline, was obtained from intermediate 55 
by using hydrochloric acid. 
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3.2 Synthetic approaches to the Silent agonist derivatives 
3.2.1 diEPP derivatives 
3.2.1.1 Synthesis of compounds 6a-u 
The experimental work on diEPP derivatives described in this thesis has been carried out in 
Gainesville (FL, USA) under the supervision of Dr. Nicole A. Horenstein during my one year 
stay at the Department of Chemistry, University of Florida as a visiting researcher.  
diEPP derivative 6a-q and 6t-u were synthesized applying the two steps synthetic protocol 
depicted in Scheme 9.  
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The key reaction involved the appropriate substituted aryl halides and 1-
ethylpiperazine, which were reacted in a copper-catalyzed Ullman-type reaction to obtain 
formation of a carbon-nitrogen bond in presence of the catalytic complex formed by copper 
iodide and L-proline, accordingly to a procedure previously mentioned, to provide the 
coupled intermediates 57-75. Depending on the different reactivity of the halides towards 
the coupling reaction, potassium carbonate or potassium phosphate tribasic was used as 
base. Indeed, aryl bromides, being less reactive, need stronger basic condition to efficiently 
undergo the desired coupling. [66, 67, 68, 69] The coupling reaction was inhibited by 
sterically hindered aryl halides, like ortho-substituents (59 and 69), and this inhibition 
resulted to be greater compared to N-aryl-5-hydroxyindoles. Aryl iodides usually provided 
better coupling yields (52-83%) than bromides (20-64%). The coupled piperazines 57-75 
were converted into the corresponding quaternary ammonium salts 6a-q and 6t-u by 
reaction with iodoethane. The carboxamide derivatives 6r and 6s were obtained by 
hydration of the corresponding nitriles 6p and 6s in presence of acetaldoxime and 
tetrakis(triphenylphosphine)palladium(0) (Scheme 10). [85]  
 
 
 
3.2.1.2 Synthesis of compound 7 
To achieve the phenylamino diEPP analogue 7 (Scheme 11), commercially available 
1-ethyl-4-piperidone and aniline underwent a one-pot reductive amination in presence of 
sodium cyanoborohydride, at pH 6-7, to give intermediate 76. [86] The pH discriminates the 
ratio of reduction between imine and carbonyl compounds induced by sodium 
cyanoborohydride: at pH of 3-4 carbonyl compounds are readily reduced to alcohols, while 
at 6-7 reductive amination selectively happens. [87] Protection of the aromatic amino 
group of 76 was obtained with trifluoroacetic anhydride (TFAA) and triethylamine, [88] 
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affording intermediate 77, which was subsequently reacted with iodoethane to provide the 
quaternary ammonium salt 78. Finally, cleavage of the trifluoroacetyl group refluxing 78 
with potassium carbonate in a mixture of methanol-water [88, 89] led the desired final 
compound 7. 
 
 
3.2.1.3 Synthesis of compound 8 
The diEPP derivative 8 was synthesized according to the synthetic procedure 
reported in Scheme 12, with the key step being represented by the Wittig-Horner reaction 
between 1-ethyl-4-piperidone and diethyl benzylphosphonate in presence of sodium 
hydride and [15-crown-5] to give the alkene intermediate 79. [90] The crown ether was 
found to be essential to accelerate the reaction rate by complexing the cation from sodium 
hydride. The olefinated product 79 was then converted into the corresponding quaternary 
ammonium salt by treatment with iodoethane, affording the final product 8. 
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3.2.2 Quinuclidine derivatives 
3.2.2.1 Synthesis of compounds 9a-h and 10a-h 
The key intermediate to derivatives 9a-h and 10a-h is represented by bromo-Δ2–
isoxazoline 83, synthesized exploiting a 1,3-dipolar cycloaddition-based approach by 
reacting the dipolaphile 81 and the 1,3-dipole nitrile oxide, in situ generated from its stable 
precursor 1,1-dibromoformaldoxime (82) (Scheme 13). [64]  
 
 
 
Quinuclidin-3-one underwent a Wittig-Horner reaction with the appropriate ylide in a basic 
medium to afford quantitatively the alkene derivative 80. Without further purification, 3-
methylenequinuclidine 80 was subsequently reacted with borane in tetrahydrofuran 
complex to obtain the corresponding boranyl protected intermediate 81. The boron 
complex 81 was converted into the spirocyclic derivative 83 by virtue of a 1,3-dipolar 
cycloaddition reaction with 82, synthesized from glyoxylic acid, in presence of potassium 
carbonate. [64] The key intermediate 83 underwent, in basic medium, efficient nucleophilic 
displacement of the bromine atom by suitably meta-substituted benzyl alcohols to provide 
the corresponding isoxazolines 84-90 and the free base derivative 94 (Scheme 14).  
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The nucleophilic substitution reaction between 83 and the appropriate alcohol fairly 
proceeded in presence of sodium hydride. The synthesis of 94 was performed with 
potassium carbonate in acetonitrile and directly afforded the tertiary amine base since the 
cleavage of the boranyl group occurred simultaneously. Treatment of intermediates 84-90 
with trifluoroacetic acid in acetone readily afforded the corresponding quinuclidine free 
bases 91-93 and 95-98 in quantitative yields. [64] Tertiary amines 91-98 were treated with 
fumaric acid to provide the related crystalline salts 9a-h or, alternatively, with methyl 
iodide to give the corresponding methyl quaternary ammonium salts 10a-h (Scheme 15). 
[64] 
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3.2.2.2 Synthesis of compounds 11a-m and 12a-g 
Derivatives 11a-m and 12a-m were synthesized exploiting the procedure depicted 
in Schemes 16-20. First, quinuclidin-3-one was converted into methyl quinuclidinylidene 
acetate 99 by means of a Wittig-Horner reaction with trimethyl phosphonoacetate and 
sodium hydride (Scheme 16). [91] The Wittig olefination provided the desired alkene in a 
mixture of the two isomers (E) and (Z), which were not separated and directly treated with 
hydrogen in presence of palladium on charcoal catalyst to achieve reduction of the olefinic 
double bond and obtain intermediate 100. [92]  
 
 
 
Similarly to the previous series approach, protection of the basic center of the 
quinuclidine ring with borane complex provided the N-boranyl methyl ester 101. When the 
protection was performed on intermediate 99, the subsequent reduction hardly occurred, 
while cleavage of the boranyl protecting group happened. The key step to the final 
compounds 11a-m and 12a-m is represented by a cycloaddition reaction between methyl 
ester 101 and variously substituted amidoximes 102-114 (Figure 27). At first, methyl ester 
100 was directly reacted with the appropriate amidoxime to gain the corresponding 1,2,4-
oxadiazole derivative, but poor reaction yields and tricky purification steps occurred. 
The appropriate amidoximes 102-114 were either purchased or readily and quantitatively 
synthesized from the corresponding nitrile precursors according to a general standard 
literature procedure, by refluxing them with hydroxylamine (Scheme 17). [91]  
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Figure 27. Amidoximes used in the synthesis of 1,2,4-oxadiazoles derivatives. 
 
Oxadiazole intermediates 115-126 were synthesized, according to the general protocol 
depicted in Scheme 18, by reacting the free quinuclidine base ester 100 or the N-boranyl 
methyl ester 101 with the appropriate amidoxime in presence of an excess of a base, either 
sodium hydride or cesium carbonate. While successfully affording the oxadiazole 
compound in most cases (115, 123-126), sodium hydride protocol provided intermediates 
116-121 only in traces (less than 10% yield) and 122 poorly. Therefore, for compounds 116-
122 the use of cesium carbonate was successfully explored and the coupling reaction of 
amidoximes 103-109 with the methyl ester 101 proceeded smoothly, affording the desired 
1,2,4-oxadiazole intermediates 116-122 in high yields. Besides providing the desired 
derivatives in greater quantities, cesium carbonate allowed the reaction to occur in non-
anhydrous conditions and in presence of air atmosphere.  
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Treatment of intermediates 115-126 with trifluoroacetic acid in acetone afforded the 
quinuclidinyl free bases 127-139 quantitatively, which were then reacted either with 
fumaric acid or methyl iodide in methanol to give, respectively, the desired final fumaric 
salts 11a-m (Scheme 19) or the quaternary methyl ammonium derivatives 12a-g (Scheme 
20). The planned methyl derivative 12h-m have not been achieved yet. 
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4.1 General pharmacological considerations 
The pharmacological assays performed on the novel derivatives synthesized during 
this experimental PhD project were carried out in the research group coordinated by Prof. 
Roger L. Papke at the Department of Pharmacology and Therapeutics, College of Medicine, 
University of Florida, Gainesville. Here are reported the pharmacological results available 
only for some target compounds, because many derivatives are still under investigation. 
The alpha 7 activity profile of the tested compounds was evaluated in 
electrophysiological assays using human alpha7 nAChRs expressed in Xenopus oocytes and 
two electrode voltage clamping. 
As previously mentioned in the introduction chapter, the relationship between the 
peak current and the net charge evoked by agonist application to the alpha7 receptor 
depends on the effective agonist concentration applied. This phenomenon is ascribable to 
the concentration-dependent desensitization of this receptor subtype induced by high 
levels of agonist bind site occupancy and permits to estimate the EC50 (half maximal 
effective concentration) and Imax (maximal inhibition) values for a tested drug from the 
single-concentration responses evoked by application of the compound. [93] For each 
compound, the ratio of net charge to peak current allows estimation of the functional 
concentration, which correspond to the EC50 for that compound. The efficacy of a 
compound can be estimated from the comparison between the net charge response of the 
compound to the expected value of net charge response obtained by a full agonist applied 
at the estimated functional concentration. In the investigation of the agonist activity of a 
novel compound, the experiments were carried out using acetylcholine at a concentration 
of 60 µM as full agonist; this specific concentration corresponds to the EC80 for the net 
charge response of ACh. Therefore, peak currents and net charges measured for a specific 
compound and normalized for the ACh control offer an idea of the relationship between 
the compound concentration tested (i.e. 30 µM) and its EC80. The concentration of the 
tested compound which leads to a ratio of the normalized measures equaled one would 
correspond to the same effective concentration as 60 µM ACh. The potency of a compound 
tested at a specific concentration can be estimated by the relative value of the net charge 
response and varies independently from the compound efficacy. Specifically, compounds 
with a high peak current to net charge ratio, but small net charge are likely to be less 
efficacious than less potent. The explanation for the present consideration derive from the 
alpha7 receptor synchronization which causes extremely sharp peak responses with 
minimal net charge area, [25] resulting in an over-estimation of the response when 
evaluated considering the peak current. 
 Depending on the specific aim of the investigation, the electrophysiological assays 
performed followed different protocols and the main features are here summarized.  
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ALPHA7 AGONIST ACTIVITY. Experiments to test the agonist activity of a compound 
consist in two initial controls, the test and a control at the end. All the controls involve 
application of ACh at a concentration of 60 µM, while the test consists in application of 30 
µM of the compound. The average response of the two initial controls is taken as reference 
value to normalize the compound response. The concentration of 30 µM proved to the best 
value for testing the compound since it is high enough to provide a detectable response 
and low enough to avoid possible complications, like channel blocking. Finally, the control 
at the end of the test aims at determining the desensitization or rundown of the alpha7 
receptor. For the generation of a concentration-response curve (CRC), ACh controls and 
experimental compounds applications alternated. The responses evoked at the alpha7 
nAChR were quantified as peak current and net charge and analyzed. 
POSITIVE ALLOSTERIC MODULATION OF THE ALPHA7 nAChR. Experiments to test 
the allosteric modulation induced by the tested compound consist in the evaluation of first 
the agonist profile followed by the proper allosteric modulation. The test to assess the 
agonist activity is performed in the same conditions depicted in the previous subchapter, 
applying 30 µM of tested compound. In the investigation of the allosteric component, the 
test aims at determining the rate of potentiation in the receptor response evoked by the 
putative allosteric modulator co-application. The test consists of two initial controls, the 
test and a control at the end. All the controls involve application of ACh at a concentration 
of 60 µM, while the test consists in a co-application of 60 µM of ACh with usually 30 µM of 
tested compound, or even higher compound concentrations. The average response of the 
two initial controls is taken as reference value to normalize the compound response. 
Finally, the control at the end of the test aims at determining the desensitization or 
rundown of the alpha7 receptor. For the generation of a concentration-response curve 
(CRC), ACh controls and experimental compound co-applications alternated. The responses 
evoked at the alpha7 nAChR were quantified as peak current and net charge and analyzed. 
SILENT AGONISM OF THE ALPHA7 nAChR. In order to evaluate the silent agonism 
profile of the novel derivatives, the partial agonism activity and the potentiated response in 
presence of the type II PAM PNU-120596 were quantified and compared. The induction of 
PAM-sensitive desensitization, typical of a silent agonist, was detected evaluating the net 
charge response evoked by co-application of the tested compound PNU-120596. In details, 
experiments consist in two initial controls, the test and a control at the end. All the controls 
involve application of ACh at a concentration of 60 µM, while the test consists in a co-
application of 30 µM of the compound with 10 µM of PNU-120596. The average response 
of the two initial controls is taken as reference value to normalize the compound response. 
Finally, the control at the end of the test aims at determining the desensitization or 
rundown of the alpha7 receptor. The corresponding values were reported relative to the 
control response evoked by 60 µM ACh alone. The responses evoked at the alpha7 nAChR 
were quantified as peak current and net charge and analyzed. 
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4.2 Pharmacological evaluation of 5-hydroxyindole derivatives  
The alpha7 nAChR profile of the target 5HI N-aryl derivatives 1a-e was defined 
according to the experimental procedures described in the general section and the results 
are reported in Table 1. 
 
 
Table 1. Electrophysiological data of derivatives 1a-e on human alpha7 nAChRs expressed in 
Xenopus oocytes. Data are reported as mean ± SEM (standard error of mean) and relative to the 
control ACh. Agonist response refers to receptor response to 30 M application of test compound. 
Agonist potentiated response refers to receptor response with 60 M ACh (agonist) and 30 M test 
compound co-application. 
 
The set of data collected on human alpha7 nAChRs expressed by Xenopus oocytes 
suggests that linking a variously substituted aromatic ring on the nitrogen atom of 5-
hydroxyindole (5-HI) does not lead to improvement of the parent compound PAM activity. 
Indeed, despite not showing agonist activity at the receptor subtype of interest, the tested 
compounds were not able to further improve the 5-HI agonist potentiated response. 
However, derivatives 1a, 1b and 1d displayed a PAM activity comparable to the one of the 
reference compound 5-HI, suggesting that the PAM binding pocket of the alpha7 receptor 
well tolerate bulky groups on the indole moiety. 
 
The activity profile of the novel 5HI C-aryl derivatives 2a-g was investigated 
according to the experimental procedures described in the general section and the results 
are reported in Table 2 and Table 3. 
Differently from the N-aryl series, electrophysiological assays data performed on 5-
hydoxyindole derivatives 2a-g showed interesting results. In particular, 2b (4-hydroxy-2-
methylphenyl), 2f (2-chloro-4-(methylamino)phenyl) and 2g (2-chloro-4-hydroxyphenyl) 
derivatives showed enhanced PAM activity compared to the parent compound, thus 
suggesting that the modifications in C-2 position of the indole system are favourable. Polar 
substituents in the para position of the aryl ring are well-tolerated, but not sufficient to 
induce PAM activity improvement. Indeed, all derivatives 2a-g are characterized by the 
presence of polar groups in para, but only the few of them with an additional substitution 
in the ortho position display enhanced PAM activity (2b, 2f, and 2g). Noteworthy, para 
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substitution per se as well as primary aniline lead to suppression of the allosteric 
component (see data on compounds 2c-e). From these experimental evidences it is possible 
to hypothesize that di-substituted phenyl rings linked to position 2 of 5-HI lead to 
potentiation of the PAM activity of the parent compound. In particular, the best results 
were obtained with hydroxyl or methylamino groups in para and methyl or chloro groups in 
ortho of the aromatic ring, leading to compound 2b which shows a potentiated activity (net 
charge) (2.386±0.159) double of the parent compound 5-HI (1.252±0.112) and comparable 
to the one of genistein (2.733± 0.162). 
 
 
Table 2. Electrophysiological data of derivatives 2a-g on human alpha7 nAChRs expressed in 
Xenopus oocytes. Data are reported as mean ± SEM (standard error of mean) and relative to the 
control ACh. Agonist response refers to receptor response to 30 M application of test compound. 
Agonist potentiated response refers to receptor response with 60 M ACh (agonist) and 30 M test 
compound co-application. 
 
The most promising compounds were tested at different concentrations (Table 3) 
and the corresponding CRCs were generated (Figure 28). According to the data collected, all 
the three derivatives showed better PAM activity compared to the reference compound at 
any of the concentrations tested. Compound 2g is more potent and about twice as 
efficacious as 5-HI, while derivatives 2b and 2f are far more efficacious than the parent 
compound, but not much more potent.  
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Table 3. CRCs Electrophysiological data of derivatives 2b, 2f and 2g on human alpha7 
nAChRs expressed in Xenopus oocytes. Data are reported as mean ± SEM (standard error of mean) 
and relative to the control ACh. Agonist potentiated response refers to receptor response with 60 M 
ACh (agonist) and the reported concentration of the test compound co-application. 
 
 
 
 
Figure 28. Net-charge responses collected in CRCs experiments performed in oocytes 
expressing human 7 receptors for derivatives 2b, 2f and 2g compared to 5-HI. 
 
CRCs data further confirmed the improvement in positive allosteric modulation achieved 
with the new derivatives 2b, 2f and 2g, both in potency and in efficacy and therefore the 
relevance of substitutions in ortho and para positions of the phenyl ring. Starting from 
them, new modifications were addressed to these highlighted positions by introducing 
different polar groups in para and methyl or halogens in ortho, thus obtaining compounds 
2h-m, as previously mentioned in the aim section. These new derivatives, together with 3 
and 4a-b, are currently under investigation to evaluate their PAM activity. 
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4.3 Pharmacological evaluation of genistein derivatives  
The potential positive allosteric modulatory profile of the novel genistein-related 
derivatives 5a-c was investigated according to the general protocols illustrated in the 
general pharmacological consideration section and the results are summarized in Table 4. 
The parent compound genistein was included in the series for comparison.  
The novel derivatives were first assessed to determine the corresponding agonist activity. 
Ideally, the agonist activity of a compound planned to be a PAM should be very low, if not 
equal to zero. In the case of the present compounds, all the new genistein-related 
derivatives did not show agonism towards the alpha7 nAChR subtype, therefore becoming 
candidates for PAM activity investigation.  
 
Table 4. Electrophysiological data of derivatives 5a-c on human alpha7 nAChRs expressed in 
Xenopus oocytes. Data are reported as mean ± SEM (standard error of mean) and relative to the 
control ACh. Agonist response refers to receptor response to 30 M application of test compound. 
Agonist potentiated response refers to receptor response with 60 M ACh (agonist) and 30 M test 
compound co-application. 
 
As reported in Table 4, co-application of the tested compound (30 M) with the control 
represented by the agonist acetylcholine (60 M) did not lead to any improvement in the 
PAM activity compared to the parent compound genistein, which remains the best PAM of 
the series. Indeed, derivatives 5a-c, when co-applied with ACh, evoked an alpha7 
potentiated response lower than the one evoked by genistein. In the least two cases (5b 
and 5c) no potentiation occurred, since for these two compounds, the net charges 
measured after co-application with ACh equal the responses evoked by ACh alone. Only 
compound 5a was able to induce potentiation in the agonist evoked response, showing a 
potentiated response close to the one of the parent compound (0.66-fold of the genistein 
potentiation). Indeed, substitutions with either methoxide or amino groups lead to 
suppression of the PAM activity of the compound.  
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4.4 Pharmacological evaluation of diEPP derivatives  
 The activity profile of diEPP derivatives 6a-u, 7 and 8 synthesized was evaluated 
according to the experimental procedures highlighted in the general chapter and the results 
are summarized in Tables 5. The parent compound diEPP was included in the series for 
comparison. [57]  
 
Table 5. Electrophysiological data of diEPP derivatives 6a-u, 7 and 8 on human alpha7 
nAChRs expressed in Xenopus oocytes. Data are reported as mean ± SEM (standard error of mean) 
and relative to the control ACh. Agonist response refers to receptor response to 30 M application of 
test compound. Potentiated response refers to receptor response with 30 M test compound and 10 
M PNU-120596 co-application. 
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According to these results, the electrophysiological profile of the novel diEPP derivatives 
6a-u is greatly influenced by the nature and sensitive to the position of the aryl substituent. 
Indeed, the tested compounds exhibited a broad range of activities at the alpha7 receptor 
subtype, including partial agonism and various degrees of silent agonism, while some 
compounds were effectively inactive, displaying no agonism and very weak silent agonism. 
 
Partial agonists  
Among the tested compounds, some derivatives emerged as partial agonists of the 
alpha7 nAChR. Compounds 6c (ortho-methyl), 6k (para-chloro), 6m (ortho-chloro), 6n 
(para-bromo), 6p (para-cyano), 6t (meta-hydroxy) and 6u (2-naphthalene) were identified 
as alpha7 partial agonists according to their ability to evoke a net charge response, when 
applied alone, greater than the threshold value of a tenth of the ACh control (Table 6).  
 
 
Table 6. Electrophysiological data of diEPP derivatives, emerged as partial agonists, on 
human alpha7 nAChRs expressed in Xenopus oocytes. Data are reported as mean ± SEM (standard 
error of mean) and relative to the control ACh. Agonist response refers to receptor response to 30 M 
application of test compound.  
 
According to the considerations previously introduced about the alpha7 receptor 
pharmacology, at a specific functional concentration, a partial agonist would have net 
charges responses lower than that predicted for a full agonist. As depicted in Table 3, 
compounds 6c, 6k, 6m, 6n, 6p, 6t and 6u have a ratio peak current to net charge lower than 
one, thus confirming their partial agonism profile. Among this set of compounds, the 6k 
(para-chloro) and 6u (2-naphthalene) diEPP derivatives presented the greatest peak current 
to net charge ratios, therefore they are the most potent partial agonists of the series. Being 
a partial agonist, the meta-hydroxyl compound 6t, suggested a unique hydrogen bond 
interaction of the phenolic group capable of inducing a conducting state of the alpha7 
receptor. Based on the observations concerning the estimation of potency and efficacy 
from peak currents and net charges evoked at the alpha7 receptor, compound 6c (ortho-
methyl) and compound 6m (ortho-chloro) are the most efficacious diEPP derivatives of the 
series, suggesting that ortho-substituents of the diEPP moiety promoted alpha7 partial 
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agonism. Indeed, despite not having the best estimated potency, they show the highest net 
charge responses. Insertion of a naphthalene group (6u) on the diEPP structure was meant 
to investigate the endurance of the alpha7 binding pocket towards groups with a greater 
bulkiness. The partial agonism activity of the compound suggests larger groups promote 
conductive states of the receptor.  
 
Inactive compounds  
 Within the diEPP set of compounds synthesized, four derivatives showed no 
significant activity at the selected nicotinic receptor subtype. Indeed, compounds 6b (meta-
methyl), 6e (meta-methoxide), 6f (ortho, para-methoxide), 6j (meta-fluoro) and 6q (meta-
cyano) lacked of both the partial agonist and the silent agonist activities (Table 7).  
 
Table 7. Electrophysiological data of inactive diEPP derivatives on human alpha7 nAChRs 
expressed in Xenopus oocytes. Data are reported as mean ± SEM (standard error of mean) and 
relative to the control ACh. Agonist response refers to receptor response to 30 M application of test 
compound. Potentiated response refers to receptor response with 30 M test compound and 10 M 
PNU-120596 co-application. 
 
 
Silent agonists  
 Within the diEPP series, several substitutions on the aromatic ring of the parent 
compound led to compounds exhibiting the desired alpha7 silent agonism profile, with little 
or no partial agonism activity, and a potentiated response evoked by PNU-120596 greater 
than the parent compound diEPP (Table 8). Compounds 6a (para-methyl), 6d (para-
methoxide), 6g (para-trifluoromethyl), 6h (meta-trifluoromethyl), 6i (para-fluoro), 6l (meta-
chloro), 6o (meta-bromo), 6r (para-carboxamide) and 6s (meta-carboxamide) emerged as 
alpha7 silent agonists. The two diEPP derivatives 7 and 8, characterized by a piperidine 
instead of a piperazines ring, showed enhanced alpha7 silent agonism compared to the 
parent compound, thus suggesting that the nitrogen atom of the N-aryl bond does not play 
an essential role in silent agonism within the diEPP framework. [57]  
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Table 8. Electrophysiological data of diEPP derivatives, emerged as silent agonists, on 
human alpha7 nAChRs expressed in Xenopus oocytes. Data are reported as mean ± SEM (standard 
error of mean) and relative to the control ACh. Agonist response refers to receptor response to 30 M 
application of test compound. Potentiated response refers to receptor response with 30 M test 
compound and 10 M PNU-120596 co-application. Highlighted the best silent agonists of the series. 
 
The results collected on the alpha7 receptor suggested that the substituents 
introduced on the aromatic ring of the parent compound diEPP influenced the silent 
agonism activity by means of different effects. Compared to the reference compound 
diEPP, enhancement of the silent agonism may arise from either decrement of the agonism, 
increase of the potentiated PNU-120596 response induced by greater induction and 
stabilization of the desensitized state, or both effects.  
By modifications of the diEPP moiety several derivatives with enhanced silent agonism 
were achieved and, in particular, the best results were obtained with substitutions 
addressed to the meta and the para positions of the aromatic ring involving small-to-
medium size groups. In particular, compounds 6g (para-trifluoromethyl), 6i (para-fluoro), 6r 
(para-carboxamide) and 6s (meta-carboxamide) showed the best silent agonism profile of 
the series (Figure 29). Despite being quite different in the possible interactions with the 
receptor binding site, in the diEPP series the trifluoromethyl group, fluorine atoms and 
carboxamides greatly enhanced the alpha7 silent agonist activity of the parent compound. 
To attribute the observed profile to a specific common effect, the properties of these 
functional groups were examined: 
 polarity: it was the first property considered due to the presence of fluorine in 6g and 6i, 
and oxygen or amino groups in 6r and 6s. However, polarity by itself is not sufficient to 
fully explain enhanced silent agonism, since not all polar groups induced this behavior, 
i.e. the hydroxyl group of derivative 6t; 
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 lipophilicity: in previously reported cases, fluorine and the trifluoromethyl groups 
proved to enhance the lipophilicity of a compound. [94] If enhanced lipophilicity was the 
key to silent agonism improvement, substituents like methyl would increase the silent 
agonist activity compared to the parent compound, but, within the tested series, both 
meta- (6b) and ortho-methyl (6c) derivatives failed to effectively promote the desired 
profile, further supporting the hypothesis of polar interactions involved in the silent 
activity; 
 hydrogen bonding: it takes part to protein-ligand binding and while carboxamide groups 
are known to be good hydrogen bond acceptors, fluorine does not really participate to 
them. Therefore, if hydrogen bonds were the reasons for the observed profile, 
carboxamides would show greater improvement than the other groups, and this is not 
the case.  
 
 
 
 Figure 29. Electrophysiological data of the best silent agonists of the diEPP series. Normalized 
response refers to receptor response to 30 M application of test compound. Normalized potentiated 
response to receptor response with 30 M test compound and 10 M PNU-120596 co-application. 
Data are reported as net charge mean ± SEM (standard error of mean) and relative to the control 
ACh. 
 
The enhanced silent agonism achieved with trifluoromethyl, fluoro and 
carboxamide groups arose from a combination of multifactorial effects, which bear in 
common the ability to selectively stabilize the desensitized state of the alpha7 receptor 
sensitive to PNU-120596 conferred by point-to-point interactions between the tested 
compounds and the binding pocket of the receptor.  
Introduction of a halogen group in the meta position of the diEPP aromatic moiety 
produced intriguing results and the potentiated response with PNU co-application 
increased from fluoro to chloro to bromo diEPP derivatives, therefore halogen bonding 
interactions were accounted for silent agonism. The halogen bond consists in a noncovalent 
interaction occurring between a covalently bonded halogen atom and a negatively charged 
atom in another molecule. [95, 96] Polarizability and electronegativity of the halogen 
involved affect the strength of the resulting bond: the greater halogen polarizability and the 
lower the electronegativity of the halogen give rise to the stronger halogen bonds, and the 
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potency of the halogen bond interaction increases in the order fluorine-chlorine-bromine-
iodine. [97, 98] Fluorine is the least polarizable and the most electronegative halogen, and 
therefore the least prone to form halogen bonds. Considering the meta-substituted diEPP 
derivatives, the potentiated responses evoked by PAM co-application increased from 
fluorine (6j), to hydrogen (diEPP parent compound), to chlorine (6l), to bromine (6o). The 
observed trend is consistent with the halogen-bond interaction hypothesis between the 
compound and an appropriate electron-donor residue within the receptor binding pocket. 
According to this hypothesis, electron-rich or electron-donating substituents in the meta 
position would show low silent agonism profile, and diEPP derivatives data support this 
statement. Indeed, meta-methoxide (6e) and meta-cyano (6q) diEPP derivatives showed 
PAM-dependent responses respectively half and equivalent to the one evoked by the 
parent compound.  
Conversely to the meta position, chlorine and bromine substitutions in the ortho or 
the para positions did not result in compounds characterized by the silent agonism profile, 
but rather in partial agonists. The para-fluoro (6i) and the para-trifluoromethyl (6g) diEPP 
derivatives, however, represent two of the best silent agonists of the series, thus indicating 
a unique behavior of fluorine groups, difficult to explain in absence of high resolution 
structure. [94] However, the most likely hypothesis to explain the activity showed by 
fluorine diEPP relies on the fluorine bond.  
In some cases, when the quaternary ammonium diEPP derivative appeared as a 
silent agonist, the corresponding tertiary amine was investigated. The activities of the 
selected ethyl phenyl piperazines 63 (para-trifluoromethyl), 65 (para-fluoro), 68 (meta-
chloro) and 71 (meta-bromo) are reported in Table 9. These compounds were mostly 
inactive at the alpha7 receptor, with no partial agonism and weak responses evoked by 
PAM co-application. Within these tertiary amine compounds, compound 71 showed a silent 
agonist activity 5-fold greater than the parent compound and close to the corresponding 
quaternary derivative. Consistent with these results, the permanent positive charge is not 
mandatory for silent agonist activity, when suitable structural features are present 
independently from the core charged nitrogen. The present statement becomes particularly 
relevant in the development of silent agonists required to cross the blood-brain barrier to 
explicate their therapeutic functions. However, in order to target the peripheral immune 
system to exert anti-inflammatory activities, quaternary ammonium salts of the series 
emerged as better candidates according to their superior silent agonism profile.  
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Table 9. Comparison between tertiary amine and quaternary ammonium salts of some silent 
agonists of the diEPP series. . Electrophysiological data of diEPP derivatives, emerged as silent 
agonists, on human alpha7 nAChRs expressed in Xenopus oocytes. Data are reported as mean ± SEM 
(standard error of mean) and relative to the control ACh. Agonist response refers to receptor 
response to 30 M application of test compound. Potentiated response refers to receptor response 
with 30 M test compound and 10 M PNU-120596 co-application. 
 
Aiming at investigating the alpha7 silent agonism profile with structural 
modifications of the diEPP moiety, compounds 7 and 8 were synthesized to test the 
influence of the nitrogen atom in the piperazine ring attached to the phenyl group on the 
silent agonism. In both cases, the tested compounds showed enhanced PNU-120596 
potentiation compared to the parent compound, with 7 been superior for the better ratio 
of desensitization to residual partial agonism compared to 8. Indeed, compound 7 evoked a 
partial agonism response not detectable within experimental error. The more flexibility 
conferred by the amino bridge to compound 7 with respect to the methylene bridge of 
compound 8 may be ascribable for the observed difference. 
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5.1 Materials and methods 
1H and 13C NMR spectra were recorded on a Varian Mercury-300 (300 and 75 MHz, 
respectively) or Varian Inova-500 (500 and 126 MHz) instruments. Chemical shifts (δ scale) 
are reported in parts-per-million (ppm) and coupling constants (J) in hertz (Hz). For each 
compound analyzed, the specific deuterated solvent (CDCl3, CD3OD, (CD3)2CO, or (CD3)2SO) 
used is reported. Chemical shifts ( scale) are reported in parts per million (ppm) relative to 
the peak of the internal standard TMS ( = 0.00 ppm) for CDCl3, CD3OD, (CD3)2CO or relative 
to the central peak of the solvent ( = 2.50 ppm for (CD3)2SO) in 1H NMR and relative to the 
central peak of the solvent ( = 77.16 ppm for CDCl3, 49.00 for CD3OD, 39.52 for (CD3)2SO 
(DMSO-d6), and 29.84 for (CD3)2CO) in 13C NMR. Processing of the spectra was performed 
with MestReNova 8.1.1. 
Mass spectra (ESI-MS) were registered with Varian 320 LC-MS/MS instrument, on a 
Hewlett-Packard 5988A spectrometer or on an Agilent 6220 ESI TOF (Santa Clara, CA) mass 
spectrometer equipped with electrospray and DART sources operated in positive ion mode. 
Data are reported as mass/charge ratio (M/Z).  
Melting points were obtained on a Büchi Mod. B 540 instrument or on an MFB-
595010M Gallenkamp apparatus equipped with a digital thermometer, and not corrected.  
Reactions were monitored by TLC analyses performed on commercial silica gel 60 
F254 aluminium sheets/glass plates (Merck or EMD Millipore) or neutral alumina TLC plates 
(Fluka). Unless otherwise noted, the TLC analyses were performed on silica gel sheets/glass 
plates. Spots were observed with UV-lamp (λ = 365 nm) and/or evidenced with different 
TLC stains: a solution of KMnO4 in 0.1 N NaOH, a 5% solution of phosphomolybdic acid in 
ethanol and, for amines and quaternary ammonium salts, Dragendorff reagent (a solution 
of KBiI4 in CH3COOH and H2O).  
Column chromatographies were performed on silica gel Sigma-Aldrich (230-400 
mesh) or neutral alumina as stationary phase; eluents have been specified time to time. 
All reagents were of reagent quality or were purified before use. Organic solvents 
for the reactions were of analytical grade or were purified by standard procedures. Several 
reactions were carried out in anhydrous condition (flame-dried glassware) and under inert 
(argon or nitrogen) atmosphere; those conditions are implied whenever in the synthetic 
procedure dry solvents are listed. 
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5.2 Synthesis of PAM derivatives 
5.2.1 5-Hydroxyindole derivatives  
5.2.1.1 General procedure for N-methylation of anilines (14-17)  
The appropriate aniline (1 equiv) was dissolved in MeOH under argon atmosphere. 
Formaldehyde 37% (5 equiv) and sodium methoxide (5 equiv) were subsequently added. 
The reaction mixture was heated to reflux (65°C) for 2h and then cooled to 0°C with an ice 
bath. Sodium borohydride (5 equiv) was then slowly added. The reaction mixture was 
heated to reflux again for 1h and monitored by TLC in cyclohexane/EtOAc 4:1. Upon 
completion, the mixture was cooled to room temperature, concentrated under reduced 
pressure, slowly diluted with water and then extracted with EtOAc (x 3). The organic layers 
were combined, dried over Na2SO4, filtered and concentrated in vacuo to give the desired 
methylated compound quantitatively. 
5.2.1.2 General procedure for the synthesis of sulfonamides (18-19)  
To a solution of the appropriate sulfonyl chloride in acetonitrile (0.10 mL/mmol 
sulfonyl chloride), cooled at 0°C, the appropriate amine was added dropwise. The resulting 
mixture was stirred at room temperature till complete consumption of the starting 
materials (which usually occurred within 10 min), then diluted with deionized water and 
extracted with EtOAc (x 3). The combined organic phases were dried over Na2SO4, filtered 
and concentrated under reduced pressure to provide the pure desired compound in 
quantitative yields. 
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4-iodo-N-methylaniline (14) 
The title compound was prepared according to general 
procedure 5.2.1.1 by reacting 4-iodoaniline (865 mg, 3.95 mmol,  
1 equiv), formaldehyde 37% (1.47 mL, 19.75 mmol, 5 equiv) and 
sodium borohydride (747 mg, 19.75 mmol, 5 equiv). Evaporation of 
the solvent afforded the desired compound as a yellow oil  
(909 mg, yield 99%). 
 
14: yellow oil; TLC (PMA): Rf = 0.55 (cyclohexane/EtOAc 4:1).  
1H NMR (CDCl3, 300 MHz) δ 7.45 (d, J = 8.3 Hz, 2H), 6.40 (d, J = 8.3 Hz, 2H), 3.72  
(br s, 1H), 2.80 (s, 3H). 
13C NMR (CDCl3, 75 MHz) δ 148.7, 137.6, 114.6, 77.6, 30.5. 
 
 
3-chloro-4-iodo-N-methylaniline (15) 
The title compound was prepared according to general 
procedure 5.2.1.1 by reacting 3-chloro-4-iodoaniline (1 g, 3.95 
mmol, 1 equiv), formaldehyde 37% (1.47 mL, 19.75 mmol,  
5 equiv) and sodium borohydride (747 mg, 19.75 mmol, 5 equiv). 
Evaporation of the solvent afforded the desired compound as a 
yellow oil (1.01 g, yield 96%). 
 
15: yellow oil; TLC (PMA): Rf = 0.51 (cyclohexane/EtOAc 4:1). 
1H NMR (CDCl3, 300 MHz) δ 7.53 (d, J = 8.7 Hz, 1H), 6.73 (d, J = 2.7 Hz, 1H), 6.26  
(dd, J = 8.7, 2.7 Hz, 1H), 4.16 (br s, 1H), 2.81 (s, 3H). 
13C NMR (CDCl3, 75 MHz) δ 150.3, 139.9, 138.7, 113.1, 112.7, 80.5, 30.5. 
 
 
4-bromo-N,3-dimethylaniline (16) 
The title compound was prepared according to general 
procedure 5.2.1.1 by reacting 4-bromo-3-methylaniline (300 mg, 
1.61 mmol, 1 equiv), formaldehyde 37% (600 L, 8.05 mmol, 5 
equiv) and sodium borohydride (305 mg, 8.05 mmol, 5 equiv). 
Evaporation of the solvent afforded the desired compound as a 
yellow oil (296 mg, yield 92%). 
 
16: yellow oil; TLC (PMA): Rf = 0.42 (cyclohexane/EtOAc 9:1). 
1H NMR (CDCl3, 300 MHz) δ 7.31 (d, J = 8.6 Hz, 1H), 6.49 (d, J = 2.8 Hz, 1H), 6.33  
(dd, J = 8.6, 2.9 Hz, 1H), 3.65 (br s, 1H), 2.81 (s, 3H), 2.35 (s, 3H). 
13C NMR (CDCl3, 75 MHz) δ 148.7, 138.1, 132.6, 114.7, 111.6, 111.5, 30.7, 23.1. 
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4-bromo-2-chloro-N-methylaniline (17) 
The title compound was prepared according to general 
procedure 5.2.1.1 by reacting 4-bromo-2-chloroaniline (300 mg, 
1.45 mmol, 1 equiv), formaldehyde 37% (540 L, 7.25 mmol,  
5 equiv) and sodium borohydride (274 mg, 7.25 mmol, 5 equiv). 
Evaporation of the solvent afforded the desired compound as a 
yellow oil (313 mg, yield 98%). 
 
17: yellow oil; TLC (PMA): Rf = 0.51 (cyclohexane/EtOAc 4:1). 
1H NMR (CDCl3, 300 MHz) δ 7.22 (d, J = 1.7 Hz, 1H), 7.09 (dd, J = 8.7, 1.6 Hz, 1H), 6.32 (d, J = 
8.7 Hz, 1H), 4.21 (br s, 1H), 2.70 (s, 3H). 
13C NMR (CDCl3, 75 MHz) δ 144.1, 131.0, 130.5, 119.5, 111.6, 107.2, 30.2. 
 
 
4-bromo-3-methylbenzenesulfonamide (18) 
The title compound was prepared according to general 
procedure 5.2.1.2 by reacting 4-bromo-3-methylbenzene-1-
sulfonyl chloride (200 mg, 0.75 mmol, 1 equiv) and aqueous 
ammonia (340 L) in acetonitrile (80 L). Evaporation of the 
solvent afforded the desired compound as a yellow oil  
(184 mg, yield 98%). 
 
18: yellow oil; TLC (PMA): Rf = 0.42 (cyclohexane/EtOAc 9:1). 
1H NMR (CDCl3, 300 MHz) δ 7.72 (d, J = 2.2 Hz, 1H), 7.61 (d, J = 8.3 Hz, 1H), 7.52 (dd, J = 8.4, 
2.1 Hz, 1H), 4.86 (br s, 2H), 2.40 (s, 3H). 
13C NMR (CD3OD, 75 MHz) δ 144.4, 140.3, 134.0, 129.8, 129.2, 126.1, 23.0. 
 
 
4-bromo-N,3-dimethylbenzenesulfonamide (19) 
The title compound was prepared according to general 
procedure 5.2.1.1 by reacting 4-bromo-3-methylbenzene-1-
sulfonyl chloride (200 mg, 0.75 mmol, 1 equiv) and methylamine 
solution 40% in water (350 L) in acetonitrile (80 L). 
Evaporation of the solvent afforded the desired compound as a 
yellow oil (190 mg, yield 96%). 
 
19: yellow oil; TLC (PMA): Rf = 0.42 (cyclohexane/EtOAc 9:1). 
1H NMR (CDCl3, 300 MHz) δ 7.66 (d, J = 2.1 Hz, 1H), 7.60 (d, J = 8.3 Hz, 1H), 7.46 (dd, J = 8.4, 
2.3 Hz, 1H), 4.97 (br s, 1H), 2.57 (s, 3H), 2.39 (s, 3H). 
13C NMR (CDCl3, 75 MHz) δ 139.6, 138.0, 133.2, 130.1, 129.2, 126.0, 29.3, 23.1. 
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5.2.1.3 Experimental procedures for the synthesis of 1a-f 
5.2.1.3.1 General procedure for N-arylation of 5-methoxyindole 
(20-26)  
5.2.1.3.1.1: The coupling reaction was carried out under inert argon atmosphere. 5-
methoxyindole (13) (1.1 equiv), K2CO3 (2.5 equiv), CuI (0.05 equiv) and D-proline (0.1 equiv) 
were dissolved in DMSO (2 mL/mmol arylbenzene). The mixture was gently heated to 110°C  
(± 5°C) under an inert atmosphere for 20 min, then the appropriate aryl halide (1 equiv) 
was added dropwise. The reaction was stirred at 110°C till complete consumption of the 
starting materials. Upon completion, the cooled solution was first filtered through a Celite 
pad, then partitioned between EtOAc and deionized water, and the aqueous layer extracted 
with EtOAc (x 3). The combined organic phases were washed with brine, dried over Na2SO4, 
filtered and concentrated under reduced pressure. The crude material was subsequently 
purified by silica gel column chromatography to give the pure product. 
5.2.2.3.1.2: The coupling reaction was carried out under inert argon atmosphere. 5-
methoxyindole (13) (1 equiv, 1M), K3PO4 (2.1 equiv), CuI (0.05 equiv),  
N,N’-dimethylethylenediamine (0.2 equiv) and the appropriate aryl halide (1.2 equiv) were 
dissolved in dry THF. The mixture was gently heated to 80°C (± 5°C) under an inert 
atmosphere till complete consumption of the starting materials. Upon completion (48h), 
the cooled solution was diluted with EtOAc, filtered through a plug of silica gel and eluted 
with EtOAc. The filtrate was concentrated under reduced pressure and then the crude 
material was purified by silica gel column chromatography to provide the pure product. 
 
5.2.1.3.2 General procedure for demethylation (1a-f)  
The reaction was carried out in anhydrous conditions and under inert argon 
atmosphere. To a stirred solution of the appropriate methoxy derivative (1 equiv) in dry 
CH2Cl2 (5.5 mL/mmol methoxy derivative), cooled at -78°C, 1M BBr3 in hexanes (3 
equiv/methoxy group) was added dropwise. The reaction mixture was stirred at -78°C for 
1.5h and then at RT for 12h. Upon completion, the reaction was cooled at 0°C, quenched by 
the addition of 5% aqueous solution of Na2CO3 and extracted with CH2Cl2/i-PrOH 9:1 (x 3). 
The combined organic layers were washed with brine, dried over Na2SO4, filtered, and 
evaporated under reduced pressure. The crude material was purified by silica gel column 
chromatography eluting in CH2Cl2/MeOH to afford the pure product. 
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5-methoxy-1-(4-methoxyphenyl)-1H-indole (20) 
The title compound was prepared according 
to general procedure 5.2.1.3.1.1 by reacting  
5-methoxyindole (13) (800 mg, 5.44 mmol, 1.1 equiv) 
and 4-iodoanisole (1.16 g, 4.95 mmol, 1 equiv). Upon 
completion (TLC in cyclohexane/EtOAc 9:1), standard 
workup was applied and the crude material was 
purified by silica gel column chromatography eluting 
in cyclohexane/EtOAc 95:5 to give the pure product 
as a yellow oil (925 mg, yield 74%).  
20: yellow oil; TLC (KMnO4; PMA): Rf = 0.33 (cyclohexane/EtOAc 9:1). 
1H NMR (CDCl3, 300 MHz) δ 7.31 (d, J = 8.9 Hz, 2H), 7.27 (d, J = 9.0 Hz, 1H), 7.18  
(d, J = 3.2 Hz, 1H), 7.06 (d, J = 2.5 Hz, 1H), 6.95 (d, J = 8.9 Hz, 2H), 6.79 (dd, J = 8.9, 2.5 Hz, 
1H), 6.50 (d, J = 3.2 Hz, 1H), 3.80 (s, 6H). 
13C NMR (CDCl3, 75 MHz) δ 158.1, 154.5, 133.0, 131.6, 129.5, 128.7, 125.6, 114.7, 112.4, 
111.2, 102.6, 55.8, 55.5. 
 
 
1-(4-hydroxyphenyl)-1H-indol-5-ol (1a) 
The title compound was prepared according 
to general procedure 5.2.1.3.2 by reacting 20  
(925 mg, 3.65 mmol, 1 equiv) and 1M BBr3 in 
hexanes (22 mL, 22 mmol, 6 equiv) in dry CH2Cl2. 
Upon completion (TLC in CH2Cl2/MeOH 95:5), 
standard workup was applied and the crude material 
was purified by silica gel column chromatography 
eluting in CH2Cl2/MeOH 98:2 to give the pure 
product as a white solid (286 mg, yield 35%). 
1a: white solid; TLC (KMnO4; PMA): Rf = 0.40 (CH2Cl2/MeOH 95:5); m.p.: 141.9°C;  
MS (ESI) m/z for C14H12NO2+ [M+H]+ calcd. 226.1, found 226.0. 
1H NMR (CD3OD, 300 MHz) δ 7.08 (d, J = 8.7 Hz, 3H), 7.04 (d, J = 3.1 Hz, 1H), 6.90  
(d, J = 1.9 Hz, 1H), 6.79 (d, J = 8.7 Hz, 2H), 6.61 (dd, J = 8.8, 2.1 Hz, 1H), 6.29 (d, J = 2.7 Hz, 
1H). 
13C NMR (CD3OD, 75 MHz) δ 157.0, 151.8, 133.3, 132.7, 131.2, 129.7, 126.6, 117.0, 112.8, 
111.7, 105.9, 102.7.  
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5-methoxy-1-(4-methoxy-2-methylphenyl)-1H-indole (21) 
The title compound was prepared according 
to general procedure 5.2.1.3.1.1 by reacting  
5-methoxyindole (13) (1 g, 6.79 mmol, 1.1 equiv) and  
4-bromo-3-methylanisole (1.24 mg, 6.17 mmol,  
1 equiv). Upon completion (TLC in 
cyclohexane/EtOAc 95:5), standard workup was 
applied and the crude material was purified by silica 
gel column chromatography eluting in 
cyclohexane/EtOAc 98:2 to give the pure product as 
a brown oil (483 mg, yield 29%).  
21: brown oil; TLC (KMnO4; PMA): Rf = 0.39 (cyclohexane/EtOAc 95:5). 
1H NMR (CDCl3, 300 MHz) δ 7.09 (d, J = 8.5 Hz, 1H), 7.03 (d, J = 2.3 Hz, 1H), 6.98  
(d, J = 3.1 Hz, 1H), 6.80 (d, J = 8.9 Hz, 1H), 6.76 (d, J = 2.8 Hz, 1H), 6.74 – 6.67 (m, 2H), 6.45 
(dd, J = 3.1, 0.5 Hz, 1H), 3.74 (s, 3H), 3.72 (s, 3H), 1.90 (s, 3H). 
13C NMR (CDCl3, 75 MHz) δ 159.2, 154.4, 137.4, 132.8, 131.4, 129.6, 129.2, 128.6, 116.2, 
112.3, 111.9, 111.3, 102.5, 101.9, 55.9, 55.5, 17.9. 
 
 
1-(4-hydroxy-2-methylphenyl)-1H-indol-5-ol (1b) 
The title compound was prepared according 
to general procedure 5.2.1.3.2 by reacting 21  
(100 mg, 0.37 mmol, 1 equiv) and 1M BBr3 in 
hexanes (2.25 mL, 2.25 mmol, 6 equiv) in dry CH2Cl2. 
Upon completion (TLC in CH2Cl2/MeOH 98:2), 
standard workup was applied and the crude material 
was purified by silica gel column chromatography 
eluting in CH2Cl2/MeOH 98:2 to give the pure 
product as a white solid (61 mg, yield 69%). 
1b: white solid; TLC (KMnO4; PMA): Rf = 0.30 (CH2Cl2/AcOEt 93:7); m.p.: 58.1-61.4°C;  
MS (ESI) m/z for C15H14NO2+ [M+H]+ calcd. 240.1, found 240.0. 
1H NMR (CD3OD, 300 MHz) δ 6.93 (d, J = 3.2 Hz, 1H), 6.90 (dd, J = 4.4, 1.3 Hz, 1H), 6.88 (d, J 
= 2.2 Hz, 1H), 6.68 (d, J = 2.8 Hz, 1H), 6.65 – 6.57 (m, 2H), 6.55 (dd, J = 8.8, 2.3 Hz, 1H), 6.29 
(d, J = 3.1 Hz, 1H), 1.77 (s, 3H). 
13C NMR (CD3OD, 75 MHz) δ 158.3, 151.7, 138.4, 133.9, 131.5, 130.6, 130.3, 130.1, 118.2, 
114.4, 112.7, 111.7, 105.7, 102.0, 17.6.  
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4-(5-methoxy-1H-indol-1-yl)aniline (22) 
The title compound was prepared according 
to general method 5.2.1.3.1.1 by reacting  
5-methoxyindole (13) (1.30 g, 8.83 mmol, 1.1 equiv) 
and 4-iodoaniline (1.76 g, 8.03 mmol, 1 equiv). Upon 
completion (TLC in cyclohexane/EtOAc 4:1), standard 
workup was applied and the crude material was 
purified by silica gel column chromatography eluting 
in cyclohexane/EtOAc 85:15 to give the pure product 
as a brown oil (1.04 g, yield 54%).  
22: brown oil; TLC (KMnO4; PMA): Rf = 0.25 (cyclohexane/EtOAc 4:1). 
1H NMR (CDCl3, 300 MHz) δ 7.20 (d, J = 8.9 Hz, 1H), 7.11 – 7.03 (m, 3H), 7.01  
(d, J = 1.7 Hz, 1H), 6.78 – 6.69 (m, 1H), 6.56 (dd, J = 8.5, 1.4 Hz, 2H), 6.44 – 6.39 (m, 1H), 
3.72 (s, 3H), 3.54 (br s, 2H). 
13C NMR (CDCl3, 75 MHz) δ 154.3, 145.3, 131.8, 130.9, 129.3, 128.9, 125.7, 115.6, 112.2, 
111.3, 102.6, 102.1, 55.9. 
 
 
1-(4-aminophenyl)-1H-indol-5-ol (1c) 
The title compound was prepared according 
to general procedure 5.2.1.3.2 by reacting 22 (1.04 g, 
4.36 mmol, 1 equiv) and 1M BBr3 in hexanes  
(13.1 mL, 13.08 mmol, 3 equiv) in dry CH2Cl2. Upon 
completion (TLC in CH2Cl2/MeOH 95:5), standard 
workup was applied and the crude material was 
purified by silica gel column chromatography eluting 
in CH2Cl2/MeOH 98:2 to give the pure product as a 
white solid (476 mg, yield 49%). 
1c: white solid; TLC (KMnO4; PMA): Rf = 0.31 (CH2Cl2/MeOH 98); m.p.: 134.0-135.7°C;  
MS (ESI) m/z for C14H13N2O+ [M+H]+ calcd. 225.1, found 225.0. 
1H NMR ((CD3)2SO, 300 MHz) δ 8.78 (br s, 1H), 7.33 (d, J = 3.1 Hz, 1H), 7.17  
(d, J = 8.8 Hz, 1H), 7.13 (d, J = 8.6 Hz, 2H), 6.90 (d, J = 1.8 Hz, 1H), 6.69 (d, J = 8.7 Hz, 2H), 
6.64 (dd, J = 8.9, 2.3 Hz, 1H), 6.38 (dd, J = 3.1, 0.6 Hz, 1H), 5.24 (br s, 2H). 
13C NMR ((CD3)2SO, 75 MHz) δ 151.1, 147.4, 130.4, 129.3, 128.8, 128.1, 124.9, 114.3, 111.8, 
110.6, 104.4, 101.1. 
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4-(5-methoxy-1H-indol-1-yl)-N-methylaniline (23) 
The title compound was prepared according 
to general procedure 5.2.1.3.1.2 by reacting  
5-methoxyindole (13) (400 mg, 2.72 mmol, 1 equiv) 
and 4-iodo-N-methylaniline (14) (760 mg, 3.26 mmol,  
1.2 equiv). Upon completion (TLC in 
cyclohexane/CH2Cl2 1:1), standard workup was 
applied and the crude material was purified by silica 
gel column chromatography eluting in 
cyclohexane/CH2Cl2 3:2 to afford the desired product 
as a yellow oil (244 mg, yield 36%). 
23: yellow oil; TLC (KMnO4; PMA): Rf = 0.28 (cyclohexane/EtOAc 9:1). 
1H NMR (CDCl3, 300 MHz) δ 7.25 (d, J = 8.9 Hz, 1H), 7.18 (d, J = 8.8 Hz, 2H), 7.14  
(d, J = 3.4 Hz, 1H), 7.04 (d, J = 2.4 Hz, 1H), 6.76 (dd, J = 8.9, 2.4 Hz, 1H), 6.60 (d, J = 8.8 Hz, 
2H), 6.46 (dd, J = 3.1, 0.8 Hz, 1H), 3.78 (s, 3H), 2.79 (s, 3H). 
13C NMR (CDCl3, 75 MHz) δ 154.4, 148.1, 132.0, 130.0, 129.3, 129.0, 126.0, 112.9, 112.3, 
111.4, 102.6, 102.0, 56.0, 31.0. 
 
1-(4-(methylamino)phenyl)-1H-indol-5-ol (1d) 
The title compound was prepared according 
to general procedure 5.2.1.3.2 by reacting 23 (244 
mg, 0.97 mmol, 1 equiv) and 1M BBr3 in hexanes  
(2.9 mL, 2.90 mmol, 3 equiv) in dry CH2Cl2. Upon 
completion (TLC in CH2Cl2/MeOH 95:5), standard 
workup was applied and the crude material was 
purified by silica gel column chromatography eluting 
in CH2Cl2/MeOH 98:2 to give the pure product as an 
off-white solid (70 mg, yield 30%). 
1d: off-white solid; TLC (KMnO4; PMA): Rf = 0.34 (CH2Cl2/MeOH 98:2); m.p.: 61.5°C;  
MS (ESI) m/z for C15H15N2O+ [M+H]+ calcd. 239.1, found 239.0. 
1H NMR (CDCl3, 300 MHz) δ 7.22 – 7.14 (m, 3H), 7.13 (d, J = 3.1 Hz, 1H), 6.97  
(d, J = 2.4 Hz, 1H), 6.67 – 6.58 (m, 3H), 6.39 (d, J = 3.1 Hz, 1H), 4.23 (br s, 2H), 2.78 (s, 3H). 
13C NMR (CDCl3, 75 MHz) δ 149.7, 147.9, 132.1, 130.2, 129.6, 129.4, 126.0, 113.2, 111.8, 
111.3, 105.3, 101.7, 31.1.  
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3-chloro-4-(5-methoxy-1H-indol-1-yl)aniline (24) 
The title compound was prepared according 
to general method 5.2.1.3.1.1 by reacting  
5-methoxyindole (13) (800 mg, 5.44 mmol, 1.1 equiv) 
and 3-chloro-4-iodoaniline (1.26 g, 4.95 mmol, 1 
equiv). Upon completion (TLC in cyclohexane/EtOAc 
4:1), standard workup was applied and the crude 
material was purified by silica gel column 
chromatography eluting in cyclohexane/EtOAc 85:15 
to give the pure product as a brown oil  
(424 mg, yield 36%).  
24: brown oil; TLC (KMnO4; PMA): Rf = 0.23 (cyclohexane/EtOAc 4:1). 
1H NMR (CDCl3, 300 MHz) δ 7.08 – 7.01 (m, 3H), 6.89 (dd, J = 8.9, 0.5 Hz, 1H), 6.74 (dd, J = 
8.9, 2.4 Hz, 1H), 6.70 (d, J = 2.5 Hz, 1H), 6.52 – 6.44 (m, 2H), 3.76 (s, 3H), 3.61 (br s, 2H). 
13C NMR (CDCl3, 75 MHz) δ 154.4, 147.3, 132.8, 132.7, 130.2, 129.9, 128.7, 127.4, 115.9, 
113.8, 112.3, 111.4, 102.7, 102.2, 56.0. 
 
 
1-(4-amino-2-chlorophenyl)-1H-indol-5-ol (1e) 
The title compound was prepared according 
to general procedure 5.2.1.3.2 by reacting 3-chloro-
4-(5-methoxy-1H-indol-1-yl)aniline (24) (424 mg, 
1.55 mmol, 1 equiv) and 1M BBr3 in hexanes  
(4.65 mL, 4.65 mmol, 3 equiv) in dry CH2Cl2. Upon 
completion (TLC in CH2Cl2/MeOH 95:5), standard 
workup was applied and the crude material was 
purified by silica gel column chromatography eluting 
in CH2Cl2/MeOH 99:1 to give the pure product as a 
yellowish solid (76 mg, yield 19%). 
1e: yellowish solid; TLC (KMnO4; PMA): Rf = 0.49 (CH2Cl2/MeOH 95:5); m.p.: 133.1°C;  
MS (ESI) m/z for C14H12ClN2O+ [M+H]+ calcd. 259.1, found 259.0. 
1H NMR (CD3OD, 300 MHz) δ 7.12 – 7.06 (m, 2H), 6.96 (dd, J = 2.3, 0.5 Hz, 1H), 6.87 (d, J = 
2.5 Hz, 1H), 6.81 (dd, J = 8.7, 0.7 Hz, 1H), 6.73 – 6.63 (m, 2H), 6.41 (dd, J = 3.1, 0.8 Hz, 1H), 
3.76 – 3.63 (m, 0.3H, DIPE 13% residual), 1.12 (d, J = 6.1 Hz, 1.5H, DIPE 13% residual). 
13C NMR (CD3OD, 75 MHz) δ 151.9, 150.5, 133.9, 133.5, 131.0, 130.9, 130.4, 127.3, 116.3, 
114.7, 112.7, 111.8, 105.7, 102.3. 
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3-chloro-4-(5-methoxy-1H-indol-1-yl)-N-methylaniline (25) 
The title compound was prepared according 
to general procedure 5.2.1.3.1.2 by reacting  
5-methoxyindole (13) (124 mg, 0.84 mmol, 1 equiv) 
and 3-chloro-4-iodo-N-methylaniline (15) (271 mg,  
1.01 mmol, 1.2 equiv). Upon completion (TLC in 
cyclohexane/CH2Cl2 1:1), standard workup was 
applied and the crude material was purified by silica 
gel column chromatography eluting in 
cyclohexane/CH2Cl2 3:2 to  afford the desired 
product as a yellow oil (137 mg, yield 57%). 
25: yellow oil; TLC (KMnO4; PMA): Rf = 0.21 (cyclohexane/CH2Cl2 1:1). 
1H NMR (CDCl3, 300 MHz) δ 7.07 (d, J = 9.2 Hz, 1H), 7.04 (d, J = 1.1 Hz, 1H), 6.90  
(d, J = 8.9 Hz, 1H), 6.74 (dd, J = 8.9, 2.3 Hz, 1H), 6.61 (d, J = 2.6 Hz, 1H), 6.47 (dd, J = 3.1, 0.8 
Hz, 1H), 6.42 (dd, J = 8.6, 2.5 Hz, 1H), 3.76 (s, J = 4.0 Hz, 3H), 2.73 (s, 3H). 
13C NMR (CDCl3, 75 MHz) δ 154.4, 149.8, 133.0, 132.8, 130.0, 130.0, 128.6, 126.0, 112.7, 
112.2, 111.5, 111.3, 102.6, 102.0, 56.0, 30.6. 
 
 
1-(2-chloro-4-(methylamino)phenyl)-1H-indol-5-ol (1f) 
The title compound was prepared according 
to general procedure 5.2.1.3.2 by reacting 25  
(137 mg, 0.48 mmol, 1 equiv) and 1M BBr3 in 
hexanes (1.44 mL, 1.44 mmol, 3 equiv) in dry CH2Cl2. 
Upon completion (TLC in CH2Cl2/MeOH 98:2), 
standard workup was applied and the crude material 
was purified by silica gel column chromatography 
eluting in CH2Cl2/MeOH 99:1 to give the pure 
product as a white solid (26 mg, yield 20%),which 
resulted to be unstable and quickly degraded to a 
violet oil. 
1f: white solid (previous degradation); TLC (KMnO4; PMA): Rf = 0.36 (CH2Cl2/MeOH 98:2). 
1H NMR (CD3OD, 300 MHz) δ 7.02 (d, J = 8.6 Hz, 1H), 6.98 (d, J = 3.2 Hz, 1H), 6.86  
(d, J = 2.3 Hz, 1H), 6.71 (d, J = 8.7 Hz, 1H), 6.64 (d, J = 2.6 Hz, 1H), 6.56 (dd, J = 8.8, 2.3 Hz, 
1H), 6.50 (dd, J = 8.6, 2.6 Hz, 1H), 6.31 (d, J = 3.2 Hz, 1H), 2.70 (s, 3H). 
13C NMR (CD3OD, 75 MHz) δ 152.2, 151.9, 134.0, 133.8, 131.0, 130.4, 126.4, 113.2, 112.6, 
112.1, 111.8, 105.7, 102.3, 30.4.  
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5.2.1.4  Experimental procedures for the synthesis of 2a-m, 3 
and 4a-b 
5.2.2.4.1 General procedure for the Suzuki-Miyaura cross-
coupling (28-40 and 42)  
The coupling reaction was carried out under inert argon atmosphere. To a stirred 
and degassed solution of N-Boc-5-methoxy-2-indolylboronic acid (27) (1.4 equiv), 
appropriate aryl halide (1 equiv) and Pd(PPh3)4 (0.05 equiv) in 1,2-dimethoxyethane (18 
mL/mmol indole) was added a degassed aqueous  solution of 2M Na2CO3 (4.2 equiv). The 
resulting mixture was stirred at reflux (95-100°C) till complete consumption of the starting 
material. Upon completion (TLC cyclohexane/EtOAc), deionized water (13 mL/mmol indole) 
was added to the cooled solution, the organic layer was separated and the water phase was 
extracted with EtOAc (x 3). The combined organic phases were dried over Na2SO4, filtered 
and concentrated under reduced pressure. The crude material was purified by silica gel 
column chromatography to give the cross-coupling pure product. 
 
5.2.1.4.2 General procedure for demethylation and Boc cleavage 
(2a-m and 3)  
The reaction was carried out in anhydrous conditions and under inert argon 
atmosphere. To a stirred solution of the appropriate methoxy intermediate (1 equiv) in dry 
CH2Cl2 (5.5 mL/mmol methoxy intermediate), cooled at -78°C, 1M BBr3 in hexanes (3 
equiv/methoxy group, 1 equiv/Boc group) was added dropwise. The reaction mixture was 
stirred at -78°C for 1.5h and then at RT for 12h. Upon completion, the reaction was cooled 
at 0°C, quenched by the addition of 5% aqueous solution of Na2CO3 and extracted with 
CH2Cl2 (x 3). The combined organic layers were washed with brine, dried over Na2SO4, 
filtered and evaporated under reduced pressure. The crude material was subsequently 
purified by silica gel column chromatography to give the pure product. 
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tert-butyl 5-methoxy-2-(4-methoxyphenyl)-1H-indole-1-carboxylate (28)  
The title compound was prepared 
according to general procedure 5.2.1.4.1 by 
reacting N-Boc-5-methoxy-2-indolylboronic 
acid (27) (400 mg, 1.37 mmol, 1.4 equiv) 
with 4-iodoanisole (230 mg, 0.98 mmol, 1 
equiv). The mixture was heated at 95°C for 
2.5h. Upon completion (TLC cyclohexane/EtOAc 9:1), after standard workup, the crude 
material was purified by silica gel column chromatography eluting in cyclohexane/EtOAc 
97:3 to provide the pure product as a pale yellow oil (277 mg, yield 80%). 
28: pale yellow oil; TLC (KMnO4; PMA): Rf = 0.33 (cyclohexane/EtOAc 9:1). 
1H NMR (CDCl3, 300 MHz) δ 7.99 (d, J = 9.0 Hz, 1H), 7.24 (d, J = 8.8 Hz, 2H), 6.91 (d, J = 2.5 
Hz, 1H), 6.84 (dd, J = 9.0, 2.4 Hz, 3H), 6.34 (s, 1H), 3.76 (s, 3H), 3.75 (s, 3H), 1.27 (s, 9H). 
13C NMR (CDCl3, 75 MHz) δ 159.3, 156.1, 150.4, 141.2, 132.1, 130.2, 130.0, 127.5, 116.2, 
113.3, 112.8, 109.6, 102.9, 83.3, 55.8, 55.5, 27.8. 
 
 
2-(4-hydroxyphenyl)-1H-indol-5-ol (2a) 
The title compound was prepared 
according to general procedure 5.2.1.4.1 by 
reacting 28 (260 mg, 0.74 mmol, 1 equiv) 
with 1M BBr3 (6.66 mL, 6.66 mmol) in dry 
CH2Cl2. Upon completion (TLC in 
CH2Cl2/MeOH 95:5), standard workup was 
applied and the crude material was purified by silica gel column chromatography eluting in 
CH2Cl2/MeOH 95:5 to give the pure product as a white solid (94 mg, yield 57%). 
1a: white solid; TLC (KMnO4; PMA): Rf = 0.25 (CH2Cl2/MeOH 95:5); m.p.: 244°C (dec.);  
MS (ESI) m/z per C14H12NO2+ [M+H+]+ calcd. 226.1, found 226.1.  
1H NMR (CD3OD, 300 MHz) δ 7.48 (d, J = 8.6 Hz, 1H), 7.08 (d, J = 8.6 Hz, 1H), 6.79 (d, J = 2.3 
Hz, 1H), 6.74 (d, J = 8.7 Hz, 1H), 6.53 (dd, J = 8.6, 2.4 Hz, 1H), 6.38 (s, 1H), 3.25 (s, 0.16H, 5% 
MeOH residual)). 
13C NMR (CD3OD, 75 MHz) δ 158.0, 151.5, 140.5, 133.6, 131.5, 127.4, 126.0, 116.6, 112.2, 
111.9, 105.0, 97.5.  
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tert-butyl 5-methoxy-2-(4-methoxy-2-methylphenyl)-1H-indole-1-carboxylate (29) 
The title compound was prepared 
according to general procedure 5.2.1.4.2 by 
reacting N-Boc-5-methoxy-2-indolylboronic 
acid (27) (400 mg, 1.37 mmol, 1.4 equiv) 
with 4-bromo-3-methylanisole (140 L, 197 
mg, 0.98 mmol, 1 equiv). The mixture was 
heated at 95°C for 3h. Upon completion (TLC cyclohexane/EtOAc 9:1), after standard 
workup, the crude material was purified by silica gel column chromatography eluting in 
cyclohexane/EtOAc 98:2 to provide the pure product as a pale yellow oil (284 mg,  
yield 79%). 
29: pale yellow oil; TLC (KMnO4; PMA): Rf = 0.41 (cyclohexane/EtOAc 9:1). 
1H NMR (CDCl3, 300 MHz) δ 8.06 (d, J = 9.0 Hz, 1H), 7.08 (d, J = 8.2 Hz, 1H), 6.92 (d, J = 2.4 
Hz, 1H), 6.85 (dd, J = 9.0, 2.5 Hz, 1H), 6.73 – 6.62 (m, 2H), 6.26 (s, 1H), 3.76 (s, 3H), 3.73 (s, 
3H), 2.07 (s, 3H), 1.18 (s, 9H). 
13C NMR (CDCl3, 75 MHz) δ 159.6, 156.0, 150.2, 140.0, 138.8, 131.5, 130.7, 130.1, 127.9, 
116.4, 115.2, 112.7, 110.3, 109.6, 102.8, 82.8, 55.8, 55.4, 27.7, 20.4. 
 
 
2-(4-hydroxy-2-methylphenyl)-1H-indol-5-ol (2b) 
The title compound was prepared 
according to general procedure 5.2.1.4.2 by 
reacting tert-butyl 5-methoxy-2-(4-methoxy-
2-methylphenyl)-1H-indole-1-carboxylate 
(29) (260 mg, 0.71 mmol, 1 equiv) with 1M 
BBr3 (6.39 mL, 6.39 mmol, 9 equiv) in dry 
CH2Cl2. Upon completion (TLC in CH2Cl2/MeOH 95:5), standard workup was applied and the 
crude material was purified by silica gel column chromatography eluting in CH2Cl2/MeOH 
95:5 to give the pure product as a light yellow solid (93 mg, yield 55%). 
2b: light yellow solid; TLC (KMnO4; PMA): Rf = 0.30 (CH2Cl2/MeOH 95:5); m.p.: 199.5°C;  
MS (ESI) m/z per C15H14NO2+ [M+H+]+ calcd. 240.1, found 239.9.  
1H NMR (CD3OD, 300 MHz) δ 7.19 (d, J = 8.3 Hz, 1H), 7.08 (d, J = 8.6 Hz, 1H), 6.83 (d, J = 2.3 
Hz, 1H), 6.65 – 6.52 (m, 3H), 6.15 (s, 1H), 5.31 (s, 0.08H, 3% MeOH residual), 2.28 (s, 3H). 
13C NMR (CD3OD, 75 MHz) δ 157.8, 151.2, 140.1, 138.6, 132.9, 131.4, 131.0, 126.2, 118.3, 
113.8, 112.1, 111.8, 104.9, 101.5, 21.4.  
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tert-butyl 2-(4-aminophenyl)-5-methoxy-1H-indole-1-carboxylate (30) 
The title compound was prepared 
according to general procedure 5.2.1.4.1 by 
reacting N-Boc-5-methoxy-2-indolylboronic 
acid (27) (1 g, 3.44 mmol, 1.4 equiv) with 4-
iodoaniline (538 mg, 2.45 mmol, 1 equiv). 
The mixture was heated at 95°C for 2h. 
Upon completion (TLC cyclohexane/EtOAc 9:1), after standard workup, the crude material 
was purified by silica gel column chromatography eluting in cyclohexane/EtOAc 9:1 to 4:1 
to provide the pure product as a brown oil (334 mg, yield 40%). 
30: brown oil; TLC (KMnO4; PMA): Rf = 0.17 (cyclohexane/EtOAc 4:1). 
1H NMR (CDCl3, 300 MHz) δ 7.97 (d, J = 9.0 Hz, 1H), 7.12 (d, J = 8.2 Hz, 2H), 6.91 (d, J = 2.6 
Hz, 1H), 6.83 (dd, J = 9.0, 2.6 Hz, 1H), 6.63 (d, J = 8.3 Hz, 2H), 6.32 (s, 1H), 3.77 (s, 3H), 1.29 
(s,9H). 
13C NMR (CDCl3, 75 MHz) δ 156.0, 150.5, 145.9, 141.8, 132.1, 130.3, 129.9, 125.4, 116.1, 
114.6, 112.5, 109.1, 102.9, 83.2, 55.8, 27.9. 
 
 
2-(4-aminophenyl)-1H-indol-5-ol (2c) 
The title compound was prepared 
according to general procedure 5.2.1.4.2 by 
reacting tert-butyl 2-(4-aminophenyl)-5-
methoxy-1H-indole-1-carboxylate (30) (300 
mg, 0.89 mmol, 1 equiv) with 1M BBr3 (3.56 
mL, 3.56 mmol, 4 equiv) in dry CH2Cl2. Upon 
completion (TLC in CH2Cl2/MeOH 98:2), standard workup was applied and the crude 
material was purified by silica gel column chromatography eluting in CH2Cl2/MeOH 98:2 to 
give the pure product as a light-grey solid (80 mg, yield 40%). 
2c: light grey solid; TLC (KMnO4; PMA): Rf = 0.19 (CH2Cl2/MeOH 98:2); m.p.: 257.3°C (dec.); 
MS (ESI) m/z per C14H13N2O+ [M+H+]+ calcd. 225.1, found 225.0. 
1H NMR ((CD3)2SO, 300 MHz) δ 10.83 (s, 1H), 8.52 (s, 1H), 7.46 (d, J = 8.5 Hz, 2H), 7.09 (d, J = 
8.5 Hz, 1H), 6.75 (d, J = 2.0 Hz, 1H), 6.61 (d, J = 8.5 Hz, 2H), 6.51 (dd, J = 8.5, 2.3 Hz, 1H), 6.39 
(s, 1H), 5.23 (s, 2H). 
13C NMR ((CD3)2SO, 75 MHz) δ 150.6, 148.2, 139.5, 131.2, 129.8, 125.9, 120.2, 113.9, 111.0, 
110.3, 103.3, 94.9. 
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tert-butyl 5-methoxy-2-(4-(methylamino)phenyl)-1H-indole-1-carboxylate (31) 
The title compound was prepared 
according to general procedure 5.2.1.4.1 by 
reacting N-Boc-5-methoxy-2-indolylboronic 
acid (27) (1.45 g, 4.97 mmol, 1.4 equiv) with 
4-iodo-N-methylaniline (14) (827 mg, 3.55 
mmol, 1 equiv). The mixture was heated at 
95°C for 2h. Upon completion (TLC cyclohexane/EtOAc 9:1), after standard workup, the 
crude material was purified by silica gel column chromatography eluting in 
cyclohexane/EtOAc 9:1 to 85:15 to provide the pure product as a brown oil (486 mg,  
yield 39%). 
31: brown oil; TLC (KMnO4; PMA): Rf = 0.22 (cyclohexane/EtOAc 9:1).  
1H NMR (CDCl3, 300 MHz) δ 7.97 (d, J = 9.0 Hz, 1H), 7.22 – 7.14 (m, 3H), 6.91  
(d, J = 2.5 Hz, 1H), 6.83 (dd, J = 9.0, 2.6 Hz, 1H), 6.66 (d, J = 8.6 Hz, 2H), 6.33 (s, J = 0.6 Hz, 
1H), 3.78 (s, J = 7.5 Hz, 4H), 2.82 (s, 3H), 1.31 (s, J = 9.8 Hz, 9H). 
13C NMR (CDCl3, 75 MHz) δ 156.1, 150.5, 146.8, 141.7, 132.2, 130.3, 130.0, 126.0, 116.1, 
113.5, 112.6, 109.3, 102.9, 83.3, 55.8, 29.8, 27.9. 
 
 
2-(4-(methylamino)phenyl)-1H-indol-5-ol (2d) 
The title compound was prepared 
according to general procedure 5.2.1.4.2 by 
reacting tert-butyl 5-methoxy-2-(4-(methyl-
amino)phenyl)-1H-indole-1-carboxylate (31) 
(480 mg, 1.36 mmol, 1 equiv) with 1M BBr3 
(5.44 mL, 5.44 mmol, 4 equiv) in dry CH2Cl2. 
Upon completion (TLC in CH2Cl2/MeOH 98:2), standard workup was applied and the crude 
material was purified by silica gel column chromatography eluting in CH2Cl2/MeOH 98:2 to 
give the pure product as a light grey solid (105 mg, yield 32%). 
2d: light grey solid; TLC (KMnO4; PMA): Rf = 0.30 (CH2Cl2/MeOH 98:2); m.p.: 246.2°C (dec.); 
MS (ESI) m/z per C15H15N2O+ [M+H+]+ calcd. 239.1, found 239.0. 
1H NMR ((CD3)2SO, 300 MHz) δ 10.87 (s, 1H), 8.53 (s, 1H), 7.54 (d, J = 8.5 Hz, 2H), 7.09 (d, J = 
8.6 Hz, 1H), 6.74 (d, J = 2.3 Hz, 1H), 6.58 (d, J = 8.7 Hz, 2H), 6.50 (dd, J = 8.6, 2.3 Hz, 1H), 6.40 
(s, 1H), 5.83 (q, J = 4.8 Hz, 1H), 2.71 (d, J = 5.0 Hz, 3H). 
13C NMR ((CD3)2SO, 75 MHz) δ 150.6, 149.3, 139.4, 131.2, 129.8, 125.9, 120.0, 111.7, 111.0, 
110.4, 103.3, 95.0, 29.6. 
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tert-butyl 2-(4-amino-2-chlorophenyl)-5-methoxy-1H-indole-1-carboxylate (32) 
The title compound was prepared 
according to general procedure 5.2.1.4.1 by 
reacting N-Boc-5-methoxy-2-indolylboronic 
acid (27) (1 g, 3.44 mmol, 1.4 equiv) with 3-
chloro-4-iodoaniline (624 mg, 2.45 mmol, 1 
equiv). The mixture was heated at 95°C for 
5h. Upon completion (TLC cyclohexane/EtOAc 9:1), after standard workup, the crude 
material was purified by silica gel column chromatography eluting in cyclohexane/EtOAc 9:1 
to 85:15 to provide the pure product as a light brown oil (899 mg, yield 98%). 
32: light brown oil; TLC (KMnO4; PMA): Rf = 0.19 (cyclohexane/EtOAc 9:1). 
1H NMR (CDCl3, 300 MHz) δ 8.06 (d, J = 9.0 Hz, 1H), 7.02 (d, J = 8.2 Hz, 1H), 6.91 (d, J = 2.4 
Hz, 1H), 6.84 (dd, J = 9.0, 2.6 Hz, 1H), 6.62 (d, J = 2.2 Hz, 1H), 6.46 (dd, J = 8.2, 2.3 Hz, 1H), 
6.30 (s, 1H), 3.74 (s, 3H), 1.25 (s, 9H). 
13C NMR (CDCl3, 75 MHz) δ 155.8, 150.1, 147.6, 138.1, 134.9, 131.7, 131.6, 129.8, 124.3, 
116.3, 115.1, 113.0, 112.8, 110.0, 103.0, 82.9, 55.7, 27.7. 
 
 
2-(4-amino-2-chlorophenyl)-1H-indol-5-ol (2e) 
The title compound was prepared 
according to general procedure 5.2.1.4.2 by 
reacting tert-butyl 2-(4-amino-2-chloro 
phenyl)-5-methoxy-1H-indole-1-carboxylate 
(32) (899 mg, 2.41 mmol, 1 equiv) with 1M 
BBr3 (9.64 mL, 9.64 mmol, 4 equiv) in dry 
CH2Cl2. Upon completion (TLC in CH2Cl2/MeOH 95:5), standard workup was applied and the 
crude material was purified by silica gel column chromatography eluting in CH2Cl2/MeOH 
98:2 to give the pure product as a yellowish solid (486 mg, 78%). 
2e: yellowish solid; TLC (KMnO4; PMA): Rf = 0.36 (CH2Cl2/MeOH 95:5); m.p.: 174.6°C; MS 
(ESI) m/z per C14H12ClN2O+ [M+H+]+ calcd. 259.1, found 259.0 
1H NMR (CD3OD, 300 MHz) δ 7.35 (d, J = 8.4 Hz, 1H), 7.19 (d, J = 8.6 Hz, 1H), 6.90 (d, J = 2.2 
Hz, 1H), 6.81 (d, J = 2.3 Hz, 1H), 6.67 (dd, J = 4.0, 2.3 Hz, 1H), 6.64 (dd, J = 4.2, 2.3 Hz, 1H), 
6.50 (s, 1H), 3.48 (q, J = 7.0 Hz, 0.19H, 6% Et2O residual), 1.17 (t, J = 7.0 Hz, 0.33H, 6% Et2O 
residual). 
13C NMR (CD3OD, 75 MHz) δ 151.3, 149.6, 137.8, 133.4, 132.8, 132.0, 130.6, 130.6, 122.1, 
117.0, 114.8, 112.3, 112.2, 104.9, 101.9.  
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tert-butyl 2-(2-chloro-4-(methylamino)phenyl)-5-methoxy-1H-indole-1-
carboxylate (33) 
The title compound was prepared 
according to general procedure 5.2.1.4.1 by 
reacting N-Boc-5-methoxy-2-indolylboronic 
acid (27) (344 mg, 1.18 mmol, 1.4 equiv) 
with 3-chloro-4-iodo-N-methylaniline (15) 
(225 mg, 0.84 mmol, 1 equiv). The mixture 
was heated at 95°C for 5h. Upon completion (TLC cyclohexane/EtOAc 9:1), after standard 
workup, the crude material was purified by silica gel column chromatography eluting in 
cyclohexane/EtOAc 9:1 to provide the pure product as a light brown oil (185 mg, yield 56%). 
33: light brown oil; TLC (KMnO4; PMA): Rf = 0.26 (cyclohexane/EtOAc 9:1). 
1H NMR (CDCl3, 300 MHz) δ 8.06 (d, J = 9.0 Hz, 1H), 7.07 (d, J = 8.3 Hz, 1H), 6.93  
(d, J = 2.4 Hz, 1H), 6.85 (dd, J = 9.0, 2.6 Hz, 1H), 6.56 (d, J = 2.3 Hz, 1H), 6.41 (dd, J = 8.3, 2.4 
Hz, 1H), 6.31 (s, 1H), 3.76 (s3H), 2.74 (s, 3H), 1.27 (s, 9H). 
13C NMR (CDCl3, 75 MHz) δ 155.9, 150.2, 138.4, 135.1, 131.6, 129.9, 122.9, 116.4, 113.0, 
112.2, 110.4, 110.0, 102.9, 82.8, 55.8, 30.7, 27.8. 
 
 
2-(2-chloro-4-(methylamino)phenyl)-1H-indol-5-ol (2f) 
The title compound was prepared 
according to general procedure 5.2.1.4.2 by 
reacting tert-butyl 2-(2-chloro-4-(methyl-
amino)phenyl)-5-methoxy-1H-indole-1-
carboxylate (33) (185 mg, 0.48 mmol, 1 
equiv) with 1M BBr3 (1.92 mL, 1.92 mmol, 4 
equiv) in dry CH2Cl2. Upon completion (TLC in CH2Cl2/MeOH 98:2), standard workup was 
applied and the crude material was purified by silica gel column chromatography eluting in 
CH2Cl2 – MeOH 99:1 to give the pure product as a light yellow solid (70 mg, 54%). 
2f: light yellow solid; TLC (KMnO4; PMA): Rf = 0.36 (CH2Cl2/MeOH 98:2); m.p.: 148.8°C;  
MS (ESI) m/z per C15H14ClN2O+ [M+H+]+ calcd. 273.1, found 273.0. 
1H NMR (CD3OD, 300 MHz) δ 7.29 (d, J = 8.5 Hz, 1H), 7.09 (d, J = 8.6 Hz, 1H), 6.80 (d, J = 2.4 
Hz, 1H), 6.58 (d, J = 2.4 Hz, 1H), 6.54 (dd, J = 8.6, 2.4 Hz, 1H), 6.50 (dd, J = 8.6, 2.4 Hz, 1H), 
6.40 (s, 1H), 2.69 (s, 3H). 
13C NMR (CD3OD, 75 MHz) δ 151.7, 151.4, 138.1, 133.8, 132.9, 132.0, 130.8, 121.0, 113.9, 
113.8, 112.3, 112.2, 112.1, 104.9, 101.7, 101.7, 30.3. 
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tert-butyl 2-(2-chloro-4-hydroxyphenyl)-5-methoxy-1H-indole-1-carboxylate (34) 
The title compound was prepared 
according to general procedure 5.2.1.4.1 by 
reacting N-Boc-5-methoxy-2-indolylboronic 
acid (27) (400 mg, 1.37 mmol, 1.4 equiv) 
with 4-bromo-3-chlorophenol (204 mg, 0.98 
mmol, 1 equiv). The mixture was heated at 
95°C for 5h. Upon completion (TLC cyclohexane/EtOAc 9:1), after standard workup, the 
crude material was purified by silica gel column chromatography eluting in 
cyclohexane/EtOAc 9:1 to provide the pure product as a brown oil (190 mg, yield 52%). 
34: brown oil; TLC (KMnO4; PMA): Rf = 0.28 (cyclohexane/EtOAc 85:15). 
1H NMR (CDCl3, 300 MHz) δ 8.02 (d, J = 9.0 Hz, 1H), 7.12 (d, J = 8.3 Hz, 1H), 6.94 (d, J = 2.5 
Hz, 1H), 6.91 – 6.83 (m, 1H), 6.81 (d, J = 2.5 Hz, 1H), 6.65 (dd, J = 8.3, 2.5 Hz, 1H), 6.47 (br s, 
1H), 6.33 (s, 1H), 3.77 (s, 3H), 1.29 (s, 9H). 
13C NMR (CDCl3, 75 MHz) δ 156.8, 155.9, 150.3, 137.7, 134.9, 131.8, 131.5, 129.9, 126.6, 
116.4, 113.7, 113.3, 110.6, 103.3, 83.7, 55.9, 27.8. 
 
 
2-(2-chloro-4-hydroxyphenyl)-1H-indol-5-ol (2g) 
The title compound was prepared 
according to general procedure 5.2.1.4.2 by 
reacting tert-butyl 2-(2-chloro-4-hydroxy-
phenyl)-5-methoxy-1H-indole-1-carboxylate 
(34) (190 mg, 0.51 mmol, 1 equiv) with 1M 
BBr3 (3.06 mL, 3.06 mmol) in dry CH2Cl2. 
Upon completion (TLC in CH2Cl2/MeOH 95:5), standard workup was applied and the crude 
material was purified by silica gel column chromatography eluting in CH2Cl2/MeOH 95:5 to 
give the pure product as a white solid (91 mg, yield 69%). 
2g: white solid; TLC (KMnO4; PMA): Rf = 0.30 (CH2Cl2/MeOH 95:5); m.p.: 198.4°C;  
MS (ESI) m/z per C14H11ClNO2+ [M+H+]+ calcd. 260.1, found 260.0. 
1H NMR (CD3OD, 300 MHz) δ 7.43 (d, J = 8.5 Hz, 1H), 7.22 (d, J = 8.7 Hz, 1H), 7.00 – 6.93 (m, 
2H), 6.80 (dd, J = 8.5, 2.5 Hz, 1H), 6.71 (dd, J = 8.6, 2.4 Hz, 1H), 6.56 (s, J = 0.7 Hz, 1H), 5.37 
(s, 0.07H, 4% CH2Cl2 residual). 
13C NMR (CD3OD, 75 MHz) δ 158.6, 151.3, 137.2, 133.5, 132.9, 132.4, 130.5, 124.7, 118.0, 
115.5, 112.5, 112.4, 105.1, 102.4. 
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tert-butyl 5-methoxy-2-(2-methyl-4-(methylamino)phenyl)-1H-indole-1-
carboxylate (35) 
The title compound was prepared 
according to general procedure 5.2.1.4.1 by 
reacting N-Boc-5-methoxy-2-indolylboronic 
acid (27) (306 mg, 1.05 mmol, 1.4 equiv) 
with 4-bromo-N,3-dimethylaniline (16) (150 
mg, 0.75 mmol, 1 equiv). The mixture was 
heated at 95°C for 3h. Upon completion (TLC cyclohexane/EtOAc 9:1), after standard 
workup, the crude material was purified by silica gel column chromatography eluting in 
cyclohexane/EtOAc 9:1 to provide the pure product as a yellow oil (212 mg, yield 77%). 
35: yellow oil; TLC (KMnO4; PMA): Rf = 0.45 (cyclohexane/EtOAc 4:1). 
1H NMR (CDCl3, 300 MHz) δ 8.04 (d, J = 9.0 Hz, 1H), 6.95 (d, J = 7.8 Hz, 1H), 6.90 (d, J = 2.5 
Hz, 1H), 6.81 (dd, J = 9.0, 2.6 Hz, 1H), 6.38 – 6.28 (m, 2H), 6.23 (s, 1H), 3.73 (s, 3H), 2.71 (s, 
3H), 2.00 (s, 3H), 1.19 (s, 9H). 
13C NMR (CDCl3, 75 MHz) δ 155.9, 150.3, 149.4, 141.0, 138.0, 131.5, 130.6, 130.2, 124.2, 
116.3, 113.4, 112.4, 109.3, 109.1, 102.8, 82.5, 55.7, 30.8, 27.7, 20.3. 
 
 
2-(2-methyl-4-(methylamino)phenyl)-1H-indol-5-ol (2h) 
The title compound was prepared 
according to general procedure 5.2.1.4.2 by 
reacting tert-butyl 5-methoxy-2-(2-methyl-
4-(methylamino)phenyl)-1H-indole-1-
carboxylate (35) (212 mg, 0.58 mmol, 1 
equiv) with 1M BBr3 (2.32 mL, 2.32 mmol, 4 
equiv) in dry CH2Cl2. Upon completion (TLC in CH2Cl2/MeOH 95:5), standard workup was 
applied and the crude material was purified by silica gel column chromatography eluting in 
CH2Cl2/MeOH 95:5 to give the pure product as a yellowish solid (134 mg, yield 91%). 
2h: yellowish solid; TLC (KMnO4; PMA): Rf = 0.47 (CH2Cl2/MeOH 95:5); m.p.: 90.5°C (dec.); 
MS (ESI) m/z per C16H17N2O+ [M+H+]+ calcd. 253.1, found 253.2.  
1H NMR (CD3OD, 300 MHz) δ 7.27 (d, J = 8.1 Hz, 1H), 7.16 (d, J = 8.6 Hz, 1H), 6.89 (d, J = 2.2 
Hz, 1H), 6.62 (dd, J = 8.6, 2.4 Hz, 1H), 6.57 – 6.47 (m, 2H), 6.22 (s, 1H), 3.75 – 3.64 (m, 0.2H, 
DIPE residual), 2.78 (s, 3H), 2.39 (s, 3H), 1.11 (d, J = 6.1 Hz, 1.4H, 12% DIPE residual). 
13C NMR (CD3OD, 75 MHz) δ 151.2, 150.6, 140.7, 137.8, 132.8, 131.0, 130.8, 123.3, 115.8, 
112.0, 111.5, 111.2, 104.8, 30.7, 21.6. 
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tert-butyl 2-(3-chloro-4-(methylamino)phenyl)-5-methoxy-1H-indole-1-
carboxylate (36) 
The title compound was prepared 
according to general procedure 5.2.1.4.1 by 
reacting N-Boc-5-methoxy-2-indolylboronic 
acid (27) (516 mg, 1.77 mmol, 1.4 equiv) 
with 4-bromo-2-chloro-N-methylaniline (17) 
(279 mg, 1.26 mmol, 1 equiv). The mixture 
was heated at 95°C for 1h. Upon completion (TLC cyclohexane/EtOAc 95:5), after standard 
workup, the crude material was purified by silica gel column chromatography eluting in 
cyclohexane/EtOAc 95:5 to provide the pure product as a yellow oil (394 mg, yield 81%). 
36: yellow oil; TLC (KMnO4; PMA): Rf = 0.41 (cyclohexane/EtOAc 95:5). 
1H NMR (CD3OD, 300 MHz) δ 8.00 (d, J = 9.1 Hz, 1H), 7.18 (d, J = 2.0 Hz, 1H), 7.10 (dd, J = 
8.3, 2.0 Hz, 1H), 6.94 (d, J = 2.5 Hz, 1H), 6.83 (dd, J = 9.0, 2.6 Hz, 1H), 6.59 (d, J = 8.4 Hz, 1H), 
6.32 (s, 1H), 2.84 (s, 3H), 1.28 (s, 9H). 
13C NMR (CD3OD, 75 MHz) δ 157.4, 151.6, 146.3, 141.8, 133.4, 131.5, 130.4, 129.4, 124.5, 
119.0, 116.7, 113.6, 110.7, 110.1, 103.8, 84.2, 56.0, 30.4, 27.9. 
 
 
2-(3-chloro-4-(methylamino)phenyl)-1H-indol-5-ol (2i) 
The title compound was prepared 
according to general procedure 5.2.1.4.2 by 
reacting tert-butyl 2-(3-chloro-4-(methyl-
amino)phenyl)-5-methoxy-1H-indole-1-
carboxylate (36) (394 mg, 1.02 mmol, 1 
equiv) with 1M BBr3 (4.08 mL, 4.08 mmol, 4 
equiv) in dry CH2Cl2. Upon completion (TLC in CH2Cl2/MeOH 95:5), standard workup was 
applied and the crude material was purified by silica gel column chromatography eluting in 
CH2Cl2/MeOH 98:2 to give the pure product as a white solid (236 mg, yield 85%). 
2i: white solid; TLC (KMnO4; PMA): Rf = 0.54 (CH2Cl2/MeOH 95:5); m.p.: 200.7°C (dec.);  
MS (ESI) m/z per C15H14ClN2O+ [M+H+]+ calcd. 273.1, found 273.0. 
1H NMR (CD3OD, 300 MHz) δ 7.63 (d, J = 2.1 Hz, 1H), 7.50 (dd, J = 8.5, 2.1 Hz, 1H), 7.17 (d, J 
= 8.6 Hz, 1H), 6.90 (d, J = 2.3 Hz, 1H), 6.68 – 6.60 (m, 2H), 6.44 (s, 1H), 2.83 (s, 3H). 
13C NMR (CD3OD, 75 MHz) δ 151.5, 145.9, 139.8, 133.6, 131.5, 126.6, 125.9, 123.4, 120.2, 
112.2, 111.9, 111.9, 105.0, 97.4, 30.4. 
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tert-butyl 2-(3-chloro-4-phenoxyphenyl)-5-methoxy-1H-indole-1-carboxylate (37) 
The title compound was 
prepared according to general procedure 
5.2.1.4.1 by reacting N-Boc-5-methoxy-2-
indolylboronic acid (27) (200 mg, 0.69 
mmol, 1.4 equiv) with 1-benzyloxy-4-
bromo-2-chlorobenzene (146 mg, 0.49 
mmol, 1 equiv). The mixture was heated at 95°C for 5h. Upon completion (TLC 
cyclohexane/EtOAc 95:5), after standard workup, the crude material was purified by silica 
gel column chromatography eluting in cyclohexane/EtOAc 95:5, and then further purified 
by another column chromatography in cyclohexane/CH2Cl2 3:7 to provide the pure product 
as a yellow oil (202 mg, yield 89%). 
37: yellow oil; TLC (KMnO4; PMA): Rf = 0.41 (cyclohexane/EtOAc 95:5).  
1H NMR (CDCl3, 300 MHz) δ 8.01 (d, J = 9.1 Hz, 1H), 7.45 – 7.38 (m, 2H), 7.38 – 7.22 (m, 3H), 
7.20 – 7.18 (m, 1H), 7.18 – 7.12 (m, 1H), 6.92 (d, J = 2.5 Hz, 2H), 6.91 – 6.83 (m, 2H), 6.37 (s, 
1H), 5.15 (s, 2H), 3.79 (s, 3H), 1.26 (s, 9H). 
13C NMR (CDCl3, 75 MHz) δ 156.2, 153.7, 150.1, 139.5, 136.5, 132.2, 130.9, 129.9, 128.7, 
128.7, 128.1, 128.0, 127.2, 122.6, 116.3, 113.4, 113.2, 110.1, 103.0, 83.6, 70.9, 55.8, 27.8. 
 
 
 
2-(3-chloro-4-hydroxyphenyl)-1H-indol-5-ol (2j) 
The title compound was prepared 
according to general procedure 5.2.1.4.2 by 
reacting tert-butyl 2-(3-chloro-4-phenoxy-
phenyl)-5-methoxy-1H-indole-1-carboxylate 
(37) (202 mg, 0.44 mmol, 1 equiv) with 1M 
BBr3 (2.20 mL, 2.20 mmol, 5 equiv) in dry 
CH2Cl2. Upon completion (TLC in CH2Cl2/MeOH 95:5), standard workup was applied and the 
crude material was purified by silica gel column chromatography eluting in CH2Cl2/MeOH 
97:3 to give the pure product as a white solid (65 mg, yield 78%). 
2j: white solid; TLC (KMnO4; PMA): Rf = 0.60 (cyclohexane/CH2Cl2 3:7); m.p.: 210.0°C (dec.); 
MS (ESI) m/z per C14H11ClNO2+ [M+H+]+ calcd. 260.1, found 259.6. 
1H NMR (CD3OD, 300 MHz) δ 7.70 (t, J = 2.5 Hz, 1H), 7.51 (dt, J = 8.5, 2.6 Hz, 1H), 7.22 – 7.15 
(m, 1H), 6.95 (dd, J = 8.5, 2.8 Hz, 1H), 6.89 (t, J = 2.4 Hz, 1H), 6.69 – 6.61 (m, 1H), 6.54 – 6.50 
(m, 1H), 3.34 (s, 0.07H, 2% MeOH residual). 
13C NMR (CD3OD, 75 MHz) δ 153.6, 151.6, 139.0, 133.7, 131.3, 127.4, 125.8, 122.1, 117.9, 
112.5, 112.3, 105.1, 98.3. 
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tert-butyl 5-methoxy-2-(2-methyl-4-sulfamoylphenyl)-1H-indole-1-carboxylate 
(38) 
The title compound was prepared 
according to general procedure 5.2.1.4.1 by 
reacting N-Boc-5-methoxy-2-indolylboronic 
acid (27) (244 mg, 0.84 mmol, 1.4 equiv) 
with 4-bromo-3-methylbenzenesulfonamide 
(18) (150 mg, 0.60 mmol, 1 equiv). The 
mixture was heated at 95°C for 3h. Upon completion (TLC cyclohexane/EtOAc 7:3), after 
standard workup, the crude material was purified by silica gel column chromatography 
eluting in cyclohexane/EtOAc 7:3 to provide the pure product as a yellow oil (200 mg,  
yield 80%). 
38: yellow oil; TLC (KMnO4; PMA): Rf = 0.28 (cyclohexane/EtOAc 7:3).  
1H NMR (CDCl3, 300 MHz) δ 8.02 (d, J = 9.0 Hz, 1H), 7.78 – 7.64 (m, 2H), 7.28  
(d, J = 8.0 Hz, 1H), 6.90 (d, J = 2.4 Hz, 1H), 6.86 (dd, J = 9.0, 2.5 Hz, 1H), 6.28 (s, 1H), 5.37 (br 
s, 2H), 3.74 (s, 3H), 2.13 (s, 3H), 1.17 (s, 9H). 
13C NMR (CDCl3, 75 MHz) δ 156.1, 149.7, 141.7, 139.9, 138.9, 137.9, 131.5, 130.2, 129.9, 
127.1, 123.3, 116.5, 113.5, 110.2, 103.2, 83.8, 55.8, 27.6, 20.0. 
 
 
4-(5-hydroxy-1H-indol-2-yl)-3-methylbenzenesulfonamide (2k) 
The title compound was prepared 
according to general procedure 5.2.1.4.2 by 
reacting tert-butyl 5-methoxy-2-(2-methyl-
4-sulfamoylphenyl)-1H-indole-1-carboxylate 
(38) (145 mg, 0.35 mmol, 1 equiv) with 1M 
BBr3 (1.40 mL, 1.40 mmol, 4 equiv) in dry 
CH2Cl2. Upon completion (TLC in CH2Cl2/MeOH 95:5), standard workup was applied and the 
crude material was purified by silica gel column chromatography eluting in CH2Cl2/MeOH 
95:5 to give the pure product as a white solid (76 mg, yield 72%). 
2k: white solid; TLC (KMnO4; PMA): Rf = 0.47 (CH2Cl2/MeOH 95:5); m.p.: 257.9°C;  
MS (ESI) m/z per C15H15N2O3S+ [M+H+]+ calcd. 303.1, found 302.9.  
1H NMR (CD3OD, 300 MHz) δ 7.84 (d, J = 0.7 Hz, 1H), 7.78 (dd, J = 8.2, 2.0 Hz, 1H), 7.66 (d, J 
= 8.2 Hz, 1H), 7.24 (d, J = 8.7 Hz, 1H), 6.96 (d, J = 2.3 Hz, 1H), 6.72 (dd, J = 8.7, 2.4 Hz, 1H), 
6.51 (s, J = 0.7 Hz, 1H), 3.35 (s, 0.67H, 22% MeOH residual), 2.59 (s, 3H). 
13C NMR (CD3OD, 75 MHz) δ 151.7, 143.1, 138.2, 138.0, 137.8, 133.5, 130.7, 130.2, 129.4, 
124.6, 113.4, 112.6, 105.3, 103.9, 21.6. 
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tert-butyl 5-methoxy-2-(2-methyl-4-(N-methylsulfamoyl)phenyl)-1H-indole-1-
carboxylate (39) 
The title compound was prepared 
according to general procedure 5.2.1.4.1 by 
reacting N-Boc-5-methoxy-2-indolylboronic 
acid (27) (162 mg, 0.56 mmol, 1.4 equiv) 
with 4-bromo-3-methylbenzenesulfonamide 
(19) (105 mg, 0.40 mmol, 1 equiv). The 
mixture was heated at 95°C for 3h. Upon completion (TLC cyclohexane/EtOAc 7:3), after 
standard workup, the crude material was purified by silica gel column chromatography 
eluting in cyclohexane/EtOAc 7:3 to provide the pure product as a yellow oil (167 mg,  
yield 98%). 
39: yellow oil; TLC (KMnO4; PMA): Rf = 0.38 (cyclohexane/EtOAc 7:3). 
1H NMR (CDCl3, 300 MHz) δ 8.08 (d, J = 9.1 Hz, 1H), 7.72 – 7.60 (m, 2H), 7.33  
(d, J = 7.9 Hz, 1H), 6.95 (d, J = 2.5 Hz, 1H), 6.89 (dd, J = 9.0, 2.5 Hz, 1H), 6.32 (s, 1H), 4.83 (q, 
J = 5.3 Hz, 1H), 3.78 (s, 3H), 2.62 (d, J = 5.4 Hz, 3H), 2.17 (s, 3H), 1.16 (s, 9H). 
13C NMR (CDCl3, 75 MHz) δ 156.3, 149.7, 140.2, 139.0, 138.4, 137.9, 131.6, 130.3, 129.9, 
128.0, 124.3, 116.5, 113.6, 110.2, 103.2, 83.5, 55.8, 29.4, 27.6, 20.1. 
 
 
4-(5-hydroxy-1H-indol-2-yl)-N,3-dimethylbenzenesulfonamide (2l) 
The title compound was prepared 
according to general procedure 5.2.1.4.2 by 
reacting tert-butyl 5-methoxy-2-(2-methyl-
4-(N-methylsulfamoyl)phenyl)-1H-indole-1-
carboxylate (39) (167 mg, 0.39 mmol, 1 
equiv) with 1M BBr3 (1.56 mL, 1.56 mmol, 4 
equiv) in dry CH2Cl2. Upon completion (TLC in CH2Cl2/MeOH 95:5), standard workup was 
applied and the crude material was purified by silica gel column chromatography eluting in 
CH2Cl2/MeOH 95:5 to give the pure product as a yellowish solid (115 mg, yield 93%). 
2l: yellowish solid; TLC (KMnO4; PMA): Rf = 0.38 (CH2Cl2/MeOH 95:5); m.p.: 160.0°C (dec.); 
MS (ESI) m/z per C16H17N2O3S+ [M+H+]+ calcd. 317.1, found 317.1. 
1H NMR (CD3OD, 300 MHz) δ 7.79 – 7.67 (m, 3H), 7.25 (d, J = 8.7 Hz, 1H), 6.96 (d, J = 2.0 Hz, 
1H), 6.73 (dd, J = 8.7, 2.4 Hz, 1H), 6.53 (s, 1H), 3.35 (s, 0.10H, 3% MeOH residual), 2.59 (s, 
3H), 2.56 (s, 3H). 
13C NMR (CD3OD, 75 MHz) δ 151.8, 138.7, 138.7, 138.2, 137.6, 133.5, 130.7, 130.4, 125.7, 
113.5, 112.6, 105.3, 104.0, 29.3, 21.6.  
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tert-butyl 2-(2-fluoro-4-sulfamoylphenyl)-5-methoxy-1H-indole-1-carboxylate (40) 
The title compound was prepared 
according to general procedure 5.2.1.4.1 by 
reacting N-Boc-5-methoxy-2-indolylboronic 
acid (27) (100 mg, 0.34 mmol, 1.4 equiv) 
with 4-bromo-3-fluorobenzenesulfonamide 
(62 mg, 0.25 mmol, 1 equiv). The mixture 
was heated at 95°C for 5h. Upon completion (TLC cyclohexane/EtOAc 7:3), after standard 
workup, the crude material was purified by silica gel column chromatography eluting in 
cyclohexane/EtOAc 3:2 to provide the pure product as a yellow oil (106 mg, yield 100%). 
40: yellow oil; TLC (KMnO4; PMA): Rf = 0.30 (cyclohexane/EtOAc 7:3). 
1H NMR (CD3OD, 300 MHz) δ 8.07 (d, J = 9.1 Hz, 1H), 7.79 (dd, J = 8.0, 1.8 Hz, 1H), 7.68 (dd, J 
= 8.2, 1.4 Hz, 1H), 7.64 (dd, J = 6.4, 5.6 Hz, 1H), 7.11 (d, J = 2.5 Hz, 1H), 6.97 (dd, J = 9.1, 2.6 
Hz, 1H), 6.67 (s, 1H), 3.84 (s, 3H), 1.35 (s, 9H). 
13C NMR (CDCl3, 75 MHz) δ 159.6 (d, J = 253.0 Hz), 156.2, 149.8, 143.1 (d, J = 7.0 Hz), 132.9, 
132.2, 131.1 (d, J = 3.3 Hz), 129.6, 128.3 (d, J = 5.4 Hz), 122.1 (d, J = 3.7 Hz), 116.5, 114.4, 
113.7 (d, J = 25.4 Hz), 112.1, 103.3, 84.3, 55.9, 27.8. 
 
 
3-fluoro-4-(5-hydroxy-1H-indol-2-yl)benzenesulfonamide (2m) 
The title compound was prepared 
according to general procedure 5.2.1.4.2 by 
reacting tert-butyl 2-(2-fluoro-4-
sulfamoylphenyl)-5-methoxy-1H-indole-1-
carboxylate (40) (106 mg, 0.25 mmol, 1 
equiv) with boron tribromide 1M (1.0 mL, 
1.0 mmol, 4 equiv) in dry CH2Cl2. Upon completion (TLC in CH2Cl2/MeOH 95:5), standard 
workup was applied and the crude material was purified by silica gel column 
chromatography eluting in CH2Cl2/MeOH 97:3 to give the pure product as a yellowish solid 
(65 mg, yield 78%). 
2m: yellowish solid; TLC (KMnO4; PMA): Rf = 0.55 (CH2Cl2/MeOH 9:1); m.p.: 240.7°C (dec.); 
MS (ESI) m/z per C14H12FN2O3S+ [M+H+]+ calcd. 307.1, found 306.9. 
1H NMR (CD3OD, 300 MHz) δ 7.95 (t, J = 7.9 Hz, 1H), 7.79 – 7.66 (m, 2H), 7.28 (dd, J = 8.8, 
0.5 Hz, 1H), 6.99 – 6.87 (m, 2H), 6.76 (dd, J = 8.7, 2.4 Hz, 1H), 3.35 (s, 0.24H, 8% MeOH 
residual). 
13C NMR (CD3OD, 75 MHz) δ 159.9 (d, J = 252.4 Hz), 152.1, 144.3 (d, J = 7.1 Hz), 134.0, 132.0 
(d, J = 2.9 Hz), 130.7 (d, J = 1.2 Hz), 128.9 (d, J = 3.9 Hz), 125.8 (d, J = 12.2 Hz), 123.4 (d, J = 
3.4 Hz), 115.4 (d, J = 26.2 Hz), 114.6, 112.9, 105.4, 104.8 (d, J = 8.9 Hz). 
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tert-butyl 4-bromo-1H-pyrazole-1-carboxylate (41) 
4-bromo-1H-pyrazole (0.98 g, 6.7 mmol, 1 equiv) was 
dissolved in CH2Cl2 (18 mL), Boc2O (2.19 g, 10.0 mmol, 1.5 
equiv), Et3N (3.5 mL) and DMAP (65 mg, 0.67 mmol, 0.10 equiv) 
were added and the resulting mixture was stirred at RT for 30 
min. Upon completion (TLC cyclohexane/EtOAc 9:1), the solvent 
was evaporated and the residue was extracted with EtOAc (x 3). 
The crude material was then purified by silica gel column chromatography eluting in 
cyclohexane/EtOAc 9:1 to provide the pure product as a yellow oil (1.49 g, yield 90%). 
41: yellow oil; TLC (KMnO4; PMA): Rf = 0.32 (cyclohexane/EtOAc 9:1). 
1H NMR (CDCl3, 300 MHz) δ 8.26 (s, 1H), 7.82 (s, 1H), 1.81 (s, 9H). 
13C NMR (CDCl3, 75 MHz) δ 144.5, 130.5, 97.4, 86.4, 28.0. 
 
 
 
 
tert-butyl 2-(1-(tert-butoxycarbonyl)-1H-pyrazol-4-yl)-5-methoxy-1H-indole-1-
carboxylate (42) 
The title compound was prepared 
according to general procedure 5.2.1.4.1 by 
reacting N-Boc-5-methoxy-2-indolylboronic 
acid (27) (300 mg, 1.03 mmol, 1.4 equiv) 
with tert-butyl 4-bromo-1H-pyrazole-1-
carboxylate (41) (182 mg, 0.74 mmol, 1 
equiv). The mixture was heated at 95°C for 5h. Upon completion (TLC cyclohexane/EtOAc 
9:1), after standard workup, the crude material was purified by silica gel column 
chromatography eluting in cyclohexane/EtOAc 4:1 to provide the pure product as a yellow 
oil (174 mg, yield 57%). 
42: yellow oil; TLC (KMnO4; PMA): Rf = 0.55 (cyclohexane/EtOAc 7:3). 
1H NMR (CD3OD, 300 MHz) δ 8.24 (s, 1H), 7.95 (d, J = 9.1 Hz, 1H), 7.83 (s, 1H), 6.93 (d, J = 2.5 
Hz, 1H), 6.84 (dd, J = 9.1, 2.6 Hz, 1H), 6.50 (s, 1H), 3.76 (s, 3H), 1.63 (s, 9H), 1.47  
(s, 9H). 
13C NMR (CD3OD, 75 MHz) δ 157.5, 151.2, 148.6, 145.6, 133.1, 131.4, 131.1, 130.7, 119.5, 
117.3, 114.4, 111.9, 103.9, 87.1, 85.2, 56.0, 28.2, 28.1. 
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2-(1H-pyrazol-4-yl)-1H-indol-5-ol (3) 
The title compound was prepared 
according to general procedure 5.2.1.4.2 by 
reacting tert-butyl 2-(1-(tert-butoxycarbo-
nyl)-1H-pyrazol-4-yl)-5-methoxy-1H-indole-
1-carboxylate (42) (174 mg, 0.42 mmol, 1 
equiv) with 1M BBr3 (2.10 mL, 2.10 mmol, 5 
equiv) in dry CH2Cl2. Upon completion (TLC in CH2Cl2/MeOH 95:5), standard workup was 
applied and the crude material was purified by silica gel column chromatography eluting in 
CH2Cl2/MeOH 9:1 to give the pure product as a white solid (65 mg, yield 78%). 
3: white solid; TLC (KMnO4; PMA): Rf = 0.38 (CH2Cl2/MeOH 9:1); m.p.: 240.1°C (dec.);  
MS (ESI) m/z per C11H10N3O+ [M+H+]+ calcd. 200.1, found 200.2. 
1H NMR (CD3OD, 300 MHz) δ 7.93 (s, 2H), 7.15 (d, J = 8.6 Hz, 1H), 6.87 (d, J = 2.3 Hz, 1H), 
6.62 (dd, J = 8.6, 2.4 Hz, 1H), 6.40 (s, 1H). 
13C NMR (CD3OD, 75 MHz) δ 151.6, 133.1, 131.4, 116.8, 112.0, 111.8, 104.9, 97.9. 
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tert-butyl 2-iodo-5-methoxy-1H-indole-1-carboxylate (43) 
In a flame dried flask, fluxed with argon, N-Boc-
5-methoxy-2-indolylboronic acid (27) (1 g, 3.44 mmol,  
1 equiv) was dissolved in dry acetonitrile (17 mL).  
N-iodosuccinimide (1.16 g, 5.16 mmol, 1.5 equiv) was 
added and the resulting mixture was heated at reflux 
(85°C) till complete consumption of the starting material, 
protected from light and air (TLC in cyclohexane/EtOAc 7:3). Upon completion (10 min), the 
solvent was removed under reduced pressure, the residue was dissolved in EtOAc. The 
organic phase was washed with deionized water (x 1), with aqueous Na2SO3 (1M, x 1), 
aqueous NaHCO3 (1M, x 1) and deionized water (x 1). The organic phase was then dried 
over Na2SO4, filtered and concentrated in vacuo. The crude was purified by two silica gel 
column chromatographies (cyclohexane/EtOAc 95:5 to 9:1 and then in cyclohexane/CH2Cl2 
7:3 to 3:2) to provide the pure product as a pale yellow oil (786 mg, yield 61%). 
43: pale yellow oil; TLC (KMnO4; PMA): Rf = 0.40 (cyclohexane/EtOAc 97:3). 
1H NMR (CDCl3, 300 MHz) δ 7.97 (s, J = 9.1 Hz, 1H), 6.91 – 6.86 (m, 2H), 6.84 (dd, J = 9.1, 2.3 
Hz, 1H), 3.83 (s, 3H), 1.71 (s, 9H). 
13C NMR (CDCl3, 75 MHz) δ 155.7, 149.1, 132.3, 131.8, 121.7, 116.2, 113.1, 101.6, 85.0, 
75.1, 55.6, 28.3. 
 
tert-butyl 5-methoxy-2-((trimethylsilyl)ethynyl)-1H-indole-1-carboxylate (44) 
In inert argon atmosphere, to a 
stirred solution of 43 (786 mg, 2.11 mmol, 1 
equiv) in dry THF (10 mL) were added Et3N 
(881 L, 639 mg, 6.32 mmol, 3 equiv) and 
then trimethylsilylacetylene (893 L, 621 
mg, 6.32 mmol, 3 equiv). The mixture was 
degassed for 10 min fluxing argon. Then, CuI (40 mg, 0.21 mmol, 0.10 equiv) and 
Pd(PPh3)2Cl2 (74 mg, 0.11 mmol, 0.05 equiv) were added and the resulting final mixture was 
stirred at RT till complete consumption of the starting material (TLC in cyclohexane/EtOAc 
97:3). Upon completion (1h), the reaction mixture was filtered over a Celite pad, washing 
with EtOAc. The filtrate was extracted with EtOAc and washed with water. The combined 
organic phases were then dried over Na2SO4, filtered and concentrated under reduced 
pressure. The crude was purified by silica gel column chromatography eluting in 
cyclohexane/EtOAc 97:3 to provide the desired product as a yellow oil (684 mg, yield 94%). 
44: yellow oil; TLC (KMnO4; PMA): Rf = 0.43 (cyclohexane/EtOAc 97:3). 
1H NMR (CDCl3, 300 MHz) δ 8.09 (d, J = 9.1 Hz, 1H), 6.97 (dd, J = 9.1, 2.5 Hz, 1H), 6.91 (d, J = 
2.4 Hz, 1H), 6.88 (s, 1H), 3.81 (s, 3H), 1.70 (s, 9H), 0.30 (s, 9H). 
13C NMR (CDCl3, 75 MHz) δ 156.2, 149.4, 131.0, 129.2, 120.7, 117.5, 116.4, 115.0, 102.4, 
100.7, 97.2, 84.3, 55.5, 28.3, -0.1. 
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tert-butyl 2-ethynyl-5-methoxy-1H-indole-1-carboxylate (45) 
To a stirred solution of tert-butyl 5-methoxy-2-
((trimethylsilyl)ethynyl)-1H-indole-1-carboxylate (44) 
(684 mg, 1.99 mmol, 1 equiv) in dry THF (20 mL), under 
argon atmosphere and cooled to 0°C, 
tetrabutylammonium fluoride (677 mg, 2.59 mmol,  
1.3 equiv) was added. The resulting mixture was 
stirred at RT and monitored by TLC (cyclohexane/EtOAc 97:3). Upon completion (30 min), 
the mixture was extracted with EtOAc (x 3). The combined organic phases were then dried 
over Na2SO4, filtered and concentrated under reduced pressure. The crude was purified by 
silica gel column chromatography eluting in cyclohexane/EtOAc 95:5 to provide the desired 
product as a yellow oil (502 mg, yield 93%). 
45: yellow oil; TLC (KMnO4; PMA): Rf = 0.30 (cyclohexane/EtOAc 97:3). 
1H NMR (CDCl3, 300 MHz) δ 8.01 (d, J = 8.8 Hz, 1H), 7.00 – 6.92 (m, 2H), 6.89 (s, 1H), 3.83 (s, 
3H), 1.68 (s, 9H). 
13C NMR (CDCl3, 75 MHz) δ 156.3, 149.5, 130.9, 129.2, 120.1, 117.5, 116.6, 115.2, 102.7, 
84.8, 83.5, 76.5, 55.8, 28.3. 
 
 
N-hydroxybenzimidoyl chloride (46) 
Benzaldehyde oxime (190 mg, 1.57 mmol, 1 equiv) was 
dissolved in CH2Cl2 and benzyl(trimethyl)ammonium 
tetrachloroiodate (657 mg, 1.57 mmol, 1 equiv) was added. The 
greenish suspension dissolved within 10 min after vigorous 
stirring at RT to result in a yellow solution. After stirring for 
additional 30 min (TLC in cyclohexane/EtOAc 9:1), the mixture 
was diluted with Et2O and the resulting precipitate was filtered 
off. The filtrate was evaporated under reduced pressure to 
provide the pure compound as a yellow oil (244 mg, yield 100%). 
46: yellow oil; TLC (KMnO4; PMA): Rf = 0.30 (cyclohexane/EtOAc 97:3). 
1H NMR (CDCl3, 300 MHz) δ 8.60 (br s, 1H), 7.86 – 7.78 (m, 2H), 7.51 – 7.38 (m, 3H). 
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tert-butyl 5-methoxy-2-(3-phenylisoxazol-5-yl)-1H-indole-1-carboxylate (47) 
To a stirred solution of tert-butyl 2-
ethynyl-5-methoxy-1H-indole-1-carboxylate 
(45) (100 mg, 0.37 mmol, 1 equiv) in dry THF 
(10 mL), under argon atmosphere, Et3N (62 
L, 45 mg, 0.44 mmol, 1.2 equiv) and N-
hydroxybenzimidoyl chloride (46) (69 mg, 
0.44 mmol, 1.2 equiv) were added. The resulting mixture was stirred at RT and monitored 
by TLC (cyclohexane/EtOAc 9:1). Upon completion (12h), the mixture was diluted with 
EtOAc and washed with saturated aqueous solution of NaHCO3 (x 2) and brine (x 1). The 
organic phase was then dried over Na2SO4, filtered and concentrated under reduced 
pressure. The crude was purified by silica gel column chromatography eluting in 
cyclohexane/EtOAc 9:1 to provide the desired product as a yellow oil (139 mg, yield 97%). 
47: yellow oil; TLC (KMnO4; PMA): Rf = 0.30 (cyclohexane/EtOAc 97:3). 
1H NMR (CDCl3, 300 MHz) δ 8.07 (d, J = 8.8 Hz, 1H), 7.83 – 7.76 (m, 2H), 7.45 – 7.37 (m, 3H), 
7.00 – 6.93 (m, 2H), 6.82 (s, 1H), 6.71 (s, 1H), 3.80 (s, 3H), 1.43 (s, 9H). 
13C NMR (CDCl3, 75 MHz) δ 164.6, 162.5, 156.4, 149.4, 132.5, 130.2, 129.1, 129.1, 126.9, 
126.3, 116.6, 115.5, 113.4, 103.3, 102.2, 84.6, 55.8, 27.9. 
 
 
2-(3-phenylisoxazol-5-yl)-1H-indol-5-ol (4a) 
The title compound was prepared 
according to general procedure 5.2.1.4.2 by 
reacting tert-butyl 5-methoxy-2-(3-phenyl-
isoxazol-5-yl)-1H-indole-1-carboxylate (47) 
(139 mg, 0.36 mmol, 1 equiv) with 1M BBr3 
(1.44 mL, 1.44 mmol, 4 equiv) in dry CH2Cl2. 
Upon completion (TLC in CH2Cl2/MeOH 98:2), standard workup was applied and the crude 
material was purified by silica gel column chromatography eluting in CH2Cl2/MeOH 98:2 to 
give the pure product as a white solid (73 mg, yield 73%). 
4a: white solid; TLC (KMnO4; PMA): Rf = 0.47 (CH2Cl2/MeOH 95:5); m.p.: 257.9°C;  
MS (ESI) m/z per C17H13N2O2+ [M+H+]+ calcd. 277.1, found 276.9. 
1H NMR (CD3OD, 300 MHz) δ 7.92 – 7.85 (m, 2H), 7.55 – 7.47 (m, 3H), 7.28 (d, J = 8.8 Hz, 
1H), 7.05 (s, 1H), 7.00 – 6.97 (m, 1H), 6.90 (d, J = 0.5 Hz, 1H), 6.81 (dd, J = 8.8, 2.4 Hz, 1H). 
13C NMR (CD3OD, 75 MHz) δ 166.2, 164.3, 152.4, 134.1, 131.3, 130.3, 130.2, 130.1, 127.8, 
126.9, 115.4, 113.2, 105.6, 103.2, 97.9. 
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tert-butyl 2-(3-(4-bromophenyl)isoxazol-5-yl)-5-methoxy-1H-indole- 
1-carboxylate (48) 
To a stirred solution of tert-butyl 2-
ethynyl-5-methoxy-1H-indole-1-carboxylate 
(45) (100 mg, 0.37 mmol, 1 equiv) in dry THF 
(10 mL), under argon atmosphere, Et3N (62 
L, 45 mg, 0.44 mmol, 1.2 equiv) and 4-
bromo-N-hydroxybenzimidoyl chloride (104 
mg, 0.44 mmol, 1.2 equiv) were added. The resulting mixture was stirred at RT and 
monitored by TLC (cyclohexane/EtOAc 9:1). Upon completion (12h), the mixture was 
diluted with EtOAc and washed with saturated aqueous solution of NaHCO3 (x 2) and brine 
(x 1). The organic phase was then dried over Na2SO4, filtered and concentrated under 
reduced pressure. The crude was purified by silica gel column chromatography eluting in 
cyclohexane/EtOAc 9:1 to provide the desired product as a yellow oil (105 mg, yield 60%). 
48: yellow oil; TLC (KMnO4; PMA): Rf = 0.29 (cyclohexane/EtOAc 97:3). 
1H NMR (CDCl3, 300 MHz) δ 8.08 – 8.02 (m, 1H), 7.67 (d, J = 8.6 Hz, 2H), 7.55 (d, J = 8.6 Hz, 
2H), 7.19 (s, 1H), 7.00 – 6.93 (m, 2H), 6.83 (s, 1H), 6.70 (s, 1H), 3.80 (s, 3H), 1.44 (s, 9H). 
13C NMR (CDCl3, 75 MHz) δ 165.0, 161.6, 156.4, 149.4, 132.6, 132.4, 129.1, 128.5, 128.1, 
126.2, 124.5, 116.7, 115.7, 113.6, 103.4, 102.0, 84.7, 55.9, 28.0. 
 
 
 
2-(3-(4-bromophenyl)isoxazol-5-yl)-1H-indol-5-ol (4b) 
The title compound was prepared 
according to general procedure 5.2.1.4.2 by 
reacting tert-butyl 2-(3-(4-bromo-
phenyl)isoxazol-5-yl)-5-methoxy-1H-indole-
1-carboxylate (48) (105 mg, 0.22 mmol,  
1 equiv) with 1M BBr3 (0.88 mL, 0.88 mmol, 
4 equiv) in dry CH2Cl2. Upon completion (TLC in CH2Cl2/MeOH 97:3), standard workup was 
applied and the crude material was purified by silica gel column chromatography eluting in 
CH2Cl2/MeOH 97:3 to give the pure product as a white solid (73 mg, yield 73%). 
4b: white solid; TLC (KMnO4; PMA): Rf = 0.47 (CH2Cl2/MeOH 95:5); m.p.: 257.9°C;  
MS (ESI) m/z per C17H12BrN2O2+ [M+H+]+ calcd. 355.1, found 355.0. 
1H NMR (CD3OD, 300 MHz) δ 7.81 (d, J = 8.6 Hz, 2H), 7.67 (d, J = 8.6 Hz, 2H), 7.28 (d, J = 8.8 
Hz, 1H), 7.04 (s, 1H), 6.98 (d, J = 2.0 Hz, 1H), 6.89 (d, J = 0.7 Hz, 1H), 6.81 (dd, J = 8.8, 2.3 Hz, 
1H). 
13C NMR (CD3OD, 75 MHz) δ 166.5, 163.3, 152.5, 134.1, 133.3, 130.3, 129.6, 129.4, 126.7, 
125.4, 115.5, 113.2, 105.6, 103.3, 97.7. 
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5.2.2 Genistein  derivatives 5a-c 
5.2.2.1 Synthesis of the key intermediate 52 
1-(2-hydroxy-4,6-bis((2-methoxyethoxy)methoxy)phenyl)ethanone (50) 
In a flame dried flask and under argon 
atmosphere, 2',4',6'-trihydroxyacetophenone mono-
hydrate (49) (7.0 g, 37.60 mmol, 1 equiv) was 
suspended in dry CH2Cl2 (210 mL), cooled at 0°C and 
stirred for 5 min to obtain an homogeneous pale-
yellow suspension. DIPEA (18.53 mL, 106.41 mmol, 
2.83 equiv) was added dropwise and the mixture was 
stirred at 0°C for 30 min. Then, at 0°C, MEM-chloride (10.13 mL, 88.74 mmol, 2.36 equiv) 
was added dropwise. The final bright yellow solution was stirred at 0°C for 1h and the 
reaction propagation was monitored by TLC (cyclohexane/EtOAc 1:1). Upon completion, 
the reaction was quenched with distilled water (100 mL), the organic layer was separated 
and then the aqueous layer was extracted with CH2Cl2 (x 3). The combined organic layers 
were dried over Na2SO4, filtered and the solvent was evaporated under reduced pressure. 
The crude product was purified by silica gel column chromatography (cyclohexane/EtOAc 
1:1) to yield 50 as a pale-yellow oil (8.03 g, yield 62%). 
50: pale-yellow oil; TLC (KMnO4; PMA): Rf = 0.30 (cyclohexane/EtOAc 1:1). 
1H NMR (CDCl3, 300 MHz) δ 6.26 (s, 2H), 5.33 (s, 2H), 5.25 (s, 2H), 3.84 – 3.77  
(m, 4H), 3.58 – 3.53 (m, 4H), 3.38 (s, 3H), 3.37 (s, 3H), 2.63 (s, 3H). 
13C NMR (CDCl3, 75 MHz) δ 203.3, 166.9, 163.5, 160.4, 107.0, 97.3, 94.2, 93.6, 93.1, 71.8, 
71.6, 68.6, 68.3, 58.2, 33.2, 33.2.  
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3-(dimethylamino)-1-(2-hydroxy-4,6-bis((2-methoxyethoxy)methoxy)phenyl)prop-
2-en-1-one (51) 
50 (6.0 g, 17.42 mmol, 1 equiv) was 
dissolved in DMF (15 mL) and DMF/DMA (2.08 g, 
17.42 mmol, 1 equiv) was added. The stirred 
solution was heated at 80°C for 6h. The reaction 
was monitored by TLC in cyclohexane/EtOAc 1:1. 
After cooling to RT, the solvent was evaporated 
under reduced pressure to 51 as a reddish oil  
(6.96 g, yield 100%).  
51: reddish oil; TLC (PMA; Dragendorff): Rf = 0.17 (cyclohexane/EtOAc 1:1). 
1H NMR (CDCl3, 300 MHz) δ 7.81 (d, J = 12.3 Hz, 1H), 6.17 (d, J = 12.3 Hz, 1H), 6.15 (s, 1H), 
6.10 (s, 1H), 5.21 (s, 2H), 5.14 (s, 2H), 3.76 – 3.68 (m, 4H), 3.49 – 3.44 (m, 4H), 3.27 (s, 6H), 
3.05 (br s, 3H), 2.82 (br s, 3H). 
13C NMR (CDCl3, 75 MHz) δ 189.6, 166.6, 161.0, 158.7, 154.5, 106.7, 97.7, 96.6, 94.3, 94.0, 
92.8, 71.4, 68.3, 67.8, 58.8, 45.1, 37.1. 
 
 
3-iodo-5,7-bis((2-methoxyethoxy)methoxy)-4H-chromen-4-one (52) 
To a vigorous stirred solution of 51 (4.43 g, 
11.09 mmol, 1 equiv) in CHCl3 (148 mL) was first 
added pyridine (1.08 mL, 13.31 mmol, 1.2 equiv) and 
then iodine portionwise (2.53 g, 9.98 mmol,  
0.9 equiv) over 1h. The reaction mixture was stirred 
for 12h at RT and monitored by TLC in 
cyclohexane/EtOAc 1:1. Upon completion, saturated 
aqueous solution of Na2S2O3 was added and the mixture was stirred at RT for 10 min.  The 
mixture was then diluted with deionized water and extracted with CH2Cl2, adding CuSO4 to 
complex pyridine. The combined organic layers were dried over Na2SO4, filtered and the 
solvents evaporated in vacuo. The crude product was purified by silica gel column 
chromatography (cyclohexane/EtOAc 1:1) to yield 52 as a yellow oil (1.92 g, yield 40%). 
52: yellow oil. TLC (PMA; Dragendorff): 0.21 (cyclohexane/EtOAc 1:1). 
1H NMR (CDCl3, 300 MHz) δ 8.03 (s, 1H), 6.70 (d, J = 2.0 Hz, 1H), 6.67 (d, J = 2.0 Hz, 1H), 5.31 
(s, 2H), 5.24 (s, 2H), 3.87 – 3.81 (m, 2H), 3.78 – 3.72 (m, 2H), 3.53 – 3.45 (m, 4H), 3.29 (s, 
3H), 3.29 (s, 3H). 
13C NMR (CDCl3, 75 MHz) δ 171.3, 161.5, 159.2, 158.0, 155.7, 108.7, 102.1, 96.8, 94.3, 93.3, 
89.3, 71.4, 68.3, 59.0, 58.9, 30.2, 29.7.  
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5.2.2.2 General procedure for the Suzuki-Miyaura cross-coupling 
(53-55)  
A solution of 52 (1 equiv), appropriate phenylboronic acid (2 equiv), Na2CO3 (3 
equiv), Pd/C 10% (10% w/w mol equiv) in 1,2-dimethoxyethane/water 1:1 (4 mL/mmol 
starting material) was heated to reflux (80-90°C) in a microwave reactor or in an oil bath 
until complete consumption of the starting material. The reaction was monitored by TLC in 
cyclohexane/EtOAc. Upon completion, the cooled mixture was filtered through a Celite pad, 
diluted with deionized water and then extracted with CH2Cl2 (x 3). The combined organic 
layers were dried over Na2SO4, filtered and evaporated under reduced pressure. The crude 
product was purified by silica gel column chromatography, eluting in cyclohexane/EtOAc to 
yield the desired pure product. 
 
5.2.2.3 General procedure for the cleavage of MEM protecting 
groups (genistein and 5a-c)  
A mixture of the 3-aryl-5,7-bis((2-methoxyethoxy)methoxy)-4H-chromen-4-one, 
CHCl3 (2.76 mL/mmol starting material), MeOH (2.76 mL/mmol starting material) and 12N 
HCl (1 mL/0.55 mmol starting material) was refluxed for 1h. The reaction was quenched 
with deionized water and the mixture was extracted with CH2Cl2 (x 3). The combined 
organic layers were washed with deionized water, dried over Na2SO4, filtered and the 
solvents evaporated under reduced pressure. The crude product was purified by silica gel 
column chromatography, eluting in CH2Cl2/MeOH to yield the desired pure product. 
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3-(4-hydroxyphenyl)-5,7-bis((2-methoxyethoxy)methoxy)-4H-chromen-4-one (53) 
The title compound was prepared 
according to the general procedure 5.2.2.2 by 
reacting 52 (250 mg, 0.52 mmol, 1 equiv) with 
4-hydroxyphenylboronic acid (144 mg,  
1.04 mmol, 2 equiv). The mixture was heated 
in an oil bath at 80°C for 2h, monitored by 
TLC in 100% EtOAc. Upon completion, the 
cooled mixture was filtered through a Celite pad, diluted with deionized water and then 
extracted with CH2Cl2 (x 3). The combined organic layers were dried over Na2SO4, filtered 
and the solvents evaporated under reduced pressure. The crude product was purified by 
silica gel column chromatography, eluting in 100% EtOAc to yield the desired product 53 
(143 mg, yield 61%). 
53: yellow oil; TLC (KMnO4; PMA): Rf = 0.36 (EtOAc). 
1H NMR (CDCl3, 300 MHz) δ 7.86 (br s, 1H), 7.70 (s, 1H), 7.26 – 7.18 (m, 2H), 6.80 (d, J = 8.6 
Hz, 2H), 6.69 (dd, J = 7.9, 2.3 Hz, 2H), 5.31 (s, 2H), 5.25 (s, 2H), 3.85 – 3.73 (m, 4H), 3.54 – 
3.43 (m, 4H), 3.31 (s, 3H), 3.27 (s, 3H). 
13C NMR (CDCl3, 75 MHz) δ 176.0, 161.3, 159.4, 158.6, 157.0, 150.7, 130.4, 126.1, 122.8, 
115.6, 110.8, 101.3, 96.7, 93.9, 93.3, 71.5, 71.4, 68.2, 68.1, 59.0, 58.8. 
 
 
5,7-dihydroxy-3-(4-hydroxyphenyl)-4H-chromen-4-one (genistein) 
The title compound was prepared 
according to general procedure 5.2.2.3 by reacting 
53 (143 mg, 0.32 mmol, 1 equiv) with 12 N HCl 
(200 L) in CHCl3 (2 mL) and MeOH (2 mL). The 
mixture was refluxed for 1h. Upon completion, the 
reaction was quenched with deionized water, and 
the mixture was extracted with CH2Cl2 (x 3). The 
combined organic layers were washed with H2O, dried over Na2SO4, filtered and the 
solvents evaporated in vacuo. The crude product was purified by silica gel column 
chromatography (CH2Cl2/MeOH 95:5) to yield the desired product as a pale yellow oil, 
which was then re-crystalized from EtOH (56 mg, yield 65%). 
genistein: white solid; TLC (KMnO4; PMA): Rf = 0.46 (CH2Cl2/MeOH 9:1); m.p.: 307.4-309.8°C 
(dec.); MS (ESI) m/z for C15H11O5+ [M+H]+ calcd. 271.1, found 271.0. 
1H NMR ((CD3)2CO, 300 MHz) δ 8.93 (br s, 1H), 8.01 (s, 1H), 7.31 (d, J = 8.7 Hz, 2H), 6.77 (d, J 
= 8.7 Hz, 2H), 6.27 (d, J = 2.2 Hz, 1H), 6.14 (d, J = 2.2 Hz, 1H), 2.97 (br s, 2H). 
13C NMR ((CD3)2CO, 75 MHz) δ 181.6, 165.0, 163.9, 159.0, 158.4, 154.3, 131.2, 124.0, 123.0, 
116.0, 106.2, 99.8, 94.5.  
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4-methoxy-2-methylphenylboronic acid (56) 
To a stirred solution of 4-bromo-3-methylanisole  
(883 L, 6.25 mmol, 1 equiv) in dry THF (6 mL), cooled at -78°C, 
2.5M n-BuLi in hexanes (6 mL, 15 mmol, 2.4 equiv) was added 
dropwise. After 1h, triisopropyl borate (3.5 mL, 15 mmol, 2.4 
equiv) was added and the reaction was warmed to RT. The 
solution was stirred at RT for 3h till complete consumption of 
the starting material (TLC in cyclohexane/EtOAc 1:1). Upon 
completion, saturated aqueous solution of NH4Cl was added and 
the mixture was extracted with CH2Cl2 (x 3). The combined organic layers were dried over 
Na2SO4, filtered and evaporated under reduced pressure. The crude material was 
subsequently purified by silica gel column chromatography eluting in cyclohexane/EtOAc 
1:1 to afford the pure product as a white solid (1.02 g, yield 98%). 
56: white solid; TLC (KMnO4; PMA): Rf = 0.32 (cyclohexane/EtOAc 1:1); m.p.: 176.6-184.6°C. 
1H NMR (CDCl3, 300 MHz,): δ 8.16 (d, J = 8.3 Hz, 1H), 6.83 (dd, J = 2.5, 8.3 Hz, 1H), 6.79 (d,  
J = 2.5 Hz, 1H), 3.86 (s, 3H), 2.79 (s, 3H). 
13C NMR (CDCl3, 75 MHz): δ 162.7, 148.8, 139.5, 116.4, 110.6, 55.2, 23.5. 
 
 
3-(4-methoxy-2-methylphenyl)-5,7-bis((2-methoxyethoxy)methoxy)-4H-chromen-
4-one (54) 
The title compound was prepared 
according to general procedure 5.2.2.2 by 
reacting 52 (150 mg, 0.31 mmol, 1 equiv) 
with 4-methoxy-2-methylphenylboronic acid 
(56) (103 mg, 0.62 mmol, 2 equiv). The 
mixture was heated in a microwave reactor 
at 80°C for 1h (TLC cyclohexane/EtOAc 1:1). 
Upon completion, the cooled mixture was filtered through a Celite pad, diluted with 
deionized water and then extracted with CH2Cl2 (x 3). The combined organic layers were 
dried over Na2SO4, filtered and the solvents evaporated in vacuo. The crude product was 
purified by silica gel column chromatography eluting in 100% EtOAc to yield the desired 
product as a dark yellow oil (122 mg, yield 83%). 
54: dark yellow oil; TLC (KMnO4; PMA): Rf = 0.50 (EtOAc). 
1H NMR (CDCl3, 300 MHz) δ 7.65 (s, 1H), 7.06 (d, J = 8.3 Hz, 1H), 6.80 – 6.72 (m, 4H), 5.36 (s, 
2H),5.33 (s, 2H), 3.91 – 3.88 (m, 2H), 3.86 – 3.82 (m, 2H), 3.80 (s, 3H), 3.59 – 3.53 (m, 4H), 
3.38 (s, 3H), 3.35 (s, 3H), 2.21 (s, 3H). 
13C NMR (CDCl3, 75 MHz) δ 175.3, 161.2, 159.7, 159.7, 158.5, 151.4, 139.6, 131.8, 126.9, 
124.2, 115.8, 111.5, 111.0, 102.6, 97.4, 94.8, 93.4, 71.6, 68.3, 59.2, 59.0, 55.3, 20.5.  
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5,7-dihydroxy-3-(4-hydroxy-2-methylphenyl)-4H-chromen-4-one (5a) 
In anhydrous conditions and under argon 
atmosphere, to a stirred solution of 54 (122 mg, 
0.26 mmol, 1 equiv) in dry CH2Cl2 (6 mL), cooled 
at -78°C, 1M BBr3 in hexanes (1.82 mL, 1.82 
mmol, 7 equiv) was slowly added. The reaction 
mixture was stirred at -78°C for 1h and then at 
RT until completion. After 2h (TLC in 
CH2Cl2/MeOH 95:5), the reaction was quenched by additioning 5% aqueous solution of 
Na2CO3 and extracted with CH2Cl2/i-PrOH 9:1 (x 3). The combined organic layers were 
washed with brine, dried over Na2SO4, filtered and evaporated in vacuo. The crude material 
wassubsequently purified by silica gel column chromatography eluting in CH2Cl2/MeOH 97:3 
and then re-crystalized from EtOH to provide the pure compound (45 mg, yield 62%). 
5a: pale yellow solid; TLC (KMnO4; PMA): Rf = 0.34 (CH2Cl2/MeOH 95:5); m.p.: 283.3-284.6°C 
(dec.); MS (ESI) m/z for C16H13O5+ [M+H]+ calcd. 285.1, found 285.1. 
1H NMR ((CD3)2CO, 300 MHz) δ 9.67 (br s, 1H), 8.43 (br s, 1H), 7.98 (s, 1H), 7.04 (d,  
J = 8.2 Hz, 1H), 6.77 (d, J = 2.3 Hz, 1H), 6.70 (dd, J = 8.2, 2.6 Hz, 1H), 6.42 (d, J = 2.2 Hz, 1H), 
6.29 (d, J = 2.1 Hz, 1H), 3.23 (br s, 1H), 2.17 (s, 3H). 
13C NMR ((CD3)2CO, 75 MHz) δ 181.6, 165.0, 163.8, 159.2, 158.5, 155.4, 140.3, 132.7, 125.1, 
122.9, 117.6, 113.3, 106.0, 99.8, 94.5, 20.3. 
 
 
5,7-dihydroxy-3-(4-methoxy-2-methylphenyl)-4H-chromen-4-one (5b) 
The title compound was prepared 
according to general procedure 5.2.2.3 by 
reacting 54 (53 mg, 0.11 mmol, 1 equiv) with 12N 
HCl (60 μL) in CHCl3 (330 μL) and MeOH (330 μL). 
The mixture was refluxed for 1h. Upon 
completion (TLC in 100% EtOAc), the reaction was 
quenched with deionized water and the mixture 
was extracted with CH2Cl2 (x 3). The combined organic layers were washed with H2O, dried 
over Na2SO4, filtered and the solvents evaporated in vacuo. The crude product was purified 
by silica gel column chromatography (CH2Cl2/MeOH 95:5) to yield the desired product as a 
yellow oil, then re-crystalized from EtOH to provide a yellowish solid (25 mg, yield 75%). 
5b: yellowish solid; TLC (KMnO4; PMA): Rf = 0.47 (CH2Cl2/MeOH 9:1); m.p.: 223.8-225.3°C 
(dec.); MS (ESI) m/z for C17H15O5+ [M+H]+ calcd. 299.1, found 299.1. 
1H NMR ((CD3)2CO, 300 MHz) δ 9.72 (br s, 1H), 8.01 (s, 1H), 7.14 (d, J = 8.3 Hz, 1H), 6.86 (d, J 
= 2.5 Hz, 1H), 6.79 (dd, J = 8.3, 2.6 Hz, 1H), 6.43 (d, J = 2.1 Hz, 1H), 6.29 (d, J = 2.1 Hz, 1H), 
3.81 (s, 3H), 3.02 (br s, 1H), 2.22 (s, 3H). 
13C NMR ((CD3)2CO, 75 MHz) δ 181.5, 165.0, 163.8, 160.9, 159.3, 155.5, 140.41, 132.7, 
125.0, 124.1, 116.3, 111.7, 99.9, 94.6, 55.5, 20.4.  
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3-(4-aminophenyl)-5,7-bis((2-methoxyethoxy)methoxy)-4H-chromen-4-one (55) 
The title compound was prepared 
according to general procedure 5.2.2.2 by 
reacting 52 (1.0 g, 2.08 mmol, 1 equiv) with  
4-aminophenylboronic acid pinacol ester (912 
mg, 4.16 mmol, 2 equiv). The mixture was 
heated in oil bath at 90°C for 3h and monitored 
by TLC in 100% EtOAc. Upon completion, the 
cooled mixture was filtered through a Celite pad, diluted with deionized water and then 
extracted with CH2Cl2 (x 3). The combined organic layers were dried over Na2SO4, filtered 
and the solvents evaporated in vacuo. The crude product was purified by silica gel column 
chromatography (EtOAc) to give the desired product as a yellow oil (600 mg, yield 65%). 
55: yellow oil; TLC (KMnO4; PMA): Rf = 0.35 (EtOAc). 
1H NMR (CDCl3, 300 MHz) δ 7.69 (s, J = 0.6 Hz, 1H), 7.25 (d, J = 8.1 Hz, 2H), 6.71 – 6.67 (m, 
2H), 6.64 (d, J = 8.2 Hz, 2H), 5.32 (s, 2H), 5.25 (s, 2H), 3.88 – 3.81 (m, 2H), 3.81 – 3.73 (m, 
2H), 3.54 – 3.44 (m, 4H), 3.31 (s, 3H), 3.29 (s, 3H). 
13C NMR (CDCl3, 75 MHz) δ 175.5, 161.0, 159.4, 158.5, 150.1, 146.5, 130.2, 126.2, 121.8, 
114.9, 111.3, 102.0, 97.1, 94.4, 93.3, 71.5, 68.2, 59.1, 59.0. 
 
 
 
3-(4-aminophenyl)-5,7-dihydroxy-4H-chromen-4-one hydrochloride (5c) 
The title compound was prepared by 
reacting 55 (133 mg, 0.30 mmol, 1 equiv) with 4M 
HCl  in 1,4-dioxane (6 mL). The mixture was stirred 
at room temperature for 2h. Upon completion 
(TLC in 100% EtOAc), the solvent was removed 
under reduced pressure and the crude was then 
re-crystalized from EtOH, affording the desired 
product as a brownish solid (80 mg, yield 87%). 
5c: brownish solid; TLC (KMnO4; PMA): Rf = 0.46 (cyclohexane/EtOAC 1:1); m.p.: 272.6-
275.0°C; MS (ESI) m/z for C15H12NO4+ [M]+ calcd. 270.1, found 270.0. 
1H NMR ((CD3)2SO, 300 MHz) δ 8.23 (s, 1H), 7.76 (d, J = 8.4 Hz, 2H), 7.47 (d, J = 8.4 Hz, 2H), 
6.38 (d, J = 2.1 Hz, 1H), 6.25 (d, J = 2.1 Hz, 1H). 
13C NMR ((CD3)2SO, 75 MHz) δ 181.9, 165.0, 164.0, 159.0, 153.7, 149.5, 130.6, 124.5, 119.9, 
114.8, 106.2, 99.7, 94.4.  
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5.3 Silent agonists derivatives 
5.3.1 Experimental procedures for the synthesis of 6a-u, 7 and 8 
5.3.1.1 General procedure for the coupling between  
1-ethylpiperazine and the appropriate aryl halide (57-75)  
The coupling reaction is carried out in anhydrous conditions and under argon 
atmosphere. In a flame-dried and argon fluxed flask, K2CO3 (2 equiv, for aryl iodide) or 
K3PO4 (2 equiv, for aryl bromide), CuI (0.1 equiv), and L-proline (0.2 equiv) were suspended 
in dry DMSO (1.6 mL/mmol 1-ethylpiperazine). Then, the appropriate aryl halide (1 equiv) 
and 1-ethylpiperazine (1.5 equiv) were subsequently added. The resulting mixture was 
heated at 90-100°C until completion (TLC in hexanes/EtOAc 9:1). Upon completion, to the 
cooled mixture was added deionized water, the organic layer was separated, and the 
aqueous layer was extracted with EtOAc (x 3). The combined organic layers were washed 
once with saturated brine, dried over anhydrous MgSO4, filtered and concentrated under 
reduced pressure. The residue was purified on a silica gel column chromatography eluted 
with a mixture of EtOAc/MeOH to provide the corresponding pure aniline. When coupling 
aryl di-bromides, 1-ethylpiperazine and the aryl bromide were used in a 1:1 stoichiometric 
ratio. 
 
5.3.1.2 General procedure for ethylation (6a-q and 6t-u)  
In a sealed vial, the coupled compound 57-75 (1 equiv) was dissolved in dry THF and 
some copper was added as stabilizer. EtI (7 equiv) was added and the resulting mixture was 
heated at 90°C until complete consumption of the starting material (TLC in CH2Cl2/MeOH 
9:1). Upon completion, the mixture was cooled to RT and the solvent removed under 
reduced pressure. The crude was then purified by re-crystallization from a proper solvent, 
directly or after a chromatography (silica column, elution in CH2Cl2/MeOH 9:1).. 
 
5.3.1.3 General procedure for hydration of nitrile to amide (6r-s)  
In anhydrous conditions and under argon atmosphere, in a sealed vial, the 
appropriate benzonitrile derivative (2 equiv), acetaldoxime (4 equiv) and Pd(PPh3)4 (0.1 
equiv) were put in a sealed vial and dissolved in EtOH. The resulting mixture was refluxed 
until complete consumption of the starting material and monitored by TLC on neutral 
alumina CH2Cl2/MeOH 95:5 or 85:15. Upon completion, the reaction was cooled to RT, 
filtered through a Celite pad and washed with hot EtOH. The solvent was evaporated under 
reduced pressure and the residue was purified with neutral alumina column 
chromatography, eluting in CH2Cl2/MeOH 95:5 to 85:15. The collected fractions were then 
re-crystallized from MeOH or EtOH to afford the pure compound. 
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1-ethyl-4-p-tolylpiperazine (57) 
The title compound was prepared according to the general 
procedure described in 5.3.1.1, by reacting 4-iodotoluene (114 mg, 
0.53 mmol, 1 equiv) and 1-ethylpiperazine (100 μL, 0.79 mmol, 1.5 
equiv). After standard workup, 57 was obtained as an orange oil (70 
mg, yield 65 %).  
57: orange oil; TLC (KMnO4): Rf = 0.51 (CH2Cl2/MeOH 9:1). 
1H NMR (CDCl3, 300 MHz) δ 6.99 (d, J = 8.2 Hz, 2H), 6.77 (d, J = 8.3 Hz, 
2H), 3.14 – 3.06 (m, 4H), 2.59 – 2.49 (m, 4H), 2.40 (q, J = 7.2 Hz, 2H), 
2.18 (s, 3H), 1.05 (t, J = 7.2 Hz, 3H).  
13C NMR (CDCl3, 75 MHz) δ 149.3, 129. 7, 129.2, 116.5, 53.0, 52.4, 
49.7, 20.5, 12.0.  
 
 
 
 
1,1-diethyl-4-p-tolylpiperazin-1-ium iodide (6a) 
According to the general procedure 5.3.1.2, EtI (141 L, 1.75 
mmol, 7 equiv) was added to a solution of 1-ethyl-4-p-tolylpiperazine 
(57) (50 mg, 0.25 mmol, 1 equiv) in dry THF. Evaporation of the 
solvent under reduced pressure afforded the crude quaternary salt 
quantitatively that was re-crystalized from i-PrOH to give the pure 
final compound as a yellow solid (60 mg, yield 68%). 
6a: yellow solid; TLC (KMnO4; Dragendorff): Rf = 0.37 (CH2Cl2/MeOH 
4:1); m.p.: 147.4-148.8°C; HMRS [M]+ (C15H25N2+) Calcd 233.2012, 
Found 233.2017. 
1H NMR ((CD3)2SO, 300 MHz) δ 7.09 (d, J = 8.3 Hz, 2H), 6.91 (d, J = 8.4 Hz, 2H), 3.58 – 3.50 
(m, 4H), 3.51 – 3.37 (m, 8H), 2.22 (s, 3H), 1.21 (t, J = 7.2 Hz, 6H). 
13C NMR ((CD3)2SO, 75 MHz) δ 147.2, 129.5, 128.8, 115.8, 56.5, 51.9, 42.0, 20.1, 6.7.  
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1-ethyl-4-m-tolylpiperazine (58) 
The title compound was prepared according to the general 
procedure described in 5.3.1.1, by reacting 3-bromotoluene (320 μL, 
450 mg, 2.63 mmol, 1 equiv) and 1-ethylpiperazine (500 μL, 3.94 
mmol, 1.5 equiv). After standard workup, 58 was obtained as a yellow 
oil (106 mg, yield 20%). 
58: yellow oil; TLC (KMnO4): Rf = 0.51 (CH2Cl2/MeOH 9:1). 
1H NMR (CDCl3, 300 MHz) δ 7.15 (tt, J = 8.1, 1.1 Hz, 1H), 6.78 – 6.74 
(m, 2H), 6.74 – 6.66 (m, 1H), 3.26 – 3.18 (m, 4H), 2.66 – 2.59 (m, 4H), 
2.49 (q, J = 7.2 Hz, 2H), 2.32 (s, 3H), 1.13 (t, J = 7.2 Hz, 3H). 
13C NMR (CDCl3, 75 MHz) δ 151.5, 138.9, 129.0, 120.7, 117.0, 113.3, 53.0, 52.4, 49.2, 21.9, 
12.0. 
 
 
 
 
 
 
1,1-diethyl-4-m-tolylpiperazin-1-ium iodide (6b) 
According to the general procedure 5.3.1.2, EtI (276 L, 3.43 
mmol, 7 equiv) was added to a solution of 1-ethyl-4-m-tolylpiperazine 
(58) (101 mg, 0.49 mmol, 1 equiv) in dry THF. Evaporation of the 
solvent under reduced pressure afforded the crude quaternary salt 
quantitatively that was first purified by silica gel column 
chromatography, eluting in CH2Cl2/MeOH 9:1, and then re-crystalized 
from THF and EtOH to give the pure final compound as yellow crystals 
(77 mg, yield 43%). 
6b: yellow crystals; TLC (KMnO4; Dragendorff): Rf = 0.37 
(CH2Cl2/MeOH 4:1); m.p.: 144.0-145.0°C; HMRS [M]+ (C15H25N2+) Calcd 233.2012 Found 
233.2023. 
1H NMR (CD3OD, 500 MHz) δ 7.16 (t, J = 7.9 Hz, 1H), 6.88 – 6.85 (m, 1H), 6.82 (dd, 1H), 6.78 
– 6.74 (m, 1H), 3.64 – 3.59 (m, 4H), 3.56 – 3.48 (m, 8H), 2.31 (s, 3H), 1.40 – 1.33 (m, 6H). 
13C NMR (CD3OD, 126 MHz) δ 150.9, 140.2, 130.1, 123.0, 118.3, 114.7, 58.8, 54.2, 44.1, 
21.7, 7.4.   
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1-ethyl-4-o-tolylpiperazine (59) 
The title compound was prepared according to the general 
procedure described in 5.3.1.1, by reacting 2-iodotoluene (1.34 mL, 
2.29 g, 10.50 mmol, 1 equiv) and 1-ethylpiperazine (2.0 mL, 15.75 
mmol, 1.5 equiv). After standard workup, 59 was obtained as a 
reddish oil (386 mg, yield 18%). 
59: reddish oil; TLC (KMnO4): Rf = 0.51 (CH2Cl2/MeOH 9:1). 
1H NMR (CDCl3, 300 MHz) δ 7.20 – 7.12 (m, 2H), 7.06 – 7.01 (m, 1H), 
7.00 – 6.94 (m, 1H), 3.00 – 2.94 (m, 4H), 2.69 – 2.57 (m, 4H), 2.51 (q, J 
= 7.3 Hz, 2H), 2.30 (s, 3H), 1.14 (t, J = 7.3 Hz, 3H).  
13C NMR (CDCl3, 75 MHz) δ 151.6, 132.6, 131.1, 126.6, 123.2, 119.1, 53.4, 52.5, 51.7, 18.0, 
12.1. 
 
 
 
 
1,1-diethyl-4-o-tolylpiperazin-1-ium iodide (6c) 
According to the general procedure 5.3.1.2, EtI (1.06 mL, 
13.16 mmol, 7 equiv) was added to a solution of 1-ethyl-4-o-
tolylpiperazine (59) (385 mg, 1.88 mmol, 1 equiv) in dry THF. 
Evaporation of the solvent under reduced pressure afforded the 
crude quaternary salt quantitatively that was re-crystalized from 
THF/ethanol/MeOH to give the pure final compound as bright white 
crystals (301 mg, yield 45%). 
6c: bright white crystals; TLC (KMnO4; Dragendorff): Rf = 0.37 
(CH2Cl2/MeOH 4:1); m.p.: 158.5-160.2°C; HMRS [M]+ (C15H25N2+) Calcd 
233.2012 Found 233.2023. 
1H NMR (CD3OD, 500 MHz) δ 7.26 – 7.16 (m, 3H), 7.07 – 7.01 (m, 1H), 3.67 – 3.62 (m, 4H), 
3.60 (q, J = 7.4 Hz, 4H), 3.29 – 3.23 (m, 4H), 2.33 (s, 3H), 1.38 (t, J = 7.1 Hz, 6H).  
13C NMR (CD3OD, 126 MHz) δ 150.6, 134.2, 132.3, 127.9, 125.8, 120.9, 59.6, 46.4, 17.9, 7.4.  
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1-ethyl-4-(4-methoxyphenyl)piperazine (60) 
 The title compound was prepared according to the general 
procedure described in 5.3.1.1, by reacting 4-iodoanisole (616 mg, 
2.63 mmol, 1 equiv) and 1-ethylpiperazine (500 μL, 3.94 mmol, 1.5 
equiv). After standard workup, 60 was obtained as a pale yellow solid 
(302 mg, yield 52%). 
60: pale yellow solid; TLC (KMnO4):  
Rf = 0.44 (CH2Cl2/MeOH 9:1); m.p.:56.6-57.8 °C. 
1H NMR (CDCl3, 300 MHz) δ 6.84 (d, J = 9.1 Hz, 2H), 6.77 (d, J = 9.2 Hz, 
2H), 3.70 (s, 3H), 3.09 – 3.02 (m, 4H), 2.60 – 2.52 (m, 4H), 2.41 (q, J = 
7.3 Hz, 2H), 1.06 (t, J = 7.2 Hz, 3H). 
13C NMR (CDCl3, 75 MHz) δ 153.7, 145.7, 118.1, 114.4, 55.5, 52.9, 52.3, 50.6, 12.0. 
 
 
 
 
 
 
1,1-diethyl-4-(4-methoxyphenyl)piperazin-1-ium iodide (6d) 
According to the general procedure 5.3.1.2, EtI (692 L, 8.61 
mmol, 7 equiv) was added to a solution of 1-ethyl-4-(4-
methoxyphenyl)piperazine (60) (270 mg, 1.23 mmol, 1 equiv) in dry 
THF. Evaporation of the solvent under reduced pressure afforded the 
crude quaternary salt quantitatively that was re-crystalized from THF 
and EtOH to give the pure final compound as bright yellowish crystals 
(334 mg, yield 72%). 
6d: bright yellowish crystal; TLC (KMnO4; Dragendorff): Rf = 0.35 
(CH2Cl2/MeOH 4:1); m.p.: 150.5-153.1°C; HMRS [M]+ (C15H25N2O+) 
Calcd 249.1961 Found 249.1972. 
1H NMR (CD3OD, 500 MHz) δ 7.01 (d, J = 9.1 Hz, 2H), 6.88 (d, J = 9.1 Hz, 2H), 3.75 (s, 3H), 
3.65 – 3.59 (m, 4H), 3.54 (q, J = 7.3 Hz, 4H), 3.45 – 3.39 (m, 4H), 1.36 (t, J = 7.3 Hz, 6H). 
13C NMR (CD3OD, 126 MHz) δ 156.4, 145.0, 119.9, 115.6, 59.0, 56.0, 54.3, 45.4, 7.4.  
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1-ethyl-4-(3-methoxyphenyl)piperazine (61) 
The title compound was prepared according to the general 
procedure described in 5.3.1.1, by reacting 3-iodoanisole (1.25 mL, 
2.46 g, 10.50 mmol, 1 equiv) and 1-ethylpiperazine (2.0 mL, 15.75 
mmol, 1.5 equiv). After standard workup, 61 was obtained as a red oil 
(1.62 g, yield 70%). 
61: red oil; TLC (KMnO4): Rf = 0.50 (CH2Cl2/MeOH 9:1). 
1H NMR (CDCl3, 300 MHz) δ 7.08 (t, J = 8.2 Hz, 1H), 6.46 (ddd, J = 8.3, 
2.3, 1.0 Hz, 1H), 6.39 (t, J = 2.3 Hz, 1H), 6.33 (ddd, J = 8.2, 2.3, 0.9 Hz, 
1H), 3.70 (s, 3H), 3.17 – 3.10 (m, 4H), 2.55 – 2.49 (m, 4H), 2.39 (q, J = 
7.2 Hz, 2H), 1.05 (t, J = 7.2 Hz, 3H). 
13C NMR (CDCl3, 75 MHz) δ 160.7, 152.8, 129.8, 108.9, 104.4, 102.5, 55.2, 52.9, 52.4, 49.1, 
12.1. 
 
 
 
 
1,1-diethyl-4-(3-methoxyphenyl)piperazin-1-ium iodide (6e) 
According to the general procedure 5.3.1.2, EtI (1.28 mL, 
15.96 mmol, 7 equiv) was added to a solution of 1-ethyl-4-(3-
methoxyphenyl)piperazine (61) (503 mg, 2.28 mmol, 1 equiv) in dry 
THF. Evaporation of the solvent under reduced pressure afforded the 
crude quaternary salt quantitatively that was re-crystalized from THF 
and EtOH to give the pure final compound as white crystals (649 mg, 
yield 76%). 
6e: white crystals; TLC (KMnO4; Dragendorff): Rf = 0.35 (CH2Cl2/MeOH 
4:1); m.p.: 146.0-147.0°C; HMRS [M]+ (C15H25N2O+) Calcd 249.1961, 
Found 249.1966. 
1H NMR (CD3OD, 500 MHz) δ 7.19 (t, J = 8.2 Hz, 1H), 6.62 (dd, J = 8.3, 2.1 Hz, 1H), 6.57 (t, J = 
2.4 Hz, 1H), 6.51 (dd, J = 8.2, 2.3 Hz, 1H), 3.77 (s, 3H), 3.64 – 3.60 (m, 4H), 3.57 – 3.48 (m, 
8H), 1.36 (t, J = 7.4 Hz, 6H).  
13C NMR (CD3OD, 126 MHz) δ 162.2, 152.2, 131.1, 110.1, 107.3, 104.0, 58.7, 55.8, 54.3, 
44.0, 7.4.   
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1-(2,4-dimethoxyphenyl)-4-ethylpiperazine (62) 
The title compound was prepared according to the general 
procedure described in 5.3.1.1, by reacting 1-bromo-2,4-
dimethoxybenzene (2.28 g, 1.51 mL, 10.5 mmol, 1 equiv) and 1-
ethylpiperazine (2.0 mL, 15.75 mmol, 1.5 equiv). After standard 
workup, 62 was obtained as a brown oil (839 mg, yield 32%). 
62: brown oil; TLC (KMnO4): Rf = 0.36 (CH2Cl2/MeOH 9:1). 
1H NMR (CDCl3, 300 MHz) δ 6.88 (d, J = 8.5 Hz, 1H), 6.48 (d, J = 2.6 Hz, 
1H), 6.43 (ddd, J = 8.6, 2.7, 0.8 Hz, 1H), 3.84 (s, 3H), 3.78 (s, 3H), 3.14 – 
2.97 (m, 4H), 2.75 – 2.57 (m, 4H), 2.49 (q, J = 7.2 Hz, 2H), 1.13 (t, J = 
7.2 Hz, 3H). 
13C NMR (CDCl3, 75 MHz) δ 156.2, 153.5, 135.4, 118.6, 103.4, 100.0, 55.6, 55.5, 53.3, 52.5, 
51.3, 12.1. 
 
 
4-(2,4-dimethoxyphenyl)-1,1-diethylpiperazin-1-ium iodide (6f) 
According to the general procedure 5.3.1.2, EtI (1.13 mL, 
14.07 mmol, 7 equiv) was added to a solution of 1-(2,4-
dimethoxyphenyl)-4-ethylpiperazine (62) (502 mg, 2.01 mmol, 1 
equiv) in dry THF. Evaporation of the solvent under reduced pressure 
afforded the crude quaternary salt quantitatively that was re-
crystalized from THF and EtOH to give the pure final compound as a 
white solid (236 mg, yield 29%). 
6f: white solid; TLC (KMnO4; Dragendorff):Rf = 0.34 (CH2Cl2/MeOH 
4:1); m.p.: 187.0-188.8°C; HMRS [M]+ (C16H27N2O2+) Calcd 279.2067 
Found 279.2078. 
1H NMR (CD3OD, 300 MHz) δ 7.01 (d, J = 8.6 Hz, 1H), 6.57 (d, J = 2.7 Hz, 1H), 6.49 (dd, J = 
8.7, 2.7 Hz, 1H), 3.84 (s, 3H), 3.76 (s, 3H), 3.64 – 3.49 (m, 8H), 3.36 – 3.31 (m, 4H), 1.36 (t, J 
= 7.3 Hz, 6H).  
13C NMR (CD3OD, 75 MHz) δ 158.8, 155.2, 133.8, 121.5, 105.3, 100.9, 59.3, 56.2, 56.0, 54.5, 
45.6, 7.5.   
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1-ethyl-4-(4-(trifluoromethyl)phenyl)piperazine (63) 
The title compound was prepared according to the general 
procedure described in 5.3.1.1, by reacting 1-iodo-4-
(trifluoromethyl)benzene (2.86 g, 1.54 mL, 10.50 mmol, 1 equiv) and 
1-ethylpiperazine (2.0 mL, 15.75 mmol, 1.5 equiv). After standard 
workup, 63 was obtained as a white solid (2.20 g, yield 81%). 
63: white solid; TLC (KMnO4): Rf = 0.51 (CH2Cl2/MeOH 9:1); m.p.: 56.3-
56.5°C; HMRS [M+H]+ (C13H18F3N2+) Calcd 259.1417, Found 259.1426. 
1H NMR (CDCl3, 300 MHz) δ 7.48 (d, J = 8.6 Hz, 2H), 6.92 (d, J = 8.6 Hz, 
2H), 3.36 – 3.26 (m, 4H), 2.64 – 2.56 (m, 4H), 2.48 (q, J = 7.2 Hz, 2H), 
1.14 (t, J = 7.2 Hz, 3H). 
13C NMR (CDCl3, 126 MHz) δ 153.5, 126.4, 125.0 (q, J = 276 Hz) 120.4 (q, J = 37 Hz), 114.5, 
52.7, 52.5, 48.1, 12.1.  
 
 
1,1-diethyl-4-(4-(trifluoromethyl)phenyl)piperazin-1-ium iodide (6g) 
According to the general procedure 5.3.1.2, EtI (1.55 mL, 
19.32 mmol, 7 equiv) was added to a solution of 1-ethyl-4-(4-
(trifluoromethyl)phenyl)piperazine (63) (714 mg, 2.76 mmol, 1 equiv) 
in dry THF. Evaporation of the solvent under reduced pressure 
afforded the crude quaternary salt quantitatively that was purified by 
silica gel column chromatography, eluting in CH2Cl2/MeOH 95:5 to 9:1 
affording a yellow solid (546 mg, yield 48%). Then, it was re-
crystalized from MeOH to give the pure final compound as white 
crystals (70 mg, yield 6%). 1H NMR spectrum comparison before and 
after re-crystallization revealed the crude product was more than 95% 
pure. 
6g: white crystals; TLC (KMnO4; Dragendorff): Rf = 0.48 in CH2Cl2/MeOH 75:25); m.p.: 175.2-
175.5°C; HMRS [M]+ (C15H22F3N2+) Calcd 287.1730 Found 287.1723.  
1H NMR ((CD3)2SO, 300 MHz) δ 7.59 (d, J = 8.4 Hz, 2H), 7.16 (d, J = 8.6 Hz, 2H), 3.74 – 3.61 
(m, 4H), 3.61 – 3.54 (m, 4H), 3.50 (q, J = 7.2 Hz, 4H), 1.23 (t, J = 7.2 Hz, 6H).  
13C NMR ((CD3)2SO, 75 MHz) δ 151.9, 124.8 (q, J = 271 Hz), 126.2 (q, J = 4 Hz), 119.0 (q, J = 
32 Hz), 114.6, 56.1, 51.9, 40.5, 6.8.   
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1-ethyl-4-(3-(trifluoromethyl)phenyl)piperazine (64) 
The title compound was prepared according to the general 
procedure described in 5.3.1.1, by reacting 3-bromobenzotrifluoride 
(2.36 g, 1.47 mL, 10.50 mmol, 1 equiv) and 1-ethylpiperazine (2.0 mL, 
15.75 mmol, 1.5 equiv). After standard workup, 64 was obtained as a 
yellow oil (1.73 g, yield 64%). 
64: yellow oil; TLC (KMnO4): Rf = 0.54 (CH2Cl2/MeOH 9:1);  
HMRS [M+H]+ (C13H18F3N2+) Calcd 259.1417, Found 259.1423. 
1H NMR (CDCl3, 300 MHz) δ 7.39 – 7.29 (m, 1H), 7.14 – 7.10 (m, 1H), 
7.09 – 7.03 (m, 2H), 3.31 – 3.21 (m, 4H), 2.66 – 2.57 (m, 4H), 2.48 (q, J 
= 7.2 Hz, 2H), 1.13 (t, J = 7.2 Hz, 3H). 
13C NMR (CDCl3, 126 MHz) δ 151.5, 131.5 (q, J = 31 Hz) 129.6, 124.4, (q, J = 271 Hz) 118.6, 
115.7, 112.1, 52.7, 52.4, 48.7, 12.1.  
 
 
 
1,1-diethyl-4-(3-(trifluoromethyl)phenyl)piperazin-1-ium iodide (6h) 
According to the general procedure 5.3.1.2, EtI (1.53 mL, 
18.97 mmol, 7 equiv) was added to a solution of 1-ethyl-4-(3-
(trifluoromethyl)phenyl)piperazine (64) (701 mg, 2.71 mmol, 1 equiv) 
in dry THF. Evaporation of the solvent under reduced pressure 
afforded the crude quaternary salt quantitatively that was re-
crystalized from MeOH to give the pure final compound as yellowish 
crystals (235 mg, yield 21%).  
6h: yellowish crystals; TLC (KMnO4): Rf = 0.48 (CH2Cl2/MeOH 75:25); 
m.p.: 207-208°C; HMRS [M]+ (C15H22F3N2+) Calcd 287.1730 Found 
287.1738.  
1H NMR (CD3OD, 300 MHz) δ 7.52 – 7.43 (m, 1H), 7.32 – 7.26 (m, 2H), 7.23 – 7.16 (m, 1H), 
3.69 – 3.60 (m, 8H), 3.56 (q, J = 7.3 Hz, 4H), 3.34 (s, methanol), 1.45 – 1.30 (m, 6H). 
13C NMR (CD3OD, 75 MHz) 151.3, 132.5 (q, J = 32 Hz), 131.2, 125.7 (q, J = 273 Hz), 120.7, 
118.0, 113.5, 58.5, 54.3, 43.4, 7.5.  
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1-ethyl-4-(4-fluorophenyl)piperazine (65) 
The title compound was prepared according to the general 
procedure described in 5.3.1.1, by reacting 4-fluoroiodobenzene (2.33 
g, 1.21 mL, 10.50 mmol, 1 equiv) and 1-ethylpiperazine (2.0 mL, 15.75 
mmol, 1.5 equiv). After standard workup, 65 was obtained as 
yellowish solid (1.77 g, yield 81%). 
65: yellowish solid; TLC (KMnO4): Rf = 0.46 (CH2Cl2/MeOH 9:1);  
m.p.: 30.0-30.5°C. 
1H NMR (CDCl3, 300 MHz) δ 7.02 – 6.92 (m, 2H), 6.92 – 6.84 (m, 2H), 
3.20 – 3.10 (m, 4H), 2.66 – 2.57 (m, 4H), 2.48 (q, J = 7.3 Hz, 2H), 1.13 
(t, J = 7.2 Hz, 3H).  
13C NMR (CDCl3, 75 MHz) δ 157.2 (d, J = 239 Hz), 148.1, 117.8 (d, J = 7.7 Hz), 115.5 (d, J = 
22.2 Hz), 52.9, 52.4, 50.2, 12.1. 
 
 
 
1,1-diethyl-4-(4-fluorophenyl)piperazin-1-ium iodide (6i) 
According to the general procedure 5.3.1.2, EtI (1.90 mL, 
23.66 mmol, 7 equiv) was added to a solution of 1-ethyl-4-(4-
fluorophenyl)piperazine (65) (704 mg, 3.38 mmol, 1 equiv) in dry THF. 
Evaporation of the solvent under reduced pressure afforded the 
crude quaternary salt quantitatively that was re-crystalized from THF 
and EtOH to give the pure final compound as white crystals (478 mg, 
yield 39%).  
6i: white crystals; TLC (KMnO4; Dragendorff): Rf = 0.31 (CH2Cl2/MeOH 
4:1); m.p.: 194.0-194.3°C; HMRS [M]+ (C14H22FN2+) Calcd 237.1762 
Found 237.1767. 
1H NMR (CD3OD, 300 MHz) δ 7.08 – 7.04 (m, 2H), 7.04 – 7.01 (m, 2H), 3.66 – 3.59 (m, 4H), 
3.58 – 3.50 (m, 4H), 3.50 – 3.43 (m, 4H), 1.43 – 1.30 (m, 6H).  
13C NMR (CD3OD, 75 MHz) δ 159.2 (d, J = 240 Hz), 147.6, 119.7 (d, J = 8 Hz), 116.6 (d, J = 23 
Hz), 58.8, 54.3, 44.8, 7.5.  
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1-ethyl-4-(3-fluorophenyl)piperazine (66) 
The title compound was prepared according to the general 
procedure described in 5.3.1.1, by reacting 3-fluoroiodobenzene (2.33 
g, 1.23 mL, 10.50 mmol, 1 equiv) and 1-ethylpiperazine (2.0 mL, 15.75 
mmol, 1.5 equiv). After standard workup, 66 was obtained as a yellow 
oil (697 mg, yield 75%). 
66: yellow oil; TLC (KMnO4): Rf = 0.49 (CH2Cl2/MeOH 9:1). 
1H NMR (CDCl3, 300 MHz) δ 7.23 – 7.12 (m, 1H), 6.71 – 6.64 (m, 1H), 
6.63 – 6.55 (m, 1H), 6.55 – 6.47 (m, 1H), 3.27 – 3.17 (m, 4H), 2.64 – 
2.54 (m, 4H), 2.47 (q, J = 7.2 Hz, 2H), 1.13 (t, J = 7.2 Hz, 3H).  
13C NMR (CDCl3, 75 MHz) δ 164.0 (d, J = 243 Hz), 153.1 (d, J = 10 Hz), 130.2 (d, J = 10 Hz), 
111.1 (d, J = 2 Hz), 105.8 (d, J = 22 Hz), 102.7 (d, J = 25 Hz), 52.8, 52.5, 48.7, 12.1. 
 
 
 
 
 
 
1,1-diethyl-4-(3-fluorophenyl)piperazin-1-ium iodide (6j) 
According to the general procedure 5.3.1.2, EtI (2.17 mL, 
26.95 mmol, 7 equiv) was added to a solution of 1-ethyl-4-(3-
fluorophenyl)piperazine (66) (801 mg, 3.85 mmol, 1 equiv) in dry THF. 
Evaporation of the solvent under reduced pressure afforded the 
crude quaternary salt quantitatively that was purified by silica gel 
column chromatography, eluting in CH2Cl2/MeOH 9:1. Despite several 
attempts in different solvents, crystals were not obtained. The pure 
final compound was afforded as an off-white solid (901 mg, yield 
64%).  
6j: off-white solid; TLC (KMnO4; Dragendorff): Rf = 0.33 in CH2Cl2/MeOH 4:1); m.p.: 125.0-
127.0 °C; HMRS [M]+ (C14H22FN2+) Calcd 237.1762 Found 237.1760. 
1H NMR ((CD3)2SO, 300 MHz) δ 7.35 – 7.23 (m, 1H), 6.92 – 6.80 (m, 2H), 6.71 – 6.61 (m, 1H), 
3.62 – 3.51 (m, 8H), 3.48 (q, J = 7.2 Hz, 4H), 1.22 (t, J = 7.2 Hz, 6H).  
13C NMR ((CD3)2SO, 75 MHz) δ 163.1 (d, J = 241 Hz), 151.1 (d, J = 10 Hz), 130.5 (d, J = 10 Hz), 
111.0 (d, J = 2 Hz), 105.7 (d, J = 21 Hz), 102.1 (d, J = 25 Hz), 56.1, 51.9, 41.1, 6.8.   
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1-(4-chlorophenyl)-4-ethylpiperazine (67) 
The title compound was prepared according to the general 
procedure described in 5.3.1.1, by reacting 4-chlorobromobenzene 
(504 mg, 2.63 mmol, 1 equiv) and 1-ethylpiperazine (500 μL, 3.94 
mmol, 1.5 equiv). After standard workup, 67 was obtained as a pale 
orange oil (146 mg, yield 25%). 
67: pale orange oil; TLC (KMnO4): Rf = 0.55 (CH2Cl2/MeOH 9:1); HMRS 
[M+H]+ (C12H18ClN2+) Calcd 225.1153, Found 225.1155. 
1H NMR (CDCl3, 300 MHz) δ 7.13 (d, J = 9.1 Hz, 2H), 6.77 (d, J = 9.0 Hz, 
2H), 3.15 – 3.08 (m, 4H), 2.57 – 2.51 (m, 4H), 2.41 (q, J = 7.2 Hz, 2H), 
1.06 (t, J = 7.2 Hz, 3H). 
13C NMR (CDCl3, 75 MHz) δ 150.1, 129.1, 124.6, 117.3, 52.8, 52.5, 49.3, 12.1.  
 
 
 
 
 
 
4-(4-chlorophenyl)-1,1-diethylpiperazin-1-ium iodide (6k) 
According to the general procedure 5.3.1.2, EtI (366 L, 4.55 
mmol, 7 equiv) was added to a solution of 1-(4-chlorophenyl)-4-
ethylpiperazine (67) (146 mg, 0.65 mmol, 1 equiv) in dry THF. 
Evaporation of the solvent under reduced pressure afforded the 
crude quaternary salt quantitatively that was re-crystalized from THF 
and EtOH to give the pure final compound a yellowish solid (126 mg, 
yield 51%). 
6k: yellowish solid; TLC (KMnO4; Dragendorff): Rf = 0.33 
(CH2Cl2/MeOH 4:1); m.p.: 151.0-152.1°C; HMRS [M]+ (C14H22ClN2+) 
Calcd 253.1466, Found 253.1476 [M], 255.1449 [M+2]. 
1H NMR (CD3OD, 500 MHz) δ 7.27 (d, J = 9.1 Hz, 2H), 7.01 (d, J = 9.0 Hz, 2H), 3.65 – 3.60 (m, 
4H), 3.57 – 3.50 (m, 8H), 1.36 (t, J = 7.2 Hz, 6H). 
13C NMR (CD3OD, 126 MHz) δ 149.6, 130.1, 127.0, 118.9, 58.6, 54.3, 43.9, 7.4.  
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1-(3-chlorophenyl)-4-ethylpiperazine (68) 
The title compound was prepared according to the general 
procedure described in 5.3.1.1, by reacting 1-chloro-3-iodobenzene 
(1.3 mL, 2.50 g, 10.50 mmol, 1 equiv) and 1-ethylpiperazine (2.0 mL, 
15.75 mmol, 1.5 equiv). After standard workup, 68 was obtained as an 
orange oil (1.96 g, yield 83%). 
68: orange oil; TLC (KMnO4): Rf = 0.53 (CH2Cl2/MeOH 9:1). 
HMRS [M+H]+ (C12H18ClN2+) Calcd 225.1153, Found 225.1149 
1H NMR (CDCl3, 300 MHz) δ 7.15 (t, J = 8.1 Hz, 1H), 6.88 (t, J = 2.2 Hz, 
1H), 6.82 – 6.75 (m, 2H), 3.25 – 3.19 (m, 4H), 2.62 – 2.56 (m, 4H), 2.47 
(q, J = 7.2 Hz, 2H), 1.13 (t, J = 7.2 Hz, 3H).  
13C NMR (CDCl3, 75 MHz) δ 152.4, 135.0, 130.0, 119.2, 115.7, 113.8, 52.7, 52.4, 48.7, 12.1.  
 
 
 
 
 
 
4-(3-chlorophenyl)-1,1-diethylpiperazin-1-ium iodide (6l) 
According to the general procedure 5.3.1.2, EtI (1.25 mL, 
15.61 mmol, 7 equiv) was added to a solution of 1-(3-chlorophenyl)-4-
ethylpiperazine (68) (501 mg, 2.23 mmol, 1 equiv) in dry THF. 
Evaporation of the solvent under reduced pressure afforded the 
crude quaternary salt quantitatively that was re-crystalized from THF 
and EtOH to give the pure final compound as white crystals (412 mg, 
yield 48%). 
6l: white crystals; TLC (KMnO4; Dragendorff): Rf = 0.33 (CH2Cl2/MeOH 
4:1); m.p.: 155.0-156.3°C; HMRS [M]+ (C14H22ClN2+) Calcd 253.1466, 
Found 253.1475 [M], 255.1443 [M+2]. 
1H NMR (CD3OD, 300 MHz) δ 7.26 (t, J = 8.2 Hz, 1H), 7.05 (t, J = 2.2 Hz, 1H), 6.96 (ddd, J = 
8.4, 2.5, 0.9 Hz, 1H), 6.90 (ddd, J = 7.9, 1.9, 0.8 Hz, 1H), 3.66 – 3.60 (m, 4H), 3.60 – 3.48 (m, 
8H), 1.37 (t, J = 7.2 Hz, 6H).  
13C NMR (CD3OD, 126 MHz) δ 152.1, 136.1, 131.5, 121.6, 117.2, 115.6, 58.5, 54.3, 43.5, 7.4.   
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1-(2-chlorophenyl)-4-ethylpiperazine (69) 
The title compound was prepared according to the general 
procedure described in 5.3.1.1, by reacting 1-chloro-2-iodobenzene 
(2.50 g, 10.50 mmol, 1 equiv) and 1-ethylpiperazine (2.0 mL, 15.75 
mmol, 1.5 equiv). After standard workup, 69 was obtained as a brown 
oil (110 mg, yield 5%). 
69: brown oil; TLC (KMnO4): Rf = 0.53 (CH2Cl2/MeOH 9:1). 
1H NMR (CDCl3, 300 MHz) δ 7.35 (dd, J = 7.9, 1.5 Hz, 1H), 7.22 (td, J = 
7.3, 1.5 Hz, 1H), 7.06 (dd, J = 8.0, 1.6 Hz, 1H), 6.97 (td, J = 7.6, 1.5 Hz, 
1H), 3.18 – 3.06 (m, 4H), 2.75 – 2.62 (m, 4H), 2.53 (q, J = 7.2 Hz, 2H), 
1.14 (t, J = 7.2 Hz, 3H).  
13C NMR (CDCl3, 75 MHz) δ 149.3, 130.7, 128.9, 127.7, 123.8, 120.5, 53.0, 52.4, 51.1, 12.0. 
 
 
 
 
4-(2-chlorophenyl)-1,1-diethylpiperazin-1-ium iodide (6m) 
According to the general procedure 5.3.1.2, EtI (276 L, 3.43 
mmol, 7 equiv) was added to a solution of 1-(2-chlorophenyl)-4-
ethylpiperazine (69) (110 mg, 0.49 mmol, 1 equiv) in dry THF. 
Evaporation of the solvent under reduced pressure afforded the 
crude quaternary salt quantitatively that was first purified by silica gel 
column chromatography, eluting in CH2Cl2/MeOH 95:5, and then re-
crystalized from THF and EtOH to give the pure final compound as 
white crystals (40 mg, yield 21%). 
6m: white crystals; TLC (KMnO4; Dragendorff): Rf = 0.33 (CH2Cl2/MeOH 
4:1); m.p.: 154.1-156.8°C; HMRS [M]+ (C14H22ClN2+) Calcd 253.1472, Found 253.1483 [M], 
255.1437 [M+2]. 
1H NMR (CD3OD, 300 MHz) δ 7.47 – 7.39 (m, 1H), 7.37 – 7.28 (m, 2H), 7.17 – 7.06 (m, 1H), 
3.73 – 3.54 (m, 8H), 3.51 – 3.38 (m, 4H), 1.38 (t, J = 7.2 Hz, 6H).  
13C NMR (CD3OD, 75 MHz) δ 148.4, 131.7, 130.0, 129.2, 126.5, 122.4, 59.3, 54.5, 45.7, 7.4.   
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1-(4-bromophenyl)-4-ethylpiperazine (70) 
The title compound was prepared according to the general 
procedure described in 5.3.1.1, by reacting 1,4-dibromobenzene (2.48 
g, 10.50 mmol, 1 equiv) and 1-ethylpiperazine (1.33 mL, 10.50 mmol, 
1.5 equiv). After standard workup, 70 was obtained as a off-white 
solid (913 mg, yield 32%). 
70: off-white solid; TLC (KMnO4): Rf = 0.49 (CH2Cl2/MeOH 9:1); m.p.: 
85.0-85.5°C. 
1H NMR (CDCl3, 300 MHz) δ 7.33 (d, J = 9.0 Hz, 2H), 6.79 (d, J = 9.0 Hz, 
2H), 3.24 – 3.13 (m, 4H), 2.65 – 2.55 (m, 4H), 2.47 (q, J = 7.2 Hz, 2H), 
1.13 (t, J = 7.2 Hz, 3H). 
13C NMR (CDCl3, 75 MHz) δ 150.4, 131.9, 117.6, 111.8, 52.8, 52.4, 49.1, 12.1. 
 
 
 
 
4-(4-bromophenyl)-1,1-diethylpiperazin-1-ium iodide (6n) 
According to the general procedure 5.3.1.2, EtI (1.08 mL, 
13.44 mmol, 7 equiv) was added to a solution of 1-(4-bromophenyl)-
4-ethylpiperazine (70) (517 mg, 1.92 mmol, 1 equiv) in dry THF. 
Evaporation of the solvent under reduced pressure afforded the 
crude quaternary salt quantitatively that was first purified by silica gel 
column chromatography, eluting in CH2Cl2/MeOH 9:1 and then re-
crystalized from THF and EtOH to give the pure final compound as 
white crystals (220 mg, yield 27%).  
6n: white crystals; TLC (KMnO4; Dragendorff): Rf = 0.37 (CH2Cl2/MeOH 
75:25); m.p.: 182.5-183.6°C; HMRS [M]+ (C14H22BrN2+) Calcd 297.0961 
Found 297.0965 [M], 299.0945 [M+2]. 
1H NMR (CD3OD, 300 MHz) δ 7.40 (d, J = 9.0 Hz, 2H), 6.97 (d, J = 9.1 Hz, 2H), 3.67 – 3.48 (m, 
12H), 1.42 – 1.32 (m, 6H). 
13C NMR (CD3OD, 75 MHz) δ 150.0, 133.1, 119.2, 114.1, 58.5, 54.2, 43.7, 7.3.  
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1-(3-bromophenyl)-4-ethylpiperazine (71) 
The title compound was prepared according to the general 
procedure described in 5.3.1.1, by reacting 1,3-dibromobenzene (3.72 
g, 1.90 mL, 15.75 mmol, 1 equiv) and 1-ethylpiperazine (2.0 mL, 15.75 
mmol, 1.5 equiv). After standard workup, 71 was obtained as a 
reddish oil (1.60 g, yield 38%). 
71: reddish oil; TLC (KMnO4): Rf = 0.49 in CH2Cl2/MeOH 9:1; HMRS 
[M+H]+ (C12H18BrN2+) Calcd 269.0648, Found 269.0641. 
1H NMR (CDCl3, 300 MHz) δ 7.09 (t, J = 8.1 Hz, 1H), 7.05 – 7.01 (m, 
1H), 6.97 – 6.91 (m, 1H), 6.86 – 6.79 (m, 1H), 3.26 – 3.16 (m, 4H), 2.63 
– 2.53 (m, 4H), 2.46 (q, J = 7.2 Hz, 2H), 1.12 (t, J = 7.2 Hz, 3H).  
13C NMR (CDCl3, 75 MHz) δ 152.5, 130.3, 123.3, 122.1, 118.6, 114.3, 52.7, 52.4, 48.7, 12.1.  
 
 
 
 
4-(3-bromophenyl)-1,1-diethylpiperazin-1-ium iodide (6o) 
According to the general procedure 5.3.1.2, EtI (1.60 mL, 
19.95 mmol, 7 equiv) was added to a solution of 1-(3-bromophenyl)-
4-ethylpiperazine (71) (768 mg, 2.85 mmol, 1 equiv) in dry THF. 
Evaporation of the solvent under reduced pressure afforded the 
crude quaternary salt quantitatively that was re-crystalized from THF 
and EtOH to give the pure final compound as brownish/off-white 
crystals (403 mg, yield 33%).  
6o: brownish/off-white crystals; TLC (KMnO4; Dragendorff): Rf = 0.37 
(CH2Cl2/MeOH 75:25); m.p.: 198.8-199.5°C; HMRS [M]+ (C14H22BrN2+) 
Calcd 297.0966 Found 297.0963 [M], 299.0944 [M+2]. 
1H NMR (CD3OD, 300 MHz) δ 7.23 – 7.16 (m, 2H), 7.08 – 6.98 (m, 2H), 3.67 – 3.50 (m, 12H), 
1.37 (t, J = 7.2 Hz, 6H).  
13C NMR (CD3OD, 75 MHz) δ 152.3, 131.8, 124.6, 124.1, 120.1, 116.1, 58.5, 54.2, 43.5, 7.5.  
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4-(4-ethylpiperazin-1-yl)benzonitrile (72) 
The title compound was prepared according to the general 
procedure described in 5.3.1.1, by reacting 4-bromobenzonitrile (191 
mg, 1.05 mmol, 1 equiv) and 1-ethylpiperazine (200 μL, 1.57 mmol, 
1.5 equiv) After standard workup, 72 was obtained as an orange oil 
(142 mg, yield 63%). 
72: orange oil; TLC (KMnO4): Rf = 0.48 (CH2Cl2/MeOH 9:1);  
HMRS [M+H]+ (C13H18N3+) Calcd 216.1495, Found 216.1499. 
1H NMR (CDCl3, 300 MHz) δ 7.41 (d, J = 8.8 Hz, 1H), 6.79 (d, J = 9.3 Hz, 
1H), 3.31 – 3.25 (m, 4H), 2.55 – 2.49 (m, 4H), 2.41 (q, J = 7.2 Hz, 2H), 
1.06 (t, J = 7.2 Hz, 3H).  
13C NMR (CDCl3, 75 MHz) δ 153.4, 133.5, 120.2, 114.2, 100.2, 52.4, 52.4, 47.2, 12.0.  
 
 
 
 
 
 
4-(4-cyanophenyl)-1,1-diethylpiperazin-1-ium iodide (6p) 
According to the general procedure 5.3.1.2, EtI (371 L, 4.62 
mmol, 7 equiv) was added to a solution of 4-(4-ethylpiperazin-1-
yl)benzonitrile (72) (142 mg, 0.66 mmol, 1 equiv) in dry THF. 
Evaporation of the solvent under reduced pressure afforded the 
crude quaternary salt quantitatively that was first purified by silica gel 
column chromatography, eluting in CH2Cl2/MeOH 9:1, and then re-
crystalized from THF and EtOH to give the pure final compound as 
light yellow crystals (35 mg, yield 14%). 
6p: light yellow crystals; TLC (KMnO4; Dragendorff): Rf = 0.31 
(CH2Cl2/MeOH 4:1); m.p.: 197.4-198.2°C; HMRS [M]+ (C15H22N3+) Calcd 
244.1808, Found 244.1813. 
1H NMR (CD3OD, 300 MHz) δ 7.61 (d, J = 9.1 Hz, 2H), 7.12 (d, J = 9.1 Hz, 2H), 3.80 – 3.68 (m, 
4H), 3.68 – 3.62 (m, 4H), 3.56 (q, J = 7.2 Hz, 4H), 1.37 (t, J = 7.2 Hz, 6H). 
13C NMR (CD3OD, 75 MHz) δ 153.6, 134.6, 120.6, 116.2, 102.5, 58.2, 54.3, 42.1, 7.6.  
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3-(4-ethylpiperazin-1-yl)benzonitrile (73) 
The title compound was prepared according to the general 
procedure described in 5.3.1.1, by reacting 3-bromobenzonitrile (1.92 
g, 10.50 mmol, 1 equiv) and 1-ethylpiperazine (2.0 mL, 15.75 mmol, 
1.5 equiv). After standard workup, 73 was obtained as a pale orange 
oil (1.36 g, yield 60%). 
73: pale orange oil; TLC (KMnO4): Rf = 0.48 (CH2Cl2/MeOH 9:1). 
1H NMR (CDCl3, 500 MHz) δ 7.35 – 7.28 (m, 1H), 7.14 – 7.07 (m, 3H), 
3.29 – 3.22 (m, 4H), 2.65 – 2.58 (m, 4H), 2.48 (q, J = 7.2 Hz, 2H), 1.14 
(t, J = 7.2 Hz, 3H). 
13C NMR (CDCl3, 126 MHz) δ 151.5, 130.0, 122.5, 119.9, 119.5, 118.5, 
113.2, 52.6, 52.4, 48.5, 12.1. 
 
 
 
 
 
 
4-(3-cyanophenyl)-1,1-diethylpiperazin-1-ium iodide (6q) 
According to the general procedure 5.3.1.2, EtI (1.45 mL, 
18.06 mmol, 7 equiv) was added to a solution of 3-(4-ethylpiperazin-
1-yl)benzonitrile (73) (555 mg, 2.58 mmol, 1 equiv) in dry THF. 
Evaporation of the solvent under reduced pressure afforded the 
crude quaternary salt quantitatively that was first purified by silica gel 
column chromatography, eluting in CH2Cl2/MeOH 9:1 to 4:1, and then 
re-crystalized from THF/ethanol/MeOH to give the pure final 
compound as colorless crystals (140 mg, yield 15%). 
6q: colorless crystals; TLC (KMnO4; Dragendorff): Rf = 0.31 
(CH2Cl2/MeOH 4:1); m.p.: 210-212°C; HMRS [M]+ (C15H25N2+) Calcd 
244.1808 Found 244.1812. 
1H NMR (CD3OD, 300 MHz) δ 7.50 – 7.40 (m, 1H), 7.40 – 7.32 (m, 2H), 7.22 (dt, J = 7.4, 1.3 
Hz, 1H), 3.72 – 3.62 (m, 8H), 3.58 (q, J = 7.3 Hz, 4H), 1.38 (t, J = 7.3 Hz, 6H). 
13C NMR (CD3OD, 75 MHz) δ 151.3, 131.5, 124.9, 121.7, 119.9, 114.2, 58.4, 54.2, 43.1, 7.4.   
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4-(4-carbamoylphenyl)-1,1-diethylpiperazin-1-ium iodide (6r) 
The title compound was prepared according to the general 
procedure 5.3.1.3, by reacting 4-(4-cyanophenyl)-1,1-
diethylpiperazin-1-ium iodide 6p (230 mg, 0.62 mmol, 2 equiv), 
acetaldoxime (73 mg, 1.24 mmol, 4 equiv) and Pd(PPh3)4 (35 mg, 0.03 
mmol, 0.1 equiv) in EtOH. After standard workup, the crude was first 
purified by silica neutral alumina column chromatography, eluting in 
CH2Cl2/MeOH 95:5 to 85:15 and then re-crystalized from EtOH to give 
the pure final compound as a white solid (18 mg, yield 7%).  
6r: white solids; TLC (alumina-KMnO4; Dragendorff): Rf = 0.42 
(CH2Cl2/MeOH 4:1); m.p.: 238-239°C; HMRS [M]+ (C15H24N3O+) Calcd 
262.1914 Found 262.1923. 
1H NMR (CD3OD, 300 MHz) δ 7.84 (d, J = 8.8 Hz, 2H), 7.07 (d, J = 8.9 Hz, 2H), 3.73 – 3.60 (m, 
8H), 3.55 (q, J = 7.3 Hz, 4H), 1.37 (t, J = 7.3 Hz, 6H). 
13C NMR (CD3OD, 75 MHz) δ 171.9, 153.4, 130.3, 125.8, 115.7, 58.3, 54.1, 42.6, 7.3.  
 
 
4-(3-carbamoylphenyl)-1,1-diethylpiperazin-1-ium iodide (6s) 
The title compound was prepared according to the general 
procedure 5.3.1.3. by reacting 4-(3-cyanophenyl)-1,1-
diethylpiperazin-1-ium iodide 6q (273 mg, 0.74 mmol, 2 equiv), 
acetaldoxime (87 mg, 1.48 mmol, 4 equiv) and Pd(PPh3)4 (46 mg, 
0.04 mmol, 0.1 equiv) in EtOH. After standard workup, the crude 
was first purified by silica neutral alumina column chromatography, 
eluting in CH2Cl2/MeOH 95:5 to 85:15 and then re-crystalized from 
MeOH to give the pure final compound as yellow crystals (77 mg, 
yield 27%).  
6s: yellow crystals; TLC (alumina-KMnO4; Dragendorff): Rf = 0.42 (CH2Cl2/MeOH 4:1); m.p.: 
212-213°C; HMRS [M]+ (C15H24N3O+) Calcd 262.1914 Found 262.1905.  
1H NMR (CD3OD, 300 MHz) δ 7.54 – 7.51 (m, 1H), 7.45 – 7.35 (m, 2H), 7.26 – 7.21 (m, 1H), 
3.68 – 3.59 (m, 8H), 3.56 (q, J = 7.3 Hz, 4H), 3.34 (s, MeOH 3% residual), 1.37 (t, J = 7.3 Hz, 
6H).  
13C NMR (CD3OD, 75 MHz) δ 172.3, 151.0, 135.9, 130.5, 120.9, 120.8, 116.4, 58.6, 54.2, 
43.7, 7.4.  
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3-(4-ethylpiperazin-1-yl)phenol (74) 
The title compound was prepared according to the general 
procedure described in 5.3.1.1, by reacting 3-iodophenol (2.31 g, 
10.50 mmol, 1 equiv) and 1-ethylpiperazine (2.0 mL, 15.75 mmol, 1.5 
equiv). After standard workup, 74 was obtained as a brown solid (703 
mg, yield 32%). 
74: brown solid; TLC (KMnO4): Rf = 0.38 (CH2Cl2/MeOH 85:15); m.p.: 
150.3-151.6°C; HMRS [M+H]+ (C12H19N2O+) Calcd 207.1492, Found 
207.1496. 
1H NMR (CD3OD, 300 MHz) δ 7.03 (t, J = 8.1 Hz, 1H), 6.45 (ddd, J = 8.2, 
2.4, 0.9 Hz, 1H), 6.40 (t, J = 2.3 Hz, 1H), 6.30 (ddd, J = 8.0, 2.3, 0.9 Hz, 1H), 5.48 (s, CH2Cl2), 
3.20 – 3.11 (m, 4H), 2.68 – 2.57 (m, 4H), 2.49 (q, J = 7.2 Hz, 2H), 1.14 (t, J = 7.2 Hz, 3H).   
13C NMR (CD3OD, 75 MHz) δ 159.2, 154.0, 130.8, 109.0, 108.3, 104.5, 53.7, 53.3, 50.0, 11.8.   
 
 
 
 
 
1,1-diethyl-4-(3-hydroxyphenyl)piperazin-1-ium iodide (6t) 
According to the general procedure 5.3.1.2, EtI (1.33 mL, 
16.59 mmol, 7 equiv) was added to a solution of 3-(4-ethylpiperazin-
1-yl)phenol (74) (489 mg, 2.37 mmol, 1 equiv) in dry THF. Evaporation 
of the solvent under reduced pressure afforded the crude quaternary 
salt quantitatively that was first purified by silica gel column 
chromatography, eluting in CH2Cl2/MeOH 9:1 to 85:15, and then re-
crystalized from EtOH to give the pure final compound as off-white 
solid (186 mg, yield 22%). 
6t: off-white solid; TLC (KMnO4; Dragendorff): Rf = 0.38 (CH2Cl2/MeOH 
75:25); m.p.: 200-203°C; HMRS [M]+ (C14H23N2O+) Calcd 235.1805 
Found 235.1806. 
1H NMR ((CD3)2SO, 300 MHz) δ 9.26 (s, 1H), 7.04 (t, J = 8.1 Hz, 1H), 6.48 – 6.41 (m, 1H), 6.38 
– 6.34 (m, 1H), 6.33 – 6.27 (m, 1H), 3.59 – 3.37 (m, 12H), 1.21 (t, J = 7.1 Hz, 6H).  
13C NMR ((CD3)2SO, 75 MHz) δ 158.1, 150.7, 129.7, 107.1, 106.6, 102.6, 56.4, 51.9, 41.5, 6.8.   
 CHAPTER V – Experimental section 
 
 
128 
 
1-ethyl-4-(naphthalen-2-yl)piperazine (75) 
The title compound was prepared according to the general 
procedure described in 5.3.1.1, by reacting 2-bromonaphthalene 
(2.17 g, 10.5 mmol, 1 equiv) and 1-ethylpiperazine (2.0 mL, 15.75 
mmol, 1.5 equiv). After standard workup, 75 was obtained as a 
brownish solid (1.02 g, yield 40%). 
75: brownish solid; TLC (KMnO4): Rf = 0.38 (CH2Cl2/MeOH 9:1); m.p.: 
69.1-70.0°C. 
1H NMR (CDCl3, 300 MHz) δ 7.76 – 7.65 (m, 3H), 7.39 (ddd, J = 8.1, 6.8, 
1.4 Hz, 1H), 7.33 – 7.24 (m, 2H), 7.12 (d, J = 2.5 Hz, 1H), 3.39 – 3.27 
(m, 4H), 2.74 – 2.62 (m, 4H), 2.60 (s, DMSO), 2.51 (q, J = 7.2 Hz, 2H), 1.15 (t, J = 7.2 Hz, 3H). 
13C NMR (CDCl3, 75 MHz) δ 149.3, 134.7, 128.8, 128.6, 127.5, 126.8, 126.3, 123.4, 119.4, 
110.3, 53.0, 52.5, 49.6, 41.1 ((CH3)2SO) residual), 12.2. 
 
 
 
1,1-diethyl-4-(naphthalen-2-yl)piperazin-1-ium iodide (6u) 
According to the general procedure 5.3.1.2, EtI (1.21 mL, 
15.05 mmol, 7 equiv) was added to a solution of 1-ethyl-4-
(naphthalen-2-yl)piperazine (75) (516 mg, 2.15 mmol, 1 equiv) in dry 
THF. Evaporation of the solvent under reduced pressure afforded the 
crude quaternary salt quantitatively that was first purified by silica gel 
column chromatography, eluting in CH2Cl2/MeOH 9:1 to 4:1, and then 
re-crystalized from THF and EtOH to give the pure final compound as 
a yellowish solid (430 mg, yield 51%). 
6u: yellowish solid; TLC (KMnO4; Dragendorff): Rf = 0.38 
(CH2Cl2/MeOH 75:25); m.p.: 218-219°C; HMRS [M]+ (C18H25N2+) Calcd 
269.2018 Found 269.2013. 
1H NMR ((CD3)2SO, 300 MHz) δ 7.86 – 7.81 (m, 1H), 7.81 – 7.73 (m, 2H), 7.48 – 7.39 (m, 2H), 
7.35 – 7.26 (m, 2H), 3.68 – 3.57 (m, 8H), 3.52 (q, J = 7.1 Hz, 4H), 1.25 (t, J = 7.2 Hz, 6H).  
13C NMR ((CD3)2SO, 75 MHz) δ 147.1, 134.0, 128.6, 128.1, 127.3, 126.6, 126.4, 123.5, 118.5, 
109.8, 56.4, 52.0, 41.8, 6.8.   
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1-ethyl-N-phenylpiperidin-4-amine (76) 
The reductive amination with NaBH3CN was carried out in 
anhydrous conditions and under argon atmosphere. Aniline (1.41 
mL, 15.47 mmol, 1 equiv) was dissolved in dry MeOH, freshly 
distilled from Na. To this solution, 1-ethyl-4-piperidone (2.5 mL, 
18.56 mmol, 1.2 equiv) and NaBH3CN (1.17 g, 18.56 mmol, 1.2 
equiv) were subsequently added. The pH of the solution was 
adjusted to 6-7 with glacial acetic acid and then the resulting was 
stirred at RT (TLC in CH2Cl2/MeOH 95/5). Complete consumption of 
the starting material was not achieved, even after stirring for seven 
days and heating at reflux. The reaction was then quenched with 
saturated aqueous solution of NaHCO3 and methanol was removed under reduced 
pressure. The residue was partitioned between EtOAc and water, and extracted with EtOAc 
(x 3). The combined organic layers were dried over MgSO4, filtered and concentrated in 
vacuo. The residue was purified on silica gel column chromatography, eluting in 
CH2Cl2/MeOH 93:7 to provide the desired product as an off-white solid (1.88 g, yield 59%). 
76: off-white solid; TLC (KMnO4): Rf = 0.33 (CH2Cl2/MeOH 75:25); m.p.: 43.0-44.6°C; HMRS 
[M+H]+ (C13H21N2+) Calcd 205.1699 Found 205.1701. 
1H NMR (CD3OD, 300 MHz) δ 7.13 – 7.06 (m, 2H), 6.68 – 6.57 (m, 3H), 3.41 – 3.32 (m, 1H), 
3.11 – 3.00 (m, 2H), 2.59 (q, J = 7.3 Hz, 2H), 2.39 – 2.26 (m, 2H), 2.12 – 2.01 (m, 2H), 1.60 – 
1.45 (m, 2H), 1.15 (t, J = 7.3 Hz, 3H). 
13C NMR (CD3OD, 75 MHz) δ 148.9, 130.1, 118.2, 114.8, 53.2, 52.9, 50.6, 32.4, 11.7. 
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N-(1-ethylpiperidin-4-yl)-2,2,2-trifluoro-N-phenylacetamide (77) 
In a flame-dried and argon-flushed flask, 1-ethyl-N-
phenylpiperidin-4-amine (76) (1.53 g, 7.46 mmol, 1 equiv) was 
dissolved in dry CH2Cl2 (75 mL) and cooled 0 °C. Triethylamine 
(4.20 mL, 29.9 mmol, 4 equiv) was added, and then trifluoroacetic 
anhydride (3.20 mL, 22.4 mmol, 3 equiv) was slowly added 
dropwise. The resulting mixture was stirred at 0°C until complete 
consumption of the starting material (5h; TLC in CH2Cl2/MeOH 
95:5). Upon completion, deionized water was then added to 
quench the reaction at 0°C. The organic layer was washed with 
saturated brine, dried over MgSO4, filtered and concentrated in 
vacuo. The residue was purified by silica gel column chromatography, eluting in 
CH2Cl2/MeOH 95:5 to 9:1. The isolated fraction was then further purified on a silica gel 
column chromatography eluting in EtOAc/MeOH 100:0 to 9:1 to afford the desired product 
as a yellow solid (911 mg, yield 41%). 
77: yellow solid; TLC (KMnO4): Rf = 0.50 (CH2Cl2/MeOH 9:1); m.p.: 50.2-51.3°C; HMRS 
[M+H]+ (C15H20F3N2O+) Calcd 301.1522 Found 301.1531. 
1H NMR (CDCl3, 300 MHz) δ 7.45 – 7.34 (m, 3H), 7.19 – 7.10 (m, 2H), 4.55 (tt, J = 12.2, 4.0 
Hz, 1H), 3.03 – 2.92 (m, 2H), 2.37 (q, J = 7.2 Hz, 2H), 2.11 – 1.98 (m, 2H), 1.89 – 1.78 (m, 2H), 
1.55 – 1.38 (m, 2H), 1.02 (t, J = 7.2 Hz, 3H). 
13C NMR (CDCl3, 75 MHz) δ 156.7 (q, J = 35 Hz), 134.8, 130.6, 129.4, 128.9, 116.5 (q, J = 289 
Hz), 55.3, 52.4, 52.1, 29.7, 12.1.  
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1,1-diethyl-4-(2,2,2-trifluoro-N-phenylacetamido)piperidinium iodide (78) 
According to the general procedure 5.3.1.2, EtI (782 L, 
9.73 mmol, 7 equiv) was added to a solution of N-(1-ethylpiperidin-
4-yl)-2,2,2-trifluoro-N-phenylacetamide (77) (417 mg, 1.39 mmol, 1 
equiv) in dry THF. The reaction was monitored by TLC in 
CH2Cl2/MeOH 95:5 and was complete after 22h at 90°C. 
Evaporation of the solvent under reduced pressure afforded the 
crude quaternary salt quantitatively that was purified by silica gel 
column chromatography, eluting in CH2Cl2/MeOH 94:6 to 9:1 to 
afford the pure final compound as a yellow solid (520 mg,  
yield 82%).  
78: yellow solid; TLC (KMnO4): Rf = 0.40 (CH2Cl2/MeOH 75:25); m.p.: 141.0-142.0°C; HMRS 
[M]+ (C17H24F3N2O+) Calcd 329.1835 Found 329.1849. 
1H NMR (CD3OD, 300 MHz) δ 7.58 – 7.46 (m, 3H), 7.46 – 7.33 (m, 2H), 4.69 – 4.53 (m, 1H), 
3.72 – 3.59 (m, 2H), 3.53 – 3.21 (m, 6H), 2.25 – 1.97 (m, 4H), 1.32 (t, J = 7.3 Hz, 3H), 1.22 (t, J 
= 7.3 Hz, 3H). 
13C NMR ((CD3)2SO, 75 MHz) δ 155.4 (q, J =34 Hz), 134.9, 130.0, 129.8, 129.2, 115.9 (q, J = 
289 Hz), 57.4, 56.0, 54.9 (residual CH2Cl2), 53.2, 47.3, 22.7, 7.1, 6.7.  
 
 
1,1-diethyl-4-(phenylamino)piperidinium iodide (7) 
Under argon atmosphere, 1,1-diethyl-4-(2,2,2-trifluoro-N-
phenylacetamido)piperidinium iodide (78) (400 mg, 0.88 mmol, 1 
equiv) was dissolved in a mixture of MeOH/water 7:1 (49:7 mL). 
K2CO3 (1.46 g, 10.56 mmol, 12 equiv) was added at RT and the 
resulting mixture was heated at 65°C until complete consumption 
of the starting material, which occurred in 1h (TLC in CH2Cl2/MeOH 
9:1). Upon completion, the mixture was cooled to RT and the 
solvents removed under reduced pressure. The crude was 
dissolved in MeOH and then filtered through cotton to remove 
precipitates. The filtrate was concentrated in vacuo and then 
purified on a silica gel column chromatography (CH2Cl2/MeOH 9:1 to 85:15) to afford the 
pure compound as a light yellow solid (173 mg). The compound was further purified by re-
crystalization from hot EtOH to provide white crystals (79 mg, yield 25%). 
7: white crystals; TLC (KMnO4): Rf = 0.37 (CH2Cl2/MeOH 75:25); m.p.: 203-204°C; HMRS [M]+ 
(C15H25N2+) Calcd 233.2012 Found 233.2010. 
1H NMR (CD3OD, 500 MHz) δ 7.12 (t, J = 7.5 Hz, 2H), 6.71 (d, J = 7.9 Hz, 2H), 6.65 (t, J = 7.4 
Hz, 1H), 3.76 – 3.68 (m, 1H), 3.63 – 3.56 (m, 2H), 3.50 (q, J = 7.1 Hz, 2H), 3.46 – 3.36 (m, 4H), 
2.25 – 2.15 (m, 2H), 1.94 – 1.83 (m, 2H), 1.35 (t, J = 7.3 Hz, 3H), 1.31 (t, J = 7.3 Hz, 3H). 
13C NMR ((CD3)2SO, 75 MHz) δ 147.2, 129.1, 116.3, 112.8, 55.6, 55.0, 49.5, 45.4, 25.0, 7.2, 
6.7.   
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4-benzylidene-1-ethylpiperidine (79) 
The reaction was carried out in anhydrous conditions and 
under argon atmosphere. Diethyl benzylphosphonate (1.2 mL, 5.57 
mmol, 1.5 equiv) was dissolved in dry THF (17 mL) and 15-crown-5 
(150 µL, 0.76 mmol, 0.2 equiv) was added. Then, at 0°C, sodium 
hydride 60% dispersion in mineral oil (223 mg, 5.57 mmol, 1.5 
equiv) was added portionwise. The resulting mixture was stirred at 
0°C for 40 min and then a solution of 1-ethyl-4-
3.71 mmol, 1 equiv) in dry THF (30 mL) was slowly added dropwise 
at 0°C. The reaction mixture was stirred for 10 min at 0°C, then 
allowed to warm up and stir at RT until completion (TLC in 
CH2Cl2/MeOH 9:1), which occurred after 4 days. Upon completion, the mixture was cooled 
to 0°C, diluted with deionized water, and then extracted with EtOAc (x 3). The combined 
organic layers were washed with saturated aqueous solution of NaHCO3 and saturated 
brine, then dried over MgSO4, filtered and concentrated under reduced pressure to give a 
yellow oil. The crude was purified on a silica gel column chromatography eluting in 
CH2Cl2/MeOH 96:4 to afford the desired product as a pale yellowish oil (337 mg, yield 45 %). 
79: pale yellowish oil; TLC (KMnO4; Dragendorff): Rf = 0.33 (CH2Cl2/MeOH 85:15). 
1H NMR (CD3OD, 300 MHz) δ 7.33 – 7.26 (m, 2H), 7.21 – 7.15 (m, 3H), 6.35 (s, 1H), 2.65 (dd, 
J = 6.5, 5.1 Hz, 2H), 2.58 – 2.49 (m, 6H), 2.48 – 2.42 (m, 2H), 1.15 (t, J = 7.3 Hz, 3H). 
13C NMR (CD3OD, 75 MHz) δ 139.2, 138.8, 129.9, 129.2, 127.4, 125.1, 55.7, 54.9, 53.2, 36.4, 
29.3, 11.8.  
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4-benzylidene-1,1-diethylpiperidinium iodide (8) 
According to the general procedure 5.3.1.2, EtI (940 L, 
11.69 mmol, 7 equiv) was added to a solution of 4-benzylidene-1-
ethylpiperidine (79) (337 mg, 1.67 mmol, 1 equiv) in EtOH. The 
reaction was monitored by TLC in CH2Cl2/MeOH 9:1 and was 
complete after 51h at 90°C. Evaporation of the solvent under 
reduced pressure afforded the crude quaternary salt quantitatively 
that was purified by silica gel column chromatography, eluting in 
CH2Cl2/MeOH 95:5 to 75:25. The product was then further purified 
by a second silica column eluting in CH2Cl2/MeOH 95:5 to 75:25 
and by re-crystallization in EtOH/MeOH 1:1 to afford the pure 
product as white crystals (18 mg, yield 3%).  
8: white crystals; TLC (KMnO4; Dragendorff): Rf = 0.34 (CH2Cl2/MeOH 4:1); m.p.: 84.5-
86.0°C; HMRS [M]+ (C16H24N+) Calcd 230.1903 Found 230.1900. 
1H NMR (CD3OD, 300 MHz) δ 7.41 – 7.30 (m, 2H), 7.30 – 7.20 (m, 3H), 6.59 (s, 1H), 3.51 (q, J 
= 7.1 Hz, 6H), 3.41 – 3.34 (m, 2H), 2.91 – 2.81 (m, 2H), 2.81 – 2.73 (m, 2H), 1.34 (tt, J = 7.3, 
1.9 Hz, 6H);  
13C NMR (CD3OD, 126 MHz) δ 137.6, 132.2, 129.9, 129.5, 128.7, 128.2, 59.9, 59.2, 54.1, 
30.3, 24.1, 7.5.   
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5.3.2 Experimental procedures for the synthesis of 9a-h, 10a-h 
5.3.2.1 Synthesis of bromo-Δ2–isoxazoline 83 
3-Methylene-1-azabicyclo[2.2.2]octane (80) 
3-quinuclidinone hydrochloride, commercially available, was 
dissolved in a concentrated aqueous solution of K2CO3 (pH = 12) and 
the resulting mixture was extracted with CH2Cl2 (x 5). The organic 
layers were dried over anhydrous Na2SO4, filtered and concentrated 
under reduced pressure to provide the free base as a colorless, 
amorphous solid. Under argon atmosphere, to a stirred suspension of potassium tert-
butoxide (29.8 g, 265.2 mmol, 1.4 equiv) in dry Et2O (500 mL) at 0°C, 
methyltriphenylphosphonium bromide (101.5 g, 284.1 mmol, 1.5 equiv) was added. The 
resulting mixture turned yellow during stirring and it was refluxed for 45 min. After cooling 
it down to 0°C, a solution of quinuclidin-3-one (23.7 g, 189.4 mmol, 1 equiv) in dry Et2O was 
added dropwise. The final mixture was then stirred overnight at RT and monitored by TLC in 
CH2Cl2/MeOH 4:1 + 3 drops of aqueous NH3. Upon completion, the reaction was quenched 
with acetone, filtered under vacuum and washed with Et2O. The filtrate was concentrated 
under reduced pressure using a cold bath since the desired product was found to be 
volatile, affording the desired compound as a white solid (23.3 g, yield 100%). 
80: white solid; TLC (Dragendorff): Rf = 0.30 (CH2Cl2/MeOH 4:1); m.p.: 63.5-64.2°C. 
1H-NMR (CDCl3, 300 MHz): δ 4.72 – 4.65 (m, 1H), 4.60 – 4.55 (m, 1H), 3.39 (br s, 2H), 2.87 – 
2.69 (m, 4H), 2.44 – 2.28 (m, 1H), 1.70 – 1.52 (m, 4H).  
13C-NMR (CDCl3, 75 MHz): δ 152.5, 103.8, 55.8, 47.6, 32.5, 31.6, 29.7, 28.3. 
 
Borane-3-methylene-1-azabicyclo[2.2.2]octane complex (81) 
Under argon atmosphere, 3-methylenequinuclidine (80) (23.3 
g, 189.4 mmol, 1 equiv) was dissolved in dry THF (100 mL) and cooled 
to 0°C. A solution of 1.0 M BH3 in THF (190 mL, 189.4 mmol, 1 equiv) 
was then added dropwise and the mixture was stirred at RT for 1.5h, 
monitored by TLC in CH2Cl2/MeOH 4:1 and cyclohexane/EtOAc 7:3. 
Upon completion, the reaction was concentrated in vacuum and the resulting crude was 
purified by silica gel column chromatography, eluting in cyclohexane/EtOAc 7:3 to give the 
pure N-boranyl product as colorless solid (19.6 g, yield 84%). 
81: colorless solid; TLC (KMnO4): Rf = 0.65 (cyclohexane/EtOAc 7:3); m.p.: 70-72°C.  
1H NMR (CDCl3, 300 MHz) δ 4.96 – 4.91 (m, 1H), 4.78 – 4.73 (m, 1H), 3.60 (br s, 2H), 3.13 – 
2.91 (m, 4H), 2.61 – 2.53 (m, 1H), 1.93 – 1.74 (m, 4H). 
13C-NMR (CDCl3, 75 MHz): δ 144.7, 106.7, 61.2, 54.1, 31.4, 26.4. 
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Dibromoformaldoxime (82) 
 A three-neck round-bottom flask was equipped with a 
mechanical stirrer, a thermometer and a dropper. Glyoxylic acid 
monohydrate (31.1 g, 338 mmol, 1 equiv) was dissolved in 200 mL of 
deionized water. Under vigorous mechanical stirring, hydroxylamine 
hydrochloride (23.5 g, 338 mmol, 1 equiv) was added and the 
resulting mixture was stirred at RT for 20h. Then, NaHCO3 (58.8 g, 
700 mmol, 2.07 equiv) was added portionwise at RT. A solution of bromine (24.1 mL, 470 
mmol, 1.4 equiv) in CH2Cl2 (125 mL) was added dropwise to the biphasic system, cooled to 
6°C with an ice bath, so that the system temperature would not go over 10°C. The final 
light-green mixture was stirred at RT for additional 3h, after which the organic layer was 
separated, and the water phase was extracted with CH2Cl2 (x 3). The combined organic 
phases were dried over anhydrous Na2SO4, filtered and concentrated under reduced 
pressure to reduce the volume of CH2Cl2, and then n-hexane was added till colorless 
crystals began to form. The solution was then cooled at -20°C till the crystallization was 
complete. The crystalline solid was filtered under vacuum and washed with n-hexane to 
provide the pure compound as colorless crystals (18.0 g, yield 26%). 
82: colorless crystals; TLC (KMnO4): Rf = 0.65 (cyclohexane/EtOAc 7:3); m.p.: 67-68.5°C. 
1H-NMR ((CD3)2SO, 300 MHz): δ 12.67 (s, 1H). 
 
 
(±)-3-Bromo-1-oxa-2,7-diaza-7-boranyl-7,10-ethanospiro[4.5]dec-2-ene (83) 
Dibromoformaldoxime (82) (5.0 g, 24.6 mmol, 0.67 equiv) 
was added portionwise to a suspension of 81 (5.0 g, 36.5 mmol, 1 
equiv) and K2CO3 (25.3 g, 182.7 mmol, 5 equiv) in EtOAc (120 mL). 
The reaction mixture was stirred at room temperature for 24h with 
further additions of dibromoformaldoxime to achieve complete 
consumption of the starting material 81. Once the cycloaddition 
was completed, the mixture was filtered over a septum under vacuum and washed with 
EtOAc. The solvent was evaporated under reduced pressure and the residue was purified by 
silica gel column chromatography eluting in cyclohexane/EtOAc 1:1 to afford the desired 
cycloadduct 83, which crystallized as colorless prisms from EtOAc (4.50 g, yield 48%). 
83: colorless prisms; TLC (KMnO4; Dragendorff): Rf = 0.18 (cyclohexane/EtOAc 2:3); m.p.: 
127-128°C. 
1H NMR (CDCl3, 300 MHz) δ 3.34 (dd, J = 14.6, 1.9 Hz, 1H), 3.26 (d, J = 17.5 Hz, 1H), 3.06 (d, J 
= 17.5 Hz, 1H), 3.14 – 2.87 (m, 5H), 2.35 – 2.21 (m, 1H), 2.21 – 2.13 (m, 1H), 1.97 – 1.84 (m, 
1H), 1.75 – 1.60 (m, 2H). 
13C-NMR (CDCl3, 75 MHz): δ 136.4, 85.8, 65.5, 52.5, 51.7, 51.1, 30.7, 22.1, 20.1. 
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5.3.2.2 General procedure for the coupling reaction between 83 
and the appropriate phenyl alcohol (84-90)  
In anhydrous conditions and under argon atmosphere, to a solution of the 
appropriate phenyl alcohol (1.5 equiv) in dry THF (3.5 mL/mmol 83), cooled to 0°C, NaH 
60% dispersion in mineral oil (1.65 equiv) was added portionwise. The mixture was stirred 
for 30 min at RT. After cooling to 0°C, a solution of bromo-Δ2–isoxazoline 83 (1 equiv) in dry 
THF (3.5 mL/mmol 83) was added dropwise and the final mixture was stirred at RT for 2h. 
Upon completion (TLC in cyclohexane/EtOAc 2:3), the reaction was quenched with 
saturated aqueous solution of NaHCO3. The aqueous phase was then repeatedly extracted 
with CH2Cl2 (x 3). The combined organic phases were dried over anhydrous Na2SO4, filtered 
and concentrated in vacuum. The residue was then purified by silica gel column 
chromatography eluting in cyclohexane/EtOAc 2:3 to provide the pure product 84-90. 
 
5.3.2.3 General procedure for the cleavage of BH3 group (91-98)  
Under argon atmosphere, alkoxy N-boranyl Δ2-isoxazoline derivatives 84-90 were 
dissolved in acetone (3.5 mL/mmol 84-90) and cooled to 0°C. A solution of CF3COOH (5 
equiv) in acetone (3.5 mL/mmol 84-90) was added dropwise and the resulting mixture was 
stirred at RT overnight (TLC in cyclohexane/EtOAc 2:3 or CH2Cl2/MeOH 95:5). Upon 
completion, the mixture was concentrated under reduced pressure and the residue was 
diluted with water. The aqueous solution (pH = 1-2) was extracted with Et2O (x 1). The 
residual aqueous phase was basified with Na2CO3 and the desired product was extracted 
with CH2Cl2 (x 3), dried over anhydrous Na2SO4, filtered and concentrated under reduced 
pressure to provide compounds 91-98, which were directly used in the next step without 
further purification. 
 
5.3.2.4 General procedure for salification (9a-h)  
The appropriate derivative 91-98 (1 equiv) was dissolved in MeOH (5 mL/mmol 91-
98), asolution of fumaric acid (1 equiv) in MeOH (2 mL/mmol 91-98) was added and the 
mixture was stirred at RT for 2 h. The solvent was then removed under reduced pressure 
affording the crude salt quantitatively, followed by re-crystallization from a proper solvent 
to give the desired final compound 9a-h. 
 
5.3.2.5 General procedure for methylation (10a-h)  
The appropriate derivative 91-98 (1 equiv) was dissolved in MeOH (5 mL/mmol 91-
98) and methyl iodide (8.0 equiv) was added. The mixture was stirred overnight at RT (TLC 
in CH2Cl2/MeOH 4:1). Upon complete consumption of the starting material, the solvent and 
the excess of methyl iodide were removed by evaporation under reduced pressure, 
providing the crude N-methylated analogues 10a-h quantitatively. The pure compounds 
were then re-crystalized from a proper solvent. 
 CHAPTER V – Experimental section 
 
 
137 
 
(±)-3-(3-(trifluoromethyl)benzyl)oxy-1-oxa-2,7-diaza-7-boranyl-7,10-
ethanospiro[4.5]dec-2-ene (84) 
The title compound was prepared 
according to the general procedure described in 
5.3.2.2, by reacting 83 (200 mg, 0.77 mmol, 1 
equiv), (3-(trifluoromethyl)phenyl)methanol (204 
mg, 1.16 mmol, 1.5 equiv) and NaH 60% dispersion 
in mineral oil (51 mg, 1.28 mmol, 1.65 equiv). After 
standard workup, 84 was obtained as a yellow oil 
(219 mg, yield 81%). 
84: yellow oil; TLC (Dragendorff): Rf = 0.38 (cyclohexane/EtOAc 2:3). 
1H NMR (CDCl3, 300 MHz) δ 7.63 – 7.38 (m, 2H), 5.11 (s, 2H), 3.29 (dd, J = 14.4, 1.6 Hz, 1H), 
3.06 (d, J = 16.8 Hz, 1H), 3.16 – 2.80 (m, 5H), 2.88 (d, J = 16.6 Hz, 1H), 2.38 – 2.14 (m, 2H), 
1.95 – 1.77 (m, 1H), 1.77 – 1.51 (m, 2H). 
13C NMR (CDCl3, 75 MHz) δ 165.6, 136.1, 131.5, 131.0 (q, J = 32.5 Hz), 129.2, 125.4 (q, J = 3.7 
Hz), 124.8 (q, J = 3.6 Hz), 123.9 (q, J = 272.3 Hz), 84.5, 71.0, 65.4, 52.2, 51.5, 42.1, 30.2, 21.8, 
19.7. 
 
 
 
(±)-3-(3-(trifluoromethyl)benzyl)oxy-1-oxa-2,7-diaza-7,10-ethanospiro[4.5] 
dec-2-ene (91) 
The title compound was obtained according 
to the general procedure 5.3.2.3 by reacting 84 
(219 mg, 0.62 mmol, 1 equiv) and CF3COOH (239 
L, 3.1 mmol, 5 equiv) in acetone. After 
disappearance of the starting material (TLC in 
cyclohexane/EtOAc 2:3 and CH2Cl2/MeOH 9:1), 
standard workup was applied to provide the 
desired compound (132 mg, yield 63%). 
91: yellow oil; TLC (Dragendorff): Rf = 0.41 (CH2Cl2/MeOH 4:1). 
1H NMR (CDCl3, 300 MHz) δ 7.62 – 7.55 (m, 1H), 7.55 – 7.37 (m, 3H), 5.10 (s, 2H), 3.18 (dd, J 
= 14.6, 1.8 Hz, 1H), 3.04 (d, J = 16.4 Hz, 1H), 2.89 (dd, J = 12.1, 4.3 Hz, 1H), 2.84 – 2.58 (m, 
5H), 2.13 – 1.99 (m, 1H), 1.99 – 1.93 (m, 1H), 1.66 – 1.53 (m, 1H), 1.53 – 1.41 (m, 1H), 1.41 – 
1.28 (m, 1H). 
13C NMR (CDCl3, 75 MHz) δ 165.8, 136.7, 131.5, 130.6 (d, J = 29.2 Hz), 129.1, 125.3 
(d, J = 3.8 Hz), 124.8 (d, J = 3.1 Hz), 124.0 (d, J = 272.3 Hz), 86.9, 70.6, 62.9, 46.8, 46.5, 42.4, 
30.8, 23.7, 21.0. 
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(±)-3-(3-(trifluoromethyl)benzyl)oxy-1-oxa-2,7-diaza-7,10-ethanospiro[4.5]dec-2-
ene fumarate (9a) 
The fumarate derivative 9a was 
prepared according to the general procedure 
5.3.2.4 by reacting 91 (132 mg, 0.39 mmol, 1 
equiv) and fumaric acid (45 mg, 0.39 mmol, 1 
equiv) in MeOH. The crude salt was 
recrystallized from i-PrOH to provide the pure 
compound as a white solid (166 mg,  
yield 93%). 
9a: white solid; TLC (alumina-Dragendorff):  
Rf = 0.40 (CH2Cl2/MeOH 98:2); m.p.: 114.3- 115.1°C; MS (ESI) m/z for C17H20F3N2O2+ [M+H]+ 
calcd. 341.2, found 340.8. 
1H NMR (CD3OD, 300 MHz) δ 7.77 – 7.71 (m, 1H), 7.71 – 7.54 (m, 3H), 6.69 (s, 2H), 5.22 (s, 
2H), 3.57 (s, 2H), 3.42 – 3.21 (m, 5H), 3.16 (d, J = 16.9 Hz, 1H), 2.43 – 2.26 (m, 2H), 2.13 – 
1.98 (m, 1H), 1.98 – 1.77 (m, 2H). 
13C NMR (CD3OD, 75 MHz) δ 170.9, 167.7, 138.4, 136.0, 132.9, 131.9 (q, J = 32.3 Hz), 130.5, 
126.2 (q, J = 3.6 Hz), 125.8 (q, J = 3.7 Hz), 125.5 (q, J = 271.8 Hz), 85.1, 71.9, 60.2, 47.4, 46.8, 
42.4, 30.8, 20.9, 19.1. 
 
(±)-3-(3-(trifluoromethyl)benzyl)oxy-1-oxa-2,7-diaza-7,10-ethanospiro[4.5]dec-2-
ene methyl iodide (10a) 
According to the general procedure 
5.3.2.5, CH3I (135 L, 2.16 mmol, 8 equiv) was 
added to a solution of the free base 91 (91 mg, 
0.27 mmol, 1 equiv) in MeOH. Evaporation of 
the solvent under reduced pressure afforded 
the crude quaternary salt quantitatively and 
then it was re-crystalized from EtOAc/i-PrOH to 
give the pure final compound as a white solid 
(61 mg, yield 47%). 
10a: white solids; TLC (alumina-Dragendorff): Rf = 0.33 (CH2Cl2/MeOH 9:1); m.p.: 141.3-
142.0°C; MS (ESI) m/z for C18H22F3N2O2+ [M]+ calcd. 355.2, found 355.0. 
1H NMR (CD3OD, 300 MHz) δ 7.77 – 7.55 (m, 4H), 5.24 (s, 2H), 3.87 (dd, J = 13.8, 2.7 Hz, 1H), 
3.73 (dd, J = 13.7, 2.7 Hz, 1H), 3.61 – 3.37 (m, 4H), 3.37 (d, J = 16.8 Hz, 1H), 3.22 (d, J = 16.9 
Hz, 1H), 3.06 (s, 3H), 2.41 (dd, J = 11.5, 7.8 Hz, 2H), 2.22 – 2.07 (m, 1H), 2.07 – 1.91 (m, 2H). 
13C NMR (CD3OD, 75 MHz) δ 167.6, 138.3, 133.0, 131.9 (q, J = 32.3 Hz), 130.5, 126.2 (q, J = 
3.8 Hz), 125.8 (q, J = 3.9 Hz), 125.5 (q, J = 271.4 Hz), 85.4, 72.0, 69.6, 57.8, 57.2, 52.4, 42.4, 
30.6, 22.1, 20.3. 
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(±)-3-(3-fluorobenzyl)oxy-1-oxa-2,7-diaza-7-boranyl-7,10-ethanospiro[4.5]dec-2-
ene (85) 
The title compound was prepared 
according to the general procedure described in 
5.3.2.2, by reacting 83 (200 mg, 0.77 mmol, 1 
equiv), (3-fluorophenyl)methanol (146 mg, 1.16 
mmol, 1.5 equiv) and NaH 60% dispersion in 
mineral oil (51 mg, 1.28 mmol, 1.65 equiv). After 
standard workup, 85 was obtained as a yellow oil 
(206 mg, yield 88%). 
85: yellow oil; TLC (Dragendorff): Rf = 0.42 (cyclohexane/EtOAc 2:3). 
1H NMR (CDCl3, 300 MHz) δ 7.28 (td, J = 9.3, 4.6 Hz, 1H), 7.08 (d, J = 7.8 Hz, 1H), 7.06 – 7.00 
(m, 1H), 7.00 – 6.94 (m, 1H), 5.06 (s, 2H), 3.33 (dd, J = 14.6, 2.1 Hz, 1H), 3.11 – 2.89 (m, 6H), 
2.85 (d, J = 16.5 Hz, 1H), 2.38 – 2.24 (m, 1H), 2.24 – 2.17 (m, 1H), 1.96 – 1.81 (m, 1H), 1.73 – 
1.55 (m, 2H). 
13C NMR (CDCl3, 75 MHz) δ 165.6, 162.8 (d, J = 246.5 Hz), 137.5 (d, J = 7.5 Hz), 130.3 (d, J = 
8.4 Hz), 123.8 (d, J = 3.1 Hz), 115.6 (d, J = 21.1 Hz), 115.1 (d, J = 22.0 Hz), 84.4, 71.1, 71.1, 
65.5, 52.2, 51.5, 42.2, 30.2, 21.9, 19.8. 
 
 
(±)-3-(3-fluorobenzyl)oxy-1-oxa-2,7-diaza-7,10-ethanospiro[4.5]dec-2-ene (92) 
The title compound was obtained 
according to the general procedure 5.3.2.3 by 
reacting 84 (180 mg, 0.59 mmol, 1 equiv) and 
CF3COOH (227 L, 2.95 mmol, 5 equiv) in acetone. 
After disappearance of the starting material (TLC in 
cyclohexane/EtOAc 2:3 and CH2Cl2/MeOH 9:1), 
standard workup was applied to provide the 
desired compound (132 mg, yield 77%). 
92: yellow oil; TLC (Dragendorff): Rf = 0.44 (CH2Cl2/MeOH 95:5). 
1H NMR (CDCl3, 300 MHz) δ 7.31 – 7.19 (m, 1H), 7.10 – 7.05 (m, 1H), 7.05 – 6.99 (m, 1H), 
6.99 – 6.91 (m, 1H), 5.04 (s, 2H), 3.19 (dd, J = 14.6, 1.6 Hz, 1H), 3.03 (d, J = 16.4 Hz, 1H), 2.91 
(dd, J = 14.6, 1.9 Hz, 1H), 2.85 – 2.57 (m, 5H), 2.15 – 1.99 (m, 1H), 1.99 – 1.91 (m, 1H), 1.66 
– 1.52 (m, 1H), 1.52 – 1.41 (m, 1H), 1.41 – 1.28 (m, 1H). 
13C NMR (CDCl3, 75 MHz) δ 165.8, 162.8 (d, J = 246.4 Hz), 138.0 (d, J = 7.5 Hz), 130.1 (d, J = 
8.2 Hz), 123.6 (d, J = 3.1 Hz), 115.3 (d, J = 21.1 Hz), 115.0 (d, J = 22.0 Hz). 86.7, 70.6, 70.6, 
62.8, 46.7, 46.4, 42.3, 30.7, 23.6, 20.9. 
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(±)-3-(3-fluorobenzyl)oxy-1-oxa-2,7-diaza-7,10-ethanospiro[4.5]dec-2-ene 
fumarate (9b) 
The fumarate derivative 9b was prepared 
according to the general procedure 5.3.2.4 by 
reacting 92 (110 mg, 0.38 mmol, 1 equiv) and 
fumaric acid (44 mg, 0.38 mmol, 1 equiv) in MeOH. 
The crude salt was recrystallized from i-PrOH to 
provide the pure compound as off-white solid (136 
mg, yield 95%). 
9b: off-white solid; TLC (alumina-Dragendorff): Rf = 
0.33 (CH2Cl2/MeOH 98:2); m.p.: 171.8-172.3°C; MS 
(ESI) m/z for C16H20FN2O2+ [M+H]+ calcd. 291.2, found 291.1. 
1H NMR (CD3OD, 300 MHz) δ 7.44 – 7.34 (m, 1H), 7.25 – 7.19 (m, 1H), 7.19 – 7.13 (m, 1H), 
7.13 – 7.03 (m, 1H), 6.68 (s, 1.5H), 5.14 (s, 2H), 3.56 (s, 2H), 3.42 – 3.19 (m, 5H), 3.16 (d, J = 
16.7 Hz, 1H), 2.42 – 2.26 (m, 2H), 2.11 – 1.97 (m, 1H), 1.97 – 1.76 (m, 2H). 
13C NMR (CD3OD, 75 MHz) δ 169.5 (d, J = 260.7 Hz), 165.9, 139.7 (d, J = 7.5 Hz), 136.1, 131.4 
(d, J = 8.2 Hz), 124.9 (d, J = 3.0 Hz), 116.2 (d, J = 21.4 Hz), 115.8 (d, J = 22.5 Hz), 85.0, 72.0, 
60.3, 47.4, 46.8, 42.4, 30.8, 21.0, 19.1.  
 
 
(±)-3-(3-fluorobenzyl)oxy-1-oxa-2,7-diaza-7,10-ethanospiro[4.5]dec-2-ene methyl 
iodide (10b) 
According to the general procedure 
5.3.2.5, CH3I (105 L, 1.68 mmol, 8 equiv) was 
added to a solution of the free base 92 (60 mg, 
0.21 mmol, 1 equiv) in MeOH. Evaporation of the 
solvent under reduced pressure afforded the 
crude quaternary salt quantitatively and then it 
was re-crystalized from acetone and Et2O to give 
the pure final compound as a white solid (59 mg, 
yield 65%). 
10b: white solid; TLC (alumina-Dragendorff): Rf = =.30 in CH2Cl2/MeOH 9:1; m.p.: 172.7-
173.6°C; MS (ESI) m/z for C17H22FN2O2+ [M]+ calcd. 305.2, found 304.8. 
1H NMR (CD3OD, 300 MHz) δ 7.40 (td, J = 8.0, 5.9 Hz, 1H), 7.22 (d, J = 7.9 Hz, 1H), 7.17 (dd, J 
= 9.7, 2.2 Hz, 1H), 7.08 (td, J = 8.3, 1.9 Hz, 1H), 5.16 (s, 2H), 3.85 (dd, J = 13.8, 2.6 Hz, 1H), 
3.73 (dd, J = 13.7, 2.7 Hz, 1H), 3.61 – 3.33 (m, 4H), 3.36 (d, J = 16.9 Hz, 1H), 3.20 (d, J = 16.9 
Hz, 1H), 3.06 (s, 3H), 2.48 – 2.33 (m, 2H), 2.21 – 2.07 (m, 1H), 2.07 – 1.91 (m, 2H). 
13C NMR (CD3OD, 75 MHz) δ 167.7, 164.2 (d, J = 244.7 Hz), 139.6 (d, J = 7.4 Hz), 131.4 (d, J = 
8.3 Hz), 124.9 (d, J = 3.0 Hz), 116.2 (d, J = 21.3 Hz), 115.8 (d, J = 22.4 Hz), 85.4, 72.0, 69.6, 
57.8, 57.2, 52.4, 42.4, 30.6, 22.1, 20.3. 
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(±)-3-(3-chlorobenzyl)oxy-1-oxa-2,7-diaza-7-boranyl-7,10-ethanospiro[4.5]dec-2-
ene (86) 
 
The title compound was prepared 
according to the general procedure described in 
5.3.2.2, by reacting 83 (200 mg, 0.77 mmol, 1 
equiv), (3-chlorophenyl)methanol (165 mg, 1.16 
mmol, 1.5 equiv) and NaH 60% dispersion in 
mineral oil (51 mg, 1.28 mmol, 1.65 equiv). After 
standard workup, 86 was obtained as a yellow oil 
(222 mg, yield 90%). 
86: yellow oil¸ TLC (Dragendorff): Rf = 0.40 (cyclohexane/EtOAc 2:3). 
1H NMR (CDCl3, 300 MHz) δ 7.33 – 7.24 (m, 2H), 7.23 – 7.16 (m, 2H), 5.04 (s, 2H), 3.33 (dd, J 
= 14.5, 2.0 Hz, 1H), 3.12 – 2.89 (m, 6H), 2.84 (d, J = 16.5 Hz, 1H), 2.38 – 2.23 (m, 1H), 2.23 – 
2.16 (m, 1H), 1.95 – 1.80 (m, 1H), 1.72 – 1.54 (m, 2H). 
13C NMR (CDCl3, 75 MHz) δ 165.6, 137.1, 134.6, 130.0, 128.9, 128.3, 126.4, 84.4, 71.1, 65.5, 
52.2, 51.5, 42.3, 30.2, 21.9, 19.8. 
 
 
(±)-3-(3-chlorobenzyl)oxy-1-oxa-2,7-diaza-7,10-ethanospiro[4.5]dec-2-ene (93) 
The title compound was obtained according 
to the general procedure 5.3.2.3 by reacting 86 
(110 mg, 0.34 mmol, 1 equiv) and CF3COOH (131 
L, 1.7 mmol, 5 equiv) in acetone. After 
disappearance of the starting material (TLC in 
cyclohexane/EtOAc 2:3 and CH2Cl2/MeOH 9:1), 
standard workup was applied to provide the 
desired compound (84 mg, yield 81%). 
93: yellow oil; TLC (Dragendorff): Rf = 0.38 (CH2Cl2/MeOH 9:1). 
1H NMR (CDCl3, 300 MHz) δ 7.34 – 7.28 (m, 1H), 7.26 – 7.21 (m, 2H), 7.21 – 7.14 (m, 1H), 
5.02 (s, 2H), 3.18 (dd, J = 14.6, 1.6 Hz, 1H), 3.03 (d, J = 16.4 Hz, 1H), 2.94 (dd, J = 14.6, 1.6 
Hz, 1H), 2.85 – 2.58 (m, 5H), 2.14 – 2.00 (m, 1H), 2.00 – 1.93 (m, 1H), 1.68 – 1.53 (m, 1H), 
1.53 – 1.27 (m, 2H). 
13C NMR (CDCl3, 75 MHz) δ 165.8, 137.6, 134.5, 129.9, 128.6, 128.2, 126.3, 86.7, 70.6, 62.8, 
46.7, 46.5, 42.4, 30.7, 23.6, 20.9. 
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(±)-3-(3-chlorobenzyl)oxy-1-oxa-2,7-diaza-7,10-ethanospiro[4.5]dec- 
2-ene fumarate (9c) 
The fumarate derivative 9c was prepared 
according to the general procedure 5.3.2.4 by 
reacting 93 (60 mg, 0.20 mmol, 1 equiv) and 
fumaric acid (23 mg, 0.20 mmol, 1 equiv) in MeOH. 
The crude salt was recrystallized from 1-PrOH to 
provide the pure compound as a white solid (73 
mg, yield 93%). 
9c: white solid; TLC (alumina-Dragendorff): Rf = 
0.36 (CH2Cl2/MeOH 98:2); m.p.: 164.6- 165.3°C; 
MS (ESI) m/z for C16H20ClN2O2+ [M+H]+ calcd. 307.1, found 307.9 [M+H]+, 310.2 [M+2+H]+. 
1H NMR (CD3OD, 300 MHz) δ 7.47 – 7.42 (m, 1H), 7.40 – 7.30 (m, 3H), 6.69 (s, 1.5H), 5.13 (s, 
2H), 3.55 (s, 2H), 3.41 – 3.18 (m, 5H), 3.13 (d, J = 16.9 Hz, 1H), 2.43 – 2.24 (m, 2H), 2.11 – 
1.96 (m, 1H), 1.96 – 1.76 (m, 2H). 
13C NMR (CD3OD, 75 MHz) δ 171.1, 167.7, 139.3, 136.1, 135.4, 131.2, 129.6, 129.2, 127.5, 
85.1, 71.9, 60.3, 47.4, 46.8, 42.4, 30.8, 21.0, 19.1. 
 
 
 
(±)-3-(3-chlorobenzyl)oxy-1-oxa-2,7-diaza-7,10-ethanospiro[4.5]dec- 
2-ene methyl iodide  (10c) 
According to the general procedure 
5.3.2.5, CH3I (565 L, 9.07 mmol, 8 equiv) was 
added to a solution of the free base 93 (348 mg, 
1.13 mmol, 1 equiv) in MeOH. Evaporation of the 
solvent under reduced pressure afforded the 
crude quaternary salt quantitatively and then it 
was re-crystalized from acetone to give the pure 
final compound as a white solid (294 mg,  
yield 58%). 
10c: white solid; TLC (alumina-Dragendorff): Rf = 0.34 (CH2Cl2/MeOH 9:1);  m.p.: 157.9-
159.8°C; MS (ESI) m/z for C17H22ClN2O2+ [M]+ calcd. 321.1, found 321.2 [M+H]+, 323.2 
[M+2+H]+. 
1H NMR (CD3OD, 300 MHz) δ 7.47 – 7.43 (m, 1H), 7.39 – 7.31 (m, 3H), 5.14 (s, 2H), 3.87 (dd, 
J = 13.8, 2.7 Hz, 1H), 3.73 (dd, J = 13.7, 2.7 Hz, 1H), 3.60 – 3.36 (m, 4H), 3.36 (d, J = 16.9 Hz, 
1H), 3.21 (d, J = 16.9 Hz, 1H), 3.06 (s, 3H), 2.49 – 2.31 (m, 2H), 2.21 – 2.07 (m, 1H), 2.07 – 
1.91 (m, 2H). 
13C NMR (CD3OD, 75 MHz) δ 167.6, 139.2, 135.4, 131.2, 129.6, 129.2, 127.5, 85.4, 72.0, 
69.6, 57.8, 57.2, 52.3, 42.4, 30.6, 22.1, 20.3. 
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(±)-3-(3-bromobenzyl)oxy-1-oxa-2,7-diaza-7,10-ethanospiro[4.5]dec- 
2-ene (94) 
The coupling reaction was performed 
following a procedure distinct from the general 
protocol 5.3.2.2, which, in a single step, directly 
afforded the title compound since the cleavage of 
the BH3 group occurred immediately. Intermediate 
83 (400 mg, 1.55 mmol, 1 equiv) was dissolved in 
MeCN (6 mL), K2CO3 (641 mg, 4.64 mmol, 3 equiv) 
and then (3-bromophenyl)methanol (867 mg, 4.64 
mmol, 3 equiv) were slowly added. The mixture 
was heated to 75°C and monitored by TLC (cyclohexane/EtOAc 2:3). Since no new spots 
were detected in TLC, NaH 60% dispersion in mineral oil (100 mg, 2.50 mmol) was added to 
induce the formation of the desired compound. After disappearance of the starting 
compound (2h), the reaction was quenched with satured aqueous solution of NaHCO3, and 
extracted with CH2Cl2 (x 3). The combined organic phases were dryied over anhydrous 
Na2SO4, filtered and concentrated in vacuum. The residue was purified by silica gel column 
chromatography eluting in cyclohexane/EtOAc 7:3 to provide the pure desired compound 
(172 mg, yield 32%). 
94: yellow oil; TLC (Dragendorff): Rf = 0.21 in CH2Cl2/MeOH 9:1 (TLC stains: Dragendorff). 
1H NMR (CDCl3, 300 MHz) δ 7.50 – 7.43 (m, 1H), 7.43 – 7.36 (m, 1H), 7.26 – 7.12 (m, 2H), 
5.02 (s, 2H), 3.24 (d, J = 14.5 Hz, 1H), 3.05 (dd, J = 15.6, 3.8 Hz, 2H), 2.96 – 2.75 (m, 5H), 2.20 
– 2.06 (m, 1H), 2.06 – 1.99 (m, 1H), 1.75 – 1.61 (m, 1H), 1.61 – 1.50 (m, 1H), 1.50 – 1.36 (m, 
1H). 
13C NMR (CDCl3, 75 MHz) δ 165.8, 137.7, 131.6, 131.1, 130.2, 126.8, 122.7, 86.1, 70.6, 62.0, 
46.6, 46.3, 42.3, 30.6, 22.9, 20.4. 
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(±)-3-(3-bromobenzyl)oxy-1-oxa-2,7-diaza-7,10-ethanospiro[4.5]dec- 
2-ene fumarate (9d) 
The fumarate derivative 9d was prepared according to the general procedure 
5.3.2.4 by reacting 94 (172 mg, 0.49 mmol, 1 equiv) and fumaric acid (57 mg, 0.49 mmol, 1 
equiv) in MeOH. The crude salt was recrystallized from 1-PrOH to provide the pure 
compound as a off-white solid (208 mg, yield 91%). 
9d: off-white solid; TLC (alumina-Dragendorff): Rf = 0.42 (CH2Cl2/MeOH 98:2); m.p.: 151.4-
152.2°C; MS (ESI) m/z for C16H20BrN2O2+ [M+H]+ calcd. 351.1, found 351.4 [M+H]+, 353.5 
[M+2+H]+. 
1H NMR (CD3OD, 300 MHz) δ 7.58 (s, 1H), 7.53 – 7.45 (m, 1H), 7.37 (d, J = 7.7 Hz, 1H), 7.28 
(t, J = 7.7 Hz, 1H), 6.68 (s, 2H), 5.11 (s, 2H), 3.57 (s, 2H), 3.42 – 3.21 (m, 5H), 3.15 (d, J = 16.9 
Hz, 1H), 2.42 – 2.24 (m, 2H), 2.12 – 1.97 (m, 1H), 1.97 – 1.78 (m, 2H). 
13C NMR (CD3OD, 75 MHz) δ 171.3, 167.7, 139.4, 136.1, 132.5, 132.1, 131.4, 127.9, 123.3, 
85.0, 71.8, 60.0, 47.1, 46.5, 42.4, 30.8, 20.8, 19.0. 
 
 
(±)-3-(3-bromobenzyl)oxy-1-oxa-2,7-diaza-7,10-ethanospiro[4.5]dec- 
2-ene methyl iodide (10d) 
According to the general procedure 
5.3.2.5, CH3I (169 L, 2.72 mmol, 8 equiv) was 
added to a solution of the free base 94 (119 mg, 
0.34 mmol, 1 equiv) in MeOH. Evaporation of the 
solvent under reduced pressure afforded the 
crude quaternary salt quantitatively and then it 
was re-crystalized from EtOH/i-PrOH to give the 
pure final compound as a yellow solid (77 mg, 
yield 46%). 
10d: yellow solid; TLC (alumina-Dragendorff): Rf = 0.33 (CH2Cl2/MeOH 9:1); m.p.: 171.3-
172.5°C; MS (ESI) m/z for C17H22BrN2O2+ [M]+ calcd. 365.1, found 364.9 [M+H]+, 367.2 
[M+2+H]+. 
1H NMR (CD3OD, 300 MHz) δ 7.63 – 7.57 (m, 1H), 7.55 – 7.47 (m, 1H), 7.39 (d, J = 7.7 Hz, 
1H), 7.30 (t, J = 7.8 Hz, 1H), 5.13 (s, 2H), 3.85 (dd, J = 13.8, 2.6 Hz, 1H), 3.72 (dd, J = 13.7, 2.7 
Hz, 1H), 3.61 – 3.39 (m, 4H), 3.35 (d, J = 16.9 Hz, 1H), 3.20 (d, J = 16.9 Hz, 1H), 3.05 (s, 3H), 
2.50 – 2.31 (m, 2H), 2.20 – 2.07 (m, 1H), 2.07 – 1.89 (m, 2H). 
13C NMR (CD3OD, 75 MHz) δ 167.6, 139.4, 132.6, 132.2, 131.4, 128.0, 123.4, 85.4, 71.9, 
69.6, 57.8, 57.2, 52.4, 42.4, 30.6, 22.1, 20.3. 
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(±)-3-(3-iodobenzyl)oxy-1-oxa-2,7-diaza-7-boranyl-7,10-ethanospiro[4.5]dec-2-ene 
(87) 
The title compound was prepared 
according to the general procedure described in 
5.3.2.2, by reacting 83 (200 mg, 0.77 mmol, 1 
equiv), (3-iodophenyl)methanol (272 mg, 1.16 
mmol, 1.5 equiv) and NaH 60% dispersion in 
mineral oil (51 mg, 1.28 mmol, 1.65 equiv). After 
standard workup, 87 was obtained as a yellow oil 
(234 mg, yield 74%). 
87: yellow oil; TLC (Dragendorff): Rf = 0.44 
(cyclohexane/EtOAc 2:3). 
1H NMR (CDCl3, 300 MHz) δ 7.75 – 7.70 (m, 1H), 7.67 (dd, J = 7.9, 1.1 Hz, 1H), 7.32 (d, J = 7.7 
Hz, 1H), 7.10 (t, J = 7.8 Hz, 1H), 5.05 (s, 2H), 3.35 (dd, J = 14.5, 1.9 Hz, 1H), 3.19 – 2.94 (m, 
6H), 2.90 (d, J = 16.6 Hz, 1H), 2.40 – 2.21 (m, 2H), 2.00 – 1.84 (m, 1H), 1.78 – 1.60 (m, 2H). 
13C NMR (CDCl3, 75 MHz) δ 165.5, 137.8, 137.4, 137.1, 130.4, 127.5, 94.4, 84.4, 70.9, 65.5, 
52.2, 51.5, 42.3, 30.2, 21.9, 19.8. 
 
 
(±)-3-(3-iodobenzyl)oxy-1-oxa-2,7-diaza-7,10-ethanospiro[4.5]dec- 
2-ene (95) 
The title compound was obtained according 
to the general procedure 5.3.2.3 by reacting 87 
(234 mg, 0.57 mmol, 1 equiv) and CF3COOH (220 
L, 2.85 mmol, 5 equiv) in acetone. After 
disappearance of the starting material (TLC in 
cyclohexane/EtOAc 2:3 and CH2Cl2/MeOH 9:1), 
standard workup was applied to provide the 
desired compound (132 mg, yield 58%). 
95: yellow oil; TLC (Dragendorff): Rf = 0.32 (CH2Cl2/MeOH 4:1) 
1H NMR (CDCl3, 300 MHz) δ 7.71 – 7.63 (m, 1H), 7.60 (dd, J = 7.9, 1.2 Hz, 1H), 7.26 (d, J = 7.7 
Hz, 1H), 7.03 (t, J = 7.8 Hz, 1H), 4.99 (s, 2H), 3.18 (dd, J = 14.6, 1.8 Hz, 1H), 3.03 (d, J = 16.4 
Hz, 1H), 2.88 (dd, J = 14.7, 1.8 Hz, 1H), 2.89 – 2.56 (m, 5H), 2.12 – 1.99 (m, 1H), 1.99 – 1.93 
(m, 1H), 1.66 – 1.53 (m, 1H), 1.53 – 1.42 (m, 1H), 1.42 – 1.28 (m, 1H). 
13C NMR (CDCl3, 75 MHz) δ 165.8, 137.9, 137.5, 137.1, 130.3, 127.4, 94.4, 86.8, 70.4, 62.9, 
46.8, 46.5, 42.4, 30.8, 23.7, 21.0. 
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(±)-3-(3-iodobenzyl)oxy-1-oxa-2,7-diaza-7,10-ethanospiro[4.5]dec-2-ene fumarate 
(9e) 
The fumarate derivative 9e was 
prepared according to the general procedure 
5.3.2.4 by reacting 95 (132 mg, 0.33 mmol, 1 
equiv) and fumaric acid (28 mg, 0.33 mmol, 1 
equiv) in MeOH. The crude salt was 
recrystallized from EtOH/i-PrOH to provide the 
pure compound as a white solid (139 mg, yield 
88%). 
9e: white solid; TLC (alumina-Dragendorff):  
Rf = 0.42 (CH2Cl2/MeOH 98:2); m.p.: 154.1-155.3°C; MS (ESI) m/z for C16H20IN2O2+ [M+H]+ 
calcd. 399.1, found 398.6. 
1H NMR (CD3OD, 300 MHz) δ 7.81 – 7.76 (m, 1H), 7.70 (d, J = 7.9 Hz, 1H), 7.40 (d, J = 7.7 Hz, 
1H), 7.15 (t, J = 7.8 Hz, 1H), 6.68 (s, 1.5H), 5.09 (s, 2H), 3.55 (s, 2H), 3.41 – 3.18 (m, 5H), 3.14 
(d, J = 16.9 Hz, 1H), 2.42 – 2.25 (m, 2H), 2.11 – 1.96 (m, 1H), 1.96 – 1.77 (m, 2H). 
13C NMR (CD3OD, 75 MHz) δ 170.9, 167.7, 139.4, 138.6, 138.2, 136.0, 131.4, 128.5, 94.8, 
84.9, 71.8, 60.0, 47.2, 46.6, 42.4, 30.8, 20.8, 19.0. 
 
 
(±)-3-(3-iodobenzyl)oxy-1-oxa-2,7-diaza-7,10-ethanospiro[4.5]dec-2-ene methyl 
iodide (10e) 
According to the general procedure 
5.3.2.5, CH3I (140 L, 2.24 mmol, 8 equiv) was 
added to a solution of the free base 95 (110 mg, 
0.28 mmol, 1 equiv) in MeOH. Evaporation of 
the solvent under reduced pressure afforded the 
crude quaternary salt quantitatively and then it 
was re-crystalized from MeOH to give the pure 
final compound as a white solid (77 mg, yield 
51%). 
10e: white crystals; TLC (alumina-Dragendorff):Rf = 0.36 (CH2Cl2/MeOH 9:1); m.p.: 201.8-
202.4°C (dec.); MS (ESI) m/z for C17H22IN2O2+ [M]+ calcd. 413.1, found 413.1. 
1H NMR ((CD3)2SO, 300 MHz) δ 7.83 – 7.79 (m, 1H), 7.77 – 7.71 (m, 1H), 7.48 – 7.42 (m, 1H), 
7.21 (t, J = 7.8 Hz, 1H), 5.09 (s, 2H), 3.80 (dd, J = 13.7, 2.5 Hz, 1H), 3.68 (dd, J = 13.7, 2.5 Hz, 
1H), 3.55 – 3.24 (m, 5H), 3.17 (d, J = 16.9 Hz, 1H), 2.97 (s, 3H), 2.35 – 2.25 (m, 1H), 2.23 – 
2.08 (m, 1H), 2.06 – 1.92 (m, 1H), 1.92 – 1.77 (m, 2H). 
13C NMR ((CD3)2SO, 75 MHz) δ 166.0, 138.1, 137.0, 136.6, 130.6, 127.5, 94.7, 84.0, 70.0, 
67.2, 55.3, 55.0, 50.9, 40.8, 28.6, 20.5, 18.8. 
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(±)-3-(3-methylbenzyl)oxy-1-oxa-2,7-diaza-7-boranyl-7,10-ethanospiro[4.5]dec-2-
ene (88) 
The title compound was prepared 
according to the general procedure described in 
5.3.2.2, by reacting 83 (200 mg, 0.77 mmol, 1 
equiv), m-tolylmethanol (142 mg, 1.16 mmol, 1.5 
equiv) and NaH 60% dispersion in mineral oil (51 
mg, 1.28 mmol, 1.65 equiv). After standard workup, 
88 was obtained as a pale yellow viscous oil (170 
mg, yield 74%). 
88: pale yellow viscous oil; TLC (Dragendorff): Rf = 0.53 (cyclohexane/EtOAc 2:3). 
1H NMR (CDCl3, 300 MHz) δ 7.14 (t, J = 7.4 Hz, 1H), 7.09 – 6.96 (m, 3H), 4.95 (s, 2H), 3.22 (d, 
J = 14.3 Hz, 1H), 3.04 – 2.72 (m, 7H), 2.23 (s, 3H), 2.20 – 2.08 (m, 2H), 1.86 – 1.71 (m, 1H), 
1.66 – 1.46 (m, 2H). 
13C NMR (CDCl3, 75 MHz) δ 165.8, 138.4, 134.9, 129.5, 129.1, 128.5, 125.5, 84.1, 72.1, 65.4, 
52.1, 51.5, 42.3, 30.1, 21.8, 21.3, 19.7. 
 
 
(±)-3-(3-methylbenzyl)oxy-1-oxa-2,7-diaza-7,10-ethanospiro[4.5]dec-2-ene (96) 
The title compound was obtained according 
to the general procedure 5.3.2.3 by reacting 96 
(170 mg, 0.57 mmol, 1 equiv) and CF3COOH (220 
L, 2.85 mmol, 5 equiv) in acetone. After 
disappearance of the starting material (TLC in 
cyclohexane/EtOAc 2:3 and CH2Cl2/MeOH 9:1), 
standard workup was applied to provide the 
desired compound (105 mg, yield 65%). 
96: colorless viscous oil; TLC (Dragendorff): Rf = 0.26 (CH2Cl2/MeOH 4:1). 
1H NMR (CDCl3, 300 MHz) δ 7.25 – 7.14 (m, 1H), 7.14 – 7.02 (m, 3H), 5.01 (s, 2H), 3.18 (dd, J 
= 14.6, 1.9 Hz, 1H), 3.01 (d, J = 16.4 Hz, 1H), 2.93 – 2.84 (m, 1H), 2.84 – 2.57 (m, 5H), 2.29 (s, 
3H), 2.14 – 1.99 (m, 1H), 1.99 – 1.93 (m, 1H), 1.68 – 1.51 (m, 1H), 1.51 – 1.40 (m, 1H), 1.40 – 
1.26 (m, 1H). 
13C NMR (CDCl3, 75 MHz) δ 166.1, 138.3, 135.5, 129.4, 129.2, 128.6, 125.5, 86.6, 
71.7, 62.9, 46.8, 46.6, 42.5, 30.7, 23.7, 21.4, 21.0. 
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(±)-3-(3-methylbenzyl)oxy-1-oxa-2,7-diaza-7,10-ethanospiro[4.5]dec- 
2-ene fumarate (9f) 
The fumarate derivative 9f was 
prepared according to the general procedure 
5.3.2.4 by reacting 96 (105 mg, 0.37 mmol, 1 
equiv) and fumaric acid (43 mg, 0.37 mmol, 1 
equiv) in MeOH. The crude salt was 
recrystallized from EtOH to provide the pure 
compound as a white solid (130 mg, yield 
95%). 
9f: white solid; TLC (alumina-Dragendorff):  
Rf = 0.36 (CH2Cl2/MeOH 98:2); m.p.: 123.4-124.8°C; MS (ESI) m/z for C17H23N2O2+ [M+H]+ 
calcd. 287.2, found 287.2. 
1H NMR (CD3OD, 300 MHz) δ 7.30 – 7.11 (m, 4H), 6.68 (s, 1.5H), 5.08 (s, 2H), 3.56 (s, 2H), 
3.43 – 3.19 (m, 5H), 3.13 (d, J = 16.8 Hz, 1H), 2.34 (s, 3H), 2.45 – 2.25 (m, 2H), 2.11 – 1.97 
(m, 1H), 1.97 – 1.76 (m, 2H). 
13C NMR (CD3OD, 75 MHz) δ 171.3, 168.0, 139.4, 136.8, 136.1, 130.2, 130.0, 129.5, 126.4, 
84.8, 73.0, 60.2, 47.3, 46.7, 42.5, 30.8, 21.4, 20.9, 19.1. 
 
 
 
(±)-3-(3-methylbenzyl)oxy-1-oxa-2,7-diaza-7,10-ethanospiro[4.5]dec- 
2-ene methyl iodide (10f) 
According to the general procedure 
5.3.2.5, CH3I (85 L, 1.36 mmol, 8 equiv) was 
added to a solution of the free base 96 (46 mg, 
0.17 mmol, 1 equiv) in MeOH. Evaporation of the 
solvent under reduced pressure afforded the 
crude quaternary salt quantitatively and then it 
was re-crystallized from EtOH/i-PrOH to give the 
pure final compound (42 mg, yield 57%). 
10f: white solid; TLC (alumina-Dragendorff): Rf = 
0.34 (CH2Cl2/MeOH 9:1); m.p.: 173.6-174.4°C (dec.); MS (ESI) m/z for C18H25N2O2+ [M]+ calcd. 
301.2, found 300.4. 
1H NMR (CD3OD, 300 MHz) δ 7.32 – 7.10 (m, 4H), 5.09 (s, 2H), 3.83 (dd, J = 13.8, 2.4 Hz, 1H), 
3.72 (dd, J = 13.7, 2.5 Hz, 1H), 3.64 – 3.32 (m, 5H), 3.17 (d, J = 16.9 Hz, 1H), 3.05 (s, 3H), 2.48 
– 2.37 (m, 2H), 2.34 (s, 3H), 2.22 – 2.07 (m, 1H), 2.07 – 1.90 (m, 2H). 
13C NMR (CD3OD, 75 MHz) δ 167.9, 139.4, 136.8, 130.3, 130.0, 129.5, 126.4, 85.2, 73.1, 
69.6, 57.8, 57.2, 52.4, 42.5, 30.6, 22.1, 21.4, 20.4. 
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(±)-3-(3-methoxybenzyl)oxy-1-oxa-2,7-diaza-7-boranyl-7,10-ethanospiro[4.5]dec-
2-ene (89) 
The title compound was prepared 
according to the general procedure described in 
5.3.2.2, by reacting 83 (200 mg, 0.77 mmol, 1 
equiv), (3-methoxyphenyl)methanol (160 mg, 
1.16 mmol, 1.5 equiv) and NaH 60% dispersion in 
mineral oil (51 mg, 1.28 mmol, 1.65 equiv). After 
standard workup, 89 was obtained as a yellowish 
oil (219 mg, yield 90%). 
89: yellowish oil; TLC (Dragendorff):  
Rf = 0.38 (cyclohexane/EtOAc 2:3). 
1H NMR (CDCl3, 300 MHz) δ 7.24 (td, J = 7.4, 1.4 Hz, 1H), 6.89 (d, J = 7.6 Hz, 1H), 6.87 – 6.81 
(m, 2H), 5.04 (s, 2H), 3.76 (s, 3H), 3.33 (dd, J = 14.6, 2.2 Hz, 1H), 3.11 – 2.89 (m, 6H), 2.84 (d, 
J = 16.5 Hz, 1H), 2.39 – 2.24 (m, 1H), 2.24 – 2.17 (m, 1H), 1.96 – 1.80 (m, 1H), 1.73 – 1.54 
(m, 2H). 
13C NMR (CDCl3, 75 MHz) δ 165.7, 159.6, 136.5, 129.6, 120.3, 114.1, 113.6, 84.1, 71.7, 65.3, 
55.1, 52.0, 51.3, 42.0, 30.0, 21.6, 19.6. 
 
(±)-3-(3-methoxybenzyl)oxy-1-oxa-2,7-diaza-7,10-ethanospiro[4.5]dec- 
2-ene (97) 
The title compound was obtained according 
to the general procedure 5.3.2.3 by reacting 89 
(170 mg, 0.54 mmol, 1 equiv) and CF3COOH (208 
L, 2.7 mmol, 5 equiv) in acetone. After 
disappearance of the starting material (TLC in 
cyclohexane/EtOAc 2:3 and CH2Cl2/MeOH 9:1), 
standard workup was applied to provide the 
desired compound (124 mg, yield 76%). 
97: yellow oil; TLC (Dragendorff): Rf = 0.24 (CH2Cl2/MeOH 4:1). 
1H NMR (CDCl3, 300 MHz) δ 7.27 – 7.19 (m, 1H), 6.93 – 6.87 (m, 1H), 6.87 – 6.84 (m, 1H), 
6.82 (ddd, J = 8.2, 2.6, 0.8 Hz, 1H), 5.03 (s, 2H), 3.75 (s, 3H), 3.20 (dd, J = 14.6, 2.0 Hz, 1H), 
3.03 (d, J = 16.4 Hz, 1H), 2.89 (dd, J = 14.7, 2.1 Hz, 1H), 2.85 – 2.56 (m, 5H), 2.15 – 2.01 (m, 
1H), 2.01 – 1.94 (m, 1H), 1.67 – 1.52 (m, 1H), 1.53 – 1.28 (m, 2H). 
13C NMR (CDCl3, 75 MHz) δ 165.9, 159.7, 137.0, 129.6, 120.4, 114.0, 113.6, 86.5, 71.3, 62.7, 
55.2, 46.7, 46.4, 42.4, 30.6, 23.5, 20.9. 
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(±)-3-(3-methoxybenzyl)oxy-1-oxa-2,7-diaza-7,10-ethanospiro[4.5]dec- 
2-ene fumarate (9g) 
The fumarate derivative 9g was 
prepared according to the general procedure 
5.3.2.4 by reacting 97 (105 mg, 0.35 mmol, 1 
equiv) and fumaric acid (40 mg, 0.35 mmol, 1 
equiv) in MeOH. The crude salt was 
recrystallized from i-PrOH to provide the pure 
compound as a white solid (134 mg, yield 
98%). 
9g: white solid; TLC (alumina-Dragendorff):  
Rf = 0.32 (CH2Cl2/MeOH 98:2); m.p.: 136.4-137.2°C; MS (ESI) m/z for C17H23N2O3+ [M+H]+ 
calcd. 303.2, found 302.8. 
1H NMR (CD3OD, 300 MHz) δ 7.28 (t, J = 8.1 Hz, 1H), 6.99 – 6.93 (m, 2H), 6.93 – 6.87 (m, 1H), 
6.69 (s, 1.5H), 5.10 (s, 2H), 3.79 (s, 3H), 3.53 (s, 2H), 3.43 – 3.16 (m, 5H), 3.12 (d, J = 16.8 Hz, 
1H), 2.41 – 2.26 (m, 2H), 2.09 – 1.96 (m, 1H), 1.95 – 1.76 (m, 2H). 
13C NMR (CD3OD, 75 MHz) δ 171.0, 167.9, 161.3, 138.4, 136.1, 130.7, 121.4, 115.0, 114.8, 
84.9, 72.8, 60.4, 55.7, 47.4, 46.8, 42.5, 30.8, 21.0, 19.2. 
 
 
(±)-3-(3-methoxybenzyl)oxy-1-oxa-2,7-diaza-7,10-ethanospiro[4.5]dec- 
2-ene methyl iodide (10g) 
According to the general procedure 5.3.2.5, 
CH3I (90 L, 1.44 mmol, 8 equiv) was added to a 
solution of the free base 97 (54 mg, 0.18 mmol, 1 
equiv) in MeOH. Evaporation of the solvent under 
reduced pressure afforded the crude quaternary salt 
quantitatively and then it was treated with  
n-hexanes to give the pure final compound as a 
white solid (72 mg, yield 90%). 
10g: white solid; TLC (alumina-Dragendorff):  
Rf = 0.30 (CH2Cl2/MeOH 9:1); m.p.: 59.3-61.8°C; MS (ESI) m/z for C18H25N2O3+ [M]+ calcd. 
317.2, found 317.1. 
1H NMR (CD3OD, 300 MHz) δ 7.33 – 7.25 (m, 1H), 7.00 – 6.94 (m, 2H), 6.91 (dd, J = 8.2, 2.4 
Hz, 1H), 5.11 (s, 2H), 3.85 (dd, J = 13.8, 2.6 Hz, 1H), 3.80 (s, J = 1.7 Hz, 3H), 3.72 (dd, J = 13.7, 
2.7 Hz, 1H), 3.61 – 3.39 (m, 4H), 3.35 (d, J = 16.9 Hz, 1H), 3.19 (d, J = 16.9 Hz, 1H), 3.06 (s, 
3H), 2.48 – 2.32 (m, 2H), 2.21 – 2.07 (m, 1H), 2.07 – 1.90 (m, 2H). 
13C NMR (CD3OD, 75 MHz) δ 167.8, 161.3, 138.3, 130.7, 121.4, 115.0, 114.8, 85.2, 72.9, 
69.6, 57.8, 57.2, 55.8, 52.3, 42.5, 30.6, 22.1, 20.4. 
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(±)-3-(naphthalen-2-ylmethoxy)-1-oxa-2,7-diaza-7-boranyl-7,10-
ethanospiro[4.5]dec-2-ene (90) 
The title compound was prepared 
according to the general procedure described in 
5.3.2.2, by reacting 83 (300 mg, 1.16 mmol, 1 
equiv), 2-naphthylmethanol (275 mg, 1.74 
mmol, 1.5 equiv) and NaH 60% dispersion in 
mineral oil (76 mg, 1.91 mmol, 1.65 equiv). After 
standard workup, 90 was obtained as a pale 
yellow oil (305 mg, yield 78%). 
90: pale yellow oil; TLC (Dragendorff):  
Rf = 0.47 (cyclohexane/EtOAc 2:3). 
1H NMR (CDCl3, 300 MHz) δ 7.82 – 7.71 (m, 4H), 7.46 – 7.36 (m, 3H), 5.20 (s, 2H), 3.25 (dd, J 
= 14.5, 1.8 Hz, 1H), 3.04 – 2.74 (m, 7H), 2.29 – 2.16 (m, 1H), 2.16 – 2.09 (m, 1H), 1.84 – 1.69 
(m, 1H), 1.63 – 1.46 (m, 2H). 
13C NMR (CDCl3, 75 MHz) δ 165.7, 133.3, 133.1, 132.5, 128.5, 128.1, 127.7, 127.7, 126.6, 
126.5, 125.8, 84.2, 72.1, 65.4, 52.1, 51.4, 42.3, 30.1, 21.8, 19.7. 
 
 
(±)-3-(naphthalen-2-ylmethoxy)-1-oxa-2,7-diaza-7,10-ethanospiro[4.5]dec-2-ene 
(98) 
The title compound was obtained according 
to the general procedure 5.3.2.3 by reacting 90 
(305 mg, 0.90 mmol, 1 equiv) and CF3COOH (347 
L, 4.50 mmol, 5 equiv) in acetone. After 
disappearance of the starting material (TLC in 
cyclohexane/EtOAc 2:3 and CH2Cl2/MeOH 9:1), 
standard workup was applied to provide the 
desired compound (164 mg, yield 57%). 
98: yellow oil; TLC (Dragendorff): Rf = 0.46 (CH2Cl2/MeOH 4:1). 
1H NMR (CDCl3, 300 MHz) δ 7.83 – 7.68 (m, 4H), 7.46 – 7.34 (m, 3H), 5.20 (s, 2H), 3.25 – 3.12 
(m, 1H), 3.01 (d, J = 16.4 Hz, 1H), 2.93 – 2.54 (m, 6H), 2.14 – 2.00 (m, 1H), 2.00 – 1.91 (m, 
1H), 1.63 – 1.49 (m, 1H), 1.49 – 1.25 (m, 2H). 
13C NMR (CDCl3, 75 MHz) δ 166.0, 133.3, 133.2, 133.0, 128.4, 128.1, 127.7, 127.6, 126.4, 
126.4, 125.9, 86.5, 71.7, 62.8, 46.8, 46.5, 42.5, 30.7, 23.6, 20.9. 
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(±)-3-(naphthalen-2-ylmethoxy)-1-oxa-2,7-diaza-7,10-ethanospiro[4.5]dec-2-ene 
fumarate (9h) 
The fumarate derivative 9h was 
prepared according to the general procedure 
5.3.2.4 by reacting 98 (164 mg, 0.51 mmol, 1 
equiv) and fumaric acid (59 mg, 0.51 mmol, 1 
equiv) in MeOH. The crude salt was 
recrystallized from EtOH to provide the pure 
compound as a white solid (173 mg, yield 83%). 
9h: white solids; TLC (alumina-Dragendorff):  
Rf = 0.40 (CH2Cl2/MeOH 98:2); m.p.: 192.6-
193.4°C; MS (ESI) m/z for C20H23N2O2+ [M+H]+ calcd. 323.2, found 322.8. 
1H NMR (CD3OD, 300 MHz) δ 7.92 – 7.81 (m, 4H), 7.55 – 7.45 (m, 3H), 6.69 (s, 1.5H), 5.30 (s, 
2H), 3.57 (s, 2H), 3.40 – 3.20 (m, 5H), 3.16 (d, J = 16.9 Hz, 1H), 2.42 – 2.25 (m, 2H), 2.12 – 
1.96 (m, 1H), 1.96 – 1.76 (m, 2H). 
13C NMR (CD3OD, 75 MHz) δ 171.3, 168.0, 136.2, 134.8, 134.6, 134.3, 129.4, 129.0, 128.7, 
128.5, 127.5, 127.4, 126.8, 84.9, 73.1, 60.2, 47.3, 46.7, 42.5, 30.8, 20.9, 19.1. 
 
(±)-3-(naphthalen-2-ylmethoxy)-1-oxa-2,7-diaza-7,10-ethanospiro[4.5]dec-2-ene 
methyl iodide (10h) 
According to the general procedure 
5.3.2.5, CH3I (125 L, 2.00 mmol, 8 equiv) 
was added to a solution of the free base 98 
(81 mg, 0.25 mmol, 1 equiv) in MeOH. 
Evaporation of the solvent under reduced 
pressure afforded the crude quaternary salt 
quantitatively and then it was re-crystalized 
from acetone to give the pure final 
compound as a white solid (73 mg,  
yield 63%). 
10h: white solid; TLC (alumina-Dragendorff): Rf = 0.30 (CH2Cl2/MeOH 9:1); m.p.: 154.8-
156.2°C; MS (ESI) m/z for C21H25N2O2+ [M]+ calcd. 337.2, found 337.1. 
1H NMR (CD3OD, 300 MHz) δ 7.93 – 7.83 (m, 4H), 7.56 – 7.47 (m, 3H), 5.31 (s, 2H), 3.81 (dd, 
J = 14.0, 2.5 Hz, 1H), 3.73 (dd, J = 13.8, 2.5 Hz, 1H), 3.60 – 3.33 (m, 5H), 3.20 (d, J = 16.9 Hz, 
1H), 3.04 (s, 3H), 2.51 – 2.33 (m, 2H), 2.21 – 2.06 (m, 1H), 2.06 – 1.88 (m, 2H). 
13C NMR (CD3OD, 75 MHz) δ 167.9, 134.8, 134.6, 134.3, 129.4, 129.0, 128.7, 128.6, 127.5, 
127.4, 126.8, 85.2, 73.2, 69.6, 57.8, 57.2, 52.3, 42.5, 30.6, 22.1, 20.4. 
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5.3.3 Experimental procedures for the synthesis of 11a-m, 12a-g 
5.3.3.1 Synthesis of borane methyl 2-(quinuclidin-3-yl)acetate 
complex (101) 
 
2-(1-azabicyclo[2.2.2]oct-3-ylidene)-acetic acid methyl ester (99) 
In a flame dried flask and under argon atmosphere, 
trimethyl phosphonoacetate (7.74 mL, 48.0 mmol, 1.2 equiv) 
was dissolved in dry THF (750 mL). The solution was cooled to 
0°C with an ice bath and sodium hydride 60% dispersion in 
mineral oil (1.92 g, 48.0 mmol, 1.2 equiv) was added 
portionwise. After one hour of stirring at room temperature, 
quinuclidin-3-one (5.00 g, 40.0 mmol, 1 equiv) was added and the resulting mixture was 
stirred overnight at RT. The reaction was monitored by TLC (CH2Cl2/MeOH 9:1). Upon 
complete consumption of the starting material, the reaction was quenched with deionized 
water at 0°C (100 mL) and then the mixture was extracted once with CH2Cl2. The organic 
layer underwent an acid-base extraction: 1N HCl was added (pH = 1) and the organic phase 
removed, the acid water phase was then basified with K2CO3 (pH = 9) and extracted with 
CH2Cl2. The combined organic layers dried over anhydrous Na2SO4, filtered and 
concentrated under reduced pressure. Methyl 2-(quinuclidin-3-ylidene)acetate (99) was 
obtained as a mixture of 1:1 (E) and (Z) stereoisomers (see 1H and 13C NMR) and was 
directly reduced in the next reaction step (7.25 g, yield 100%). 
99: yellow and very viscous oil; TLC (Dragendorff): Rf = 0.40 (CH2Cl2/MeOH 9:1). 
1H NMR (CDCl3, 300 MHz) δ 5.63 (t, J = 2.5 Hz, 1H), 5.61 (t, J = 1.7 Hz, 1H), 3.94 – 3.85 (m, 
3H), 3.66 (s, 3H), 3.65 (s, 3H), 3.47 – 3.41 (m, 2H), 2.98 – 2.71 (m, 8H), 2.48 – 2.38 (m, 1H), 
1.84 – 1.56 (m, 8H). 
13C NMR (CDCl3, 75 MHz) δ 169.6, 167.9, 166.8, 166.3, 110.6, 110.3, 56.4, 50.7, 47.4, 47.2, 
33.5, 27.1, 26.1, 26.1. 
Note: in the 13C NMR, the following pairs of peaks belong to the same carbon in the two 
different stereoisomers (E and Z): 169.6 and 167.9, 166.8 and 166.3, 110.6 and 110.3. 
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1-azabicyclo[2.2.2]octane-3-acetic acid methyl ester (100) 
Methyl 2-(quinuclidin-3-ylidene)acetate (99) (7.25 g, 
40.0 mmol, 1 equiv) was dissolved in MeOH (500 mL) and 
Pd/C (725 mg, 10% w/w). The mixture was fluxed with argon 
and then it was stirred under H2 at room temperature for 1h. 
The reaction solution was filtered through a Celite pad, 
washed with MeOH, and the filtrate was concentrated under 
reduced pressure. The residue was dissolve in CH2Cl2, 1N HCl was added and the mixture 
was extracted three times with CH2Cl2. The aqueous phase was basified with sodium 
carbonate (pH = 9) and extracted three times with CH2Cl2. The combined organic phase 
were dried over anhydrous Na2SO4, filtered and the solvent evaporated in vacuum to 
provide the desired compound methyl 2-(quinuclidin-3-yl)acetate (100) in quantitative yield 
(7.33 g, yield 100%). 
100: colorless oil; TLC (Dragendorff): Rf = 0.19 (CH2Cl2/MeOH 7:3). 
1H NMR (CDCl3, 300 MHz) δ 3.67 (s, 3H), 3.22 – 3.07 (m, 1H), 2.91 – 2.71 (m, 4H), 2.43 – 2.29 
(m, 3H), 2.19 – 2.02 (m, 1H), 1.72 – 1.52 (m, 4H), 1.48 – 1.32 (m, 1H). 
13C NMR (CDCl3, 75 MHz) δ 173.3, 54.7, 51.6, 47.7, 46.8, 38.5, 32.6, 28.1, 25.2, 21.2. 
 
 
Borane 1-azabicyclo[2.2.2]octane-3-acetic acid methyl ester complex (101) 
Under argon atmosphere, methyl 2-(quinuclidin-3-
yl)acetate (100) (7.33 g, 40.0 mmol, 1 equiv) was dissolved in 
dry THF (500 mL) and cooled to 0°C. A solution of 1.0 M BH3 in 
THF (40 mL, 40.0 mmol, 1 equiv) was then slowly added 
dropwise. The resulting mixture was stirred at RT for 1.5h and 
monitored by TLC in CH2Cl2/MeOH 7:3 or cyclohexane/EtOAc 
4:1. Upon completion, the reaction was quenched with saturated aqueous solution of 
NaHCO3 and then extracted three times with CH2Cl2. The collected organic phases were 
dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure affording 
the pure N-boranyl derivative as a white solid (7.65 g, yield 97%). 
101: white solid; TLC (Dragendorff): Rf = 0.30 (cyclohexane/EtOAc 4:1); m.p.: 86.8-87.4°C. 
1H NMR (CDCl3, 300 MHz) δ 3.62 (s, 3H), 3.31 – 3.14 (m, 1H), 3.03 – 2.82 (m, 4H), 2.54 – 2.41 
(m, 1H), 2.41 – 2.22 (m, 3H), 1.85 – 1.67 (m, 4H), 1.67 – 1.47 (m, 1H). 
13C NMR (CDCl3, 75 MHz) δ 172.1, 59.7, 53.5, 52.9, 51.8, 37.8, 31.5, 26.3, 24.8, 20.1. 
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5.3.3.2 General procedure for the synthesis of amidoximes (102-
114) 
In a sealed vial, to a stirred solution of the corresponding carbonitrile (1 equiv) in 
EtOH, aqueous hydroxylamine 50% w/w (4 equiv) was added and the resulting mixture was 
heated at 90°C till complete consumption of the starting material, which usually occurred 
within 1h. Once cooled to RT, the solvent was evaporated under reduced pressure, 
providing, without further purification, the pure amidoxime quantitatively. 
 
5.3.3.3 General procedure for the synthesis of 115-126 and 135  
The title compound was obtained by reacting methyl ester 100 or 101 and the 
appropriate amidoxime 102-114.  
5.3.3.3.1: in anhydrous conditions and under inert (argon) atmosphere, the 
appropriate amidoxime (3 equiv) was suspended in dry THF and molecular sieves were 
added. After stirring at RT for 30 min, NaH 60% dispersion in mineral oil (3 equiv) was 
added portionwise at RT and the resulting mixture was heated at 50°C for 20 min. After 
cooling it down at room temperature, a solution of methyl ester 100 or 101 (1 equiv) in dry 
THF was added dropwise. The final suspension was stirred for 2h at 80°C and monitored by 
TLC in CH2Cl2/MeOH 7:3. Upon complete consumption of the starting material, standard 
workup was applied. 
5.3.3.3.2: the appropriate amidoxime (3 equiv) was suspended in THF, Cs2CO3 (3 
equiv) was added and the mixture was heated at 50°C for 20 min. After cooling it down at 
room temperature, a solution of methyl ester 100 or 101 (1 equiv) in dry THF was added 
dropwise. The final suspension was stirred for 12h at 80°C and monitored by TLC in 
CH2Cl2/MeOH 7:3. Upon complete consumption of the starting material, standard workup 
was applied. 
Standard workup for 5.3.3.3: upon complete consumption of the starting material, 
the reaction was quenched with saturated aqueous solution of NaHCO3 and diluted with 
CH2Cl2.Depending on the starting material used, the mixture underwent different 
treatment. 101: in a separatory funnel, the mixture was acidified with 1N HCl (pH = 1) and 
the organic phase removed. The organic phase was then extracted two more times with 1N 
HCl. The aqueous layers were combined, basified with sodium carbonate and extracted 
three times with CH2Cl2. 102: the mixture was extracted three times with CH2Cl2. In both 
cases, the combined organic phases were dried over anhydrous sodium sulfate, filtered and 
concentrated under reduced pressure. The residue obtained was then purified by a silica 
gel column chromatography eluting in a proper solvent mixture to afford the pure desired 
compound. 
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5.3.3.4 General procedure for the cleavage of BH3 group (127-
134 and 136-139)  
Under argon atmosphere, the 1,2,4-oxadiazole derivative 115-126 (1 equiv) was dissolved 
in acetone acetone (3.5 mL/mmol 115-126) and cooled to 0°C (ice bath). A solution of 
CF3COOH (5 equiv) in acetone (3.5 mL/mmol 115-126) was then added dropwise and the 
resulting mixture was stirred at room temperature overnight. The reaction was monitored 
by silica gel TLC (cyclohexane/EtOAc 2:3 or CH2Cl2/MeOH 95:5). Once completed, the 
solvent was removed under reduced pressure and the residue was diluted with deionized 
water. The aqueous solution (pH = 1-2) was extracted with Et2O (x 1). The residual aqueous 
phase was basified with sodium carbonate and extracted with CH2Cl2 (x 3). The combined 
organic phases were dried over anhydrous Na2SO4, filtered and evaporated in vacuum to 
afford the pure desired compound, which was directly used in the next step without further 
purification. When, in the protocol 5.3.3.3, 100 instead of 101 was used, procedure 5.3.3.4 
was not necessary since the derivative was already achieved as a free base. 
 
5.3.3.5 General procedure for salification (11a-m)  
The appropriate derivative 127-139 (1 equiv) was dissolved in MeOH (5 mL/mmol 
127-139) and a solution of fumaric acid (1 equiv) in MeOH (2 mL/mmol 127-139) was 
added. The mixture was stirred at RT for 2h (TLC in CH2Cl2/MeOH). Additional amounts of 
fumaric acid (0.5 equiv) were then added when no improvement was observed in order to 
achieve complete consumption of the starting material. Once completed, the solvent was 
removed under reduced pressure affording the crude salt quantitatively, followed by re-
crystallization from a proper solvent to give the desired final compound 11a-m. 
 
5.3.3.6 General procedure for methylation (12a-g)  
The appropriate derivative 127-139 (1 equiv) was dissolved in MeOH (5 mL/mmol 
127-139) and methyl iodide (8.0 equiv) was added. The mixture was stirred overnight at RT 
and monitored by silica gel TLC (CH2Cl2/MeOH 4:1). Upon complete consumption of the 
starting material, the solvent and the excess of methyl iodide were removed by evaporation 
under reduced pressure, thus providing the crude N-methylated analogues 12a-m 
quantitatively. The pure compounds were then re-crystalized from a proper solvent. 
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N'-hydroxy-3-(trifluoromethyl)benzimidamide (102) 
According to the general procedure 5.3.3.2, 
hydroxylamine (50% w/w in water, 430 L, 7.01 mmol, 4 
equiv) was added to a stirred solution of 3-
(trifluoromethyl)benzonitrile (234 L, 1.75 mmol, 1 equiv) 
and ethanol (6 mL) at RT. The resulting mixture was heated 
at 90°C for 1.5h. After concentration under reduced 
pressure, the desired N'-hydroxy-3-(trifluoromethyl)-
benzimidamide (102) was obtained as a pure pale yellow 
oil (350 mg, yield 98%). 
102: pale yellow oil; TLC (PMA): Rf = 0.45 (cyclohexane/EtOAc 1:1). 
1H NMR (CDCl3, 300 MHz) δ 8.77 (br s, 1H), 7.87 – 7.80 (m, 1H), 7.78 – 7.70 (m, 1H), 7.65 – 
7.57 (m, 1H), 7.50 – 7.41 (m, 1H), 4.87 (br s, 2H). 
13C NMR (CDCl3, 75 MHz) δ 151.8, 133.4, 131.3 (d, J = 32.6 Hz), 129.4, 129.3, 126.8 (q, J = 3.7 
Hz), 124.0 (q, J = 272.3 Hz), 123.1 (q, J = 3.9 Hz). 
 
 
Borane 5-(4-quinuclidin-3-ylmethyl)-3-(3-(trifluoromethyl)phenyl)-1,2,4-
oxadiazole complex (115) 
The title compound was prepared 
according to general procedure 5.3.3.3.1 by 
reacting methyl ester 101 (421 mg, 2.14 mmol, 
1 equiv), N'-hydroxy-3-(trifluoromethyl)-
benzimidamide (102) (1.31 g, 6.41 mmol, 3 
equiv) and NaH 60% dispersion in mineral oil 
(256 mg, 6.41 mmol, 3 equiv) in dry THF (10 
mL). After standard workup and silica gel column chromatography (cyclohexane/EtOAc 3:2 
to 1:1), the desired compound 115 was obtained as a pure pale yellow oil (355 mg,  
yield 47%). 
115: pale yellow oil; TLC (Dragendorff): Rf = 0.63 (cyclohexane/EtOAc 1:1). 
1H NMR (CDCl3, 300 MHz) δ 8.29 – 8.22 (m, 1H), 8.21 – 8.14 (m, 1H), 7.69 (dd, J = 7.9, 0.5 
Hz, 1H), 7.55 (t, J = 7.8 Hz, 1H), 3.37 – 3.23 (m, 1H), 3.07 – 2.86 (m, 6H), 2.61 (ddd, J = 13.5, 
6.9, 1.9 Hz, 1H), 2.57 – 2.43 (m, 1H), 1.97 – 1.85 (m, 2H), 1.85 – 1.73 (m, 2H), 1.73 – 1.58 (m, 
1H). 
13C NMR (CDCl3, 75 MHz) δ 178.1, 167.5, 131.6 (q, J = 32.9 Hz), 130.7, 129.6, 128.0 (q, J = 3.8 
Hz), 127.6, 124.5 (q, J = 3.9 Hz), 123.8 (q, J = 272.6 Hz), 59.5, 53.6, 53.0, 33.2, 30.2, 26.3, 
24.7, 20.1. 
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5-(4-quinuclidin-3-ylmethyl)-3-(3(trifluoromethyl)phenyl)-1,2,4-oxadiazole (127) 
The title compound was obtained 
according to the general procedure 5.3.3.4 by 
reacting 115 (355 mg, 1.01 mmol, 1 equiv) and 
CF3COOH (389 L, 5.05 mmol, 5 equiv) in 
acetone. After disappearance of the starting 
material (TLC in cyclohexane/EtOAc 1:1), 
standard workup was applied to provide the 
desired compound 127 (340 mg, yield 100%). 
127: yellow oil; TLC (alumina-Dragendorff): Rf = 0.43 (CH2Cl2/MeOH 9:1). 
1H NMR (CDCl3, 300 MHz) δ 8.30 – 8.22 (m, 1H), 8.17 (d, J = 7.8 Hz, 1H), 7.66 (d, J = 7.9 Hz, 
1H), 7.51 (t, J = 7.8 Hz, 1H), 3.13 (dd, J = 13.5, 9.9 Hz, 1H), 2.94 (d, J = 7.8 Hz, 2H), 2.87 – 
2.66 (m, 4H), 2.43 (ddd, J = 13.7, 6.2, 1.7 Hz, 1H), 2.31 – 2.14 (m, 1H), 1.78 – 1.48 (m, 4H), 
1.48 – 1.30 (m, 1H). 
13C NMR (CDCl3, 75 MHz) δ 179.4, 167.3, 131.5 (q, J = 32.9 Hz), 130.6, 129.5, 127.8, 127.7 (q, 
J = 3.7 Hz), 124.4 (q, J = 3.8 Hz), 123.8 (q, J = 272.4 Hz), 54.5, 47.6, 46.8, 34.3, 30.6, 27.9, 
25.0, 20.9. 
 
 
5-(4-quinuclidin-3-ylmethyl)-3-(3(trifluoromethyl)phenyl)-1,2,4-oxadiazole 
fumarate (11a) 
The fumarate derivative 11a was 
prepared according to the general procedure 
5.3.3.4 by reacting 127 (180 mg, 0.53 mmol, 1 
equiv) and fumaric acid (62 mg, 0.53 mmol, 1 
equiv) in MeOH. After 2h, additional fumaric 
acid (31 mg, 0.27 mmol, 0.5 equiv) was added 
to achieve complete consumption of the 
starting material. The crude salt was 
recrystallized from EtOAc and n-hexane to 
provide the pure compound as a white solid (111 mg, yield 41%). 
11a: white solid; TLC (alumina-Dragendorff): Rf = 0.38 (CH2Cl2/MeOH 96:4); m.p.: 128.8-
130.4°; MS (ESI) m/z for C17H19F3N3O+ [M+H]+ calcd. 338.2, found 338.1. 
1H NMR (CD3OD, 300 MHz) δ 8.30 – 8.19 (m, 2H), 7.84 – 7.74 (m, 1H), 7.73 – 7.61 (m, 1H), 
6.63 (s, 3H), 3.75 – 3.58 (m, 1H), 3.40 – 3.11 (m, 6H), 3.11 – 2.98 (m, 1H), 2.85 – 2.66 (m, 
1H), 2.07 (s, 2H), 1.98 (s, 2H), 1.87 (s, 1H). 
13C NMR (CD3OD, 75 MHz) δ 180.2, 170.0, 168.5, 135.8, 132.5 (q, J = 32.8 Hz), 131.8, 131.2, 
129.1, 129.0 (q, J = 3.6 Hz), 125.3 (q, J = 271.6 Hz), 124.9 (q, J = 3.9 Hz), 53.0, 47.6, 47.1, 
32.6, 30.1, 25.3, 24.9, 19.0.  
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5-(4-quinuclidin-3-ylmethyl)-3-(3(trifluoromethyl)phenyl)-1,2,4-oxadiazole methyl 
iodide (12a) 
According to the general procedure 
5.3.3.6, CH3I (224 L, 3.60 mmol, 8 equiv) was 
added to a solution of the free base 127 (150 
mg, 0.45 mmol, 1 equiv) in MeOH. 
Evaporation of the solvent under reduced 
pressure afforded the crude quaternary salt 
quantitatively and then it was re-crystalized 
from MeOH and Et2O to give the pure final 
compound as a white solid (147 mg,  
yield 68%). 
12a: white solid; TLC (alumina-Dragendorff): Rf = 0.30 (CH2Cl2/MeOH 9:1); m.p.: 170.3-
172.0°C (dec.); MS (ESI) m/z for C18H21F3N3O+ [M]+ calcd. 352.2, found 352.4. 
1H NMR (CD3OD, 300 MHz) δ 8.37 – 8.29 (m, 2H), 7.90 – 7.83 (m, 1H), 7.79 – 7.70 (m, 1H), 
3.96 – 3.81 (m, 1H), 3.61 – 3.47 (m, 4H), 3.43 – 3.21 (m, 3H), 3.03 (s, 3H), 3.00 – 2.85 (m, 
1H), 2.37 – 2.19 (m, 2H), 2.19 – 2.08 (m, 2H), 2.08 – 1.93 (m, 1H). 
13C NMR (CD3OD, 75 MHz) δ 179.97, 168.50, 132.48 (q, J = 32.7 Hz), 131.88, 131.23, 129.10, 
129.01 (q, J = 3.8 Hz), 125.25 (q, J = 271.5 Hz), 124.92 (q, J = 3.9 Hz), 63.01, 58.03, 57.58, 
52.65, 33.62, 30.18, 25.91, 25.22, 20.26. 
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3-fluoro-N'-hydroxybenzimidamide (103) 
According to the general procedure 5.3.3.2, 
hydroxylamine (50% w/w in water, 2.29 mL, 37.42 mmol, 4 
equiv) was added to a stirred solution of 3-
fluorobenzonitrile (1.0 mL, 9.35 mmol, 1 equiv) and ethanol 
(8 mL) at RT. The resulting mixture was heated at 90°C for 
1h. After concentration under reduced pressure, the 
desired 3-fluoro-N'-hydroxybenzimidamide (103) was 
obtained as a pure colorless oil (1.44 g, yield 100%). 
103: colorless oil; TLC (PMA): Rf = 0.51 (cyclohexane/EtOAc 1:1). 
1H NMR (CDCl3, 300 MHz) δ 7.64 (br s, 1H), 7.43 – 7.28 (m, 3H), 7.18 – 6.99 (m, 1H), 4.96 (br 
s, 2H). 
13C NMR (CDCl3, 75 MHz) δ 162.8 (d, J = 246.4 Hz), 151.9, 134.7 (d, J = 8.1 Hz), 130.4 (d, J = 
8.2 Hz), 121.7 (d, J = 3.0 Hz), 117.0 (d, J = 21.2 Hz), 113.2 (d, J = 23.4 Hz). 
 
 
Borane 3-(3-fluorophenyl)-5-(4-quinuclidin-3-ylmethyl)-1,2,4-oxadiazole complex 
(116) 
The title compound was prepared 
according to general procedure 5.3.3.3.2 by 
reacting methyl ester 101 (500 mg, 2.54 
mmol, 1 equiv), 3-fluoro-N'-hydroxy-
benzimidamide (103) (1.17 g, 7.61 mmol, 3 
equiv) and Cs2CO3 (2.48 g, 7.61 mmol, 3 
equiv) in THF (15 mL). After standard workup 
and silica gel column chromatography (cyclohexane/EtOAc 7:3), the desired compound 116 
was obtained as a pure pale yellow oil (589 mg, yield 77%). 
116: pale yellow oil; TLC (Dragendorff): Rf = 0.43 (cyclohexane/EtOAc 7:3). 
1H NMR (CDCl3, 300 MHz) δ 7.82 – 7.75 (m, 1H), 7.69 (ddd, J = 9.4, 2.6, 1.5 Hz, 1H), 7.39 (td, 
J = 8.0, 5.7 Hz, 1H), 7.14 (tdd, J = 8.4, 2.6, 1.0 Hz, 1H), 3.39 – 3.24 (m, 1H), 3.09 – 2.87 (m, 
6H), 2.62 (ddd, J = 13.6, 6.9, 2.0 Hz, 1H), 2.57 – 2.43 (m, 1H), 1.97 – 1.85 (m, 2H), 1.85 – 1.74 
(m, 2H), 1.74 – 1.59 (m, 1H). 
13C NMR (CDCl3, 75 MHz) δ 177.8, 167.6, 162.9 (d, J = 246.7 Hz), 130.7 (d, J = 8.1 Hz), 128.6 
(d, J = 8.6 Hz), 123.2 (d, J = 3.2 Hz), 118.4 (d, J = 21.2 Hz), 114.5 (d, J = 23.7 Hz), 59.4, 53.6, 
52.9, 33.1, 30.1, 26.2, 24.6, 20.0. 
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3-(3-fluorophenyl)-5-(4-quinuclidin-3-ylmethyl)-1,2,4-oxadiazole (128) 
The title compound was obtained 
according to the general procedure 5.3.3.4 by 
reacting 116 (589 mg, 1.96 mmol, 1 equiv) 
and CF3COOH (753 L, 9.78 mmol, 5 equiv) in 
acetone. After disappearance of the starting 
material (TLC in cyclohexane/EtOAc 1:1), 
standard workup was applied to provide the 
desired compound 128 (529 mg, yield 94%). 
128: yellow oil; TLC (alumina-Dragendorff): Rf = 0.48 (CH2Cl2/MeOH 95:5). 
1H NMR (CDCl3, 300 MHz) δ 7.79 – 7.72 (m, 1H), 7.65 (ddd, J = 9.5, 2.5, 1.5 Hz, 1H), 7.33 (td, 
J = 8.1, 5.8 Hz, 1H), 7.07 (tdd, J = 8.4, 2.6, 0.9 Hz, 1H), 3.17 – 3.03 (m, 1H), 2.89 (d, J = 7.9 Hz, 
2H), 2.84 – 2.62 (m, 4H), 2.39 (ddd, J = 13.7, 6.2, 1.8 Hz, 1H), 2.25 – 2.09 (m, 1H), 1.73 – 1.57 
(m, 2H), 1.57 – 1.43 (m, 2H), 1.43 – 1.28 (m, 1H). 
13C NMR (CDCl3, 75 MHz) δ 179.00, 167.17, 162.63 (d, J = 246.7 Hz), 130.35 (d, J = 8.2 Hz), 
128.73 (d, J = 8.6 Hz), 122.89 (d, J = 3.1 Hz), 117.84 (d, J = 21.2 Hz), 114.20 (d, J = 23.6 Hz), 
54.31, 47.41, 46.60, 34.00, 30.37, 27.74, 24.76, 20.67. 
 
 
3-(3-fluorophenyl)-5-(4-quinuclidin-3-ylmethyl)-1,2,4-oxadiazole fumarate (11b) 
The fumarate derivative 11b was 
prepared according to the general procedure 
5.3.3.5 by reacting 128 (220 mg, 0.77 mmol, 1 
equiv) and fumaric acid (89 mg, 0.77 mmol, 1 
equiv) in MeOH. The crude salt was 
recrystallized from EtOAc and n-hexane to 
provide the pure compound as a white solid 
(89 mg, yield 29%). 
11b: white solid; TLC (alumina-Dragendorff): Rf = 0.57 (CH2Cl2/MeOH 9:1); m.p.: 158.1-
159.7°C; MS (ESI) m/z for C16H19FN3O+ [M+H]+ calcd. 288.2, found 288.0. 
1H NMR (CD3OD, 300 MHz) δ 7.92 – 7.85 (m, 1H), 7.76 (ddd, J = 9.6, 2.6, 1.5 Hz, 1H), 7.55 
(td, J = 8.0, 5.7 Hz, 1H), 7.30 (tdd, J = 8.5, 2.7, 1.0 Hz, 1H), 6.68 (s, 2H), 3.72 (ddd, J = 12.8, 
10.2, 2.4 Hz, 1H), 3.46 – 3.17 (m, 6H), 3.12 (ddd, J = 13.0, 7.1, 1.8 Hz, 1H), 2.89 – 2.72 (m, 
1H), 2.26 – 2.09 (m, 2H), 2.09 – 1.99 (m, 2H), 1.99 – 1.84 (m, 1H). 
13C NMR (CD3OD, 75 MHz) δ 179.91, 171.38, 168.64, 164.33 (d, J = 245.4 Hz), 136.18, 132.19 
(d, J = 8.2 Hz), 130.17 (d, J = 8.5 Hz), 124.23 (d, J = 3.1 Hz), 119.26 (d, J = 21.5 Hz), 115.03 (d, 
J = 24.1 Hz), 52.95, 47.54, 47.02, 32.61, 30.09, 25.29, 24.93, 18.97. 
. 
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3-(3-fluorophenyl)-5-(4-quinuclidin-3-ylmethyl)-1,2,4-oxadiazole methyl iodide 
(12b) 
According to the general procedure 
5.3.3.6, CH3I (433 L, 6.96 mmol, 8 equiv) was 
added to a solution of the free base 128 (250 
mg, 0.87 mmol, 1 equiv) in MeOH. 
Evaporation of the solvent under reduced 
pressure afforded the crude quaternary salt 
quantitatively and then it was re-crystalized 
from MeOH and EtOH to give the pure final 
compound as a white solid (128 mg, yield 34%). 
12b: white solid; TLC (alumina-Dragendorff): Rf = 0.35 (CH2Cl2/MeOH 9:1); m.p.: 149.6-
151.1°C; MS (ESI) m/z for C17H21FN3O+ [M]+ calcd. 302.2, found 302.4. 
1H NMR (CD3OD, 300 MHz) δ 7.92 – 7.86 (m, 1H), 7.80 – 7.74 (m, 1H), 7.55 (td, J = 8.0, 5.9 
Hz, 1H), 7.35 – 7.26 (m, 1H), 3.94 – 3.82 (m, 1H), 3.59 – 3.46 (m, 4H), 3.40 – 3.19 (m, 3H), 
3.02 (s, 3H), 2.99 – 2.83 (m, 1H), 2.34 – 2.17 (m, 2H), 2.17 – 2.07 (m, 2H), 2.07 – 1.92 (m, 
1H). 
13C NMR (CD3OD, 75 MHz) δ 179.71, 168.65, 164.34 (d, J = 245.4 Hz), 132.20 (d, J = 8.4 Hz), 
130.14 (d, J = 8.4 Hz), 124.26 (d, J = 3.2 Hz), 119.29 (d, J = 21.5 Hz), 115.07 (d, J = 24.1 Hz), 
63.03, 58.00, 57.56, 52.64, 33.62, 30.12, 25.92, 25.22, 20.25.   
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3-chloro-N'-hydroxybenzimidamide (104) 
According to the general procedure 5.3.3.2, 
hydroxylamine (50% w/w in water, 2.67 mL, 43.62 mmol, 4 
equiv) was added to a stirred solution of 3-
chlorobenzonitrile (1.50 g, 10.90 mmol, 1 equiv) and 
ethanol (8 mL) at RT. The resulting mixture was heated at 
90°C for 1h. After concentration under reduced pressure, 
the desired 3-chloro-N'-hydroxybenzimidamide (104) was 
obtained as a pure colorless oil (1.86 g, yield 100%). 
104: colorless oil; TLC (PMA): Rf = 0.51 (cyclohexane/EtOAc 1:1). 
1H NMR ((CD3)2SO, 300 MHz) δ 9.77 (s, 1H), 7.73 – 7.69 (m, 1H), 7.65 (dt, J = 6.7, 1.8 Hz, 1H), 
7.44 – 7.35 (m, 2H), 5.88 (s, 2H). 
13C NMR ((CD3)2SO, 75 MHz) δ 149.6, 135.4, 132.9, 130.0, 128.6, 125.1, 123.9.
 
 
 
 
Borane 3-(3-chlorophenyl)-5-(4-quinuclidin-3-ylmethyl)-1,2,4-oxadiazole complex 
(117) 
The title compound was prepared 
according to general procedure 5.3.3.3.2 by 
reacting methyl ester 101 (400 mg, 2.03 mmol, 
1 equiv), 3-chloro-N'-hydroxybenzimidamide 
(104) (1.04 g, 6.09 mmol, 3 equiv) and Cs2CO3 
(1.98 g, 6.09 mmol, 3 equiv) in THF (10 mL). 
After standard workup and silica gel column 
chromatography (cyclohexane/EtOAc 7:3), the desired compound 117 was obtained as a 
pure pale yellow oil (609 mg, yield 95%). 
117: white solid; TLC (Dragendorff): Rf = 0.42 (cyclohexane/EtOAc 7:3); m.p.: 159.0-160.3°C.  
1H NMR (CDCl3, 300 MHz) δ 8.01 – 7.97 (m, 1H), 7.88 (dt, J = 7.5, 1.5 Hz, 1H), 7.42 (ddd, J = 
8.1, 2.0, 1.4 Hz, 1H), 7.35 (t, J = 7.8 Hz, 1H), 3.39 – 3.24 (m, 1H), 3.09 – 2.86 (m, 6H), 2.61 
(ddd, J = 13.6, 6.9, 2.1 Hz, 1H), 2.57 – 2.42 (m, 1H), 1.99 – 1.85 (m, 2H), 1.85 – 1.73 (m, 2H), 
1.73 – 1.59 (m, 1H). 
13C NMR (CDCl3, 75 MHz) δ 177.9, 167.6, 135.1, 131.5, 130.4, 128.4, 127.7, 125.6, 59.5, 
53.7, 53.0, 33.2, 30.2, 26.3, 24.7, 20.1. 
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3-(3-chlorophenyl)-5-(4-quinuclidin-3-ylmethyl)-1,2,4-oxadiazole (129) 
The title compound was obtained 
according to the general procedure 5.3.3.4 by 
reacting 118 (609 mg, 1.92 mmol, 1 equiv) and 
CF3COOH (740 L, 9.59 mmol, 5 equiv) in 
acetone. After disappearance of the starting 
material (TLC in cyclohexane/EtOAc 1:1), 
standard workup was applied to provide the 
desired compound 129 (531 mg, yield 91%). 
129: white solid; TLC (alumina-Dragendorff): Rf = 0.57 (CH2Cl2/MeOH 9:1); m.p.: 90.7-
93.1°C. 
1H NMR (CDCl3, 300 MHz) δ 8.04 – 7.96 (m, 1H), 7.94 – 7.84 (m, 1H), 7.45 – 7.28 (m, 2H), 
3.21 – 3.06 (m, 1H), 2.94 (d, J = 7.8 Hz, 2H), 2.88 – 2.67 (m, 4H), 2.50 – 2.37 (m, 1H), 2.23 
(dd, J = 15.4, 7.4 Hz, 1H), 1.80 – 1.49 (m, 4H), 1.49 – 1.32 (m, 1H). 
13C NMR (CDCl3, 75 MHz) δ 179.2, 167.3, 134.9, 131.2, 130.2, 128.6, 127.5, 125.4, 54.6, 
47.7, 46.8, 34.3, 30.6, 28.0, 25.0, 20.9. 
 
 
3-(3-chlorophenyl)-5-(4-quinuclidin-3-ylmethyl)-1,2,4-oxadiazole fumarate 
(11c) 
The fumarate derivative 11c was 
prepared according to the general procedure 
5.3.3.5 by reacting 129 (250 mg, 0.82 mmol, 1 
equiv) and fumaric acid (96 mg, 0.82 mmol, 1 
equiv) in MeOH. The crude salt was 
recrystallized from EtOH and acetone to 
provide the pure compound as a white solid 
(153 mg, yield 48%). 
11c: white solid; TLC (alumina-Dragendorff): Rf = 0.47 (CH2Cl2/MeOH 9:1); m.p.: 152.2-
153.6°C; MS (ESI) m/z for C16H19ClN3O+ [M+H]+ calcd. 304.1, found 304.1 [M+H]+, 306.3 
[M+2+H]+. 
1H NMR (CD3OD, 300 MHz) δ 8.04 (dd, J = 2.4, 1.1 Hz, 1H), 7.98 (dt, J = 7.2, 1.5 Hz, 1H), 7.59 
– 7.54 (m, 1H), 7.54 – 7.47 (m, 1H), 6.67 (s, 1.5H), 3.72 (ddd, J = 12.8, 10.2, 2.4 Hz, 1H), 3.46 
– 3.17 (m, 6H), 3.11 (ddd, J = 13.1, 7.1, 1.6 Hz, 1H), 2.88 – 2.72 (m, 1H), 2.27 – 2.09 (m, 2H), 
2.09 – 1.99 (m, 2H), 1.99 – 1.85 (m, 1H). 
13C NMR (CD3OD, 75 MHz) δ 179.9, 171.5, 168.5, 136.2, 136.0, 132.4, 131.8, 129.9, 128.2, 
126.6, 53.0, 47.6, 47.0, 32.6, 30.1, 25.3, 25.0, 19.0.  
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3-(3-chlorophenyl)-5-(4-quinuclidin-3-ylmethyl)-1,2,4-oxadiazole methyl iodide 
(12c) 
According to the general procedure 
5.3.3.6, CH3I (466 L, 7.48 mmol, 8 equiv) was 
added to a solution of the free base 129 (284 
mg, 0.94 mmol, 1 equiv) in MeOH. 
Evaporation of the solvent under reduced 
pressure afforded the crude quaternary salt 
quantitatively and then it was re-crystalized 
from MeOH and EtOH to give the pure final 
compound as a white solid (194 mg,  
yield 46%). 
12c: white solid; TLC (alumina-Dragendorff): Rf = 0.37 (CH2Cl2/MeOH 85:15); m.p.: 118.6-
120.1°C; MS (ESI) m/z for C17H21ClN3O+ [M]+ calcd. 318.1, found 318.5 [M+H]+, 320.3 
[M+2+H]+. 
1H NMR (CD3OD, 300 MHz) δ 8.06 – 8.03 (m, 1H), 8.02 – 7.97 (m, 1H), 7.59 – 7.54 (m, 1H), 
7.54 – 7.47 (m, 1H), 3.95 – 3.81 (m, 1H), 3.61 – 3.46 (m, 4H), 3.42 – 3.19 (m, 3H), 3.03 (s, 
3H), 2.98 – 2.84 (m, 1H), 2.36 – 2.17 (m, 2H), 2.17 – 2.08 (m, 2H), 2.08 – 1.92 (m, 1H). 
13C NMR (CD3OD, 75 MHz) δ 179.7, 168.5, 136.0, 132.4, 131.8, 129.9, 128.2, 126.7, 63.0, 
58.0, 57.6, 52.7, 33.6, 30.2, 25.9, 25.2, 20.3. 
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3-bromo-N'-hydroxybenzimidamide (105) 
According to the general procedure 5.3.3.2, 
hydroxylamine (50% w/w in water, 2.02 mL, 32.96 mmol, 4 
equiv) was added to a stirred solution of 3-
bromobenzonitrile (1.50 g, 8.24 mmol, 1 equiv) and ethanol 
(8 mL) at RT. The resulting mixture was heated at 90°C for 
1h. After concentration under reduced pressure, the desired 
3-fluoro-N'-hydroxybenzimidamide (105) was obtained as a 
pure colorless oil (1.77 g, yield 100%). 
105: colorless oil; TLC (PMA): Rf = 0.51 (cyclohexane/EtOAc 1:1). 
1H NMR (CDCl3, 300 MHz) δ 7.75 – 7.69 (m, 1H), 7.53 – 7.45 (m, 2H), 7.20 (dd, J = 9.4, 6.4 
Hz, 1H), 4.79 (br s, 2H). 
13C NMR (CDCl3, 75 MHz) δ 151.6, 134.6, 133.2, 130.3, 129.2, 124.6, 122.9. 
 
 
 
 
 
Borane 3-(3-bromophenyl)-5-(4-quinuclidin-3-ylmethyl)-1,2,4-oxadiazole complex 
(118) 
The title compound was prepared 
according to general procedure 5.3.3.3.2 by 
reacting methyl ester 101 (300 mg, 1.52 
mmol, 1 equiv), 3-bromo-N'-
hydroxybenzimidamide (105) (982 mg, 4.57 
mmol, 3 equiv) and Cs2CO3 (1.49 g, 4.57 
mmol, 3 equiv) in THF (10 mL). After standard 
workup and silica gel column chromatography (cyclohexane/EtOAc 7:3), the desired 
compound 118 was obtained as a pure pale yellow oil (490 mg, yield 89%). 
118: white solid; TLC (Dragendorff): Rf = 0.42 (cyclohexane/EtOAc 7:3); m.p.: 155.2-155.8°C. 
1H NMR (CDCl3, 300 MHz) δ 8.15 (t, J = 1.8 Hz, 1H), 7.96 – 7.89 (m, 1H), 7.57 (ddd, J = 8.0, 
2.0, 1.0 Hz, 1H), 7.29 (t, J = 7.9 Hz, 1H), 3.38 – 3.23 (m, 1H), 3.07 – 2.87 (m, 6H), 2.62 (ddd, J 
= 13.7, 6.9, 2.1 Hz, 1H), 2.57 – 2.41 (m, 1H), 1.99 – 1.85 (m, 2H), 1.85 – 1.73 (m, 2H), 1.73 – 
1.58 (m, 1H). 
13C NMR (CDCl3, 75 MHz) δ 177.9, 167.5, 134.4, 130.6, 128.7, 126.1, 123.1, 59.6, 53.7, 53.1, 
33.3, 30.3, 26.4, 24.8, 20.2. 
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3-(3-bromophenyl)-5-(4-quinuclidin-3-ylmethyl)-1,2,4-oxadiazole (130) 
The title compound was obtained 
according to the general procedure 5.3.3.4 by 
reacting 118 (490 mg, 1.35 mmol, 1 equiv) 
and CF3COOH (521 L, 6.77 mmol, 5 equiv) in 
acetone. After disappearance of the starting 
material (TLC in cyclohexane/EtOAc 1:1), 
standard workup was applied to provide the 
desired compound 130 (400 mg, yield 85%). 
130: white solid; TLC (alumina-Dragendorff): Rf = 0.51 (CH2Cl2/MeOH 9:1); m.p.: 107.6-
108.8°C. 
1H NMR (CDCl3, 300 MHz) δ 8.19 – 8.14 (m, 1H), 7.97 – 7.90 (m, 1H), 7.60 – 7.52 (m, 1H), 
7.28 (t, J = 7.9 Hz, 1H), 3.21 – 3.07 (m, 1H), 2.94 (d, J = 7.9 Hz, 2H), 2.89 – 2.68 (m, 4H), 2.43 
(ddd, J = 13.7, 6.2, 1.1 Hz, 1H), 2.30 – 2.15 (m, 1H), 1.86 – 1.48 (m, 4H), 1.49 – 1.33 (m, 1H). 
13C NMR (CDCl3, 75 MHz) δ 179.3, 167.3, 134.2, 130.5, 128.9, 126.0, 123.0, 54.6, 47.7, 46.9, 
34.3, 30.7, 28.1, 25.0, 21.0. 
 
 
 
3-(3-bromophenyl)-5-(4-quinuclidin-3-ylmethyl)-1,2,4-oxadiazole fumarate (11d) 
The fumarate derivative 11d was 
prepared according to the general procedure 
5.3.3.5 by reacting 130 (200 mg, 0.57 mmol, 1 
equiv) and fumaric acid (67 mg, 0.57 mmol, 1 
equiv) in MeOH. The crude salt was 
recrystallized from EtOH and acetone to 
provide the pure compound as a white solid 
(137 mg, yield 55%). 
11d: white solid; TLC (alumina-Dragendorff): Rf = 0.42 (CH2Cl2/MeOH 95:5); m.p.: 141.9-
143.8°C; MS (ESI) m/z for C16H19BrN3O+ [M+H]+ calcd. 348.1, found 348.3. [M+H]+, 350.2 
[M+2+H]+. 
1H NMR (CD3OD, 300 MHz) δ  8.19 (t, J = 1.8 Hz, 1H), 8.03 (dt, J = 7.8, 1.2 Hz, 1H), 7.71 (ddd, 
J = 8.0, 1.9, 1.0 Hz, 1H), 7.44 (t, J = 7.9 Hz, 1H), 6.67 (s, 1.5H), 3.72 (ddd, J = 12.8, 10.2, 2.4 
Hz, 1H), 3.45 – 3.17 (m, 6H), 3.11 (ddd, J = 13.0, 7.0, 1.6 Hz, 1H), 2.88 – 2.71 (m, 1H), 2.26 – 
2.10 (m, 2H), 2.10 – 1.99 (m, 2H), 1.99 – 1.85 (m, 1H). 
13C NMR (CD3OD, 75 MHz) δ 180.0, 171.5, 168.4, 136.2, 135.4, 132.0, 131.1, 130.1, 127.0, 
123.9, 53.0, 47.6, 47.1, 32.6, 30.1, 25.3, 24.9, 19.0.  
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3-(3-bromophenyl)-5-(4-quinuclidin-3-ylmethyl)-1,2,4-oxadiazole methyl iodide 
(12d) 
According to the general procedure 
5.3.3.6, CH3I (286 L, 4.59 mmol, 8 equiv) was 
added to a solution of the free base 130 (200 
mg, 0.57 mmol, 1 equiv) in MeOH. 
Evaporation of the solvent under reduced 
pressure afforded the crude quaternary salt 
quantitatively and then it was re-crystalized 
from EtOH and acetone to give the pure final 
compound as a white solid (160 mg, yield 57%). 
12d: white solid; TLC (alumina-Dragendorff): Rf = 0.51 (CH2Cl2/MeOH 85:15); m.p.: 171.1-
172.8°C (dec.); MS (ESI) m/z for C17H21BrN3O+ [M]+ calcd. 362.1, found 362.3 [M+H]+, 364.2 
[M+2+H]+. 
1H NMR (CD3OD, 300 MHz) δ 8.19 (t, J = 1.7 Hz, 1H), 8.06 – 8.01 (m, 1H), 7.71 (ddd, J = 8.1, 
2.0, 1.0 Hz, 1H), 7.45 (t, J = 7.9 Hz, 1H), 3.94 – 3.81 (m, 1H), 3.59 – 3.47 (m, 4H), 3.42 – 3.19 
(m, 3H), 3.03 (s, 3H), 3.00 – 2.83 (m, 1H), 2.34 – 2.18 (m, 2H), 2.18 – 2.08 (m, 2H), 2.08 – 
1.92 (m, 1H). 
13C NMR (CD3OD, 75 MHz) δ 179.7, 168.4, 135.4, 132.0, 131.1, 130.1, 127.1, 123.8, 63.0, 
58.0, 57.6, 52.7, 33.6, 30.2, 25.9, 25.2, 20.3. 
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N'-hydroxy-3-iodobenzimidamide (106) 
According to the general procedure 5.3.3.2, 
hydroxylamine (50% w/w in water, 1.60 mL, 26.2 mmol, 4 
equiv) was added to a stirred solution of 3-iodobenzonitrile 
(1.50 g, 6.55 mmol, 1 equiv) and ethanol (8 mL) at RT. The 
resulting mixture was heated at 90°C for 1h. After 
concentration under reduced pressure, the desired N'-
hydroxy-3-iodobenzimidamide (106) was obtained as a 
pure colorless oil (1.72 g, yield 100%). 
106: colorless oil; TLC (PMA): Rf = 0.51 (cyclohexane/EtOAc 1:1). 
1H NMR (CDCl3, 300 MHz) δ 8.57 (br s, 1H), 7.97 (t, J = 1.7 Hz, 1H), 7.74 (ddd, J = 7.9, 1.7, 1.0 
Hz, 1H), 7.58 (ddd, J = 7.8, 1.5, 1.1 Hz, 1H), 7.12 (t, J = 7.9 Hz, 1H), 4.91 (br s, 2H). 
13C NMR (CDCl3, 75 MHz) δ 151.6, 139.1, 135.0, 134.5, 130.4, 125.3, 94.5. 
 
 
 
 
Borane 3-(3-iodophenyl)-5-(4-quinuclidin-3-ylmethyl)-1,2,4-oxadiazole complex 
(119) 
The title compound was prepared 
according to general procedure 5.3.3.3.2 by 
reacting methyl ester 101 (500 mg, 2.54 
mmol, 1 equiv), N'-hydroxy-3-
iodobenzimidamide (106) (1.99 g, 7.61 mmol, 
3 equiv) and Cs2CO3 (2.48 g, 7.61 mmol, 3 
equiv) in THF (15 mL). After standard workup 
and silica gel column chromatography (cyclohexane/EtOAc 7:3), the desired compound 119 
was obtained as a pure pale yellow oil (873 mg, yield 84%). 
119: pale yellow oil; TLC (Dragendorff): Rf = 0.43 (cyclohexane/EtOAc 7:3). 
1H NMR (CDCl3, 300 MHz) δ  8.37 – 8.32 (m, 1H), 7.99 – 7.93 (m, 1H), 7.82 – 7.73 (m, 1H), 
7.19 – 7.11 (m, 1H), 3.38 – 3.23 (m, 1H), 3.09 – 2.86 (m, 6H), 2.61 (ddd, J = 13.6, 6.9, 1.7 Hz, 
1H), 2.56 – 2.42 (m, 1H), 1.98 – 1.85 (m, 2H), 1.85 – 1.74 (m, 2H), 1.74 – 1.59 (m, 1H). 
13C NMR (CDCl3, 75 MHz) δ 177.8, 167.2, 140.3, 136.3, 130.6, 128.6, 126.6, 94.5, 59.5, 53.6, 
53.0, 33.2, 30.2, 26.3, 24.7, 20.1.
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3-(3-iodophenyl)-5-(4-quinuclidin-3-ylmethyl)-1,2,4-oxadiazole (131) 
The title compound was obtained 
according to the general procedure 5.3.3.4 by 
reacting 119 (873 mg, 2.13 mmol, 1 equiv) and 
CF3COOH (822 L, 10.67 mmol, 5 equiv) in 
acetone. After disappearance of the starting 
material (TLC in cyclohexane/EtOAc 1:1), 
standard workup was applied to provide the 
desired compound 131 (768 mg, yield 91%). 
131: white solid; TLC (alumina-Dragendorff): Rf = 0.50 (CH2Cl2/MeOH 95:5); m.p.: 149.4-
150.5°C. 
1H NMR (CDCl3, 300 MHz) δ 8.44 – 8.40 (m, 1H), 8.06 – 7.99 (m, 1H), 7.85 – 7.79 (m, 1H), 
7.24 – 7.16 (m, 1H), 3.20 (dd, J = 13.5, 9.8 Hz, 1H), 3.00 (d, J = 7.9 Hz, 2H), 2.95 – 2.74 (m, 
4H), 2.49 (ddd, J = 13.7, 6.2, 1.8 Hz, 1H), 2.35 – 2.20 (m, 1H), 1.84 – 1.72 (m, 1H), 1.72 – 1.55 
(m, 3H), 1.55 – 1.39 (m, 1H). 
13C NMR (CDCl3, 75 MHz) δ 179.3, 167.1, 140.2, 136.3, 130.6, 128.9, 126.6, 94.5, 54.7, 47.8, 
47.0, 34.4, 30.8, 28.1, 25.1, 21.1. 
 
 
3-(3-iodophenyl)-5-(4-quinuclidin-3-ylmethyl)-1,2,4-oxadiazole fumarate (11e) 
The fumarate derivative 11e was 
prepared according to the general procedure 
5.3.3.5 by reacting 131 (294 mg, 0.74 mmol,  
1 equiv) and fumaric acid (86 mg, 0.74 mmol, 
1 equiv) in MeOH. The crude salt was 
recrystallized from MeOH and n-hexane to 
provide the pure compound as a white solid 
(321 mg, yield 85%). 
11e: white solid; TLC (alumina-Dragendorff): Rf = 0.59 (CH2Cl2/MeOH 9:1); m.p.: 154.4-
156.3°C; MS (ESI) m/z for C16H19IN3O+ [M+H]+ calcd. 396.1, found 396.0. 
1H NMR (CD3OD, 300 MHz) δ 8.38 (t, J = 1.7 Hz, 1H), 8.07 – 8.01 (m, 1H), 7.93 – 7.87 (m, 1H), 
7.29 (t, J = 7.9 Hz, 1H), 6.69 (s, 2H), 3.72 (ddd, J = 12.8, 10.2, 2.4 Hz, 1H), 3.45 – 3.16 (m, 6H), 
3.11 (ddd, J = 13.1, 7.0, 1.7 Hz, 1H), 2.88 – 2.72 (m, 1H), 2.26 – 2.09 (m, 2H), 2.09 – 1.98 (m, 
2H), 1.98 – 1.84 (m, 1H). 
13C NMR (CD3OD, 75 MHz) δ 179.9, 169.9, 168.2, 141.4, 137.1, 135.7, 131.9, 129.9, 127.5, 
95.0, 52.9, 47.5, 47.0, 32.6, 30.1, 25.3, 24.9, 19.0.  
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3-(3-iodophenyl)-5-(4-quinuclidin-3-ylmethyl)-1,2,4-oxadiazole methyl iodide 
(12e) 
According to the general procedure 
5.3.3.6, CH3I (344 L, 5.52 mmol, 8 equiv) was 
added to a solution of the free base 131 (271 
mg, 0.69 mmol, 1 equiv) in MeOH. 
Evaporation of the solvent under reduced 
pressure afforded the crude quaternary salt 
quantitatively and then it was re-crystalized 
from MeOH to give the pure final compound 
as a bright white crystals (167 mg, yield 45%). 
12e: bright white crystals; TLC (alumina-Dragendorff): Rf = 0.39 (CH2Cl2/MeOH 85:15); m.p.: 
233.9-236.4°C (dec.); MS (ESI) m/z for C17H21IN3O+ [M]+ calcd. 410.1, found 410.3. 
1H NMR (CD3OD, 300 MHz) δ 8.39 (t, J = 1.6 Hz, 1H), 8.09 – 8.03 (m, 1H), 7.91 (ddd, J = 7.9, 
1.8, 1.1 Hz, 1H), 7.29 (t, J = 7.9 Hz, 1H), 3.95 – 3.76 (m, 1H), 3.58 – 3.42 (m, 4H), 3.40 – 3.15 
(m, 3H), 3.01 (s, 3H), 2.97 – 2.82 (m, 1H), 2.35 – 2.18 (m, 2H), 2.18 – 2.08 (m, 2H), 2.08 – 
1.92 (m, 1H). 
13C NMR (CD3OD, 75 MHz) δ 179.7, 168.3, 141.5, 137.1, 131.9, 129.9, 127.5, 95.0, 63.1, 
58.0, 57.6, 52.7, 33.6, 30.2, 25.9, 25.2, 20.3. 
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Borane 3-phenyl-5-(4-quinuclidin-3-ylmethyl)-1,2,4-oxadiazole complex (120) 
The title compound was prepared 
according to general procedure 5.3.3.3.2 by 
reacting methyl ester 101 (500 mg, 2.54 
mmol, 1 equiv), benzamidoxime (107) (1.04 g, 
7.61 mmol, 3 equiv) and Cs2CO3 (2.48 g, 7.61 
mmol, 3 equiv) in THF (15 mL). After standard 
workup and silica gel column chromatography 
(cyclohexane/EtOAc 7:3), the desired compound 120 was obtained as a pure white solid 
(370 mg, yield 52%). 
120: white solid; TLC (Dragendorff): Rf = 0.42 (cyclohexane/EtOAc 7:3); m.p.: 129.2-130.6°C. 
1H NMR (CDCl3, 300 MHz) δ 8.03 – 7.95 (m, 2H), 7.48 – 7.37 (m, 3H), 3.36 – 3.24 (m, 1H), 
3.06 – 2.87 (m, 6H), 2.62 (ddd, J = 13.7, 7.0, 2.0 Hz, 1H), 2.57 – 2.43 (m, 1H), 1.95 – 1.84 (m, 
2H), 1.84 – 1.72 (m, 2H), 1.72 – 1.57 (m, 1H). 
13C NMR (CDCl3, 75 MHz) δ 177.5, 168.2, 131.2, 128.8, 127.3, 126.5, 59.3, 53.4, 52.8, 32.9, 
30.00, 26.0, 24.5, 19.8. 
 
 
 
 
3-phenyl-5-(4-quinuclidin-3-ylmethyl)-1,2,4-oxadiazole (132) 
The title compound was obtained 
according to the general procedure 5.3.3.4 by 
reacting 120 (370 mg, 1.31 mmol, 1 equiv) 
and CF3COOH (503 L, 6.53 mmol, 5 equiv) in 
acetone. After disappearance of the starting 
material (TLC in cyclohexane/EtOAc 1:1), 
standard workup was applied to provide the 
desired compound 132 (327 mg, yield 92%). 
132: yellow oil; TLC (Dragendorff): Rf = 0.51 (CH2Cl2/MeOH 95:5). 
1H NMR (CDCl3, 300 MHz) δ 8.04 – 7.95 (m, 2H), 7.47 – 7.35 (m, 3H), 3.21 – 3.08 (m, 1H), 
2.94 (d, J = 7.9 Hz, 2H), 2.89 – 2.69 (m, 4H), 2.45 (ddd, J = 13.7, 6.3, 1.9 Hz, 1H), 2.31 – 2.15 
(m, 1H), 1.79 – 1.63 (m, 2H), 1.63 – 1.49 (m, 2H), 1.49 – 1.35 (m, 1H). 
13C NMR (CDCl3, 75 MHz) δ 178.9, 168.4, 131.2, 128.9, 127.5, 126.9, 54.6, 47.7, 46.9, 34.3, 
30.7, 28.0, 25.0, 21.0. 
  
 CHAPTER V – Experimental section 
 
 
173 
 
3-phenyl-5-(4-quinuclidin-3-ylmethyl)-1,2,4-oxadiazole fumarate (11f) 
The fumarate derivative 11f was 
prepared according to the general procedure 
5.3.3.5 by reacting 132 (327 mg, 1.21 mmol, 1 
equiv) and fumaric acid (141 mg, 1.21 mmol, 1 
equiv) in MeOH. The crude salt was 
recrystallized from MeOH and Et2O to provide 
the pure compound as a white solid (308 mg, 
yield 66%). 
11f: white solid; TLC (alumina-Dragendorff): Rf = 0.41 (CH2Cl2/MeOH 95:5); m.p.: 141.8-
143.4°C; MS (ESI) m/z for C16H20N3O+ [M+H]+ calcd. 270.2, found 270.5. 
1H NMR (CD3OD, 300 MHz) δ 8.08 – 8.01 (m, 2H), 7.58 – 7.46 (m, 3H), 6.68 (s, 2H), 3.71 
(ddd, J = 12.8, 10.2, 2.4 Hz, 1H), 3.43 – 3.16 (m, 6H), 3.11 (ddd, J = 13.1, 7.0, 1.9 Hz, 1H), 
2.86 – 2.72 (m, 1H), 2.25 – 2.09 (m, 2H), 2.09 – 1.98 (m, 2H), 1.98 – 1.84 (m, 1H). 
13C NMR (CD3OD, 75 MHz) δ 179.6, 171.4, 169.5, 136.2, 132.5, 130.1, 128.3, 128.0, 53.0, 
47.5, 47.0, 32.7, 30.1, 25.3, 24.9, 19.0. 
 
 
 
3-phenyl-5-(4-quinuclidin-3-ylmethyl)-1,2,4-oxadiazole methyl iodide (12f) 
According to the general procedure 
5.3.3.6, CH3I (351 L, 5.64 mmol, 8 equiv) 
was added to a solution of the free base 132 
(190 mg, 0.71 mmol, 1 equiv) in MeOH. 
Evaporation of the solvent under reduced 
pressure afforded the crude quaternary salt 
quantitatively and then it was re-crystalized 
from acetone to give the pure final 
compound as a white solid (158 mg, yield 54%). 
12f: white solid; TLC (alumina-Dragendorff): Rf = 0.43 (CH2Cl2/MeOH 85:15); m.p.: 159.4-
161.2°C; MS (ESI) m/z for C17H22N3O+ [M]+ calcd. 284.2, found 284.1. 
1H NMR (CD3OD, 300 MHz) δ 8.09 – 8.03 (m, 2H), 7.58 – 7.47 (m, 3H), 3.93 – 3.80 (m, 1H), 
3.58 – 3.47 (m, 4H), 3.40 – 3.18 (m, 3H), 3.02 (s, 3H), 2.99 – 2.83 (m, 1H), 2.34 – 2.17 (m, 
2H), 2.17 – 2.07 (m, 2H), 2.07 – 1.93 (m, 1H). 
13C NMR (CD3OD, 75 MHz) δ 179.3, 169.5, 132.5, 130.1, 128.4, 127.9, 63.0, 58.0, 57.6, 52.7, 
33.6, 30.1, 25.9, 25.2, 20.3. 
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N'-hydroxy-3-methylbenzimidamide (108) 
According to the general procedure 5.3.3.2, 
hydroxylamine (50% w/w in water, 3.06 mL, 50.0 mmol, 4 
equiv) was added to a stirred solution of 3-
methylbenzonitrile (1.50 mL, 12.50 mmol, 1 equiv) and 
ethanol (8 mL) at RT. The resulting mixture was heated at 
90°C for 1h. After concentration under reduced pressure, 
the desired N'-hydroxy-3-methylbenzimidamide (108) was 
obtained as a colorless oil (1.80 g, yield 96%). 
108: colorless oil; TLC (PMA): Rf = 0.46 (cyclohexane/EtOAc 1:1). 
1H NMR (CDCl3, 300 MHz) δ 7.50 – 7.38 (m, 2H), 7.34 – 7.18 (m, 2H), 4.94 (br s, 2H), 2.37 (s, 
3H). 
13C NMR (CDCl3, 75 MHz) δ 152.9, 138.4, 132.5, 130.8, 128.6, 126.7, 123.1, 21.5. 
 
 
 
Borane 5-(4-quinuclidin-3-ylmethyl)-3-m-tolyl-1,2,4-oxadiazole complex (121) 
The title compound was prepared 
according to general procedure 5.3.3.3.2 by 
reacting methyl ester 101 (300 mg, 1.52 mmol, 
1 equiv), N'-hydroxy-3-methylbenzimidamide 
(108) (686 mg, 4.57 mmol, 3 equiv) and Cs2CO3 
(1.49 g, 4.57 mmol, 3 equiv) in THF (10 mL). 
After standard workup and silica gel column 
chromatography (cyclohexane/EtOAc 3:2 to 1:1), the desired compound 121 was obtained 
as a pure pale yellow oil (406 mg, yield, 90%). 
121: pale yellow oil; TLC (Dragendorff): Rf = 0.51 (cyclohexane/EtOAc 7:3). 
1H NMR (CDCl3, 300 MHz) δ 7.83 – 7.74 (m, 2H), 7.34 – 7.21 (m, 2H), 3.37 – 3.22 (m, 1H), 
3.06 – 2.86 (m, 6H), 2.61 (ddd, J = 13.7, 6.9, 2.0 Hz, 1H), 2.56 – 2.42 (m, 1H), 2.35 (s, 3H), 
1.96 – 1.81 (m, 2H), 1.81 – 1.71 (m, 2H), 1.71 – 1.55 (m, 1H). 
13C NMR (CDCl3, 75 MHz) δ 177.4, 168.6, 138.8, 132.2, 128.9, 128.1, 126.5, 124.7, 59.5, 
53.6, 53.0, 33.3, 30.2, 26.3, 24.7, 21.4, 20.1. 
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5-(4-quinuclidin-3-ylmethyl)-3-m-tolyl-1,2,4-oxadiazole (133) 
The title compound was obtained 
according to the general procedure 5.3.3.4 by 
reacting 121 (406 mg, 1.37 mmol, 1 equiv) and 
CF3COOH (526 L, 6.83 mmol, 5 equiv) in 
acetone. After disappearance of the starting 
material (TLC in cyclohexane/EtOAc 1:1), 
standard workup was applied to provide the 
desired compound 133 (357 mg, yield 92%). 
133: yellow oil; TLC (alumina-Dragendorff): Rf = 0.33 (CH2Cl2/MeOH 94:6). 
1H NMR (CDCl3, 300 MHz) δ 7.76 (d, J = 9.1 Hz, 2H), 7.33 – 7.20 (m, 2H), 3.72 – 3.57 (m, 1H), 
3.49 – 2.97 (m, 7H), 2.75 – 2.58 (m, 1H), 2.34 (s, 3H), 2.18 – 2.01 (m, 2H), 2.01 – 1.89 (m, 
2H), 1.89 – 1.74 (m, 1H). 
13C NMR (CDCl3, 75 MHz) δ 176.9, 168.5, 138.8, 132.2, 128.9, 128.0, 126.2, 124.5, 51.8, 
46.4, 45.8, 31.7, 29.6, 24.2, 24.2, 21.4, 18.3. 
 
 
5-(4-quinuclidin-3-ylmethyl)-3-m-tolyl-1,2,4-oxadiazole fumarate (11g) 
The fumarate derivative 11g was 
prepared according to the general procedure 
5.3.3.5 by reacting 133 (68 mg, 0.24 mmol, 1 
equiv) and fumaric acid (28 mg, 0.24 mmol, 1 
equiv) in MeOH. After 2h, additional fumaric 
acid (14 mg, 0.12 mmol, 1 equiv) was added 
(two times) to achieve complete consumption 
of the starting material. The crude salt was 
recrystallized from acetone to provide the pure compound as a white solid (109 mg, yield 
88%). 
11g: white solid; TLC (alumina-Dragendorff): Rf = 0.38 (CH2Cl2/MeOH 96:4); m.p.: 210-215°C 
(dec.); MS (ESI) m/z for C17H22N3O+ [M+H]+ calcd. 284.2, found 284.4. 
1H NMR (CD3OD, 300 MHz) δ 7.91 – 7.86 (m, 1H), 7.86 – 7.80 (m, 1H), 7.44 – 7.34 (m, 2H), 
6.76 (s, 4H), 3.74 (ddd, J = 12.8, 10.2, 2.5 Hz, 1H), 3.48 – 3.33 (m, 4H), 3.25 (dd, J = 7.7, 5.7 
Hz, 2H), 3.14 (ddd, J = 13.0, 7.1, 1.8 Hz, 1H), 2.89 – 2.74 (m, 1H), 2.42 (s, 3H), 2.28 – 2.11 (m, 
2H), 2.11 – 2.01 (m, 2H), 2.01 – 1.85 (m, 1H). 
13C NMR (CD3OD, 75 MHz) δ 179.4, 169.6, 168.1, 140.1, 135.2, 133.2, 130.0, 128.8, 127.8, 
125.5, 53.1, 47.7, 47.2, 32.6, 30.1, 25.2, 24.9, 21.4, 18.9. 
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5-(4-quinuclidin-3-ylmethyl)-3-m-tolyl-1,2,4-oxadiazole methyl iodide (12g) 
According to the general procedure 
5.3.3.6, CH3I (557 L, 8.95 mmol, 8 equiv) was 
added to a solution of the free base 133 (317 
mg, 1.12 mmol, 1 equiv) in MeOH. 
Evaporation of the solvent under reduced 
pressure afforded the crude quaternary salt 
quantitatively and then it was re-crystalized 
from MeOH and EtOH to give the pure final 
compound as a white solid (191 mg,  
yield 40%). 
12g: white solid: TLC (alumina-Dragendorff): Rf = 0.30 (CH2Cl2/MeOH 9:1); m.p.: 162.1-
164.2°C; MS (ESI) m/z for C18H24N3O+ [M]+ calcd. 298.2, found 298.1. 
1H NMR (CD3OD, 300 MHz) δ 7.90 – 7.81 (m, 2H), 7.42 – 7.33 (m, 2H), 3.95 – 3.82 (m, 1H), 
3.60 – 3.49 (m, 4H), 3.41 – 3.18 (m, 3H), 3.03 (s, 3H), 3.00 – 2.83 (m, 1H), 2.41 (s, 3H), 2.35 – 
2.22 (m, 1H), 2.22 – 2.17 (m,1), 2.17 – 2.08 (m, 2H), 2.08 – 1.95 (m, 1H). 
13C NMR (CD3OD, 75 MHz) δ 179.2, 169.6, 140.1, 133.2, 130.0, 128.8, 127.8, 125.5, 63.1, 
58.0, 57.6, 52.6, 33.6, 30.2, 25.9, 25.2, 21.4, 20.3. 
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N'-hydroxy-4-methoxybenzimidamide (109) 
According to the general procedure 5.3.3.2, 
hydroxylamine (50% w/w in water, 1.84 mL, 30.04 mmol,  
4 equiv) was added to a stirred solution of  
4-methoxybenzonitrile (1.0 g, 7.51 mmol, 1 equiv) and 
ethanol (8 mL) at RT. The resulting mixture was heated at 
90°C for 1.5h. After concentration under reduced pressure, 
the desired N'-hydroxy-4-methoxybenzimidamide (109) 
was obtained as a pure white solid (1.21 g, yield 97%). 
109: white solid; TLC (PMA): Rf = 0.30 (cyclohexane/EtOAc 1:4); m.p.: 121.0-121.5°C. 
1H NMR (CDCl3, 300 MHz) δ 7.57 (d, J = 8.9 Hz, 2H), 6.91 (d, J = 8.9 Hz, 2H), 4.90 (s, 2H), 3.83 
(s, 3H). 
13C NMR (CDCl3, 75 MHz) δ 161.1, 152.7, 127.4, 125.1, 114.2, 55.5. 
 
 
 
Borane 3-(4-methoxyphenyl)-5-(4-quinuclidin-3-ylmethyl)-1,2,4-oxadiazole 
complex (122) 
The title compound was prepared 
according to general procedure 5.3.3.3.2 by 
reacting methyl ester 101 (152 mg, 0.77 
mmol, 1 equiv), N'-hydroxy-4-
methoxybenzimidamide (109) (384 mg, 2.31 
mmol, 3 equiv) and Cs2CO3 (753 mg, 2.31 
mmol, 3 equiv) in THF (5 mL). After standard 
workup and silica gel column chromatography (cyclohexane/EtOAc 4:1 to 3:2), the desired 
compound 122 was obtained as a pure yellow oil (75 mg, yield 31%).  
122: yellow oil; TLC (Dragendorff): Rf = 0.43 in (cyclohexane/EtOAc 1:4). 
1H NMR (CDCl3, 300 MHz) δ 7.92 (d, J = 8.9 Hz, 2H), 6.92 (d, J = 9.0 Hz, 2H), 3.80 (s, 3H), 3.36 
– 3.24 (m, 1H), 3.04 – 2.88 (m, 6H), 2.62 (ddd, J = 13.7, 7.0, 2.1 Hz, 1H), 2.56 – 2.43 (m, 1H), 
1.99 – 1.82 (m, 2H), 1.82 – 1.72 (m, 2H), 1.72 – 1.57 (m, 1H). 
13C NMR (CDCl3, 75 MHz) δ 177.2, 168.2, 162.2, 129.2, 119.1, 114.4, 59.6, 55.5, 53.7, 53.0, 
33.3, 30.2, 26.3, 24.7, 20.1. 
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3-(4-methoxyphenyl)-5-(4-quinuclidin-3-ylmethyl)-1,2,4-oxadiazole (134) 
The title compound was obtained 
according to the general procedure 5.3.3.4 by 
reacting 123 (61 mg, 0.19 mmol, 1 equiv) and 
CF3COOH (73 L, 0.95 mmol, 5 equiv) in 
acetone. After disappearance of the starting 
material (TLC in cyclohexane/EtOAc 3:2), 
standard workup was applied to provide the 
desired compound 134 (57 mg, yield 100%). 
134: yellow oil; TLC (alumina-Dragendorff): Rf = 0.30 (CH2Cl2/MeOH 95:5). 
1H NMR (CDCl3, 300 MHz) δ 7.93 (d, J = 8.9 Hz, 2H), 6.91 (d, J = 8.9 Hz, 2H), 3.79 (s, 3H), 3.24 
– 3.07 (m, 1H), 2.93 (d, J = 7.9 Hz, 2H), 2.88 – 2.67 (m, 4H), 2.52 – 2.41 (m, 1H), 2.32 – 2.18 
(m, 1H), 1.82 – 1.64 (m, 2H), 1.64 – 1.36 (m, 3H). 
13C NMR (CDCl3, 75 MHz) δ 178.5, 168.1, 162.0, 129.1, 119.3, 114.4, 55.5, 54.2, 47.5, 46.7, 
34.1, 30.6, 27.7, 24.9, 20.7. 
 
3-(4-methoxyphenyl)-5-(4-quinuclidin-3-ylmethyl)-1,2,4-oxadiazole fumarate 11h) 
The fumarate derivative 11h was 
prepared according to the general procedure 
5.3.3.5 by reacting 134 (57 mg, 0.19 mmol, 1 
equiv) and fumaric acid (22 mg, 0.19 mmol, 1 
equiv) in MeOH. After 2h, additional fumaric 
acid (11 mg, 0.10 mmol, 0.5 equiv) was added 
to achieve complete consumption of the 
starting material. The crude salt was 
recrystallized from MeOH/n-hexane to provide the pure compound as a white solid (25 mg, 
yield 30%). 
11h: white solid; TLC (alumina-Dragendorff): Rf = 0.33 (CH2Cl2/MeOH 96:4); m.p.: 174.7-
175.5°C; MS (ESI) m/z for C17H22N3O2+ [M+H]+ calcd. 300.2, found 300.0. 
1H NMR (CD3OD, 300 MHz) δ 7.97 (d, J = 9.0 Hz, 2H), 7.04 (d, J = 9.0 Hz, 2H), 6.69 (s, 2.5H), 
3.86 (s, 3H), 3.77 – 3.64 (m, 1H), 3.46 – 3.26 (m, 4H), 3.22 (dd, J = 7.7, 5.5 Hz, 2H), 3.18 – 
3.05 (m, 1H), 2.87 – 2.71 (m, 1H), 2.27 – 2.09 (m, 2H), 2.09 – 1.99 (m, 2H), 1.99 – 1.84 (m, 
1H). 
13C NMR (CD3OD, 75 MHz) δ 179.2, 170.6, 169.3, 163.8, 136.0, 130.0, 120.2, 115.4, 56.0, 
53.1, 47.7, 47.1, 32.7, 30.1, 25.2, 24.9, 19.0. 
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N'-hydroxyacetimidamide (110) 
According to the general procedure 5.3.3.2, hydroxylamine 
(50% w/w in water, 25.0 mL, 384.0 mmol, 4 equiv) was added to a 
stirred solution of acetonitrile (5.0 mL, 96.0 mmol, 1 equiv) and 
ethanol (50 mL) at RT. The resulting mixture was heated at 90°C for 
3h. After concentration under reduced pressure, the desired 
acetamidoxime (110) was re-crystallized from i-PrOH (7.10 g,  
yield 100%). 
110: white solid; TLC (PMA): Rf = 0.54 (CH2Cl2/MeOH 4:1); m.p.: 134-136°C. 
1H NMR ((CD3)2SO, 300 MHz): δ 8.76 (br s, 1H), 5.33 (br s, 2H), 1.62 (s, 3H). 
13C NMR ((CD3)2SO, 75 MHz): δ 149.6, 16.7. 
 
 
 
 
3-methyl-5-(4-quinuclidin-3-ylmethyl)-1,2,4-oxadiazole (135) 
The title compound was prepared according to 
general procedure 5.3.3.3.1 by reacting methyl ester 
100 (50 mg, 0.27 mmol, 1 equiv), acetamidoxime (110) 
(61 mg, 0.82 mmol, 3 equiv) and NaH 60% dispersion 
in mineral oil (33 mg, 0.82 mmol, 3 equiv) in dry THF (2 
mL). After standard extraction, 135 was obtained as a 
pure viscous oil, therefore column chromatography was not necessary (55 mg, yield 100%). 
135: light brown oil; TLC (Dragendorff): Rf = 0.34 (CH2Cl2/MeOH 7:3). 
1H NMR (CDCl3, 300 MHz) δ 3.17 – 3.01 (m, 1H), 2.84 (d, J = 7.9 Hz, 2H), 2.81 – 2.65 (m, 4H), 
2.37 (ddd, J = 13.7, 6.3, 1.9 Hz, 1H), 2.30 (s, 3H), 2.23 – 2.07 (m, 1H), 1.73 – 1.46 (m, 4H), 
1.46 – 1.31 (m, 1H). 
13C NMR (CDCl3, 75 MHz) δ 178.5, 167.0, 54.5, 47.6, 46.8, 34.1, 30.5, 27.9, 24.9, 20.9, 11.5. 
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3-methyl-5-(4-quinuclidin-3-ylmethyl)-1,2,4-oxadiazole fumarate (11i) 
The fumarate derivative 11i was prepared 
according to the general procedure 5.3.3.5 by 
reacting 135 (55 mg, 0.27 mmol, 1 equiv) and 
fumaric acid (31 mg, 0.27 mmol, 1 equiv) in MeOH. 
After 2h, additional fumaric acid (16 mg, 0.14 mmol, 
0.5 equiv) was added to achieve complete 
consumption of the starting material. The crude salt 
was recrystallized from i-PrOH to provide the pure compound as a white solid (76 mg,  
yield 80%). 
11i: white solid; TLC (alumina-Dragendorff): Rf = 0.30 (CH2Cl2/MeOH 96:4); m.p.: 158.2-
158.8°C. MS (ESI) m/z for C11H18N3O+ [M+H]+ calcd. 208.1, found 208.2.  
1H NMR (CD3OD, 300 MHz) δ 6.70 (s, 2.5H), 3.64 (ddd, J = 12.8, 10.2, 2.4 Hz, 1H), 3.43 – 3.18 
(m, 4H), 3.14 (dd, J = 7.7, 4.4 Hz, 2H), 3.04 (ddd, J = 13.0, 7.0, 2.0 Hz, 1H), 2.77 – 2.62 (m, 
1H), 2.34 (s, 3H), 2.22 – 2.10 (m, 1H), 2.10 – 1.96 (m, 3H), 1.96 – 1.82 (m, 1H). 
13C NMR (CD3OD, 75 MHz) δ 179.1, 170.6, 168.5, 136.0, 52.9, 47.5, 47.0, 32.6, 29.9, 25.1, 
24.9, 18.9, 11.3.   
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Borane 3-(pyridin-3-yl)-5-(4-quinuclidin-3-ylmethyl)-1,2,4-oxadiazole complex 
(123) 
The title compound was prepared according 
to general procedure 5.3.3.3.1 by reacting methyl 
ester 101 (350 mg, 1.78 mmol, 1 equiv), 3-
pyridylamidoxime (111) (731 mg, 5.33 mmol, 3 
equiv) and NaH 60% dispersion in mineral oil (213 
mg, 5.33 mmol, 3 equiv) in dry THF (10 mL). After 
standard workup and silica gel column 
chromatography (cyclohexane/EtOAc 1:1), the desired compound 123 was obtained as a 
pure yellow oil (258 mg, yield 51%). 
123: yellow oil; TLC (Dragendorff): Rf = 0.28 (cyclohexane/EtOAc 1:1). 
1H NMR (CDCl3, 300 MHz) δ 9.22 (d, J = 2.1 Hz, 1H), 8.68 (dd, J = 4.9, 1.7 Hz, 1H), 8.26 (dt, J = 
8.0, 1.9 Hz, 1H), 7.37 (dd, J = 7.9, 4.9 Hz, 1H), 3.38 – 3.25 (m, 1H), 3.10 – 2.87 (m, 6H), 2.62 
(ddd, J = 13.5, 6.9, 2.0 Hz, 1H), 2.57 – 2.43 (m, 1H), 1.99 – 1.86 (m, 2H), 1.86 – 1.75 (m, 2H), 
1.75 – 1.56 (m, 1H). 
13C NMR (CDCl3, 75 MHz) δ 178.0, 166.4, 152.1, 148.5, 134.6, 123.7, 122.8, 59.3, 53.5, 52.8, 
33.0, 30.0, 26.1, 24.6, 19.9. 
 
 
3-(pyridin-3-yl)-5-(4-quinuclidin-3-ylmethyl)-1,2,4-oxadiazole (136) 
The title compound was obtained according 
to the general procedure 5.3.3.4 by reacting 124 
(258 mg, 0.91 mmol, 1 equiv) and CF3COOH (351 
L, 4.55 mmol, 5 equiv) in acetone. After 
disappearance of the starting material (TLC in 
cyclohexane/EtOAc 1:1), standard workup was 
applied to provide the desired compound 136  
(225 mg, yield 92%). 
136: yellow oil; TLC (alumina-Dragendorff): Rf = 0.30 (CH2Cl2/MeOH 85:15). 
1H NMR (CDCl3, 300 MHz) δ 9.23 (d, J = 2.0 Hz, 1H), 8.70 – 8.63 (m, 1H), 8.27 (dt, J = 8.0, 2.0 
Hz, 1H), 7.35 (ddd, J = 8.1, 4.9, 0.8 Hz, 1H), 3.21 – 3.07 (m, 1H), 2.96 (d, J = 7.9 Hz, 2H), 2.89 
– 2.67 (m, 4H), 2.44 (ddd, J = 13.7, 6.2, 1.9 Hz, 1H), 2.32 – 2.15 (m, 1H), 1.79 – 1.67 (m, 1H), 
1.67 – 1.63 (m, 1H), 1.63 – 1.49 (m, 2H), 1.49 – 1.34 (m, 1H). 
13C NMR (CDCl3, 75 MHz) δ 179.5, 166.5, 152.1, 148.7, 134.7, 123.7, 123.2, 54.6, 47.7, 46.9, 
34.4, 30.7, 28.1, 25.1, 21.0. 
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3-(pyridine-3-yl)-5-(4-quinuclidin-3-ylmethyl)-1,2,4-oxadiazole fumarate (11j) 
The fumarate derivative 11j was prepared 
according to the general procedure 5.3.3.5 by 
reacting 136 (225 mg, 0.83 mmol, 1 equiv) and 
fumaric acid (97 mg, 0.83 mmol, 1 equiv) in MeOH. 
After 2h, additional fumaric acid (48 mg, 0.42 
mmol, 0.5 equiv) was added to achieve complete 
consumption of the starting material. The crude 
salt was recrystallized from MeOH/i-PrOH to 
provide the pure compound as a white solid (185 mg, yield 54%). 
11j: white solid; TLC (alumina-Dragendorff): Rf = 0.39 (CH2Cl2/MeOH 94:6); m.p.: 182.1-
183.4°C; MS (ESI) m/z for C15H19N4O+ [M+H]+ calcd. 271.2, found 271.4. 
1H NMR (CD3OD, 300 MHz) δ 9.20 (d, J = 1.5 Hz, 1H), 8.72 (dd, J = 4.9, 1.5 Hz, 1H), 8.51 – 
8.42 (m, 1H), 7.61 (ddd, J = 8.0, 5.0, 0.8 Hz, 1H), 6.71 (s, 2.5H), 3.74 (ddd, J = 12.8, 10.2, 2.4 
Hz, 1H), 3.47 – 3.32 (m, 4H), 3.29 (dd, J = 5.2, 2.8 Hz, 2H), 3.14 (ddd, J = 13.1, 7.0, 1.9 Hz, 
1H), 2.91 – 2.74 (m, 1H), 2.31 – 2.11 (m, 2H), 2.11 – 2.00 (m, 2H), 2.00 – 1.85 (m, 1H). 
13C NMR (CD3OD, 75 MHz) δ 180.3, 169.9, 167.5, 152.7, 148.8, 136.6, 135.7, 125.7, 124.9, 
53.0, 47.6, 47.1, 32.6, 30.1, 25.3, 24.9, 19.0.  
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Borane 3-(pyridin-4-yl)-5-(4-quinuclidin-3-ylmethyl)-1,2,4-oxadiazole complex 
(124) 
The title compound was prepared according 
to general procedure 5.3.3.3.1 by reacting methyl 
ester 101 (350 mg, 1.78 mmol, 1 equiv), 4-
pyridylamidoxime (112) (731 mg, 5.33 mmol, 3 
equiv) and NaH 60% dispersion in mineral oil (213 
mg, 5.33 mmol, 3 equiv) in dry THF (10 mL). After 
standard workup and silica gel column 
chromatography (cyclohexane/EtOAc 1:1), the desired compound 124 was obtained as a 
pure yellow oil (392 mg, yield 78%). 
124: yellow oil; TLC (Dragendorff): Rf = 0.33 (cyclohexane/EtOAc 3:7). 
1H NMR ((CD3)2SO, 300 MHz) δ 8.79 (dd, J = 4.5, 1.6 Hz, 2H), 7.91 (dd, J = 4.4, 1.7 Hz, 2H), 
3.29 – 3.08 (m, 3H), 2.99 – 2.74 (m, 4H), 2.66 – 2.54 (m, 1H), 2.53 – 2.38 (m, 1H), 1.98 – 1.78 
(m, 1H), 1.78 – 1.65 (m, 2H), 1.64 – 1.42 (m, 2H). 
13C NMR ((CD3)2SO, 75 MHz) δ 179.9, 166.2, 150.9, 133.5, 120.9, 58.7, 53.0, 52.4, 32.3, 29.1, 
25.4, 24.1, 19.3. 
 
 
3-(pyridin-4-yl)-5-(4-quinuclidin-3-ylmethyl)-1,2,4-oxadiazole (137) 
The title compound was obtained according 
to the general procedure 5.3.3.4 by reacting 125 
(392 mg, 1.38 mmol, 1 equiv) and CF3COOH (532 L, 
6.90 mmol, 5 equiv) in acetone. After disappearance 
of the starting material (TLC in cyclohexane/EtOAc 
1:1), standard workup was applied to provide the 
desired compound 137 (340 mg, yield 91%). 
137: yellow oil; TLC (alumina-Dragendorff): Rf = 0.47 (CH2Cl2/MeOH 95:5). 
1H NMR (CDCl3, 300 MHz) δ 8.69 (dd, J = 4.4, 1.7 Hz, 2H), 7.85 (dd, J = 4.5, 1.7 Hz, 2H), 3.13 
(dd, J = 13.6, 9.8 Hz, 1H), 2.96 (d, J = 7.9 Hz, 2H), 2.86 – 2.67 (m, 4H), 2.42 (ddd, J = 13.8, 6.2, 
1.9 Hz, 1H), 2.28 – 2.14 (m, 1H), 1.77 – 1.47 (m, 4H), 1.47 – 1.33 (m, 1H). 
13C NMR (CDCl3, 75 MHz) δ 179.8, 166.9, 150.6, 134.2, 121.2, 54.5, 47.6, 46.8, 34.2, 30.6, 
27.9, 24.9, 20.9. 
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3-(pyridin-4-yl)-5-(4-quinuclidin-3-ylmethyl)-1,2,4-oxadiazole fumarate (11k) 
The fumarate derivative 11k was prepared 
according to the general procedure 5.3.3.5 by 
reacting 137 (340 mg, 1.26 mmol, 1 equiv) and 
fumaric acid (146 mg, 1.26 mmol, 1 equiv) in MeOH. 
After 2h, additional fumaric acid (73 mg, 0.63 mmol, 
0.5 equiv) was added to achieve complete 
consumption of the starting material. The crude salt 
was recrystallized from MeOH and EtOH to provide 
the pure compound as a white solid (168 mg, yield 30%). 
11k: white solid; TLC (alumina-Dragendorff): Rf = 0.30 in CH2Cl2/MeOH 95:5; m.p.: 187.8-
190.2°C; MS (ESI) m/z for C15H19N4O+ [M+H]+ calcd. 271.2, found 271.4. 
1H NMR (CD3OD, 300 MHz) δ 8.74 (dd, J = 4.7, 1.5 Hz, 2H), 8.04 (dd, J = 4.6, 1.6 Hz, 2H), 6.71 
(s, 3H), 3.73 (ddd, J = 12.8, 10.2, 2.4 Hz, 1H), 3.46 – 3.19 (m, 6H), 3.12 (ddd, J = 13.0, 7.0, 1.8 
Hz, 1H), 2.89 – 2.73 (m, 1H), 2.26 – 2.10 (m, 2H), 2.10 – 1.99 (m, 2H), 1.99 – 1.84 (m, 1H). 
13C NMR (CD3OD, 75 MHz) δ 180.6, 169.9, 167.9, 151.3, 136.4, 135.7, 122.8, 52.9, 47.5, 
47.0, 32.6, 30.1, 25.3, 24.9, 19.0. 
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N'-hydroxyfuran-2-carboximidamide (113) 
According to the general procedure 5.3.3.2, 
hydroxylamine (50% w/w in water, 790 L, 12.89 mmol, 4 equiv) 
was added to a stirred solution of 2-furonitrile (282 L, 3.22 
mmol, 1 equiv) and ethanol (6 mL) at RT. The resulting mixture 
was heated at 90°C for 1.5h. After concentration under reduced 
pressure, the desired N'-hydroxyfuran-2-carboxyimidamide (113) 
was obtained as a pure white solid (400 mg, yield 99%). 
113: white solid; TLC (PMA): Rf = 0.32 (cyclohexane/EtOAc 1:1). m.p.: 57.2 – 57.5°C. 
1H NMR (CDCl3, 300 MHz) δ 8.67 (br s, 1H), 7.30 (dd, J = 1.7, 0.7 Hz, 1H), 6.69 (dd, J = 3.4, 
0.6 Hz, 1H), 6.29 (dd, J = 3.5, 1.8 Hz, 1H), 5.05 (br s, 2H). 
13C NMR (CDCl3, 75 MHz) δ 145.9, 145.5, 142.9, 111.6, 108.4. 
 
 
 
Borane 3-(furan-2-yl)-5-(4-quinuclidin-3-ylmethyl)-1,2,4-oxadiazole complex (125) 
The title compound was prepared 
according to general procedure 5.3.3.3.2 by 
reacting methyl ester 101 (200 mg, 1.01 mmol, 1 
equiv), N'-hydroxyfuran-2-carboxyimidamide (113) 
(384 mg, 3.04 mmol, 3 equiv) and Cs2CO3 (992 mg, 
3.04 mmol, 3 equiv) in dry THF (10 mL). After 
standard workup and silica gel column 
chromatography (cyclohexane/EtOAc 7:3 to 3:2), the desired compound 125 was obtained 
as a pure yellow oil (158 mg, yield 57%). 
125: yellow oil; TLC (Dragendorff): Rf = 0.24 (cyclohexane/EtOAc 7:3). 
1H NMR (CDCl3, 300 MHz) δ 7.55 (dd, J = 1.8, 0.8 Hz, 1H), 7.05 (dd, J = 3.5, 0.5 Hz, 1H), 6.50 
(dd, J = 3.3, 1.8 Hz, 1H), 3.36 – 3.22 (m, 1H), 3.06 – 2.86 (m, 6H), 2.59 (ddd, J = 13.5, 7.0, 2.1 
Hz, 1H), 2.55 – 2.41 (m, 1H), 1.95 – 1.83 (m, 2H), 1.83 – 1.72 (m, 2H), 1.72 – 1.57 (m, 1H). 
13C NMR (CDCl3, 75 MHz) δ 177.6, 161.5, 145.4, 142.1, 114.1, 112.0, 59.4, 53.6, 53.0, 33.2, 
30.1, 26.3, 24.7, 20.1. 
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3-(furan-2-yl)-5-(4-quinuclidin-3-ylmethyl)-1,2,4-oxadiazole (138) 
The title compound was obtained according 
to the general procedure 5.3.3.4 by reacting 125 
(158 mg, 0.58 mmol, 1 equiv) and CF3COOH (223 
L, 2.89 mmol, 5 equiv) in acetone. After 
disappearance of the starting material (TLC in 
cyclohexane/EtOAc 7:3), standard workup was 
applied to provide the desired compound 138  
(146 mg, yield 97%). 
138: yellow oil; TLC (alumina-Dragendorff): Rf = 0.39 (CH2Cl2/MeOH 85:15). 
1H NMR (CDCl3, 300 MHz) δ 7.54 (dd, J = 1.7, 0.8 Hz, 1H), 7.05 (dd, J = 3.5, 0.7 Hz, 1H), 6.49 
(ddd, J = 3.4, 1.8, 0.7 Hz, 1H), 3.13 (dd, J = 13.0, 10.3 Hz, 1H), 2.93 (d, J = 7.9 Hz, 2H), 2.89 – 
2.67 (m, 4H), 2.43 (dd, J = 13.6, 6.3 Hz, 1H), 2.32 – 2.14 (m, 1H), 1.80 – 1.66 (m, 1H), 1.66 – 
1.48 (m, 3H), 1.48 – 1.34 (m, 1H). 
13C NMR (CDCl3, 75 MHz) δ 179.0, 161.4, 145.2, 142.4, 113.7, 111.9, 54.5, 47.7, 46.9, 34.3, 
30.6, 27.9, 25.0, 20.9. 
 
 
3-(furan-2-yl)-5-(4-quinuclidin-3-ylmethyl)-1,2,4-oxadiazole fumarate (11l) 
The fumarate derivative 11l was prepared 
according to the general procedure 5.3.3.5 by 
reacting 138 (78 mg, 0.30 mmol, 1 equiv) and 
fumaric acid (35 mg, 0.30 mmol, 1 equiv) in MeOH. 
The crude salt was recrystallized from MeOH/n-
hexane to provide the pure compound as a white 
solid (93 mg, yield 83%). 
11l: white solid; TLC (alumina-Dragendorff): Rf = 0.44 
(CH2Cl2/MeOH 94:6); m.p.: 158.5-159.3°C; MS (ESI) m/z for C14H18N3O2+ [M+H]+ calcd. 260.1, 
found 260.0. 
1H NMR (CD3OD, 300 MHz) δ 7.75 (dd, J = 1.8, 0.8 Hz, 1H), 7.15 (dd, J = 3.5, 0.6 Hz, 1H), 6.68 
(s, 2H), 6.65 (dd, J = 3.5, 1.8 Hz, 1H), 3.69 (ddd, J = 12.8, 10.2, 2.3 Hz, 1H), 3.60 (q, J = 7.1 Hz, 
0.11H, 5% Et2O residual), 3.45 – 3.27 (m, 4H), 3.23 (dd, J = 7.7, 5.1 Hz, 2H), 3.09 (ddd, J = 
13.0, 7.0, 1.8 Hz, 1H), 2.87 – 2.69 (m, 1H), 2.25 – 2.08 (m, 2H), 2.08 – 1.98 (m, 2H), 1.98 – 
1.82 (m, 1H), 1.17 (t, J = 7.0 Hz, 0.12H, 5% Et2O residual). 
13C NMR (CD3OD, 75 MHz) δ 179.5, 171.3, 162.4, 147.0, 143.5, 136.2, 115.1, 113.0, 52.9, 
47.6, 47.1, 32.6, 30.0, 25.2, 24.9, 18.9.  
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Thiophene-2-amidoxime (114) 
According to the general procedure 5.3.3.2, hydroxylamine 
(50% w/w in water, 2.63 mL, 42.96 mmol, 4 equiv) was added to a 
stirred solution of 2-thiophenecarbonitrile (1.0 mL, 10.74 mmol, 1 
equiv) and ethanol (8 mL) at RT. The resulting mixture was heated 
at 90°C for 1.5h. After concentration under reduced pressure, the 
desired thiophene-2-amidoxime (114) was obtained as a pure white 
solid (1.53 g, yield 100%). 
114: white solid; TLC (PMA): Rf = 0.52 (cyclohexane/EtOAc 1:1); m.p.: 90-96°C. 
1H NMR (CDCl3, 300 MHz) δ 7.52 – 7.08 (m, 4H), 7.01 (dd, J = 4.9, 3.9 Hz, 1H), 4.98 (br s, 2H). 
13C NMR (CDCl3, 75 MHz) δ 148.6, 134.9, 127.2, 126.8, 125.3. 
 
 
 
Borane 5-(4-quinuclidin-3-ylmethyl)-3-(thiophen-2-yl)-1,2,4-oxadiazole complex 
(126) 
The title compound was prepared according 
to general procedure 5.3.3.3.1 by reacting methyl 
ester 101 (350 mg, 1.78 mmol, 1 equiv), thiophene-
2-amidoxime (114) (758 mg, 5.33 mmol, 3 equiv) 
and NaH 60% dispersion in mineral oil (213 mg, 
5.33 mmol, 3 equiv) in dry THF (10 mL). After 
standard workup and silica gel column 
chromatography (cyclohexane/EtOAc 75:15), the desired compound 126 was obtained as a 
pure pale yellow oil (336 mg, yield 65%). 
126: pale yellow oil; TLC (Dragendorff): Rf = 0.39 (cyclohexane/EtOAc 7:3). 
1H NMR (CDCl3, 300 MHz) δ 7.71 (dd, J = 3.7, 1.2 Hz, 1H), 7.44 (dd, J = 5.0, 1.2 Hz, 1H), 7.09 
(dd, J = 5.0, 3.7 Hz, 1H), 3.37 – 3.21 (m, 1H), 3.07 – 2.85 (m, 6H), 2.60 (ddd, J = 13.6, 7.0, 2.1 
Hz, 1H), 2.55 – 2.41 (m, 1H), 1.98 – 1.84 (m, 2H), 1.84 – 1.72 (m, 2H), 1.72 – 1.53 (m, 1H). 
13C NMR (CDCl3, 75 MHz) δ 177.5, 164.5, 129.7, 129.5, 128.1, 128.0, 59.3, 53.5, 52.9, 33.1, 
30.0, 26.1, 24.6, 20.0. 
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5-(4-quinuclidin-3-ylmethyl)-3-(thiophen-2-yl)-1,2,4-oxadiazole (139) 
The title compound was obtained 
according to the general procedure 5.3.3.4 by 
reacting 126 (336 mg, 1.16 mmol, 1 equiv) and 
CF3COOH (447 L, 5.80 mmol, 5 equiv) in acetone. 
After disappearance of the starting material (TLC in 
cyclohexane/EtOAc 3:2 and CH2Cl2/MeOH 9:1), 
standard workup was applied to provide the 
desired compound 139 (320 mg, yield 100%). 
142: yellow oil; TLC (alumina-Dragendorff): Rf = 0.38 (CH2Cl2/MeOH 85:15). 
1H NMR (CDCl3, 300 MHz) δ 7.71 (d, J = 3.7 Hz, 1H), 7.42 (d, J = 5.0 Hz, 1H), 7.08 (dd, J = 5.0, 
3.7 Hz, 1H), 3.19 – 3.03 (m, 1H), 2.92 (d, J = 7.8 Hz, 2H), 2.86 – 2.65 (m, 5H), 2.41 (ddd, J = 
13.6, 6.3, 1.8 Hz, 2H), 2.29 – 2.13 (m, 1H), 1.77 – 1.47 (m, 5H), 1.47 – 1.31 (m, 1H). 
13C NMR (CDCl3, 75 MHz) δ 179.0, 164.5, 129.6, 129.3, 128.5, 128.1, 54.6, 47.8, 46.9, 34.4, 
30.7, 28.1, 25.1, 21.0. 
 
 
5-(4-quinuclidin-3-ylmethyl)-3-(thiophen-2-yl)-1,2,4-oxadiazole fumarate (11m) 
The fumarate derivative 11m was prepared 
according to the general procedure 5.3.3.5 by 
reacting 139 (320 mg, 1.16 mmol, 1 equiv) and 
fumaric acid (135 mg, 1.16 mmol, 1 equiv) in MeOH. 
The crude salt was recrystallized from acetone to 
provide the pure compound as a white solid (303 
mg, yield 72%). 
11m: white solid; TLC (alumina-Dragendorff): Rf = 0.35 (CH2Cl2/MeOH 96:4); m.p.:145.3-
146.8°C; MS (ESI) m/z for C14H18N3OS+ [M+H]+ calcd. 276.1, found 276.6. 
1H NMR (CD3OD, 300 MHz) δ 7.79 (dd, J = 3.6, 1.2 Hz, 1H), 7.68 (dd, J = 5.0, 1.1 Hz, 1H), 7.20 
(dd, J = 5.0, 3.7 Hz, 1H), 6.68 (s, 1.5H), 3.70 (ddd, J = 12.8, 10.2, 2.4 Hz, 1H), 3.46 – 3.27 (m, 
4H), 3.23 (dd, J = 7.7, 5.8 Hz, 2H), 3.11 (ddd, J = 13.0, 7.0, 1.7 Hz, 1H), 2.86 – 2.71 (m, 1H), 
2.27 – 2.09 (m, 2H), 2.09 – 1.99 (m, 2H), 1.99 – 1.85 (m, 1H). 
13C NMR (CD3OD, 75 MHz) δ 179.5, 171.4, 165.7, 136.2, 130.9, 130.8, 129.2, 129.1, 53.0, 
47.6, 47.1, 32.6, 30.0, 25.3, 24.9, 19.0. 
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The experimental activity of this PhD thesis focused on the design, synthesis and 
pharmacological evaluation of several classes of compounds, PAMs and silent agonists, to in 
depth study the mechanism of activation of the alpha7 nAChR involved in the cholinergic 
inflammatory pathway. 
 
 Chemistry 
 
 Synthesis of alpha7 PAMs derivatives 
Through a hybridization approach two sets of 5-HI compounds and were 
synthesized by connecting aromatic moiety to the nitrogen atom (1a-f) or to the 
carbon atom (2a-m, 3, 4a-b) of the indole nucleus. 
 
 Synthesis of alpha7 Silent agonists 
Three different series of new potential alpha7 silent agonists were designed and 
prepared: 
▪ diEPP analogues (6a-u, 7, 8) 
▪ quinuclidine spirocyclic-2-isoxazoline nucleus (9a-h, 10a-h) 
▪ quinuclidin-oxadiazole derivatives (11a-m, 12a-g) 
 
 
 Pharmacology 
The target compounds obtained were evaluated in electrophysiological experiments in 
Xenopus oocytes expressing human alpha7 nAChRs. To date only a few data are available 
because many derivatives are still under investigation. 
 Three compounds 2b,2f and 2g of the PAM indole series, displayed enhanced PAM 
activity with respect to the parent compund. In particular, 2b showed a potentiated 
activity two folds higher than 5-HI and comparable to the one of genistein. From 
the CRCs were generated at different concentrations, compound 2g resulted more 
potent and about twice as efficacious as 5-HI, whereas derivatives 2b and 2f turned 
out to be far more efficacious than the parent compound, but not much more 
potent. 
 The electrophysiological profile of the novel diEPP derivatives 6a-u was greatly 
influenced by the nature and sensitive to the position of the aryl substituent. 6a-u 
exhibited a broad range of activities, including partial agonism and various degrees 
of silent agonism at the alpha7 receptor subtype, while some compounds were 
effectively inactive, displaying no agonism and very weak silent agonism. In 
particular, compounds 6g, 6i, 6r and 6s showed the best silent agonism profile of 
the series. the enhanced silent agonism achieved with trifluoromethyl, fluoro and 
carboxamide groups arise from a combination of multifactorial effects, polarity, 
lipophilicity, hydrogen and fluorine bonding, which bear in common the ability to 
selectively stabilize the desensitized state of the alpha7 receptor sensitive to PNU-
120596. Besides, target derivatives 7 and 8 showed enhanced PNU-120596 
potentiation compared to the parent compound and in particular 7 appeared to be 
superior for the better ratio of desensitization to residual partial agonism compared 
to 8. 
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Abbreviations 
Solvents 
DCM or CH2Cl2: dichloromethane; CHCl3: chloroform; MeOH: methanol; EtOH: ethanol; 
EtOAc: ethyl acetate; MeCN: acetonitrile; THF: tetrahydrofuran; Et2O: diethyl ether; H2O: 
water; DMSO: dimethyl sulfoxide; DMF: dimethylformamide; CDCl3: deuterated chloroform; 
CD3OD: deuterated methanol; (CD3)2SO: deuterated dimethyl sulfoxide; (CD3)2CO: 
deuterated acetone. 
 
Reagents 
NaH: sodium hydride; NaSO4: sodium sulfate, NaHCO3: sodium bicarbonate; Na2CO3: sodium 
carbonate; K2CO3: potassium carbonate; CF3COOH: trifluoroacetic acid; CH3I: methyl iodide; 
HCl: hydrochloric acid; H2: hydrogen; Pd/C: palladium on carbon; BH3 in THF: borane 
tetrahydrofuran complex; KMnO4: potassium permanganate; PMA: phosphomolybdic acid; 
Na2S2O3: sodium thiosulfate; CuSO4: copper sulfate; n-BuLi: n-butyllithium; NH4Cl: 
ammonium chloride; CuI: copper iodide; Na2SO3: sodium sulfite; Pd(PPh3)2Cl2: 
bis(triphenylphosphine)palladium(II) dichloride; Et3N: triethylamine; Boc: tert-
butoxycarbonyl; NIS: N-iodosucinimide; BTMA ICl4: benzyl(trimethyl)ammonium 
tetrachloroiodate; DMAP: 4-(Dimethylamino)pyridine; BBr3: boron tribromide; MEM: 
methoxyethoxymethyl; Cs2CO3: cesium carbonate; EtI: iodoethane; MeI: iodomethane; 
TBAF: tetrabutylammonium fluoride; DIPEA: N,N-Diisopropylethylamine; DMF/DMA: N,N-
Dimethylformamide dimethyl acetal. 
 
Analytical characteristics: 
GENERAL – m.p.: melting point; °C: Celsius degree; RT: room temperature; h: hours; min: 
minutes; equiv.: equivalents;  
NMR Spectroscopy – MHz: megaHertz; : chemical shift (ppm); ppm: parts per million; J: 
NMR coupling constant; Hz: Hertz; s: singlet; br s: broad singlet; d: doublet; dd: double of 
doublets; ddd: double of doublet of doublet; dt: double of triplets; t: triplet; q: quartet; m: 
multiplet. 
MASS Spectroscopy – m/z: mass to charge ratio; M+: molecular ion. 
CHROMATOGRAPHY – TLC: thin layer chromatography; Rf : retention factor. 
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